var images_info;if (!images_info) images_info =[]; images_info["64"]={"64002":{"type":"graphic_table","displayName":"Oral appliance adverse effects","title":"Short-term side effects of oral appliances","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short-term side effects of oral appliances</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Dental discomfort, especially upper and lower incisors </td>\r\n                    <td>33 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Temporomandibular joint pain </td>\r\n                    <td>12.5 to 33 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dry mouth</td>\r\n                    <td>28 to 46 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Salivation</td>\r\n                    <td>38 to 50 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Gum irritation</td>\r\n                    <td>20 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bruxism</td>\r\n                    <td>12.5 percent</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 64002 Version 2.0</div></div></div>"},"64005":{"type":"graphic_diagnosticimage","displayName":"Lateral CXR showing pericardial calcium","title":"Lateral chest radiograph (CXR) showing pericardial calcium","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral chest radiograph (CXR) showing pericardial calcium</div><div class=\"cntnt\"><img style=\"width:280px; height:379px;\" src=\"images/CARD/64005_Pericardial_calcium_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral chest radiograph demonstrates coarse calcification involving the entire pericardium (arrows) in this patient who has a history of prior hemopericardium.</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 64005 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"64007":{"type":"graphic_picture","displayName":"Botulinum toxin injection - glabellar rhytides","title":"Botulinum toxin injection for glabellar rhytides","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection for glabellar rhytides</div><div class=\"cntnt\"><img style=\"width:585px; height:155px;\" src=\"images/DERM/64007_Bot_tox_inject_glab_rhyt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images of glabellar rhytides prior to botulinum toxin injection (A) and after injection (B) are shown. The patient is attempting a strong frown in both images.</div><div id=\"graphicVersion\">Graphic 64007 Version 2.0</div></div></div>"},"64008":{"type":"graphic_figure","displayName":"Mechanisms involved in persistent diarrhea","title":"Explanatory mechanisms for persistent diarrhea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Explanatory mechanisms for persistent diarrhea</div><div class=\"cntnt\"><img style=\"width:422px; height:485px;\" src=\"images/PEDS/64008_Infection_diarrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several different mechanisms can explain the development of persistent diarrhea following an episode of acute diarrhea: 1. A secondary event such as lactose intolerance or bacterial overgrowth develops during the acute episode and causes the symptoms to persist. 2. Because of special pathogen characteristics, the infectious agent is never cleared and causes prolonged illness. 3. Because of weakness in defenses (eg, immunosuppression or poor intestinal regeneration) the host is unable to efficiently clear the pathogen and recovery is delayed. 4. Multiple new infections with separate pathogens cause continued symptoms.</div><div class=\"graphic_reference\">Reproduced with permission from: Penny ME. Commentary. Pediatr Infect Dis J 1993; 12:762. Copyright Â© 1993 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64008 Version 10.0</div></div></div>"},"64009":{"type":"graphic_table","displayName":"OTC fiber supplements","title":"Over the counter fiber supplements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Over the counter fiber supplements</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Product</td>\n\n\n      <td class=\"subtitle1\">Amount</td>\n\n\n      <td class=\"subtitle1\">Frequency</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"3\">Metamucil</td>\n\n\n      <td>12 years and over: 1 teaspoon or 1 tablespoon, depending on concentration and formulation</td>\n\n\n      <td colspan=\"1\" rowspan=\"3\">1-3 times daily</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      \n\n\n      <td>6 to 12 years: 1/2 to 1 teaspoon or 1/2 tablespoon depending on concentration and formulation</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Under age 6: 1/4 to 1/2 teaspoon</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"3\">Benefiber</td>\n\n\n      <td>12 years and over: 1 to 2 tablespoons</td>\n\n\n      <td colspan=\"1\" rowspan=\"3\">1-3 times daily</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>7 to 11 years: 1/2 to 1 tablespoon</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Under age 7: 1/4 to 1/2 tablespoon</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"3\">Citrucel</td>\n\n\n      <td>12 year and over: 1 rounded tablespoon</td>\n\n\n      <td colspan=\"1\" rowspan=\"3\">1-3 times daily</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>6 to 12 years: 1/2 tablespoon</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td>Under age 6: 1/4 to 1/2 tablespoon</td>\n\n\n      \n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64009 Version 2.0</div></div></div>"},"64011":{"type":"graphic_table","displayName":"Advising about herbs","title":"Schema for advising patients about herbal products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Schema for advising patients about herbal products</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">Herbal product</td>\n\n\n\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Clinical Advice</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2\">Quality</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2\">Efficacy</td>\n\n\n      <td class=\"subtitle2\">Safety</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Present</td>\n\n      <td>AND</td>\n\n      <td>Present</td>\n\n      <td>AND</td>\n\n      <td>Present</td>\n\n      <td>Recommend</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Uncertain</td>\n\n      <td> OR</td>\n\n      <td>Uncertain</td>\n\n      <td> OR</td>\n\n      <td>Uncertain</td>\n\n      <td>Counsel and caution</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Absent</td>\n\n      <td> OR</td>\n\n      <td>Ineffective</td>\n\n      <td> OR</td>\n\n      <td>Unsafe</td>\n\n      <td>Discourage</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Saper, RB, Eisenberg, D, Phillips, R. Common dietary supplements for weight loss. Am Fam Physician 2004; 70:1731 and Weiger, WA, Smith, M, Boon, H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 2002; 137:889.</div><div id=\"graphicVersion\">Graphic 64011 Version 1.0</div></div></div>"},"64012":{"type":"graphic_table","displayName":"Drug and toxin related respiratory change","title":"Drugs and toxins associated with respiratory dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and toxins associated with respiratory dysfunction</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Tachypnea/hyperventilation</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Nicotine</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td class=\"sublist1_start\">Central hallucinogens</td> </tr> <tr> <td class=\"sublist1\">Lysergic acid diethylamide (LSD)</td> </tr> <tr> <td class=\"sublist1\">Phencyclidine</td> </tr> <tr> <td class=\"sublist1\">Designer amphetamines</td> </tr> <tr> <td class=\"sublist1\">Synthetic cannabinoids</td> </tr> <tr> <td>Anticholinergics</td> </tr> <tr> <td>Drug withdrawal states</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Dinitrophenol, pentacholorphenol</td> </tr> <tr> <td class=\"sublist1_start\">Drug-associated hepatic failure</td> </tr> <tr> <td class=\"sublist1\">Acetaminophen</td> </tr> <tr> <td class=\"sublist1\">Amanita mushrooms</td> </tr> <tr> <td class=\"sublist1_start\">Cellular asphyxiants</td> </tr> <tr> <td class=\"sublist1\">Carbon monoxide</td> </tr> <tr> <td class=\"sublist1\">Cyanide</td> </tr> <tr> <td class=\"sublist1\">Hydrogen sulfide</td> </tr> <tr> <td class=\"sublist1\">Methemoglobinemia</td> </tr> <tr> <td class=\"sublist1_start\">Toxins that induce pulmonary edema</td> </tr> <tr> <td class=\"sublist1\">Opioids</td> </tr> <tr> <td class=\"sublist1\">Pulmonary irritants</td> </tr> <tr> <td class=\"sublist1_start\">Drugs that induce metabolic acidosis (respiratory compensation)</td> </tr> <tr> <td class=\"sublist1\">Methanol</td> </tr> <tr> <td class=\"sublist1\">Ethylene glycol</td> </tr> <tr> <td class=\"sublist1\">Alcoholic ketoacidosis</td> </tr> <tr> <td class=\"sublist1\">Iron</td> </tr> <tr> <td class=\"sublist1\">Isoniazid</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bradypnea/hypoventilation</td> </tr> <tr> <td class=\"sublist1_start\">CNS depressants</td> </tr> <tr> <td class=\"sublist1\">Opioids</td> </tr> <tr> <td class=\"sublist1\">Sedative-hypnotics</td> </tr> <tr> <td class=\"sublist1\">Alcohols</td> </tr> <tr> <td class=\"sublist1\">Antidepressants</td> </tr> <tr> <td class=\"sublist1\">Antipsychotics</td> </tr> <tr> <td class=\"sublist1\">Sympatholytics</td> </tr> <tr> <td class=\"sublist1\">Volatile inhalants (solvents)</td> </tr> <tr> <td class=\"sublist1\">Cholinergics</td> </tr> <tr> <td class=\"sublist1\">Muscle relaxants</td> </tr> <tr> <td class=\"sublist1\">Antiepileptics</td> </tr> <tr> <td class=\"sublist1_start\">Respiratory muscle failure</td> </tr> <tr> <td class=\"sublist1\">Botulism</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td class=\"sublist1\">Neurotoxic snake envenomation</td> </tr> <tr> <td class=\"sublist1\">Neuromuscular blocking agents</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Paralytic shellfish poisoning (saxitoxin)</td> </tr> <tr> <td class=\"sublist1\">Puffer fish poisoning (tetrodotoxin)</td> </tr> <tr> <td class=\"sublist1\">Strychnine</td> </tr> <tr> <td class=\"sublist1\">Tetanus</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64012 Version 5.0</div></div></div>"},"64015":{"type":"graphic_table","displayName":"Osteomyelitis staging","title":"Cierny-Mader staging system for long bone osteomyelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cierny-Mader staging system for long bone osteomyelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Anatomic type </td> </tr> <tr> <td colspan=\"2\"> <p>Stage 1: Medullary osteomyelitis</p> <p>Medullary osteomyelitis denotes infection confined to the intramedullary surfaces of the bone. Hematogenous osteomyelitis and infected intramedullary rods are examples of this anatomic type.</p> </td> </tr> <tr> <td colspan=\"2\"> <p>Stage 2: Superficial osteomyelitis</p> <p>Superficial osteomyelitis is a true contiguous focus infection of bone; it occurs when an exposed infected necrotic surface of bone lies at the base of a soft-tissue wound.</p> </td> </tr> <tr> <td colspan=\"2\"> <p>Stage 3: Localized osteomyelitis</p> <p>Localized osteomyelitis is usually characterized by a full thickness, cortical sequestration, which can be removed surgically without compromising bony stability.</p> </td> </tr> <tr> <td colspan=\"2\"> <p>Stage 4: Diffuse osteomyelitis</p> <p>Diffuse osteomyelitis is a through-and-through process that usually requires an intercalary resection of the bone to arrest the disease process. Diffuse osteomyelitis includes those infections with a loss of bony stability either before or after debridement surgery.</p> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Physiologic class of host* </td> </tr> <tr> <td colspan=\"2\">Class A denotes a normal host </td> </tr> <tr> <td colspan=\"2\">Class B denotes a host with systemic compromise, local compromise, or both </td> </tr> <tr> <td colspan=\"2\">Class C denotes a host for whom the morbidity of treatment is worse than that imposed by the disease itself </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Factors affecting immune surveillance, metabolism, and local vascularity </td> </tr> <tr> <td class=\"subtitle2_single\">Systemic factors </td> <td class=\"subtitle2_single\">Local factors </td> </tr> <tr> <td class=\"indent1\">Malnutrition </td> <td class=\"indent1\">Chronic lymphedema </td> </tr> <tr> <td class=\"indent1\">Renal or hepatic failure </td> <td class=\"indent1\">Venous stasis </td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus </td> <td class=\"indent1\">Major vessel compromise </td> </tr> <tr> <td class=\"indent1\">Chronic hypoxia </td> <td class=\"indent1\">Arteritis </td> </tr> <tr> <td class=\"indent1\">Immune disease </td> <td class=\"indent1\">Small vessel disease </td> </tr> <tr> <td class=\"indent1\">Malignancy </td> <td class=\"indent1\">Extensive scarring </td> </tr> <tr> <td class=\"indent1\">Extremes of age </td> <td class=\"indent1\">Radiation fibrosis </td> </tr> <tr> <td class=\"indent1\">Immunosuppression or immune deficiency </td> <td class=\"indent1\">Neuropathy </td> </tr> <tr> <td class=\"indent1\">&nbsp; </td> <td class=\"indent1\">Tobacco abuse (&#8805;2 packs per day) </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Host factors are important for prognosticating containment of infection. A systemically and/or locally compromised host cannot isolate an infectious focus as well as a normal host, so treatment of osteomyelitis is more difficult in such patients.</div><div class=\"graphic_reference\">Adapted from Cierny G, Mader JT, Pennick H, Contemp Orthop 1985; 10:17.</div><div id=\"graphicVersion\">Graphic 64015 Version 3.0</div></div></div>"},"64018":{"type":"graphic_table","displayName":"Cancer related fatigue initial workup","title":"Cancer-related fatigue: Initial diagnostic work-up","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer-related fatigue: Initial diagnostic work-up</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> </tr> <tr> <td>Electrolytes (sodium, potassium, chloride, bicarbonate)</td> </tr> <tr> <td>Chemistry panel (creatinine, blood urea nitrogen, glucose, magnesium, calcium, phosphorus, total bilirubin, serum transaminases, alkaline phosphatase, lactic dehydrogenase, albumin, total protein)</td> </tr> <tr> <td>Thyroid stimulating hormone (TSH)</td> </tr> <tr> <td>Complete blood count (CBC) with differential and platelet count</td> </tr> <tr> <td>&nbsp;Serum testosterone, in men if&nbsp;the clinical history suggestive of hypogonadism</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Escalante CP, Manzullo MD, Valdrez R. A cancer-related fatigue clinic: Opportunities and challenges.Â J Nat Canc InstÂ 2003; 1:333. Copyright Â©2003 Jones and Bartlett Publishers.</div><div id=\"graphicVersion\">Graphic 64018 Version 5.0</div></div></div>"},"64019":{"type":"graphic_picture","displayName":"ITGCN immunostaining","title":"ITGCN immunostaining","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ITGCN immunostaining</div><div class=\"cntnt\"><img style=\"width:432px; height:355px;\" src=\"images/ONC/64019_ITGCN_immunostaining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The large neoplastic cells of ITGCN within the tubules are highlighted by c-kit immunoreactivity which is predominantly membranous (pink). The Leydig cells (arrows) and Sertoli cells (arrow heads) are labeled with inhibin (brown). Note the mast cells are also labeled with c-kit (small pink cells of the right side of photo) as an internal control.</div><div class=\"graphic_reference\">Courtesy of Ximing J Yang, MD, PhD.</div><div id=\"graphicVersion\">Graphic 64019 Version 1.0</div></div></div>"},"64021":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic carcinoma CT VII","title":"Bronchogenic carcinoma with amorphous calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchogenic carcinoma with amorphous calcification</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/PULM/64021_Bronchogenic_carcinoma_CT4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malignant, amorphous calcification in a left upper lobe bronchogenic carcinoma with metastatic disease to the left hilar lymph nodes and an accompanying small left pleural effusion.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64021 Version 3.0</div></div></div>"},"64022":{"type":"graphic_figure","displayName":"Hepcidin regulatory pathways","title":"Hepcidin regulatory pathways","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Hepcidin regulatory pathways</div><div class=\"cntnt\"><img style=\"width:542px; height:538px;\" src=\"images/HEME/64022_Hepcidin_regulatory_pathways.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of mechanisms activating hepcidin transcription. In the central part, BMP6 activates its type I and II receptors interacting with the co-receptor hemojuvelin on hepatocyte plasma membrane. This triggers the phosphorylation of SMAD1/5/8, which interacts with SMAD4; the transcriptional SMAD complex translocates to the nucleus to activate hepcidin transcription. On the left site, the potential role of HFE and TfR2 is shown. HFE binds TfR1 in competition with Tf-Fe2. High Tf-Fe2 levels display HFE that is free to bind TfR2. It is hypothesized that the HFE-TfR2 complex activates hepcidin, but the molecular mechanisms are unclear (indicated by the question mark). On the right site, IL-6, increased in inflammation, interacts with IL-6R to phosphorylate STAT3 that interacts with HAMP promoter to activate hepcidin transcription.</div><div class=\"graphic_footnotes\">BMP6: bone morphogenetic protein 6; BMPRI-II: bone morphogenetic protein type I and II receptors; HJV: hemojuvelin; HAMP: hepcidin antimicrobial peptide; Tf-Fe2: diferric transferrin; IL-6R: IL-6 receptor.</div><div id=\"graphicVersion\">Graphic 64022 Version 2.0</div></div></div>"},"64023":{"type":"graphic_picture","displayName":"Livedo racemosa in polyarteritis nodosa","title":"Livedo racemosa in polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Livedo racemosa in polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64023_Livedo_racemosa_polyarter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An irregular, branched, vascular pattern (livedo racemosa) and a few healing ulcerations are present on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64023 Version 3.0</div></div></div>"},"64024":{"type":"graphic_picture","displayName":"Esophagitis stricture","title":"Esophagitis post esophageal stricture due to lye ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophagitis post esophageal stricture due to lye ingestion</div><div class=\"cntnt\"><img style=\"width:360px; height:364px;\" src=\"images/EM/64024_Esophagitis_stricture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 9-year-old with hematemsis and a history of esophageal stricture secondary to lye ingestion. Endoscopy demonstrates patulous gastroesophageal junction with distal esophagus friability.</div><div class=\"graphic_reference\">Courtesy of Karen Murray, MD.</div><div id=\"graphicVersion\">Graphic 64024 Version 1.0</div></div></div>"},"64025":{"type":"graphic_figure","displayName":"Radius ulna anatomy","title":"Anatomy of the radius and ulna","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the radius and ulna</div><div class=\"cntnt\"><img style=\"width:390px; height:456px;\" src=\"images/EM/64025_Radiusulnaanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radius and ulna anatomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64025 Version 12.0</div></div></div>"},"64026":{"type":"graphic_picture","displayName":"Bleeding esoph varix Endosc","title":"Bleeding esophageal varix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bleeding esophageal varix</div><div class=\"cntnt\"><img style=\"width:310px; height:329px;\" src=\"images/GAST/64026_Bleeding_esoph_varix_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A jet of active bleeding is visible from an esophageal varix in a patient with cirrhosis. Bleeding from esophageal varices can be massive.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD.</div><div id=\"graphicVersion\">Graphic 64026 Version 1.0</div></div></div>"},"64027":{"type":"graphic_movie","displayName":"Pericardial effusion with tamponade subcostal view","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64027_subpref2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:297px; height:241px;\" src=\"images/CARD/64027_subpref2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal four-chamber view from a two-dimensional echocardiogram shows a massive pericardial effusion (PE) surrounding the left ventricle (LV), right atrium (RA), and right ventricle (RV), which is strikingly reduced and shows diastolic collapse. The patient had severe hemodynamic compromise and tamponade physiology.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 64027 Version 4.0</div></div></div>"},"64030":{"type":"graphic_picture","displayName":"Down syndrome facies","title":"Down syndrome facies","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Down syndrome facies</div><div class=\"cntnt\"><img style=\"width:529px; height:301px;\" src=\"images/PEDS/64030_Down_syndrome_facies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic facial features of Down syndrome depicted in a term (A) and preterm (B) infant include: epicanthal folds, slanted palpebral fissures, flat nasal bridge, and protruding tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright Â© 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 64030 Version 2.0</div></div></div>"},"64031":{"type":"graphic_algorithm","displayName":"Algorithm ileocolonic Crohn child","title":"Algorithm for management of ileocolonic Crohn disease in children","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of ileocolonic Crohn disease in children</div><div class=\"cntnt\"><img style=\"width:652px; height:455px;\" src=\"images/PEDS/64031_IleocolCrohnschild.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dashed line indicates less preferred option as compared with solid line.</div><div class=\"graphic_footnotes\">AZA: azathioprine; 6-MP: 6-mercaptopurine; MTX: methotrexate; TNF: tumor necrosis factor; IFX: infliximab.<br />* In our practice, we consider early use of anti-TNF antibodies in the following types of patients, based on limited data that suggest that they are at high risk for complicated disease:<sup>[1-3]</sup>&#xD;&#xA;<ul>&#xD;&#xA;    <li>Severe perianal disease</li>&#xD;&#xA;    <li>Steroid unresponsive</li>&#xD;&#xA;    <li>Deep fissuring ulcers in the colon</li>&#xD;&#xA;    <li>Extensive disease involving the mid-small bowel</li>&#xD;&#xA;    <li>Growth failure (if severe and/or occurring in late puberty)</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; For patients with severe disease, enteral nutrition therapy might be used in combination with glucocorticoids or other medical treatments for induction of remission.<br />&Delta; Some clinicians prefer to avoid thioprurines, because of the slight increase in absolute risk for lymphoma and nonmelanoma skin cancers. The debate continues on the benefit to risk ratio of thioprurines. Meanwhile, methotrexate or early use of anti-TNF therapies are increasingly being utilized as alternatives.<br /><span class=\"lozenge\">&loz;</span> Although aminosalicylates are attractive because of low toxicity, it is unclear if these drugs are superior to placebo in preventing relapse. As a result, immunomodulators (6-MP/AZA or MTX) or anti-TNF antibodies are generally used for maintenance therapy for patients with moderate or severe disease.<br />&sect; In general, patients requiring more than one course of glucocorticoids within one year should be advanced to a different immunomodulator or to an anti-TNF antibody.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-&alpha; vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146:383.</li>&#xD;&#xA;    <li>Turner D, Griffiths AM, Veerman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 2013; 11:1480.</li>&#xD;&#xA;    <li>Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64031 Version 12.0</div></div></div>"},"64032":{"type":"graphic_waveform","displayName":"Juvenile pattern tutorial","title":"Persistent juvenile pattern","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Persistent juvenile pattern</div><div class=\"cntnt\"><img style=\"width:531px; height:219px;\" src=\"images/CARD/64032_Juvenile_pattern_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T wave inversion in V1 to V3 in an adult is consistent with a persistent juvenile pattern.</div><div id=\"graphicVersion\">Graphic 64032 Version 2.0</div></div></div>"},"64034":{"type":"graphic_table","displayName":"Diseases associated with ILD","title":"Partial list of primary diseases associated with interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Partial list of primary diseases associated with interstitial lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sarcoidosis</td> </tr> <tr> <td class=\"sublist1_start\">Vasculitides</td> </tr> <tr> <td class=\"sublist1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"sublist1\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td class=\"sublist1_start\">Hemorrhagic syndromes</td> </tr> <tr> <td class=\"sublist1\">Anti-glomerular basement membrane antibody (Goodpasture's) disease</td> </tr> <tr> <td class=\"sublist1\">Idiopathic pulmonary hemosiderosis</td> </tr> <tr> <td>Pulmonary Langerhans cell histiocytosis (eosinophilic granuloma)</td> </tr> <tr> <td>Chronic gastric aspiration</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td>Lymphangioleiomyomatosis</td> </tr> <tr> <td>Neurofibromatosis</td> </tr> <tr> <td>Lymphangitic carcinomatosis</td> </tr> <tr> <td>Chronic pulmonary edema</td> </tr> <tr> <td>Chronic uremia</td> </tr> <tr> <td>Respiratory bronchiolitis</td> </tr> <tr> <td>Alveolar proteinosis</td> </tr> <tr> <td>Gaucher's disease</td> </tr> <tr> <td>Niemann-Pick disease</td> </tr> <tr> <td>Hermansky-Pudlak syndrome</td> </tr> <tr> <td>Pulmonary veno-occlusive disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64034 Version 4.0</div></div></div>"},"64035":{"type":"graphic_diagnosticimage","displayName":"RUL atelectasis I","title":"Right upper lobe atelectasis due to small cell carcinoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right upper lobe atelectasis due to small cell carcinoma</div><div class=\"cntnt\"><img style=\"width:371px; height:375px;\" src=\"images/PULM/64035_RUL_atelectasis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atelectatic right upper lobe produces a triangular apical opacity (arrow). The right minor fissure is retracted cranially and has an inverted S-shaped configuration (Golden's S sign) beginning at the superior part of the atelectatic lobe and curving down around the hilar mass (M).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64035 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"64036":{"type":"graphic_table","displayName":"ACR RA response criteria","title":"American College of Rheumatology 20 percent improvement criteria (ACR20)<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Rheumatology 20 percent improvement criteria (ACR20)<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">At least 20 percent&nbsp;improvement in</td> </tr> <tr> <td>1. Swollen joint counts</td> </tr> <tr> <td>2. Tender joint count</td> </tr> <tr> <td class=\"subtitle1_single\">and&nbsp;three of the following&nbsp;five variables:</td> </tr> <tr> <td>3. Patient-assessed global disease activity (eg, by VAS)</td> </tr> <tr> <td>4. Evaluator-assessed global disease activity (eg, by VAS)</td> </tr> <tr> <td>5. Patient pain assessment (eg, by VAS)</td> </tr> <tr> <td>6. Functional disability (eg, by HAQ)</td> </tr> <tr> <td>7. Acute phase response (ESR or CRP)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A 50 and 70 percent&nbsp;ACR response (ACR50 and ACR70, respectively)&nbsp;represents respective improvement of at least 50&nbsp;or 70 percent.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727.</LI>&#xD;&#xA;<LI>Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?. Arthritis Rheum 1998; 41:1564.</LI></OL></div><div id=\"graphicVersion\">Graphic 64036 Version 3.0</div></div></div>"},"64041":{"type":"graphic_table","displayName":"Tests for chronic meningitis","title":"Potentially useful diagnostic tests in patients with unexplained chronic meningitis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potentially useful diagnostic tests in patients with unexplained chronic meningitis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Examination of CSF</td> </tr> <tr> <td>Cell count with differential</td> </tr> <tr> <td>Protein</td> </tr> <tr> <td>Glucose</td> </tr> <tr> <td>Special stains (for specific pathogens, eosinophils)</td> </tr> <tr> <td>Cytology</td> </tr> <tr> <td>Cryptococcal antigen testing</td> </tr> <tr> <td class=\"subtitle1_single\">Cultures (CSF, blood, other fluids where relevant)</td> </tr> <tr> <td>Aerobic and anaerobic bacterial</td> </tr> <tr> <td>Mycobacterial (including acid-fast stains)</td> </tr> <tr> <td>Fungal</td> </tr> <tr> <td class=\"subtitle1_single\">Serologies (blood and/or CSF)</td> </tr> <tr> <td>Fungal serologic tests for <em>Histoplasma</em>, <em>Coccidioides</em>, <em>Sporothrix</em>, <em>Cryptococcus </em>(CF or immunodiffusion)</td> </tr> <tr> <td><em>Toxoplasma</em> serologies (IFA)</td> </tr> <tr> <td>Antibody tests for HIV-1, HTLV I/II (ELISA, Western blot)</td> </tr> <tr> <td>Cysticercosis serology (ELISA, immunoblot)</td> </tr> <tr> <td>Lyme serologies (ELISA, Western blot)</td> </tr> <tr> <td>VDRL</td> </tr> <tr> <td><em>Brucella</em> serology (standard tube agglutination, CF, ELISA)</td> </tr> <tr> <td>Tularemia serology</td> </tr> <tr> <td class=\"subtitle1_single\">Imaging studies</td> </tr> <tr> <td>Computed tomography</td> </tr> <tr> <td>Magnetic resonance imaging</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Tuberculin skin test or interferon-gamma release assay</td> </tr> <tr> <td>Serum and CSF 1,3-beta-D-glucan assay</td> </tr> <tr> <td>Meningeal or cortical biopsy (histopathology and culture)</td> </tr> <tr> <td>Bone marrow aspiration and biopsy (with cultures)</td> </tr> <tr> <td>Extractable nuclear antigens</td> </tr> <tr> <td>Erythrocyte sedimentation rate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; CF: complement fixation; IFA: indirect fluorescent antibody; HTLV: human T-lymphotropic virus;&nbsp;ELISA: enzyme-linked immunosorbent assay; VDRL: Venereal Disease Research Laboratory.<br />* The decision regarding which laboratory tests to perform should be based upon the clinical features of each individual patient and the probability that a specific disease is present. </div><div id=\"graphicVersion\">Graphic 64041 Version 4.0</div></div></div>"},"64042":{"type":"graphic_picture","displayName":"Bilateral ovarian cancers","title":"Uterus with bilateral ovarian malignancies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus with bilateral ovarian malignancies</div><div class=\"cntnt\"><img style=\"width:368px; height:295px;\" src=\"images/ONC/64042_Bilateral_ovarian_cancers.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo courtesy of William Mann, MD.</div><div id=\"graphicVersion\">Graphic 64042 Version 1.0</div></div></div>"},"64043":{"type":"graphic_algorithm","displayName":"ESC Athlete Screening Protocol","title":"Flow diagram illustrating the proposed screening protocol for young competitive athletes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow diagram illustrating the proposed screening protocol for young competitive athletes</div><div class=\"cntnt\"><img style=\"width:442px; height:421px;\" src=\"images/CARD/64043_ESC_Athlete_Screening_Proto.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial cardiovascular protocol includes family and personal history, physical examination with determination of blood pressure, and basal 12-lead ECG. Additional tests such as echocardiography, 24-h Holter monitoring, or stress testing, SAECG, and cardiac MRI are requested only for subjects who had positive findings at the initial evaluation. In uncertain cases, invasive tests such as contrast vetriculography (both right and left), coronary angiography, endomyocardial biopsy, and electrophysiological study may be necessary in order to confirm (or rule out) the diagnosis of cardiovascular disease. Athletes diagnosed with clinically relevant cardiovascular abnormalities are managed according to available guidelines for assessing athletic risk.</div><div class=\"graphic_footnotes\">EMB: endomyocardial biopsy; EPS: electrophysiological study; MRI: magnetic resonance imaging; SAECG: signal-averaged ECG.</div><div id=\"graphicVersion\">Graphic 64043 Version 2.0</div></div></div>"},"64045":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph TTN","title":"Chest radiograph of an infant with transient tachypnea of the newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of an infant with transient tachypnea of the newborn</div><div class=\"cntnt\"><img style=\"width:310px; height:547px;\" src=\"images/PEDS/64045_Chest_radiograph_TTN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figures A and B are radiographs of infants with transient tachypnea of the newborn (TTN). They demonstrate areas of diffuse infiltrates in the lung field and perihilar streaking indicative of retained lung fluid, consistent with the diagnosis of TTN.</div><div class=\"graphic_reference\">Courtesy of Richard Martin, MD&nbsp;and Firas Saker, MD.</div><div id=\"graphicVersion\">Graphic 64045 Version 3.0</div></div></div>"},"64047":{"type":"graphic_table","displayName":"ACCP Rx bioprosthetic valve","title":"Ninth ed: ACCP evidence-based clinical practice guidelines: Antithrombotic therapy in patients with bioprosthetic heart valves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ninth ed: ACCP evidence-based clinical practice guidelines: Antithrombotic therapy in patients with bioprosthetic heart valves</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>For the first three months after bioprosthetic mitral valve replacement (MVR), vitamin K antagonist (VKA) therapy (target INR, 2.5; range, 2.0-3.0) is suggested over no VKA therapy. </li> </ul> </td> </tr> <tr> <td> <ul> <li>For the first three months after surgical bioprosthetic aortic valve replacement (AVR) in patients who are in sinus rhythm and have no other indication for VKA therapy, aspirin (50 to 100 mg/day) is suggested over VKA therapy. </li> </ul> </td> </tr> <tr> <td> <ul> <li>For the first three months after transcatheter aortic bioprosthetic valve implantation, aspirin (50 to 100 mg/d) plus clopidogrel (75 mg/d) is suggested over VKA therapy and over no antiplatelet therapy. </li> </ul> </td> </tr> <tr> <td> <ul> <li>For the first three months after mitral valve repair with an annular ring in patients who are in sinus rhythm, antiplatelet therapy is suggested over VKA therapy. </li> </ul> </td> </tr> <tr> <td> <ul> <li>After the first three months following bioprosthetic valve replacement in patients in normal sinus rhythm, aspirin therapy is suggested over no aspirin therapy. </li> </ul> </td> </tr> <tr> <td> <ul> <li>In patients undergoing aortic valve repair, aspirin (50 to 100 mg/d) is suggested over VKA therapy. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e576S.</div><div id=\"graphicVersion\">Graphic 64047 Version 3.0</div></div></div>"},"64048":{"type":"graphic_diagnosticimage","displayName":"Intussusception lymphoma BE","title":"Intussusception of ileal lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception of ileal lymphoma</div><div class=\"cntnt\"><img style=\"width:238px; height:344px;\" src=\"images/GAST/64048_Intussusception_lymphoma_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium enema shows a large soft tissue mass in the cecum (arrows) caused by intussusception of a lymphoma arising in the terminal ileum.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 64048 Version 2.0</div></div></div>"},"64049":{"type":"graphic_form","displayName":"Headache calendar","title":"Headache calendar","html":"<div class=\"graphic\"><div style=\"width: 1054px\" class=\"figure\"><div class=\"ttl\">Headache calendar</div><div class=\"cntnt\"><img style=\"width:1034px; height:662px;\" src=\"images/NEURO/64049_Headache_diary.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Alan Rapoport, co-founder of BonTriage.</div><div id=\"graphicVersion\">Graphic 64049 Version 4.0</div></div></div>"},"64050":{"type":"graphic_table","displayName":"Verbal relationship building","title":"Verbal relationship building skills","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Verbal relationship building skills</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Strategy (PEARLS)</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Partnership</td> <td>Joint problem-solving</td> <td>\"Let's tackle this together.\"</td> </tr> <tr> <td>Empathy</td> <td>Show understanding; put feelings into words</td> <td>\"That sounds hard.\" \"You look upset.\" \"You seem discouraged.\" \"Wow!\"</td> </tr> <tr> <td>Apology (compassion)</td> <td>Show concern for \"faux pas,\" hurts, bumbles</td> <td>\"I'm sorry I (or others) hurt/offended/annoyed you.\"</td> </tr> <tr> <td>Respect</td> <td>Value patient's choices, traits and behaviors</td> <td>\"I appreciate your courage/decision/action.\" \"You have worked hard on this.\"</td> </tr> <tr> <td>Legitimization</td> <td>Normalize and validate feeling and choices</td> <td>\"Anyone would be confused/sad/irritated&nbsp;by this situation.\"</td> </tr> <tr> <td>Support</td> <td>Offer ongoing personal support</td> <td>\"I'll stick with you as long as necessary.\"</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Resist the powerful temptation to pursue clinical details when responding to a patient's emotion. Avoid actions that tend to make people feel ignored or irritated, such as judging, being defensive, persistent questioning, giving nonverbal cues of irritation, or prematurely giving information, advice, or reassurance.</div><div class=\"graphic_reference\">Adapted by permission from Clark W, Hewson M, Fry M, et al. American Academy on Physician and Patient (AAPP 1998), now the American Academy on Communication in Healthcare.</div><div id=\"graphicVersion\">Graphic 64050 Version 4.0</div></div></div>"},"64051":{"type":"graphic_diagnosticimage","displayName":"Empyema gas liquid level CT","title":"Empyema with gas-liquid level","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Empyema with gas-liquid level</div><div class=\"cntnt\"><img style=\"width:360px; height:261px;\" src=\"images/PULM/64051_Empyema_gas_liquid_level_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Empyema with large gas-liquid level in the left posterior hemithorax due to a bronchopleural fistula. The adjacent lung is compressed and partially atelectatic.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64051 Version 2.0</div></div></div>"},"64052":{"type":"graphic_diagnosticimage","displayName":"Radiographic progression of acromioclavicular arthritis","title":"Radiographic progression of acromioclavicular arthritis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Radiographic progression of acromioclavicular arthritis</div><div class=\"cntnt\"><img style=\"width:514px; height:368px;\" src=\"images/EM/64052_AC_arthritis_progr_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of four plain radiographs depicts the progression of degenerative changes seen with osteoarthritis of the acromioclavicular joint. Note the steady decrease in joint space and changes in bone appearance.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 64052 Version 4.0</div></div></div>"},"64053":{"type":"graphic_picture","displayName":"Ascaris lumbricoides in the common bile duct","title":"Ascaris lumbricoides in the common bile duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ascaris lumbricoides in the common bile duct</div><div class=\"cntnt\"><img style=\"width:413px; height:413px;\" src=\"images/GAST/64053_Ascaris_lumb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Choledochoscopy showing Ascaris lumbricoides in the common bile duct.</div><div id=\"graphicVersion\">Graphic 64053 Version 1.0</div></div></div>"},"64055":{"type":"graphic_table","displayName":"Diagnostic lab tests in polyneuropathy","title":"Diagnostic laboratoryÂ tests in polyneuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic laboratory&nbsp;tests in polyneuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Predominantly axonal pathophysiology</td> </tr> <tr> <td class=\"subtitle2_single\">Initial tests:</td> </tr> <tr> <td class=\"indent1\">Serum glucose and glycohemoglobin</td> </tr> <tr> <td class=\"indent1\">Serum vitamin B12 level</td> </tr> <tr> <td class=\"indent1\">SPEP and UPEP with immunofixation</td> </tr> <tr> <td class=\"indent1\">Thyroid function tests</td> </tr> <tr> <td class=\"indent1\">Serum antinuclear antibodies</td> </tr> <tr> <td class=\"indent1\">Erythrocyte sedimentation rate</td> </tr> <tr> <td class=\"subtitle2_single\">Additional testing, if history suggestive:</td> </tr> <tr> <td class=\"indent1\">HIV serology</td> </tr> <tr> <td class=\"indent1\">Urine/blood for heavy metals</td> </tr> <tr> <td class=\"indent1\">Urine/blood for porphyrins</td> </tr> <tr> <td class=\"indent1\">Rheumatoid factor</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren syndrome testing (anti-Ro, anti-La antibodies)</td> </tr> <tr> <td class=\"indent1\">Anti-Hu antibodies (in patients with sensory neuronopathy)</td> </tr> <tr> <td class=\"indent1\">Lyme testing</td> </tr> <tr> <td class=\"indent1\">Vitamin B1 (thiamine) erythrocyte transketolase activation assay or whole blood level</td> </tr> <tr> <td class=\"indent1\">Methylmalonic acid and homocysteine levels (in patients with borderline low serum vitamin B12 levels)</td> </tr> <tr> <td class=\"indent1\">Hepatitis screen (for types B and C)</td> </tr> <tr> <td class=\"subtitle1_single\">Predominantly demyelinating pathophysiology</td> </tr> <tr> <td class=\"subtitle2_single\">Initial tests:</td> </tr> <tr> <td class=\"indent1\">SPEP and UPEP with immunofixation</td> </tr> <tr> <td class=\"indent1\">Hepatitis screen (for types B and C)</td> </tr> <tr> <td class=\"indent1\">Lumbar puncture</td> </tr> <tr> <td class=\"subtitle2_single\">Additional testing, if history suggestive:</td> </tr> <tr> <td class=\"indent1\">Antimyelin associated glycoprotein (MAG) antibodies (in patients with predominantly sensory symptoms)</td> </tr> <tr> <td class=\"indent1\">Anti-GM1&nbsp;antibodies (in patients with predominantly motor symptoms)</td> </tr> <tr> <td class=\"indent1\">HIV</td> </tr> <tr> <td class=\"indent1\">Genetic testing for Charcot-Marie-Tooth disease; generally, the electrophysiology is also suggestive of a hereditary condition</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 64055 Version 9.0</div></div></div>"},"64056":{"type":"graphic_figure","displayName":"Risk of MI with cocaine","title":"Relative risk of myocardial infarction onset after cocaine use","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relative risk of myocardial infarction onset after cocaine use</div><div class=\"cntnt\"><img style=\"width:364px; height:341px;\" src=\"images/PC/64056_Risk_of_MI_with_cocaine.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative risk of myocardial infarction onset is plotted on a logarithmic scale for each of the three hours after cocaine use. Relative risks were estimated by comparing the frequency of cocaine use in each of the 3 hours before myocardial infarction onset to its expected frequency based on each patient's reported usual frequency of cocaine use over the prior year. Error bars indicate 95 percent CI. Dotted line represents baseline risk during periods of nonexposure to cocaine. The risk of myocardial infarction was increased 24 times over baseline in the first 60 minutes after cocaine use.</div><div class=\"graphic_reference\">Adapted from: Mittleman MA, Mintzer D, Maclure M. Circulation 1999; 99:2737.</div><div id=\"graphicVersion\">Graphic 64056 Version 2.0</div></div></div>"},"64057":{"type":"graphic_table","displayName":"Therapy for BO","title":"Potential therapies for bronchiolitis obliterans following lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential therapies for bronchiolitis obliterans following lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First line therapy</td> </tr> <tr> <td class=\"indent1\">Azithromycin</td> </tr> <tr> <td class=\"indent1\">Substitution of tacrolimus for cyclosporine</td> </tr> <tr> <td class=\"indent1\">Substitution of mycophenolate for azathioprine</td> </tr> <tr> <td class=\"subtitle1_single\">Second line therapy</td> </tr> <tr> <td class=\"indent1\">Substitution of sirolimus for azathioprine</td> </tr> <tr> <td class=\"indent1\">Everolimus</td> </tr> <tr> <td class=\"indent1\">Montelukast</td> </tr> <tr> <td class=\"subtitle1_single\">Therapy for refractory BOS</td> </tr> <tr> <td class=\"indent1\">Photopheresis</td> </tr> <tr> <td class=\"indent1\">Total lymphoid irradiation</td> </tr> <tr> <td class=\"indent1\">Plasmapheresis</td> </tr> <tr> <td class=\"indent1\">Cytolytic therapy: ATG</td> </tr> <tr> <td class=\"indent1\">Retransplantation</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The anti-CD3 antibody (OKT3) is no longer available.</div><div class=\"graphic_footnotes\">BOS: bronchiolitis obliterans syndrome; ATG: antithymocyte globulin.</div><div id=\"graphicVersion\">Graphic 64057 Version 3.0</div></div></div>"},"64058":{"type":"graphic_diagnosticimage","displayName":"Early acromegalic arthropathy","title":"Acromegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromegaly</div><div class=\"cntnt\"><img style=\"width:292px; height:324px;\" src=\"images/RHEUM/64058_Early_acromegalic_arthropat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of the hand in a 53-year-old woman who presented with enlarged hands shows thickening of the soft tissues, exaggeration of the bony tufts of the distal phalanges, and prominence of the muscular attachments of the proximal phalanges. These are all features consistent with acromegaly.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 64058 Version 2.0</div></div></div>"},"64059":{"type":"graphic_table","displayName":"Side effects of sulfasalazine and aminosalicylates","title":"Side effects of sulfasalazine and aminosalicylates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Side effects of sulfasalazine and aminosalicylates</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Common<br /> (&#62;10 percent)</td> <td class=\"subtitle1\">Uncommon<br /> (1 to 10 percent)</td> <td class=\"subtitle1\">Rare<br /> (&#60;1 percent)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sulfasalazine</strong></td> <td> <p>Nausea/headache</p> <p>Rash</p> <p>Male infertility</p> <p>Headache</p> </td> <td> <p>Abdominal pain</p> <p>Hemolytic anemia</p> <p>Leukopenia</p> <p>Thrombocytopenia</p> </td> <td> <p>Hepatitis</p> <p>Pneumonitis</p> <p>Neutropenia</p> <p>Pancreatitis</p> <p>Agranulocytosis</p> <p>Otalgia</p> </td> </tr> <tr> <td><strong>Aminosalicylates</strong></td> <td> <p>Watery diarrhea</p> <p>Abdominal pain</p> <p>Headache</p> <p>Nausea</p> </td> <td> <p>Pancreatitis</p> <p>Colitis exacerbation</p> <p>Fever/rash</p> <p>Rash</p> </td> <td> <p>Pneumonitis</p> <p>Pericarditis</p> <p>Nephritis</p> <p>Thrombocytopenia</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64059 Version 2.0</div></div></div>"},"64060":{"type":"graphic_table","displayName":"Rett and Angelman syndrome mimics","title":"Expanding spectrum of Rett syndrome-like and Angelman syndrome-like conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expanding spectrum of Rett syndrome-like and Angelman syndrome-like conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">\"Atypical\" Rett or Angelman syndrome mimics</td> <td class=\"subtitle1\">Features</td> </tr> <tr> <td>MBD5/2q31.1 microdeletion</td> <td>Minimal speech, seizures, microcephaly, behavioral disorders, short stature, coarse facies</td> </tr> <tr> <td>FOXG1/chromosome 14 microdeletion</td> <td>Congenital microcephaly, epilepsy, Rett-like phenotype, synophrys, dyskinesia</td> </tr> <tr> <td>SLC9A6 (Christianson syndrome)</td> <td>Epilepsy, ataxia, acquired microcephaly, lack of speech, slender body habitus</td> </tr> <tr> <td>TCF4 Pitt-Hopkins syndrome/18q21.1 microdeletion</td> <td>Wide mouth, fleshy lips, intermittent overbreathing</td> </tr> <tr> <td>Atypical adenylosuccinate lyase deficiency</td> <td>Hyperactivity, severe speech deficits, seizures, happy disposition, stereotypies</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Williams SR, Mullegama SV, Rosenfeld JA, et al. Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures. Eur J Hum Genet 2010; 18:436. </li>&#xD;&#xA;    <li>Jacob FD, Ramaswamy V, Andersen J, Bolduc FV. Atypical Rett syndrome with selective FOXG1 deletion detected by comparative genomic hybridization: case report and review of literature. Eur J Hum Genet 2009; 17:1577. </li>&#xD;&#xA;    <li>Bahi-Buisson N, Nectoux J, Girard B, et al. Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant. Neurogenetics 2010; 11:241. </li>&#xD;&#xA;    <li>Gilfillan GD, Selmer KK, Roxrud I, et al. SLC9A6 mutations cause X-linked mental retardation, microcephaly, epilepsy, and ataxia, a phenotype mimicking Angelman syndrome. Am J Hum Genet 2008; 82:1003. </li>&#xD;&#xA;    <li>Zweier C, Peippo MM, Hoyer J, et al. Haploinsufficiency of TCF4 causes syndromal mental retardation with intermittent hyperventilation (Pitt-Hopkins syndrome). Am J Hum Genet 2007; 80:994. </li>&#xD;&#xA;    <li>Gitiaux C, Ceballos-Picot I, Marie S, et al. Misleading behavioural phenotype with adenylosuccinate lyase deficiency. Eur J Hum Genet 2009; 17:133. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64060 Version 8.0</div></div></div>"},"64061":{"type":"graphic_figure","displayName":"Free TRAM flap reconstruction after skin sparing mastectomy","title":"Free TRAM flap reconstruction after skin sparing mastectomy","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Free TRAM flap reconstruction after skin sparing mastectomy</div><div class=\"cntnt\"><img style=\"width:535px; height:686px;\" src=\"images/SURG/64061_FreeTRAMflapbreastreconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The free TRAM (transverse rectus abdominus myocutaneous) flap completely detaches and directly transfers the lower abdominal tissue to the mastectomy site. The deep inferior epigastric artery and vein, which provide the vascular supply for the free flap, are anastomosed to local recipient vessels, using either the internal mammary or thoracodorsal arteries and veins. This can be performed to provide immediate or delayed breast reconstruction. In this drawing, a skin sparing mastectomy is depicted. This drawing depicts the blood supply anastomosis to the thoracodorsal vessels, however, the internal mammary site is also used commonly for the site of anastomosis.</div><div id=\"graphicVersion\">Graphic 64061 Version 4.0</div></div></div>"},"64062":{"type":"graphic_picture","displayName":"Proper lifting knees bent","title":"Proper lifting mechanics: Knees bent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper lifting mechanics: Knees bent</div><div class=\"cntnt\"><img style=\"width:264px; height:388px;\" src=\"images/RHEUM/64062_prop_lift_knee_bent.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 64062 Version 1.0</div></div></div>"},"64063":{"type":"graphic_table","displayName":"Therapeutic options in psoriatic juvenile idiopathic arthritis","title":"Therapeutic options in psoriatic juvenile idiopathic arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic options in psoriatic juvenile idiopathic arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intraarticular glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Triamcinolone hexacetonide</td> <td>0.5 to 1 mg/kg intraarticular, up to 40 mg depending on size of joint. Most effective glucocorticoid for joint injections; not for soft tissue injections.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methylprednisolone acetate</td> <td>1 mg/kg intraarticular or soft-tissue including dactylitis, up to 80 mg depending upon size of joint or lesion</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nonsteroidal anti-inflammatory drugs (NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Naproxen</td> <td>5 to 10 mg/kg/dose orally twice daily (maximum 1000 mg/day)</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> <td>10 mg/kg/dose orally three to four times daily (maximum 2.4 g/day)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Celecoxib</td> <td>Body weight:<br /> 10 to 25 kg: 50 mg orally twice daily<br /> &#62;25 kg: 100 mg orally twice daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disease modifying antirheumatic drugs</td> </tr> <tr> <td class=\"indent1\">Methotrexate*</td> <td>10 to 15 mg/m<sup>2</sup> per week or 0.5 to 1 mg/kg/week (maximum 25 mg per week) administered orally* or subcutaneously with folic acid 1 mg daily or leucovorin calcium</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> <td>15 to 30 mg/kg/dose orally twice daily, maximum 2 g/day</td> </tr> <tr> <td class=\"indent1\">Leflunomide</td> <td>Body weight:<br /> &#60;20 kg: 10 mg orally every other day<br /> 20 to 40 kg: 10 mg orally daily<br /> &#62;40 kg: 20 mg orally daily</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Third-line agents in uveitis</td> </tr> <tr> <td class=\"sublist2\">Mycophenolate mofetil<sup>&#182;</sup></td> <td class=\"sublist_other\">12 to 18 mg/kg or 600 mg/m<sup>2</sup> orally twice per day, maximum 3 g/day<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Cyclosporine (microemulsion)</td> <td class=\"sublist_other\">1.5 to 2.5 mg/kg orally twice per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Azathioprine</td> <td class=\"sublist_other\">1 to 2 mg/kg orally once per day or in two equal divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tumor necrosis factor (TNF) inhibitors</td> </tr> <tr> <td class=\"indent1\">Adalimumab</td> <td>Body weight:<br /> 15 to 30 kg: 20 mg subcutaneously every two weeks<br /> &#8805;30 kg: 40 mg subcutaneously every two weeks (may escalate to weekly for partial response)</td> </tr> <tr> <td class=\"indent1\">Etanercept</td> <td>0.8 mg/kg (maximum 50 mg) subcutaneously weekly</td> </tr> <tr> <td class=\"indent1\">Infliximab</td> <td>5 to 10 mg/kg intravenously every four to eight weeks (after loading doses)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Anti-TNF agents without pediatric indication</td> </tr> <tr> <td class=\"sublist2\">Certolizumab</td> <td class=\"sublist_other\">200 mg subcutaneously every two weeks (after loading doses)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Golimumab</td> <td class=\"sublist_other\">50 mg subcutaneously monthly</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">CTLA4-Ig (T cell costimulatory blocker)</td> </tr> <tr> <td class=\"indent1\">Abatacept</td> <td>10 mg/kg (maximum 1000 mg) intravenously every four weeks</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>NOTE: Treatment should be performed by clinicians who are experienced in the use, monitoring, adjustment, and drug interactions of these agents because of the potential toxicity of these drugs/combinations and the unpredictability of the disease.</strong></div><div class=\"graphic_footnotes\">* Subcutaneous administration is suggested for methotrexate doses &gt;10 mg/m<sup>2</sup> since oral absorption decreases with higher doses.<br />&para; Mycophenolate mofetil dosing shown is for immediate release oral preparation. Dose adjustment is required for conversion to the delayed-release oral preparation.</div><div id=\"graphicVersion\">Graphic 64063 Version 6.0</div></div></div>"},"64065":{"type":"graphic_figure","displayName":"Sources of CVC infection","title":"Sources of intravenous catheter-related infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sources of intravenous catheter-related infection</div><div class=\"cntnt\"><img style=\"width:366px; height:438px;\" src=\"images/ID/64065_Sources_of_CVC_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Major sources of intravenous catheter-related infection include skin colonization with migration of microorganisms along intracutaneous tract (wound infection or infection of fibrin sheath); intraluminal colonization of device or hub; hematogenous seeding from remote focus elsewhere (infection of fibrin sheath); or the delivery of contaminated infusate.</div><div id=\"graphicVersion\">Graphic 64065 Version 1.0</div></div></div>"},"64066":{"type":"graphic_table","displayName":"Drugs for hypertensive emergencies","title":"Parenteral drugs for treatment of hypertensive emergencies in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral drugs for treatment of hypertensive emergencies in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose range</td> <td class=\"subtitle1\">Onset of action (minutes)</td> <td class=\"subtitle1\">Duration of action (minutes)</td> <td class=\"subtitle1\">Adverse effects<sup>&#182;</sup></td> <td class=\"subtitle1\">Role<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Vasodilators</td> </tr> <tr> <td class=\"indent1\">Clevidipine</td> <td> <p>Initially 1 to 2 mg/hour as IV infusion with rapid titration.</p> <p>Most patients respond to 4 to 6 mg/hour and are treated with maximum doses of 16 mg/hour or less.</p> NOTE: Delivered in lipid emulsion. 1000 mL maximum per 24 hours (equivalent to 21 mg/hour) due to lipid load.</td> <td>2 to 4</td> <td>5 to 15</td> <td>Atrial fibrillation, nausea, lipid formulation contains potential allergens (eg, soy, egg)</td> <td>Hypertensive emergencies including postoperative hypertension.</td> </tr> <tr> <td class=\"indent1\">Enalaprilat</td> <td>1.25 to 5 mg every six hours IV</td> <td>15 to 30</td> <td>approximately 6 to &#62;12 hours</td> <td>Precipitous fall in pressure in high-renin states; variable response, headache, dizziness</td> <td> <p>Acute left ventricular failure.</p> <p>Due to slow onset and long duration of effect, rarely used.</p> Avoid use in AMI, renal impairment, or pregnancy.</td> </tr> <tr> <td class=\"indent1\">Fenoldopam</td> <td>Initially 0.1 mcg/kg per minute<sup>&#9674;</sup> as IV infusion titrated to a maximum of 1.6 mcg/kg per minute</td> <td>5 to 10</td> <td>30 to 60</td> <td>Tachycardia, headache, nausea, flushing</td> <td> <p>Most hypertensive emergencies.</p> Use caution or avoid with glaucoma or increased intracranial pressure.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hydralazine</td> <td>10 to 20 mg IV</td> <td>10 to 20 IV</td> <td>1 to &#8805;4 hours IV</td> <td rowspan=\"2\">Sudden precipitous drop in blood pressure, tachycardia, flushing, headache, vomiting, aggravation of angina</td> <td rowspan=\"2\"> <p>In general, hydralazine should be avoided due to its prolonged and unpredictable hypotensive effect.</p> Labetalol and nicardipine are generally preferred choices for treatment of eclampsia.</td> </tr> <tr> <td>10 to 40 mg IM</td> <td>20 to 30 IM</td> <td>4 to 6 hours IM</td> </tr> <tr> <td class=\"indent1\">Nicardipine</td> <td> <p>5 to 15 mg/hour as IV infusion.</p> Some patients may require up to 30 mg/hour.</td> <td>5 to 15</td> <td>approximately 1.5 to &#8805;4 hours</td> <td>Tachycardia, headache, dizziness, nausea, flushing, local phlebitis, edema</td> <td> <p>Most hypertensive emergencies, including pregnancy induced.</p> <p>Avoid use in acute heart failure.</p> Caution with coronary ischemia.</td> </tr> <tr> <td class=\"indent1\">Nitroglycerin (glyceryl trinitrate)</td> <td>5 to 100 mcg/minute as IV infusion</td> <td>2 to 5</td> <td>5 to 10</td> <td>Hypoxemia, tachycardia (reflex sympathetic activation), headache, vomiting, flushing, methemoglobinemia, tolerance with prolonged use</td> <td>Potential adjunct to other IV antihypertensive therapy in patients with coronary ischemia (ACS) or acute pulmonary edema.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nitroprusside</td> <td> <p>0.25 to 10 mcg/kg per minute as IV infusion.</p> <p>To minimize risk of cyanide toxicity, infusion duration should be as short as possible and not exceed 2 mcg/kg per minute.</p> Patients who receive higher doses (ie, &#62;500 mcg/kg at a rate exceeding 2 mcg/kg per minute) should receive sodium thiosulfate infusion to avoid cyanide toxicity.</td> <td>0.5 to 1</td> <td>1 to 10</td> <td>Elevated intracranial pressure, decreased cerebral blood flow, reduced coronary blood flow in CAD, cyanide and thiocyanate toxicity, nausea, vomiting, muscle spasm, flushing, sweating</td> <td> <p>In general, nitroprusside should be avoided due to its toxicity.</p> Nitroprusside should be avoided in patients with AMI, CAD, CVA, elevated intracranial pressure, renal impairment, or hepatic impairment.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Adrenergic inhibitors</td> </tr> <tr> <td class=\"indent1\">Esmolol</td> <td>250 to 500 mcg/kg loading dose over one minute; then initiate IV infusion at 25 to 50 mcg/kg per minute; titrate incrementally up to maximum of 300 mcg/kg per minute</td> <td>1 to 2</td> <td>10 to 30</td> <td>Nausea, flushing, bronchospasm, first-degree heart block, infusion-site pain; half-life prolonged in setting of anemia</td> <td> <p>Perioperative hypertension.</p> Avoid use in acute decompensated heart failure.</td> </tr> <tr> <td class=\"indent1\">Labetalol</td> <td> <p>Initial bolus of 20 mg IV followed by 20 to 80 mg IV bolus every 10 minutes (maximum 300 mg)</p> <strong>or </strong><br /> 0.5 to 2 mg/minute as IV loading infusion following an initial 20 mg IV bolus (maximum 300 mg)</td> <td>5 to 10</td> <td>2 to 4 hours</td> <td>Nausea/vomiting, paresthesias (eg, scalp tingling), bronchospasm, dizziness, nausea, heart block</td> <td> <p>Most hypertensive emergencies including myocardial ischemia, hypertensive encephalopathy, pregnancy, and postoperative hypertension.</p> <p>Avoid use in acute decompensated heart failure.</p> Use cautiously in obstructive or reactive airway.</td> </tr> <tr> <td class=\"indent1\">Metoprolol</td> <td>Initially 1.25 to 5 mg IV followed by 2.5 to 15 mg IV every three to six hours</td> <td>20</td> <td>5 to 8 hours</td> <td>Refer to labetalol</td> <td> <p>Myocardial ischemia, perioperative hypertension.</p> Avoid use in acute decompensated heart failure.</td> </tr> <tr> <td class=\"indent1\">Phentolamine</td> <td>5 to 15 mg IV bolus every 5 to 15 minutes</td> <td>1 to 2</td> <td>10 to 30</td> <td>Tachycardia, flushing, headache, nausea/vomiting</td> <td>Alternative option for catecholamine excess (eg, adrenergic crisis secondary to pheochromocytoma or cocaine overdose).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous&nbsp;injection; AMI: acute myocardial infarction; IM: intramuscular injection; ACS: acute coronary syndrome; CAD: coronary artery disease; CVA: cerebrovascular accident.<br />* The treatment of acute aortic syndromes (eg, acute aortic dissection, aortic intramural hematoma) requires specific medication management to minimize disease extension and is presented separately.&nbsp;Refer to&nbsp;UpToDate topics discussing acute aortic syndromes and acute aortic dissection.<br />Â¶ Hypotension may occur with all agents. <br />Î&nbsp;IV short-acting agents for treatment of hypertensive emergency should be administered immediately by clinicians who are trained and experienced in their titration using continuous noninvasive electronic monitoring of blood pressure, heart rate, and cardiac rhythm. Patients should be admitted to an intensive care unit as rapidly as possible. A combination of IV agents is often selected depending upon the acute indication. Refer to appropriate UpToDate clinical topic&nbsp;for suggested combinations.<br />â&nbsp;Initial fenoldopam doses in range of 0.01 to 0.3 mcg/kg per minute have been described.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Marik PE, Varon J. Hypertensive crises: Challenges and management. Chest 2007; 131:1949.</li>&#xD;&#xA;    <li>Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206.</li>&#xD;&#xA;    <li>Varon J. Treatment of acute severe hypertension: Current and newer agents. Drugs 2008; 68:283.</li>&#xD;&#xA;</ol>&#xD;&#xA;NOTE: Recommendations for parenteral treatment of hypertensive emergencies were not given in either the JNC 8 guideline (James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee [JNC 8]. JAMA 2014; 311:507) or the Joint ASH/ISH guidelines (Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension [ASH/ISH]. J Hypertens 2014; 32:3).</div><div id=\"graphicVersion\">Graphic 64066 Version 33.0</div></div></div>"},"64067":{"type":"graphic_table","displayName":"Patch breakthru bleeding","title":"Breakthrough bleeding and breakthrough bleeding/spotting by cycle","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breakthrough bleeding and breakthrough bleeding/spotting by cycle</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\">Non-comparative trial</td> <td class=\"subtitle1\" colspan=\"2\">Comparative trial</td> </tr> <tr> <td class=\"subtitle2\">Patch* (N = 1664), percent</td> <td class=\"subtitle2\">Patch* (N = 812), percent</td> <td class=\"subtitle2\">OC<sup>&#182;</sup> (N = 605), percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Breakthrough bleeding </td> </tr> <tr> <td class=\"indent2\">Cycle 1</td> <td>3.7</td> <td>3.7</td> <td>4.2</td> </tr> <tr> <td class=\"indent2\">Cycle 3</td> <td>3.7</td> <td>2.9</td> <td>4.5</td> </tr> <tr> <td class=\"indent2\">Cycle 6</td> <td>2.5</td> <td>2.7</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Cycle 9</td> <td>1.5</td> <td>1.3</td> <td>3.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Cycle 13</td> <td>1.7</td> <td>0</td> <td>2.4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Breakthrough bleeding and/or spotting</td> </tr> <tr> <td class=\"indent2\">Cycle 1</td> <td>17.5</td> <td>18.3</td> <td>11.4</td> </tr> <tr> <td class=\"indent2\">Cycle 3</td> <td>11.1</td> <td>10</td> <td>8.8</td> </tr> <tr> <td class=\"indent2\">Cycle 6 </td> <td>7.3</td> <td>9.5</td> <td>7.1</td> </tr> <tr> <td class=\"indent2\">Cycle 9</td> <td>6.5</td> <td>6.7</td> <td>4.6</td> </tr> <tr> <td class=\"indent2\">Cycle 13</td> <td>9.2</td> <td>5.5</td> <td>7.1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patch: transdermal contraceptive patch.<br />&para; OC: oral contraceptive (triphasic preparation with levonorgestrel as progestin).</div><div class=\"graphic_reference\">Adapted with permission from: Burkman, RT. The transdermal contraceptive patch: a new approach to hormonal contraception. Int J Fertil Womens Med. 2002; 47(2): 69-76. Copyright &copy; 2002 MSP International, Inc.</div><div id=\"graphicVersion\">Graphic 64067 Version 2.0</div></div></div>"},"64069":{"type":"graphic_table","displayName":"Specific anogential findings","title":"Anogenital findings specific for trauma in the evaluation of child sexual abuse*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anogenital findings specific for trauma in the evaluation of child sexual abuse*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Moderate specificity for abuse</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Acute lacerations or extensive bruising of the labia,\nperi-hymenal tissues, scrotum, or perineum (may be from unwitnessed\naccidental trauma)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Scar of posterior fourchette (the assessment of scars\nis difficult unless there was documentation of acute injury at the same\nsite)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Fresh laceration of the posterior fourchette, not\ninvolving the hymen (must be differentiated from dehisced labial\nadhesion or failure of midline fusion; may be caused by accidental\ninjury)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Perianal scar not in the midline (the assessment of\nscars is difficult unless there was documentation of acute injury at\nthe same site; may be due to other medical conditions such as Crohn's\ndisease, or previous medical procedures)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">High specificity for\nabuse</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Acute laceration of the hymen (partial or complete)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Ecchymosis (bruising) of the hymen</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Perianal lacerations extending deep to the external\nanal sphincter (not to be confused with partial failure of midline\nfusion)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Hymenal transection (healed) (ie, an area where there\nis no hymenal tissue remaining between the vaginal wall and the fossa\nor vestibular wall [also called a complete cleft]. The finding should\nbe confirmed using additional examination techniques such as a swab,\nprone knee-chest position, Foley catheter, water to float the edge of\nthe hymen)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Absence of hymenal tissue (wide areas in the\nposterior/inferior half of the hymenal rim with an absence of hymenal\ntissue, extending to the base of the hymen, which is confirmed using\nadditional positioning or other methods)</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table></div><div class=\"graphic_footnotes\">*Findings which, in the absence of a clear, timely, plausible history of accidental injury, should be reported to child protective services.&lt;span style=&quot;font-style: italic;&quot;&gt;</div><div class=\"graphic_reference\">Adapted from Adams, JA. Medical evaluation of suspected child sexual abuse. J Pediatr Adolesc Gynecol 2004; 17:191.</div><div id=\"graphicVersion\">Graphic 64069 Version 1.0</div></div></div>"},"64072":{"type":"graphic_picture","displayName":"Proximal wasting in Cushings","title":"Proximal muscle wasting in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal muscle wasting in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:208px; height:324px;\" src=\"images/ENDO/64072_Proximal_wasting_in_Cushing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">37-year-old man with Cushing's disease who followed a rigorous diet and exercise program. There is no overall weight gain and minimal centripetal redistribution of fat; however, proximal muscle (deltoid) wasting was evident.</div><div class=\"graphic_reference\">Reproduced with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 64072 Version 2.0</div></div></div>"},"64074":{"type":"graphic_waveform","displayName":"Advanced case 11","title":"Advanced case 11","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 11</div><div class=\"cntnt\"><img style=\"width:540px; height:244px;\" src=\"images/CARD/64074_Advanced_case_11.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64074 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"64075":{"type":"graphic_table","displayName":"LMW heparin pediatric doses","title":"Low molecular weight heparin and dose adjustment in pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low molecular weight heparin and dose adjustment in pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Age-dependent dose of enoxaparin</td> </tr> <tr> <td class=\"subtitle2\">&#60;2 months</td> <td class=\"subtitle2\">&#8805;2 months</td> </tr> <tr> <td><strong>Initial treatment dose</strong></td> <td>1.5 mg/kg/dose*<sup>&#916;</sup> every 12 hours</td> <td>1 mg/kg/dose*<sup>&#9674;</sup> every 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Prophylactic dose</strong></td> <td>0.75 mg/kg/dose every 12 hours</td> <td>0.5 mg/kg/dose every 12 hours</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Weight-dependent dose of dalteparin</td> </tr> <tr> <td><strong>Initial treatment dose</strong></td> <td colspan=\"2\">129 &#177; 43 units/kg*<sup>&#167;</sup> every 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Prophylactic dose</strong></td> <td colspan=\"2\">92 &#177; 52 units/kg every 24 hours</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Age-dependent dose of tinzaparin</td> </tr> <tr> <td class=\"subtitle2\">&#60;2 months</td> <td class=\"subtitle2\">&#8805;2 months</td> </tr> <tr> <td><strong>Initial treatment dose</strong></td> <td>275 units/kg* every 24 hours</td> <td> <ul> <li>2 to 12 months: 250 units/kg* </li> <li>1 to 5 years: 240 units/kg </li> <li>5 to 10 years: 200 units/kg </li> <li>10 to 16 years: 175 units/kg<sup>&#167;</sup> </li> </ul> These doses are given every 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Prophylactic dose</strong></td> <td>Not available</td> <td>Not available</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Weight-dependent dose of reviparin<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle2\">&#60;5 kg</td> <td class=\"subtitle2\">&#8805;5 kg</td> </tr> <tr> <td><strong>Initial treatment dose</strong></td> <td>150 units/kg/dose* every 12 hours</td> <td>100 units/kg/dose* every 12 hours</td> </tr> <tr> <td><strong>Prophylactic dose</strong></td> <td>50 units/kg/dose every 12 hours</td> <td>30 units/kg/dose every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For therapeutic <STRONG>treatment</STRONG>, the dose is adjusted as needed to achieve anti-Factor Xa levels between 0.5 and 1 units/mL in samples taken four to six hours after the last subcutaneous injection. For <STRONG>prophylaxis</STRONG>, there is no need for monitoring or dose adjustment. All doses are given subcutaneously.<SUP>[1]</SUP><BR>Î For enoxaparin, can also use 1.75 mg/kg/dose for term infants and 2 mg/kg/dose for preterm infants, if therapeutic level is desired with less dose adjustment.<SUP>[2,3]</SUP> 1 mg enoxaparin = 100 anti Xa units (approximately).<BR><FONT class=lozenge>â</FONT> For obese patients treated with enoxaparin, it is reasonable to use initial enoxaparin doses based on actual body weight (rather than doses based on ideal body weight).<SUP>[4]</SUP> Doses should be adjusted based on anti-factor Xa levels, as for all patients.<BR>Â§ For tinzaparin and dalteparin, we use a maximum of 18,000 units initial treatment dose for heavier patients, but we then adjust this up or down as needed to achieve target anti-Factor Xa levels.<BR>Â¥ Reviparin is not currently available in the United States.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.</li>&#xD;&#xA;    <li>Malowany JI, Monagle P, Knoppert DC, et al. Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates. Thromb Res 2008; 122:826. </li>&#xD;&#xA;    <li>Sanchez de Toledo J, Gunawardena S, Munoz R, et al. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? Cardiol Young 2010; 20:138.</li>&#xD;&#xA;    <li>Richard AA, Kim S, Moffett BS, et al. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr 2012; 162:293.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64075 Version 13.0</div></div></div>"},"64077":{"type":"graphic_diagnosticimage","displayName":"Central bronchiectasis in ABPA CT","title":"Central bronchiectasis in allergic bronchopulmonary aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central bronchiectasis in allergic bronchopulmonary aspergillosis</div><div class=\"cntnt\"><img style=\"width:349px; height:301px;\" src=\"images/PULM/64077_Central_bronchiectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central bronchiectasis in a patient with allergic bronchopulmonary aspergillosis. Multiple dilated third and fourth generation bronchi are seen. Smaller peripheral bronchi filled with mucus account for the branching linear opacities in the distal lung parenchyma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64077 Version 3.0</div></div></div>"},"64078":{"type":"graphic_table","displayName":"Guidelines for lung cancer screening","title":"Guidelines for lung cancer screening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for lung cancer screening</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"70%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organization</td> <td class=\"subtitle1\">Recommendation</td> <td class=\"subtitle1\">Year</td> </tr> <tr> <td>American Academy of Family Physicians</td> <td>Concludes that evidence is insufficient to recommend for or against low-dose CT scan screening in persons at high risk for lung cancer based on age and smoking history.</td> <td class=\"centered\">2013</td> </tr> <tr> <td>American Association of Thoracic Surgery</td> <td>Recommends annual low-dose CT scan screening for high-risk individuals (ages 55 to 79 years with 30 pack-year history of smoking and current smoker or quit within past 15 years) or age 50 with cumulative risk &#62;5% over next five years.</td> <td class=\"centered\">2012</td> </tr> <tr> <td>American Cancer Society</td> <td>Recommends annual low-dose CT scan screening for high-risk individuals (ages 55 to 74 years with 30 pack-year history of smoking and current smoker or quit within past 15 years). Informed individual decision-making before testing.</td> <td class=\"centered\">2013</td> </tr> <tr> <td>American College of Chest Physicians/American Society of Clinical Oncology</td> <td>Recommends annual low-dose CT scan screening for high-risk individuals (ages 55 to 74 years with 30 pack-year history of smoking and current smoker or quit within past 15 years).</td> <td class=\"centered\">2012</td> </tr> <tr> <td>Canadian Task Force on the Periodic Health Examination</td> <td>Recommends screening asymptomatic adults aged 55 to 74 years with at least a 30 pack-year smoking history who smoke or quit smoking &#60;15 years ago with low-dose CT every year for three consecutive years.</td> <td class=\"centered\">2016</td> </tr> <tr> <td>National Comprehensive Cancer Network</td> <td>Recommends annual low-dose CT scan screening for high-risk individuals (ages 55 to 74 years with &#8805;30 pack-year history of smoking or if no longer smoking, smoking cessation within 15 years or age &#8805;50 years with a 20 pack-year history of smoking with one additional risk factor.</td> <td class=\"centered\">2015</td> </tr> <tr> <td>US Preventive Services Task Force</td> <td>Recommends annual low-dose CT scan screening for high-risk individuals (ages 55 to 80 years with a 30 pack-year history of smoking and current smoker or quit within past 15 years). Discontinue when person has not smoked for 15 years or if limited life expectancy.</td> <td class=\"centered\">2013</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 64078 Version 13.0</div></div></div>"},"64079":{"type":"graphic_table","displayName":"Appropriate prescribing in the elderly","title":"Appropriate prescribing in the elderly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Appropriate prescribing in the elderly</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Is there an indication for the drug?</td> </tr> <tr> <td>2. Is the medication effective for the condition?</td> </tr> <tr> <td>3. Is the dosage correct?</td> </tr> <tr> <td>4. Are the directions correct?</td> </tr> <tr> <td>5. Are the directions practical?</td> </tr> <tr> <td>6. Are there clinically significant drug-drug interactions?</td> </tr> <tr> <td>7. Are there clinically significant drug-disease/condition interactions?</td> </tr> <tr> <td>8. Is there unnecessary duplication with other drugs?</td> </tr> <tr> <td>9. Is the duration of therapy acceptable?</td> </tr> <tr> <td>10. Is this drug the least expensive alternative compared with others of equal usefulness?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992; 45:1045. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64079 Version 2.0</div></div></div>"},"64080":{"type":"graphic_table","displayName":"Intraoperative PTH monitoring - Criteria used to guide surgery","title":"Intraoperative PTH monitoring - Criteria used to guide surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intraoperative PTH monitoring - Criteria used to guide surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Investigators</td> <td class=\"subtitle1\">IPM criteria</td> </tr> <tr> <td>Irvin<sup>[1-5]</sup><br /> Micolli<sup>[6]</sup><br /> Vignali<sup>[7]</sup><br /> </td> <td>&#62;50 percent PTH drop from the highest baseline at 10 minutes after gland excision</td> </tr> <tr class=\"divider_top\"> <td>Gordon<sup>[8]</sup><br /> Johnson<sup>[9]</sup><br /> Agarwal<sup>[10]</sup><br /> Gauger<sup>[11]</sup><br /> Miura<sup>[12]</sup><br /> Perrier<sup>[13]</sup><br /> Libutti<sup>[14]</sup><br /> Riss<sup>[15]</sup><br /> </td> <td>&#62;50 percent PTH drop from pre-incision at 10 minutes after gland excision</td> </tr> <tr class=\"divider_top\"> <td>Burkey<sup>[16]</sup><br /> Yang<sup>[17]</sup><br /> Chiu<sup>[18]</sup><br /> Carty<sup>[19]</sup><br /> </td> <td>&#62;50 percent PTH drop from baseline level and a return to normal range 10 minutes after gland excision</td> </tr> <tr class=\"divider_top\"> <td>Irvin<sup>[20]</sup></td> <td>&#62;50 percent PTH drop from highest baseline level and below pre-incision 10 minutes after gland excision</td> </tr> <tr class=\"divider_top\"> <td>Weber<sup>[21]</sup></td> <td>&#62;50 percent PTH drop from pre-excision at 10 minutes after gland excision</td> </tr> <tr class=\"divider_top\"> <td>Their<sup>[22]</sup></td> <td>&#62;50 percent PTH drop in 5 minutes or &#62;60 percent PTH drop from baseline at 15 minutes after gland excision</td> </tr> <tr class=\"divider_top\"> <td>Di Stasio<sup>[23]</sup></td> <td>&#62;50 percent PTH drop and return to normal range in 20 minutes</td> </tr> <tr class=\"divider_top\"> <td>Lupoli<sup>[24]</sup></td> <td>&#62;70 percent PTH drop from baseline 10 minutes after gland excision</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTH: parathyroid hormone.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999; 229:874. </li> <li>Irvin GL 3rd, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg 2004; 239:704. </li> <li>Carneiro DM, Solorzano CC, Irvin GL 3rd. Recurrent disease after limited parathyroidectomy for sporadic primary hyperparathyroidism. J Am Coll Surg 2004; 199:849. </li> <li>Carneiro DM, Solorzano CC, Nader MC, Ramirez M, Irvin GL 3rd. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 2003; 134:973. </li> <li>Carneiro DM, Irvin GL 3rd. Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration. Surgery 2000; 128:925. </li> <li>Miccoli P, Berti P, Materazzi G, Ambrosini CE, Fregoli L, Donatini G. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: A prospective randomized trial. Surg Endosc 2008; 22:398. </li> <li>Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol 2002; 146:783. </li> <li>Gordon LL, Snyder WH 3rd, Wians F Jr, Nwariaku F, Kim LT. The validity of quick intraoperative parathyroid hormone assay: an evaluation in seventy-two patients based on gross morphologic criteria. Surgery 1999; 126:1030. </li> <li>Johnson LR, Doherty G, Lairmore T, et al. Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy. Clin Chem 2001; 47:919. </li> <li>Agarwal G, Barakate MS, Robinson B, et al. Intraoperative quick parathyroid hormone versus same-day parathyroid hormone testing for minimally invasive parathyroidectomy: a cost-effectiveness study. Surgery 2001; 130:963. </li> <li>Gauger PG, Agarwal G, England BG, et al. Intraoperative parathyroid hormone monitoring fails to detect double parathyroid adenomas: a 2-institution experience. Surgery 2001; 130:1005. </li> <li>Miura D, Wada N, Arici C, Morita E, Duh QY, Clark OH. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg 2002; 26:926. </li> <li>Perrier ND, Ituarte PH, Morita E, et al. Parathyroid surgery: separating promise from reality. J Clin Endocrinol Metab 2002; 87:1024. </li> <li>Libutti SK, Alexander HR, Bartlett DL, et al. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery 1999; 126:1145. </li> <li>Riss P, Kaczirek K, Heinz G, Bieglmayer C, Niederle B. A &quot;defined baseline&quot; in PTH monitoring increases surgical success in patients with multiple gland disease. Surgery 2007; 142:398. </li> <li>Burkey SH, Van Heerden JA, Farley DR, Thompson GB, Grant CS, Curlee KJ. Will directed parathyroidectomy utilizing the gamma probe or intraoperative parathyroid hormone assay replace bilateral cervical exploration as the preferred operation for primary hyperparathyroidism? World J Surg 2002; 26:914. </li> <li>Yang GP, Levine S, Weigel RJ. A spike in parathyroid hormone during neck exploration may cause a false-negative intraoperative assay result. Arch Surg 2001; 136:945. </li> <li>Chiu B, Sturgeon C, Angelos P. Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients. Arch Surg 2006; 141:483. </li> <li>Carty SE, Worsey J, Virji MA, Brown ML, Watson CG. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery 1997; 122:1107. </li> <li>Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999; 229:874. </li> <li>Weber CJ, Ritchie JC. Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration. Surgery 1999; 126:1139. </li> <li>Thier M, Nordenstrom E, Bergenfelz A, Westerdahl J. Surgery for patients with primary hyperparathyroidism and negative sestamibi scintigraphy--a feasibility study. Langenbecks Arch Surg 2009; 394:881. </li> <li>Di Stasio E, Carrozza C, Pio Lombardi C, et al. Parathyroidectomy monitored by intra-operative PTH: the relevance of the 20 min end-point. Clin Biochem 2007; 40:595. </li> <li>Lupoli GA, Fonderico F, Panico A, et al. Stricter criteria increase the validity of a quick intraoperative parathyroid hormone assay in primary hyperparathyroidism. Med Sci Monit 2009; 15:CR111. </li> </ol></div><div id=\"graphicVersion\">Graphic 64080 Version 5.0</div></div></div>"},"64081":{"type":"graphic_diagnosticimage","displayName":"Brain MRI eight-month-old with Krabbe disease","title":"Brain MRI of an eight-month-old infant with Krabbe disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of an eight-month-old infant with Krabbe disease</div><div class=\"cntnt\"><img style=\"width:450px; height:581px;\" src=\"images/NEURO/64081_Brain_MRI_8_month_Krabbe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI of an infant age&nbsp;eight months showing classic cerebellar/dentate abnormalities (A). There is increased signal involving the periventricular and deep cerebral white matter (B and C).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Dr. Patricia Duffner.</div><div id=\"graphicVersion\">Graphic 64081 Version 4.0</div></div></div>"},"64084":{"type":"graphic_table","displayName":"Sites of Pasteurella infection","title":"Spectrum of infections caused by <EM>Pasteurella multocida</EM>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of infections caused by <EM>Pasteurella multocida</EM></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organ infected </td> <td class=\"subtitle1\">Specific infections </td> <td class=\"subtitle1\">Most common <em>Pasteurella</em> exposure </td> </tr> <tr> <td>Skin and soft tissue</td> <td> <p>Cellulitis</p> <p>Lymphangitis</p> <p>Subcutaneous abscess</p> <p>Infected decubitus or stasis ulcer</p> <p>Breast implant infection</p> <p>Surgical wound infection</p> <p>Necrotizing fasciitis</p> <p>Psoas abscess</p> </td> <td> <p>Cat bite, scratch, or lick</p> <p>Dog bite or lick</p> </td> </tr> <tr> <td>Bone or joint</td> <td> <p>Septic arthritis</p> <p>Osteomyelitis</p> <p>Septic arthritis with osteomyelitis</p> <p>Septic arthritis of knee or hip arthroplasty</p> <p>Bursitis</p> <p>Tenosynovitis</p> <p>Dental follicle</p> </td> <td> <p>Penetrating animal bite</p> <p>Distal bite or scratch in setting of abnormal joint</p> </td> </tr> <tr> <td>Respiratory tract</td> <td> <p>Pharyngitis, sinusitis, epiglottitis</p> <p>Tonsillitis, peritonsillar abscess</p> <p>Otitis media, mastoiditis</p> <p>Submandibular abscess</p> <p>Tracheobronchitis</p> <p>Pneumonia, lung abscess</p> <p>Empyema</p> <p>Glossitis, uvulitis</p> </td> <td>Non-bite animal exposure or no known exposure</td> </tr> <tr> <td>Cardiovascular system</td> <td> <p>Bacteremia, puerperal sepsis</p> <p>Endocarditis (native and prosthetic valves)</p> <p>Purulent pericarditis</p> <p>Mycotic aneurysm</p> <p>Infected vascular graft</p> </td> <td>Non-bite animal exposure or direct contact</td> </tr> <tr> <td>Central nervous system</td> <td> <p>Meningitis</p> <p>Brain abscess</p> <p>Subdural empyema</p> <p>Epidural abscess</p> </td> <td>Penetrating bite, direct contact, or non-bite exposure</td> </tr> <tr> <td>Gastrointestinal tract</td> <td> <p>Spontaneous bacterial peritonitis</p> <p>Omental or appendiceal abscess</p> <p>Peritonitis due to ruptured viscus</p> <p>Liver abscess</p> <p>Gastroenteritis</p> <p>Granulomatous hepatitis</p> <p>Peritonial dialysis-associated peritonitis</p> </td> <td>Non-bite animal exposure or no known contact</td> </tr> <tr> <td>Genitourinary tract</td> <td> <p>Cystitis or pyelonephritis</p> <p>Infected ileal loop</p> <p>Renal abscess</p> <p>Vaginitis, cervicitis</p> <p>Bartholin gland abscess</p> <p>Chorioamnionitis</p> <p>Epididymitis</p> <p>Tuboovarian abscess</p> <p>intrauterine device-associated endometritis</p> </td> <td>Non-bite animal exposure or no known contact</td> </tr> <tr> <td>Eyes</td> <td> <p>Conjunctivitis</p> <p>Corneal ulcer</p> <p>Endophthalmitis</p> </td> <td>Direct contact</td> </tr> <tr> <td>Miscellaneous</td> <td>Supportative thyroiditis</td> <td>Cat scratch</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Weber D, Wolfson JS, Swartz MN, Hooper DC. Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine 1984; 63:133.</LI>&#xD;&#xA;<LI>Klein NC, Cunha BA. Pasteurella multocida pneumonia. Semin Respir Infect 1997; 12:54.</LI></OL></div><div id=\"graphicVersion\">Graphic 64084 Version 4.0</div></div></div>"},"64085":{"type":"graphic_figure","displayName":"Pereira stitch","title":"Pereira stitch","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Pereira stitch</div><div class=\"cntnt\"><img style=\"width:514px; height:382px;\" src=\"images/OBGYN/64085_Pereira_stitch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pereira described a technique in which a series of transverse and longitudinal sutures of a delayed absorbable multifilament suture are placed around the uterus via a series of bites into the submucosal myometrium. Two or three rows of these sutures are placed in each direction to completely envelope and compress the uterus, similar to the way one might truss a stuffed roast. When the transverse sutures are brought through the broad ligament, care should be taken to avoid damaging blood vessels, ureters, and fallopian tubes. The longitudinal sutures begin and end at the last transverse suture nearest the cervix, and do not enter the uterine cavity. The myometrium should be manually compressed prior to tying down the sutures to facilitate maximal compression.</div><div class=\"graphic_reference\">Pereira, A, Nunes, F, Pedroso, S, et al. Compressive uterine sutures to treat postpartum bleeding secondary to uterine atony. Obstet Gynecol 2005; 106:569.</div><div id=\"graphicVersion\">Graphic 64085 Version 2.0</div></div></div>"},"64086":{"type":"graphic_picture","displayName":"IHC sentinel lymph node metast","title":"Immunohistochemical staining of melanoma metastasis within a sentinel lymph node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunohistochemical staining of melanoma metastasis within a sentinel lymph node</div><div class=\"cntnt\"><img style=\"width:372px; height:450px;\" src=\"images/ONC/64086_IHC_sentinel_lymph_node_met.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light photomicrographs of immunohistochemical stains for S-100 (top panel) and MART-1 (bottom panel) in a sentinel lymph node that has been counterstained with hematoxylin and eosin.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 64086 Version 2.0</div></div></div>"},"64087":{"type":"graphic_picture","displayName":"Diabetic foot ulcer 2 PI","title":"Full thickness diabetic foot ulcer and claw toe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full thickness diabetic foot ulcer and claw toe</div><div class=\"cntnt\"><img style=\"width:377px; height:211px;\" src=\"images/PI/64087_Diabetic_foot_ulcer_2_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foot from a diabetic patient with a penetrating neuropathic ulcer that is not associated with abscess formation or bone involvement (Wagner grade 2). The toes have been pulled anteriorly because the anterior tibial muscles are unopposed due to motor neuropathy-induced weakness of the intrinsic foot muscles. This promotes subluxation of the proximal interphalangeal-metatarsal joints, resulting in a claw toe appearance (arrow) and in increased pressure on the metatarsal heads, predisposing to ulcer formation at this site.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 64087 Version 2.0</div></div></div>"},"64088":{"type":"graphic_figure","displayName":"Pomeroy tubal ligation C","title":"Pomeroy tubal ligation C","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pomeroy tubal ligation C</div><div class=\"cntnt\"><img style=\"width:377px; height:380px;\" src=\"images/OBGYN/64088_PomeroytuballigationC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segment of tube being excised.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 64088 Version 1.0</div></div></div>"},"64089":{"type":"graphic_figure","displayName":"PML-RARa action","title":"PML-RARa action in acute promyelocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">PML-RARa action in acute promyelocytic leukemia</div><div class=\"cntnt\"><img style=\"width:542px; height:624px;\" src=\"images/HEME/64089_PML-RARa-action-NEW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute promyelocytic leukemia is characterized by a translocation involving the retinoic acid receptor-alpha (RARa) locus on chromosome 17. In over 90 percent of cases, there is a balanced translocation t(15;17)(q24.1;q21.1) involving the ubiquitously expressed PML gene on chromosome 15, resulting in a PML-RARa fusion protein. As shown in the upper diagram, this PML-RARa fusion protein forms a homodimer that binds to RARa target genes and acts with corepressors to block transcription of these genes. This results in blocked differentiation and enhanced self-renewal of the promyelocytes. As shown in the lower diagram, the addition of all-trans retinoic acid (ATRA) and/or arsenic trioxide results in degradation of the PML-RARa fusion protein and release of the corepressors. This allows the normal RARa to bind to target genes and promote transcription leading to differentiation of the promyelocyte to a mature granulocyte.</div><div id=\"graphicVersion\">Graphic 64089 Version 7.0</div></div></div>"},"64090":{"type":"graphic_diagnosticimage","displayName":"Ureteral stent on plain abdominal radiography","title":"Ureteral stent on plain abdominal radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteral stent on plain abdominal radiography</div><div class=\"cntnt\"><img style=\"width:294px; height:432px;\" src=\"images/SURG/64090_Uret_stent_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ureteral stents are placed endoscopically over a guidewire into the ureter. The proximal and distal curls (ie, pigtails) become apparent when the guidewire is removed. Proper positioning is indicated by placement of the proximal curl in the renal pelvis and distal curl in the bladder.</div><div id=\"graphicVersion\">Graphic 64090 Version 2.0</div></div></div>"},"64091":{"type":"graphic_diagnosticimage","displayName":"2D TTE RV outflow tract view","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the right ventricular (RV) outflow tract view showing the pulmonic valve and the pulmonary artery bifurcation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the right ventricular (RV) outflow tract view showing the pulmonic valve and the pulmonary artery bifurcation</div><div class=\"cntnt\"><img style=\"width:231px; height:269px;\" src=\"images/CARD/64091_Pulmonaryarterybifurcatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary artery (PA) bifurcation into the right (RPA) and left (LPA) pulmonary arteries can be seen in the short axis precordial view. Note that in this view, the LPA is proximal to the descending aorta (dAo).</div><div class=\"graphic_footnotes\">Ao: aorta; RVOT: right ventricular outflow tract; pv: pulmonic valve.</div><div id=\"graphicVersion\">Graphic 64091 Version 5.0</div></div></div>"},"64092":{"type":"graphic_picture","displayName":"Cutis marmorata telangiectatica congenita - arm","title":"Cutis marmorata telangiectatica congenita","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutis marmorata telangiectatica congenita</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/64092_Cutis_marm_telang_cong_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticular red patches with telangiectasias and focal atrophy are present on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64092 Version 3.0</div></div></div>"},"64093":{"type":"graphic_picture","displayName":"Bronchoscopy specimen trap","title":"Bronchoscopy specimen trap","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopy specimen trap</div><div class=\"cntnt\"><img style=\"width:336px; height:249px;\" src=\"images/PULM/64093_Bronchoscopyspectrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A specimen trap connected to the suction port of a flexible bronchoscope to collect bronchoalveolar lavage or washing fluid.</div><div id=\"graphicVersion\">Graphic 64093 Version 1.0</div></div></div>"},"64094":{"type":"graphic_table","displayName":"Anatomy of orbit","title":"Anatomy of the orbit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomy of the orbit</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle1\">Orbital structure</td>\r\n\t\t\t\t\t<td class=\"subtitle1\">Bones</td>\r\n\t\t\t\t\t<td class=\"subtitle1\">Associated structures</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Superior orbital rim, roof of orbit</td>\r\n\t\t\t\t\t\t<td>Frontal bone</td>\r\n\t\t\t\t\t\t<td>Frontal sinus, supraorbital nerve</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Lateral wall of orbit</td>\r\n\t\t\t\t\t\t<td>Sphenoid bone, zygoma</td>\r\n\t\t\t\t\t\t<td>Lateral canthal ligament</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Infraorbital rim and floor of orbit</td>\r\n\t\t\t\t\t\t<td>Zygoma, maxillary bone</td>\r\n\t\t\t\t\t\t<td>Inferior oblique and inferior rectus muscles, maxillary sinus, infraorbital nerve</td>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Medial wall of orbit</td>\r\n\t\t\t\t\t\t<td>Maxillary and ethmoid bones</td>\r\n\t\t\t\t\t\t<td>Medial rectus muscle, ethmoid sinus, medial canthal ligament, lacrimal duct system</td>\r\n\t\t\t\t\t\t\r\n\t\t\t\t</tr>\r\n\t\t\t</table></div><div id=\"graphicVersion\">Graphic 64094 Version 1.0</div></div></div>"},"64095":{"type":"graphic_diagnosticimage","displayName":"Radiographic findings of primary atrophic rhinosinusitis","title":"Radiographic findings of primary atrophic rhinosinusitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographic findings of primary atrophic rhinosinusitis</div><div class=\"cntnt\"><img style=\"width:321px; height:432px;\" src=\"images/ALLRG/64095_Atroph_rhin_exp_nasal_cavit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note expansion of nasal cavity (particularly on the left side), resorption of inferior turbinate bones, bowing of lateral nasal wall, and atrophy of nasal and turbinate mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: Chand MS, MacArthur CJ. Primary atrophic rhinitis: a summary of four cases and review of the literature. Otolaryngol Head Neck Surg 1997; 116:554. Copyright Â© 1997 Elsevier.</div><div id=\"graphicVersion\">Graphic 64095 Version 4.0</div></div></div>"},"64096":{"type":"graphic_figure","displayName":"Cholesteatoma extension","title":"Paths of extension by acquired cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paths of extension by acquired cholesteatoma</div><div class=\"cntnt\"><img style=\"width:417px; height:419px;\" src=\"images/ALLRG/64096_Cholesteatomaextension.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PS: posterior superior quadrant toward mastoid; PF: pars flaccida toward attic (pneumatized space just superior to the middle ear); TS: retraction at old tube site toward middle ear.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright Â© 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 64096 Version 15.0</div></div></div>"},"64098":{"type":"graphic_figure","displayName":"Skull growth and development","title":"Skull growth","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Skull growth</div><div class=\"cntnt\"><img style=\"width:558px; height:385px;\" src=\"images/PEDS/64098_Skull_growth_and_developmen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The brain grows from less than adult size to adult size within the first two years of life.</div><div id=\"graphicVersion\">Graphic 64098 Version 2.0</div></div></div>"},"64101":{"type":"graphic_diagnosticimage","displayName":"Lumbar radiograph in AS","title":"Lumbar vertebrae in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Lumbar vertebrae in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:497px; height:401px;\" src=\"images/RHEUM/64101_Lumbar_radiograph_in_AS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographs of lumbar vertebrae showing progressive disease in ankylosing spondylitis. Radiograph from 1940 (left panel) reveals &quot;shiny coiners&quot; (arrows) at anterior T11 and L2 vertebral bodies, an early sign of ankylosing spondylitis. A comparison of radiographs from 1940 and 1950 (right panel) also reveals progressive squaring of lumbar vertebrae. The 1950 radiograph demonstrates early development of a &quot;bamboo&quot; spine.</div><div class=\"graphic_reference\">Courtesy of Mark Robbins, MD.</div><div id=\"graphicVersion\">Graphic 64101 Version 2.0</div></div></div>"},"64106":{"type":"graphic_picture","displayName":"Fundus bowtie atrophy","title":"Bowtie atrophy","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Bowtie atrophy</div><div class=\"cntnt\"><img style=\"width:503px; height:216px;\" src=\"images/NEURO/64106_Fundus_bowtie_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundi showing temporal pallor of the left optic nerve (right) and a horizontal band of pallor (bowtie) in the right optic nerve (left).</div><div id=\"graphicVersion\">Graphic 64106 Version 2.0</div></div></div>"},"64107":{"type":"graphic_figure","displayName":"Time course thrombotic stroke","title":"Stuttering time course of thrombotic stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stuttering time course of thrombotic stroke</div><div class=\"cntnt\"><img style=\"width:384px; height:259px;\" src=\"images/NEURO/64107_Time_course_thrombotic_stro.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The course of weakness of the right limb in a patient with a thrombotic stroke reveals fluctuating symptoms, varying between normal and abnormal, progressing in a stepwise or stuttering fashion with some periods of improvement.</div><div id=\"graphicVersion\">Graphic 64107 Version 2.0</div></div></div>"},"64108":{"type":"graphic_table","displayName":"OARS community questionnaire","title":"OARS multidimensional functional assessment questionnaire: Community version","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">OARS multidimensional functional assessment questionnaire: Community version</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\" colspan=\"3\">Social resources</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">1. Are you single (never married), married, widowed, divorced, or separated?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">Single (never married)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">2</td>\r\n            <td colspan=\"2\">Married</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">3</td>\r\n            <td colspan=\"2\">Widowed</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">4</td>\r\n            <td colspan=\"2\">Divorced</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">5</td>\r\n            <td colspan=\"2\">Separated</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">2. Who lives with you?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Yes</td>\r\n            <td>No</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>No one</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Husband or wife</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Children</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Grandchildren</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Parents</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Grandparents</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Brothers and sisters</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Other relatives (does not include in-laws covered in the above categories)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Friends</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Non-related paid* helper</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&nbsp;&nbsp; 1</td>\r\n            <td>0</td>\r\n            <td>Other (specify):</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">3. How many people do you know well enough to visit with in their homes?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">3</td>\r\n            <td colspan=\"2\">Five or more</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">2</td>\r\n            <td colspan=\"2\">Three or four</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">One or two</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">0</td>\r\n            <td colspan=\"2\">None</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">4. About how many times did you talk to someone - friends, relatives, or others - on the telephone in the past week (either you called them or they called you)? (If subject has no phone, question still applies.)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">3</td>\r\n            <td colspan=\"2\">Once a day or more</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">2</td>\r\n            <td colspan=\"2\">Two to six times</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">Once</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">0</td>\r\n            <td colspan=\"2\">Not at all</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">5. How many times&nbsp;during the past week did you spend time with someone who does not live with you; that is, you went to see them or they came to visit you, or you went out to do things together?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">3</td>\r\n            <td colspan=\"2\">Once a day or more</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">2</td>\r\n            <td colspan=\"2\">Two to six times</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">Once</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">0</td>\r\n            <td colspan=\"2\">Not at all</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">6. Do you have someone you can trust and confide in?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">Yes</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">0</td>\r\n            <td colspan=\"2\">No</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">7. Do you find yourself feeling lonely quite often, sometimes, or almost never?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">0</td>\r\n            <td colspan=\"2\">Quite often</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">Sometimes</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">2</td>\r\n            <td colspan=\"2\">Almost never</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">8. Do you see your relatives and friends as often as you want to, or not?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">As often as wants to</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">0</td>\r\n            <td colspan=\"2\">Not as often as wants to</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">9. Is there someone outside this place who would give you any help at all if you were sick or disabled, for example your husband/wife, a member of your family, or a friend?</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">1</td>\r\n            <td colspan=\"2\">Yes</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">0</td>\r\n            <td colspan=\"2\">No one willing and able to help</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr>\r\n            <td colspan=\"3\">(If \"Yes\" ask a. <strong>and</strong> b.)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"3\"><strong>a. Is there anyone who would take care of you as long as needed, or only for a short time, or only someone who would help you now and then (for example, taking you to the doctor, or fixing lunch occasionally, etc)?</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">3</td>\r\n            <td colspan=\"2\">Someone who would take care of subject indefinitely (as long as needed)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">2</td>\r\n            <td colspan=\"2\">Someone who would take care of subject for a short time (a few weeks to six months)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">1</td>\r\n            <td colspan=\"2\">Someone who would help the subject now and then (taking him/her to the doctor or fixing lunch, etc)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">-</td>\r\n            <td colspan=\"2\">Not answered</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"3\"><strong>b. Who is this person?</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\" colspan=\"3\">Name:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\" colspan=\"3\">Relationship:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\" colspan=\"3\"><strong>Code:</strong> Spouse = 1, Sibling = 2, Offspring = 3, Grandchild = 4, Other kin = 5, Friend = 6, Other = 7</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=99628&#38;amp;Mode=Edit&quot;&#62;&#60;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&#62;Edit Table&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">* Includes free room.</div><div class=\"graphic_reference\">Copyright Â© 1975, 1988 Duke University, Center for the Study of Aging and Human Development. All rights reserved. May not be used for financial gain. When reporting on information gathered through this measure please acknowledge the source: Older Americans Resources and Services MFAQ. Permission for use in major studies should be obtained from the Duke Aging Center (see site address below). Further information can be obtained from the website: <A spellcheck=true href=\"https://sites.duke.edu/centerforaging/\" target=_blank>https://sites.duke.edu/centerforaging/</A>. Click on Services, then click on Older Americans ..., and from the manual referenced there.</div><div id=\"graphicVersion\">Graphic 64108 Version 3.0</div></div></div>"},"64109":{"type":"graphic_picture","displayName":"Melasma cheek","title":"Melasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melasma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64109_Melasma_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A mottled hyperpigmented patch is present on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64109 Version 6.0</div></div></div>"},"64110":{"type":"graphic_picture","displayName":"Inflammatory bowel disease colonic mucosa","title":"Inflammatory bowel disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory bowel disease</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/GAST/64110_Crohns_colonic_mucosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, a) Crohn disease. A prolific bacterial biofilm covers the colonic mucosa, multicolor FISH: Bacteroides is orange, Eubacterium rectale and Faecalibacterium prausnitzii are both red, all other groups are green. Despite close attachment to the mucosa, no bacteria can be found intracellularly in the columnar epithelium or submucosa.<br />(B) Ulcerative colitis, cytopathogenic effects of bacterial adhesion, with defects (ulcerations) of the epithelial layer and migration of bacteria into the submucosa. Despite the severe inflammation, the number of bacteria is reduced compared to regions without marked inflammation as shown in panels A/a (x1000).<br />(b) DAPI stain, only a few leukocytes are seen in the biofilm. A prolific biofilm without a leukocyte response is typical for inflammatory bowel disease patients treated with azathioprine.</div><div id=\"graphicVersion\">Graphic 64110 Version 5.0</div></div></div>"},"64111":{"type":"graphic_diagnosticimage","displayName":"EUS FNA small cell carcinoma","title":"Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of small cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of small cell carcinoma</div><div class=\"cntnt\"><img style=\"width:417px; height:341px;\" src=\"images/GAST/64111_EUS_FNA_small_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 68-year-old woman with a history of heavy tobacco use presented with three months of lethargy and progressive weight loss.<br />(Panel A) Chest CT revealed left posterior periesophageal mediastinal lymphadenopathy.<br />(Panel B) Endoscopic ultrasonography with fine needle aspiration (FNA) was requested. The needle tip can be seen entering the lymph node (LN) with the aorta adjacent to the biopsied lymph node.<br />(Panel C) Cytology demonstrated metastatic small cell carcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">From Norton ID, Wiersema MJ. Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography, Gress F, Bhattacharya I (Ed), Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 64111 Version 5.0</div></div></div>"},"64113":{"type":"graphic_table","displayName":"Presenting features NHL types","title":"Presenting features of common B and T-cell non-Hodgkin lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presenting features of common B and T-cell non-Hodgkin lymphomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"13\" width=\"6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Neoplasm</td> <td class=\"subtitle1\" rowspan=\"2\">Frequency*<sup>&#182;</sup></td> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" rowspan=\"2\">Male</td> <td class=\"subtitle1\" colspan=\"4\">Stage</td> <td class=\"subtitle1\" rowspan=\"2\">B Sx</td> <td class=\"subtitle1\" rowspan=\"2\">EN</td> <td class=\"subtitle1\" rowspan=\"2\">BM</td> <td class=\"subtitle1\" rowspan=\"2\">GI</td> <td class=\"subtitle1\" colspan=\"3\">IPI</td> </tr> <tr> <td class=\"subtitle2\">I</td> <td class=\"subtitle2\">II</td> <td class=\"subtitle2\">III</td> <td class=\"subtitle2\">IV</td> <td class=\"subtitle2\">0/1</td> <td class=\"subtitle2\">2/3</td> <td class=\"subtitle2\">4/5</td> </tr> <tr> <td>DLBCL</td> <td>31</td> <td>64</td> <td>55</td> <td>25</td> <td>29</td> <td>13</td> <td>33</td> <td>33</td> <td>71</td> <td>16</td> <td>18</td> <td>35</td> <td>46</td> <td>19</td> </tr> <tr> <td>Mediastinal DLBCL</td> <td>2</td> <td>37</td> <td>34</td> <td>10</td> <td>56</td> <td>3</td> <td>31</td> <td>38</td> <td>56</td> <td>3</td> <td>0</td> <td>52</td> <td>37</td> <td>11</td> </tr> <tr> <td>Follicular</td> <td>22</td> <td>59</td> <td>42</td> <td>18</td> <td>15</td> <td>16</td> <td>51</td> <td>28</td> <td>64</td> <td>42</td> <td>4</td> <td>45</td> <td>48</td> <td>7</td> </tr> <tr> <td>SLL/CLL</td> <td>6</td> <td>65</td> <td>53</td> <td>4</td> <td>5</td> <td>8</td> <td>83</td> <td>33</td> <td>80</td> <td>72</td> <td>3</td> <td>23</td> <td>64</td> <td>13</td> </tr> <tr> <td>MALT lymphoma</td> <td>5</td> <td>60</td> <td>48</td> <td>39</td> <td>28</td> <td>2</td> <td>31</td> <td>19</td> <td>98</td> <td>14</td> <td>50</td> <td>44</td> <td>48</td> <td>8</td> </tr> <tr> <td>Mantle cell</td> <td>6</td> <td>63</td> <td>74</td> <td>13</td> <td>7</td> <td>9</td> <td>71</td> <td>28</td> <td>81</td> <td>64</td> <td>9</td> <td>23</td> <td>54</td> <td>23</td> </tr> <tr> <td>Peripheral T-Cell</td> <td>6</td> <td>61</td> <td>55</td> <td>8</td> <td>12</td> <td>15</td> <td>65</td> <td>50</td> <td>82</td> <td>45</td> <td>15</td> <td>17</td> <td>52</td> <td>31</td> </tr> <tr> <td>ALCL</td> <td>2</td> <td>34</td> <td>69</td> <td>19</td> <td>32</td> <td>10</td> <td>39</td> <td>53</td> <td>59</td> <td>13</td> <td>9</td> <td>61</td> <td>18</td> <td>21</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BSx: B-symptoms; EN: involvement of any extranodal site, including bone marrow; BM: bone marrow involvement; Gl: gastrointestinal tract involvement; IPI: intemational prognosticindex; DLBCL: diffuse large B-cell lymphoma; SLL/CLL: small lymphocytic lymphoma/chronic lymphocytic leukemia; MALT: mucosa associated lymphoid tissue; ALCL: anaplastic large cell lymphoma.<br />* Percent of total cases.<br />Â¶ With the exception of median age at time of diagnosis, all numbers represent percent of patients with the listed feature.</div><div class=\"graphic_reference\">Data from: Armitage, JO, et al. J Clin Oncol 1998; 16:2780.</div><div id=\"graphicVersion\">Graphic 64113 Version 9.0</div></div></div>"},"64115":{"type":"graphic_figure","displayName":"Incidence of sepsis by race","title":"Population-adjusted incidence of sepsis, according to race, 1979 - 2000","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Population-adjusted incidence of sepsis, according to race, 1979 - 2000</div><div class=\"cntnt\"><img style=\"width:499px; height:335px;\" src=\"images/PULM/64115_Incidence_of_sepsis_by_race.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Points represent the annual incidence rate, and I bars the standard error.</div><div class=\"graphic_reference\">Data from: Martin, GS, Mannino, DM, Eaton, S, Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl Med 2003; 348:1546.</div><div id=\"graphicVersion\">Graphic 64115 Version 1.0</div></div></div>"},"64117":{"type":"graphic_table","displayName":"Masquerade syndromes uveitis","title":"Masquerade syndromes that mimic uveitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Masquerade syndromes that mimic uveitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Giant retinal tears</td>\n</tr>\n<tr>\n<td>Ischemia</td>\n</tr>\n<tr>\n<td>Leukemia</td>\n</tr>\n<tr>\n<td>Lymphoma</td>\n</tr>\n<tr>\n<td>Ocular melanoma</td>\n</tr>\n<tr>\n<td>Pigmentary dispersion syndrome</td>\n</tr>\n<tr>\n<td>Retinitis pigmentosa</td>\n</tr>\n<tr>\n<td>Retinoblastoma</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64117 Version 2.0</div></div></div>"},"64119":{"type":"graphic_picture","displayName":"Histology of EATL","title":"Histology of enteropathy-associated T cell lymphoma ","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Histology of enteropathy-associated T cell lymphoma </div><div class=\"cntnt\"><img style=\"width:512px; height:511px;\" src=\"images/HEME/64119_Histology_EATL_type_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The cells are large with irregularly shaped or angulated nuclei and a variable amount of cytoplasm (magnification, 250x). (B) The cells in this case expressed CD30 (magnification, 250x). The mucosa adjacent to the tumor had shortened villi (C; magnification, 100x) and &quot;top-heavy&quot; intra-epithelial infiltration by T cells (D; CD3 staining, magnification, 100x).</div><div class=\"graphic_reference\">This research was originally published in Blood. Delabie J, Harald H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood 2011; 118:148. Copyright Â© 2011 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 64119 Version 2.0</div></div></div>"},"64120":{"type":"graphic_diagnosticimage","displayName":"Liver calcifications","title":"Fetal liver calcifications","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal liver calcifications</div><div class=\"cntnt\"><img style=\"width:432px; height:366px;\" src=\"images/OBGYN/64120_Liver_calcifications.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of fetal abdomen shows multiple punctate liver calcifications without an associated mass.</div><div class=\"graphic_reference\">Reproduced with permission from: McNamara A, Levine D. Intraabdominal fetal echogenic masses: a practical guide to diagnosis and management. Radiographics 2005; 25:633. Copyright Â© 2005 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 64120 Version 4.0</div></div></div>"},"64122":{"type":"graphic_figure","displayName":"Fibroid anatomy PI","title":"Fibroid locations in the uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibroid locations in the uterus</div><div class=\"cntnt\"><img style=\"width:417px; height:587px;\" src=\"images/PI/64122_Fibroid_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures depict the various types and locations of fibroids. A woman may have one or more type of fibroid.</div><div id=\"graphicVersion\">Graphic 64122 Version 2.0</div></div></div>"},"64124":{"type":"graphic_waveform","displayName":"Intermediate case 2 with answer","title":"Sinus rhythm with complete heart block","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm with complete heart block</div><div class=\"cntnt\"><img style=\"width:527px; height:141px;\" src=\"images/CARD/64124_Intermediate_case_2_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm with complete (third-degree) heart block. There is independent atrial (as shown by the P waves) and ventricular activity, with respective rates of 83 and 43 beats/min. The wide QRS complexes may represent a junctional escape rhythm with underlying bundle branch block or an idioventricular pacemaker.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 64124 Version 2.0</div></div></div>"},"64125":{"type":"graphic_figure","displayName":"Pharmacokinetics insulin detemir","title":"Variation in pharmacokinetics of insulin detemir","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Variation in pharmacokinetics of insulin detemir</div><div class=\"cntnt\"><img style=\"width:548px; height:560px;\" src=\"images/ENDO/64125_Pharm_insulin_detemir.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Variation in pharmacokinetics of insulin detemir among six individuals given the same dose on four separate occasions (note significant peak effect at 8 to 12 hours and duration well short of 24 hours in some patients).</div><div class=\"graphic_footnotes\">GIR: glucose infusion rate.</div><div class=\"graphic_reference\">Data from: Heist T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614.</div><div id=\"graphicVersion\">Graphic 64125 Version 4.0</div></div></div>"},"64126":{"type":"graphic_picture","displayName":"Granulomatous hepatitis Light","title":"Granulomatous hepatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulomatous hepatitis</div><div class=\"cntnt\"><img style=\"width:440px; height:288px;\" src=\"images/GAST/64126_Granulomatous_hepatitis_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a liver biopsy shows a noncaseating granuloma and perigranulomatous mononuclear cell inflammation with hepatic necrosis.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 64126 Version 1.0</div></div></div>"},"64131":{"type":"graphic_figure","displayName":"Y system for peritoneal dialysis modified","title":"Y system for peritoneal dialysis (modified design)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Y system for peritoneal dialysis (modified design)</div><div class=\"cntnt\"><img style=\"width:388px; height:163px;\" src=\"images/NEPH/64131_Newer_Y_system_dialysis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Newer Y systems, in which both dialysis solutions and drain bags are preattached, may lower peritonitis rates since they more effectively flush out possible contamination during attachment than the initial Y systems and do not require patient manipulation of the connection.</div><div id=\"graphicVersion\">Graphic 64131 Version 3.0</div></div></div>"},"64133":{"type":"graphic_figure","displayName":"Action potential and ECG","title":"Relationship between myocardial action potential and surface electrocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship between myocardial action potential and surface electrocardiogram</div><div class=\"cntnt\"><img style=\"width:438px; height:269px;\" src=\"images/CARD/64133_Action_potential_and_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each phase of the myocardial action potential (numbers, upper panel) corresponds to a deflection or interval on the surface electrocardiogram (lower panel). Phase 4, the resting membrane potential, is responsible for the TQ segment; this segment has a prominent role in the ECG manifestations of ischemia during exercise testing.</div><div id=\"graphicVersion\">Graphic 64133 Version 2.0</div></div></div>"},"64134":{"type":"graphic_picture","displayName":"Subungual melanoma - finger","title":"Subungual acral lentiginous melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subungual acral lentiginous melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64134_Sub_melanoma_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma originating from the nail matrix. An area of hyperpigmentation of the proximal nail fold (Hutchinson sign) is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64134 Version 4.0</div></div></div>"},"64135":{"type":"graphic_figure","displayName":"Technique of through-knee amputation","title":"Technique of through-knee amputation","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Technique of through-knee amputation</div><div class=\"cntnt\"><img style=\"width:513px; height:700px;\" src=\"images/SURG/64135_Through-knee-amputation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64135 Version 2.0</div></div></div>"},"64137":{"type":"graphic_picture","displayName":"Slit lamp chin rest","title":"Slit lamp chin rest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slit lamp chin rest</div><div class=\"cntnt\"><img style=\"width:432px; height:406px;\" src=\"images/EM/64137_Slit_lamp_chin_rest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adjust the chin rest height so that the pupils are aligned with the marker.</div><div id=\"graphicVersion\">Graphic 64137 Version 2.0</div></div></div>"},"64138":{"type":"graphic_table","displayName":"Comparison of representative glucocorticoid preparations","title":"Comparison of representative glucocorticoid preparations<SUB>â</SUB>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of representative glucocorticoid preparations<SUB>â</SUB></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Equivalent doses* (mg)</td> <td class=\"subtitle1\">Relative anti-inflammatory activity</td> <td class=\"subtitle1\">Duration of action (hours)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Glucocorticoids</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Short acting</strong></td> </tr> <tr> <td class=\"indent2\">Hydrocortisone (cortisol)</td> <td>20</td> <td>1</td> <td>8 to 12</td> </tr> <tr> <td class=\"indent2\">Cortisone acetate</td> <td>25</td> <td>0.8</td> <td>8 to 12</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Intermediate acting</strong></td> </tr> <tr> <td class=\"indent2\">Prednisone</td> <td>5</td> <td>4</td> <td>12 to 36</td> </tr> <tr> <td class=\"indent2\">Prednisolone</td> <td>5</td> <td>4</td> <td>12 to 36</td> </tr> <tr> <td class=\"indent2\">Methylprednisolone</td> <td>4</td> <td>5</td> <td>12 to 36</td> </tr> <tr> <td class=\"indent2\">Triamcinolone</td> <td>4</td> <td>5</td> <td>12 to 36</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Long acting</strong></td> </tr> <tr> <td class=\"indent2\">Dexamethasone</td> <td>0.75</td> <td>30</td> <td>36 to 72</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Betamethasone</td> <td>0.6</td> <td>30</td> <td>36 to 72</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Mineralocorticoids</td> </tr> <tr> <td class=\"indent1\">Fludrocortisone</td> <td colspan=\"2\">Not used for an anti-inflammatory effect<sup>&#182;</sup></td> <td>12 to 36</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The mineralocorticoid effect of commonly administered&nbsp;glucocorticoids may be estimated as follows: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>20 mg hydrocortisone provides a mineralocorticoid effect that is approximately equivalent to 0.1 mg fludrocortisone.</LI>&#xD;&#xA;<LI>25 mg of cortisone acetate provides a mineralocorticoid effect that is approximately equivalent to 0.1 mg fludrocortisone.</LI>&#xD;&#xA;<LI><FONT color=black>Prednisone or prednisolone given at anti-inflammatory doses â¥50 mg per day provide a&nbsp;mineralocorticoid effect that is approximately equivalent to 0.1 mg of fludrocortisone.</FONT></LI>&#xD;&#xA;<LI><FONT color=red><FONT color=black>When given at replacement doses, </FONT><FONT color=black><FONT color=black>the other glucocorticoids listed in this table have minimal or no clinically relevant </FONT>mineralocorticoid effect</FONT>.</FONT></LI></UL></div><div class=\"graphic_footnotes\">* Equivalent anti-inflammatory dose shown is for oral or intravenous (IV) administration. Relative potency for intra-articular or intramuscular administration may vary considerably.<br />Â¶ The anti-inflammatory potency is 10 to 15 times that of&nbsp;hydrocortisone; however, fludrocortisone is not used clinically&nbsp;as an anti-inflammatory agent.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Schimmer BP, Funder JW. ACTH, Adrenal Steroids, and Pharmacology of the Adrenal Cortex. In: Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics, 12th ed, Brunton LL, Chabner BA, Knollmann BC (Eds), McGraw-Hill Education 2011.</LI>&#xD;&#xA;<LI>Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013, 9:30.</LI></OL></div><div id=\"graphicVersion\">Graphic 64138 Version 19.0</div></div></div>"},"64140":{"type":"graphic_table","displayName":"Neonatal doses MRSA","title":"Selected parenteral drug doses for infants â¤28 days of age with suspected invasive <em>Staphylococcus aureus</em> infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected parenteral drug doses for infants &le;28 days of age with suspected invasive <em>Staphylococcus aureus</em> infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"2\">Infants &#8804;7 days of age</td> <td class=\"subtitle1\" colspan=\"3\">Infants 8 to 28 days of age</td> </tr> <tr> <td class=\"subtitle2\">BW &#8804;2000 g</td> <td class=\"subtitle2\">BW &#62;2000 g</td> <td class=\"subtitle2\">BW &#8804;2000 g</td> <td class=\"subtitle2\" colspan=\"2\">BW &#62;2000 g</td> </tr> <tr> <td><strong>Oxacillin</strong></td> <td>25 mg/kg every 12 hours</td> <td>25 mg/kg every 8 hours</td> <td>25 mg/kg every 8 hours</td> <td colspan=\"2\">25 mg/kg every 6 hours</td> </tr> <tr> <td><strong>Nafcillin</strong></td> <td>25 mg/kg every 12 hours</td> <td>25 mg/kg every 8 hours</td> <td>25 mg/kg every 8 hours</td> <td colspan=\"2\">25 mg/kg every 6 hours</td> </tr> <tr> <td><strong>Gentamicin</strong>*</td> <td>5 mg/kg every 48 hours</td> <td>4 mg/kg every 24 hours</td> <td>5 mg/kg every 36 hours</td> <td colspan=\"2\">4 to 5 mg/kg every 24 hours</td> </tr> <tr> <td><strong>Linezolid</strong></td> <td>10 mg/kg every 12 hours</td> <td>10 mg/kg every 8 hours</td> <td>10 mg/kg every 8 hours</td> <td colspan=\"2\">10 mg/kg every 8 hours</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vancomycin</strong></td> <td colspan=\"5\">Dosed according to serum creatinine concentration as indicated below</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Serum creatinine concentration</td> </tr> <tr> <td class=\"subtitle2\">&#60;0.7</td> <td class=\"subtitle2\">0.7 to 0.9</td> <td class=\"subtitle2\">1.0 to 1.2</td> <td class=\"subtitle2\">1.3 to 1.6</td> <td class=\"subtitle2\">&#62;1.6</td> </tr> <tr> <td><strong>Vancomycin</strong><sup>&#182;</sup></td> <td>15 mg/kg every 12 hours</td> <td>20 mg/kg every 24 hours</td> <td>15 mg/kg every 24 hours</td> <td>10 mg/kg every 24 hours</td> <td>15 mg/kg every 48 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BW: body weight.<br />* Gentamicin is necessary to provide coverage for possible gram-negative pathogens. The optimal, individualized dose should be based on determination of serum concentrations. Doses may differ from those recommended by the package insert.<br />Â¶ Dosing algorithm for vancomycin based upon serum creatinine concentration in neonates born at gestational age &gt;28 weeks. Serum creatinine concentration will take approximately&nbsp;five to&nbsp;seven days after birth to reasonably reflect neonatal renal function. Cautious use of creatinine-based dosing strategy with frequent assessment of renal function and vancomycin serum concentrations are recommended in neonates â¤7 days old<SUP>[1]</SUP>. A vancomycin dosing method based upon post-natal age and weight is provided as an alternative to the serum creatinine-based method listed above and may be useful in some clinical situations. This particular algorithm was provided in the 2009 edition of the Red Book<SUP>[2]</SUP>.<br />Post-natal age &lt;7 days: &#xD;&#xA;<UL>&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI>&#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 12 or 18 hours</LI>&#xD;&#xA;<LI>&gt;2000 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI></UL>Post-natal age â¥7 days: &#xD;&#xA;<UL>&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI>&#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI>&#xD;&#xA;<LI>&gt;2000 g: 10 to 15 mg/kg IV every 6 or 8 hours</LI></UL></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nelson's Pediatric Antimicrobial Therapy, 21st ed, Bradley JS, Nelson JD, Cantey JB, et al (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.36.</li>&#xD;&#xA;    <li>American Academy of Pediatrics. Antibacterial drugs for newborn infants: Dose and frequency of administration. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.745.</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from: American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</div><div id=\"graphicVersion\">Graphic 64140 Version 9.0</div></div></div>"},"64141":{"type":"graphic_picture","displayName":"Intimal hyperplasia in PAH","title":"Vascular changes in pulmonary arterial hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vascular changes in pulmonary arterial hypertension</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/CARD/64141_Intimal_hyperplasia_in_PAH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary arteriole in pulmonary arterial hypertension showing both mild medial hypertrophy and marked intimal hyperplasia, leading to partial obstruction of the lumen.</div><div class=\"graphic_reference\">Courtesy of Eugene Mark, MD.</div><div id=\"graphicVersion\">Graphic 64141 Version 1.0</div></div></div>"},"64142":{"type":"graphic_picture","displayName":"Eczema herpeticum face","title":"Eczema herpeticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eczema herpeticum</div><div class=\"cntnt\"><img style=\"width:425px; height:297px;\" src=\"images/PC/64142_Eczema_herpeticum_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic crusts and vesicles due to herpes simplex virus infection are present on the face of this infant with underlying atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64142 Version 3.0</div></div></div>"},"64145":{"type":"graphic_figure","displayName":"Burn hand eschr dig","title":"Conventional escharotomy with digital escharotomy","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Conventional escharotomy with digital escharotomy</div><div class=\"cntnt\"><img style=\"width:523px; height:561px;\" src=\"images/SURG/64145_Burn_hand_eschr_dig.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64145 Version 2.0</div></div></div>"},"64146":{"type":"graphic_figure","displayName":"Doppler normal diastole","title":"Schematic of Doppler diastolic transmitral flow velocity","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Schematic of Doppler diastolic transmitral flow velocity</div><div class=\"cntnt\"><img style=\"width:501px; height:410px;\" src=\"images/CARD/64146_Doppler_normal_diastole.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During diastole, there is an initial phase of rapid transmitral flow as the mitral valve opens and the left ventricle relaxes; this early filling phase results in a peak in the transmitral flow profile referred to as the E wave. The early filling phase is followed by a period of slow filling called diastasis, during which the slowing of left ventricular relaxation and the rise in left ventricular diastolic pressure result in a decrease in transmitral flow velocity. A late phase of rapid filling occurs with atrial contraction, resulting in a second peak in the transmitral flow profile referred to as the A wave. The isovolumic relaxation time (IVRT) is the interval between the closing of the aortic valve and the opening of the mitral valve, when left ventricular relaxation begins but before left ventricular volume begins to increase. The diastolic deceleration time (DDT) is the interval between the peak early diastolic filling velocity (the peak of the E wave) and the end of the E wave, when diastasis begins. The IVRT and DDT are prolonged in patients with impaired left ventricular relaxation and shortened in patients with restrictive physiology.</div><div id=\"graphicVersion\">Graphic 64146 Version 1.0</div></div></div>"},"64147":{"type":"graphic_diagnosticimage","displayName":"Macrocystic type1 CPAM","title":"Macrocystic Type I CPAM at 26 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Macrocystic Type I CPAM at 26 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:503px; height:478px;\" src=\"images/OBGYN/64147_Macrocystic_type1_CPAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial ultrasound (A) demonstrates multiple hypoechoic cysts within the chest. Axial (B) and sagittal (C) T2w&nbsp;magnetic resonance&nbsp;images demonstrate multiple high signal cysts in the right mid lung. There is no mediastinal shift. The normal lung surround the mass and easily delineated from the cystic mass. No feeding vessel and no hydrops were identified.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 64147 Version 3.0</div></div></div>"},"64152":{"type":"graphic_diagnosticimage","displayName":"FNH MRI T2 weighted","title":"Focal nodular hyperplasia of the liver seen on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal nodular hyperplasia of the liver seen on MRI</div><div class=\"cntnt\"><img style=\"width:284px; height:216px;\" src=\"images/GAST/64152_FNH_MRI_T2_weighted.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted fat saturation magnetic resonance imaging (MRI) shows a hyperintense lesion in the left lobe of the liver (within dashed line) with a striking hyperintensive central scar (arrow).</div><div class=\"graphic_reference\">Courtesy of Douglas R LaBrecque, MD.</div><div id=\"graphicVersion\">Graphic 64152 Version 5.0</div></div></div>"},"64154":{"type":"graphic_figure","displayName":"Dobutamine echo mortality-I","title":"Extent of abnormality on dobutamine echocardiography predicts outcome","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Extent of abnormality on dobutamine echocardiography predicts outcome</div><div class=\"cntnt\"><img style=\"width:468px; height:365px;\" src=\"images/CARD/64154_Dobutamine_echo_mortality-I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 3156 patients undergoing dobutamine echocardiography, survival in patients with a normal test was significantly different from those with functional abnormalities of increasing severity, ie, number of abnormal territories.</div><div class=\"graphic_reference\">Data from Marwick, TH, Case, C, Sawada, S, J Am Coll Cardiol 2001; 37:754.</div><div id=\"graphicVersion\">Graphic 64154 Version 1.0</div></div></div>"},"64155":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 4","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:372px; height:438px;\" src=\"images/OBGYN/64155_Tx_post_vaginal_wall_def_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A longitudinal central defect is seen.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 64155 Version 2.0</div></div></div>"},"64156":{"type":"graphic_figure","displayName":"Arterial circulation to the large bowel","title":"Arterial circulation to the large bowel","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Arterial circulation to the large bowel</div><div class=\"cntnt\"><img style=\"width:486px; height:467px;\" src=\"images/ONC/64156_Anat_vascul_supply_large_bo.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IMA: inferior mesenteric artery; SMA: superior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 64156 Version 2.0</div></div></div>"},"64157":{"type":"graphic_figure","displayName":"Yellow fever Americas PI","title":"Areas in Central and South America where yellow fever is present","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Areas in Central and South America where yellow fever is present</div><div class=\"cntnt\"><img style=\"width:374px; height:432px;\" src=\"images/PI/64157_Yellow_fever_Americas_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64157 Version 2.0</div></div></div>"},"64158":{"type":"graphic_table","displayName":"Screening frail older patients","title":"Questions and simple tests for general screening assessment of frail older patients*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions and simple tests for general screening assessment of frail older patients*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Question</td> <td class=\"subtitle1\">Indicator<br /> (Scoring applies to individual domains)</td> <td class=\"subtitle1\">Alternative</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Functional status</td> </tr> <tr> <td class=\"indent1\">Activities of daily living (ADLs)</td> <td>Bathing, dressing, toileting, transferring, maintaining continence, feeding</td> <td>Able to complete without assistance; able but with difficulty; unable to complete without assistance</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Instrumental&nbsp;ADLs (IADLs)</td> <td>Using the telephone, shopping, preparing meals, housekeeping, doing laundry, using public transportation or driving, taking medication, handling finances</td> <td>Able to complete without assistance; unable to complete without assistance</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Visual impairment</strong></td> <td>Do you have difficulty driving, watching television, reading, or doing any of your daily activities because of your eyesight, even while wearing glasses?<sup>[1]</sup></td> <td>Yes indicates positive screen</td> <td>Snellen eye chart</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"><strong>Hearing impairment</strong><sup>&#182;</sup></td> <td>Is your age older than 70 years?</td> <td>1 point</td> <td class=\"divider_bottom\" rowspan=\"7\">Alternative is Audioscope<sup>[2]</sup></td> </tr> <tr> <td>Are you of male gender?</td> <td>1 point</td> </tr> <tr> <td>Do you have 12 or fewer years of education?</td> <td>1 point</td> </tr> <tr> <td>Did you ever see a doctor about trouble hearing?</td> <td>2 points</td> </tr> <tr> <td>Without a hearing aid, can you usually hear and understand what a person says without seeing his face if that person whispers to you from across the room?</td> <td>If no, 1 point</td> </tr> <tr> <td>Without a hearing aid, can you usually hear and understand what a person says without seeing his face if that person talks in a normal voice to you from across the room?</td> <td>If no, 2 points</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&#8805;3 points: positive screen</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Urinary incontinence</strong><sup>&#916;</sup></td> <td>Have you had urinary incontinence (lose your urine) that is bothersome enough that you would like to know how it could be treated?</td> <td>Yes indicates positive screen</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Malnutrition</strong></td> <td>Have you lost any weight in the last year?<sup>[3]</sup></td> <td>Loss of at least 5 percent of usual body weight in last year indicates positive screen<sup>[3]</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Gait, balance, falls</strong><sup>&#916;</sup></td> <td>Have you fallen two or more times in the past 12 months?</td> <td class=\"divider_bottom\" rowspan=\"3\">Any yes response indicates positive screen</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>Have you fallen and hurt yourself since your last doctor's visit?</td> </tr> <tr class=\"divider_bottom\"> <td>Have you been afraid of falling because of balance or walking problems?</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Depression</strong><sup>&#9674;</sup></td> <td>Over the past&nbsp;two weeks, how often have you been bothered by:</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Response score for each:</p> <p>0: not at all<br /> 1: several days<br /> 2: more than half the days<br /> 3: nearly every day</p> Total &#8805;3, positive screen</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>Little interest or pleasure in doing things?</td> </tr> <tr class=\"divider_bottom\"> <td>Feeling down, depressed, or hopeless?</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Cognitive problems</strong></td> <td>Three-item recall<sup>[4]</sup></td> <td>&#60;2 items recalled indicates positive screen<sup>[4]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Clock-drawing test<sup>[5]</sup></td> <td>Any of the following errors indicate positive screen: wrong time, no hands, missing numbers, number substitutions, repetition, refusal<sup>[5]</sup></td> </tr> <tr> <td><strong>Environmental problems</strong></td> <td>Home safety checklists<sup>[6]</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All except the Snellen eye chart, Audioscope, and evaluation for cognitive problems can be assessed by self-report using questionnaire.<br />Â¶ Questions and response indicators are from the National Health and Nutrition Examination Survey (NHANES) battery.<SUP>[7]</SUP><br />Î Questions and response indicators are from the ACOVE-2 Screener.<SUP>[8]</SUP><br /><FONT class=lozenge>â</FONT> Questions and response indicators are from the Patient Health Questionnaire-2.<SUP>[9]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Moore AA, Siu AL. Screening for common problems in ambulatory elderly. Am J Med 1996; 100:438. </li>&#xD;&#xA;    <li>Yueh B, Shapiro N, MacLean CH, Shekelle PG. Screening and management of adult hearing loss in primary care. JAMA 2003; 289:1976. </li>&#xD;&#xA;    <li>Wallace JI, Schwartz RS, LaCroix AZ, Uhlmann RF, Pearlman RA. Involuntary weight loss in older outpatients. J Am Geriatr Soc 1995; 43:329. </li>&#xD;&#xA;    <li>Siu AL. Screening for dementia and investigating its causes. Ann Intern Med 1991; 115:122. </li>&#xD;&#xA;    <li>Lessig MC, Scanlan JM, Nazemi H, Borson S. Time that tells: critical clockdrawing errors for dementia screening. Int Psychogeriatr 2008; 20:459. </li>&#xD;&#xA;    <li>Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Injury Prevention and Control. Home safety checklists. <a href=\"http://www.cdc.gov/ncipc/falls/FallPrev4.pdf\" target=\"_blank\">http://www.cdc.gov/ncipc/falls/FallPrev4.pdf</a>. Accessed June 9, 2009. </li>&#xD;&#xA;    <li>Reuben DB, Walsh K, Moore AA, et al. Hearing loss in community-dwelling older persons. J Am Geriatr Soc 1998; 46:1008. </li>&#xD;&#xA;    <li>Wenger NS, Roth CP, Shekelle PG, et al. Practice-based intervention to improve primary care for falls, urinary incontinence and dementia. J Am Geriatr Soc 2009; 57:547. </li>&#xD;&#xA;    <li>Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2. Med Care 2003; 41:1284. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Rueben DB. Medical care for the final years of life: \"When you're 83, it's not going to be 20 years.\" JAMA 2009; 302:2686. Copyright &copy; 2009 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64158 Version 19.0</div></div></div>"},"64159":{"type":"graphic_picture","displayName":"Opisthorchiasis adult","title":"Opisthorchiasis adult","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Opisthorchiasis adult</div><div class=\"cntnt\"><img style=\"width:458px; height:453px;\" src=\"images/ID/64159_Opisthorchiasis_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Adult of <em>O. felineus</em>.<br />(B) Adult of <em>O. viverrini</em>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Opisthorchiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/opisthorchiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/opisthorchiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 64159 Version 5.0</div></div></div>"},"64161":{"type":"graphic_diagnosticimage","displayName":"Bilateral facet dislocations","title":"Bilateral facet dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral facet dislocation</div><div class=\"cntnt\"><img style=\"width:281px; height:363px;\" src=\"images/PEDS/64161_Bilateral_facet_dislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral radiograph demonstrates anterior translation of approximately one-half of the superior vertebral body (C5) on the inferior vertebral body (C6).</div><div class=\"graphic_reference\">Courtesy of Charles A Reitman, MD.</div><div id=\"graphicVersion\">Graphic 64161 Version 2.0</div></div></div>"},"64162":{"type":"graphic_table","displayName":"Precursors of normal speech ","title":"Precursors of normal speech and language development in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Precursors of normal speech and language development in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">The child should be able to:</td>\n</tr>\n<tr>\n<td>Play meaningfully with toys</td>\n</tr>\n<tr>\n<td>Interact appropriately with others</td>\n</tr>\n<tr>\n<td>Demonstrate the ability to understand the world around him or her</td>\n</tr>\n<tr>\n<td>Imitate body gestures, movements of the articulators, sounds, syllables</td>\n</tr>\n<tr>\n<td>Comprehend simple verbal directions</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64162 Version 2.0</div></div></div>"},"64164":{"type":"graphic_figure","displayName":"O2 consumption during exercise","title":"Oxygen consumption and workload during exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oxygen consumption and workload during exercise</div><div class=\"cntnt\"><img style=\"width:414px; height:298px;\" src=\"images/PULM/64164_O2_consumption_during_exerc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the normal VO2-workload relationship during incremental exercise to exhaustion (blue circles). The relationship is left-shifted for obese individuals (red triangles).</div><div id=\"graphicVersion\">Graphic 64164 Version 1.0</div></div></div>"},"64166":{"type":"graphic_table","displayName":"Revised internat criteria SS","title":"Revised international classification criteria for SjÃ¶gren's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised international classification criteria for Sj&#246;gren's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"sublist1_start\">I. Ocular symptoms: a positive response to at least one of the following questions:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?</td>\n</tr>\n<tr>\n<td class=\"sublist1\">2. Do you have a recurrent sensation of sand or gravel in the eyes?</td>\n</tr>\n<tr>\n<td class=\"sublist1\">3. Do you use tear substitutes more than 3 times a day?</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">II. Oral symptoms: a positive response to at least one of the following questions:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">1. Have you had a daily feeling of dry mouth for more than 3 months?</td>\n</tr>\n<tr>\n<td class=\"sublist1\">2. Have you had recurrently or persistently swollen salivary glands as an adult?</td>\n</tr>\n<tr>\n<td class=\"sublist1\">3. Do you frequently drink liquids to aid in swallowing dry food?</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">III. Ocular signs-that is, objective evidence of ocular involvement defined as a positive result for at least one of the following two tests:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">1. Schirmer's test, performed without anaesthesia (&#8804;5 mm in 5 minutes)</td>\n</tr>\n<tr>\n<td class=\"sublist1\">2. Rose bengal score or other ocular dye score (&#8805;4 according to van Bijsterveld's scoring system)</td>\n</tr>\n<tr>\n<td>IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score &#8805;1, defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) per 4 square mm of glandular tissue</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at least one of the following diagnostic tests:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">1. Unstimulated whole salivary flow (&#8804;1.5 ml in 15 min)</td>\n</tr>\n<tr>\n<td class=\"sublist1\">2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or destructive pattern), without evidence of obstruction in the major ducts</td>\n</tr>\n<tr>\n<td class=\"sublist1\">3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">VI. Autoantibodies: presence in the serum of the following autoantibodies:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">1. Antibodies to Ro(SSA) or La(SSB) antigens, or both</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Vitali, C, Bombardieri, S, Jonsson, R, et al. Classification criteria for Sj&#246;gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:664-558. Copyright &#169;2002 BMJ Publishing Group.</div><div id=\"graphicVersion\">Graphic 64166 Version 1.0</div></div></div>"},"64167":{"type":"graphic_figure","displayName":"Ornithodoros turicata tick","title":"Ornithodoros turicata tick","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ornithodoros turicata tick</div><div class=\"cntnt\"><img style=\"width:253px; height:275px;\" src=\"images/ID/64167_Ornithodoros_turicata_tick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The <EM>Ornithodoros turicata </EM>tick is the vector of the relapsing fever agent <EM>Borrelia turicatae</EM>.</div><div class=\"graphic_reference\">Courtesy of Alan Barbour, MD.</div><div id=\"graphicVersion\">Graphic 64167 Version 3.0</div></div></div>"},"64171":{"type":"graphic_figure","displayName":"Pathogenesis hemangioma","title":"Imbalanced VEGFR1 and VEGFR2 function in hemangioma","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Imbalanced VEGFR1 and VEGFR2 function in hemangioma</div><div class=\"cntnt\"><img style=\"width:530px; height:356px;\" src=\"images/PEDS/64171_Pathogenesis_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) In normal endothelial cells (ECs), VEGF binds to VEGFR1 with higher affinity than to VEGFR2. VEGFR1, which is expressed both as soluble and transmembrane forms, acts as a sink for VEGF, thereby decreasing VEGFR2 activity and downstream signals for endothelial cells to proliferate. Panel B) Endothelial cells derived from hemangiomas express aberrant multiprotein complexes - containing integrins and mutated variants of VEGFR2 and TEM8 and possibly also other molecular components (indicated by question mark). These complexes decrease the activity of NFAT, resulting in the downregulation of VEGFR1 expression. As a consequence, more VEGF is available to bind and activate VEGFR2, causing enhanced endothelial cell proliferation.</div><div class=\"graphic_reference\">Reprinted by permission from: MacMillan Publishers Ltd. Claesson-Welsh, Lena. Healing hemangiomas. Nature Medicine 2008; 14:1147. Copyright &#169;2008.</div><div id=\"graphicVersion\">Graphic 64171 Version 1.0</div></div></div>"},"64172":{"type":"graphic_picture","displayName":"Perifollicular abnormality","title":"Perifollicular abnormalities in scurvy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perifollicular abnormalities in scurvy</div><div class=\"cntnt\"><img style=\"width:428px; height:271px;\" src=\"images/PC/64172_Perifollicular_abnormality.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this example, the perifollicular hyperkeratotic papules are quite prominent, with surrounding hemorrhage. These lesions have been misinterpreted as &quot;palpable purpura,&quot; leading to the mistaken clinical diagnosis of vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Hirschmann JV, Raugi GJ. Adult scurvy. J Am Acad Dermatol 1999; 41:895. Copyright Â© 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 64172 Version 2.0</div></div></div>"},"64173":{"type":"graphic_figure","displayName":"HRT and PE WHI","title":"HRT increases pulmonary embolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HRT increases pulmonary embolism</div><div class=\"cntnt\"><img style=\"width:389px; height:226px;\" src=\"images/ENDO/64173_HRT_and_PE_WHI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Women's Health Initiative, combined estrogen-progestin replacement therapy was associated with a significant increase in pulmonary embolism (eight more pulmonary emboli per 10,000 person-years; HR 2.13, unadjusted 95% CI 1.39-3.25).</div><div class=\"graphic_footnotes\">HRT: hormone replacement therapy; HR: hazard ratio.</div><div class=\"graphic_reference\">Data from: Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen and progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.</div><div id=\"graphicVersion\">Graphic 64173 Version 5.0</div></div></div>"},"64175":{"type":"graphic_diagnosticimage","displayName":"Decidual cyst","title":"Decidual cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decidual cyst</div><div class=\"cntnt\"><img style=\"width:354px; height:240px;\" src=\"images/OBGYN/64175_Decidual_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of a retroverted uterus shows a tiny fluid collection (arrowhead) located close to the endometrial-myometrial junction, consistent with a decidual cyst.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 64175 Version 2.0</div></div></div>"},"64178":{"type":"graphic_table","displayName":"MRSA oral antibiotics","title":"Oral antimicrobial agents for treatment of methicillin-resistant <EM>Staphylococcus aureus</EM> (MRSA) infection in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antimicrobial agents for treatment of methicillin-resistant <EM>Staphylococcus aureus</EM> (MRSA) infection in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td>Clindamycin</td> <td>300 to 450 mg orally three to four times daily</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> <td> <p>Cellulitis or drainable abscess (with or without cellulitis): 1&nbsp;or 2 DS tablets twice daily</p> <p>Osteomyelitis or septic arthritis: 4 mg/kg per dose (trimethoprim component) orally twice daily;&nbsp;for an 80 kg patient 2 DS tablets achieves a dose of 4 mg/kg*</p> </td> </tr> <tr> <td>Doxycycline</td> <td>100 mg orally twice daily</td> </tr> <tr> <td>Minocycline</td> <td>200 mg orally once, then 100 mg orally twice daily</td> </tr> <tr> <td>Linezolid</td> <td>600 mg orally twice daily</td> </tr> <tr> <td>Tedizolid</td> <td>200 mg orally once daily</td> </tr> <tr> <td>Delafloxacin</td> <td>450 mg orally twice daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.</div><div class=\"graphic_footnotes\">DS: double strength (ie, 160 mg trimethoprim with 800 mg sulfamethoxazole per tablet).<br />*&nbsp;For treatment of osteomyelitis, TMP-SMX is given with rifampin 600 mg orally once daily. </div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e10.</LI>&#xD;&#xA;<LI>Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clin Infect Dis 2011; 52:e18 (note: for TMP-SMX dose&nbsp;in osteomyelitis, see&nbsp;p e38).</LI></OL></div><div id=\"graphicVersion\">Graphic 64178 Version 21.0</div></div></div>"},"64179":{"type":"graphic_diagnosticimage","displayName":"Membranous VSD with aneurysm color still frame","title":"Membranous VSD with aneurysm color still frame","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Membranous VSD with aneurysm color still frame</div><div class=\"cntnt\"><img style=\"width:546px; height:397px;\" src=\"images/CARD/64179_Membranous_VSD_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paired long axis images with and without color flow mapping demonstrating tricuspid valve tissue apposed to the ventricular septal defect (VSD, arrows) which is partially occluding the defect. In the right hand panel, color flow mapping demonstrates residual flow around this tricuspid valve tissue.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; RV: right ventricle; AO: aorta; MV: mitral valve; arrows: VSD.</div><div id=\"graphicVersion\">Graphic 64179 Version 3.0</div></div></div>"},"64181":{"type":"graphic_waveform","displayName":"ECG ventricular trigeminy tutorial","title":"Single lead electrocardiogram (ECG) showing ventricular trigeminy","html":"<div class=\"graphic normal\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing ventricular trigeminy</div><div class=\"cntnt\"><img style=\"width:500px; height:111px;\" src=\"images/CARD/64181_Ventricular_trigeminy_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Every third beat is a ventricular premature beat (VPB). The coupling interval between the VPB and the previous sinus QRS complex is constant (fixed coupling interval). The resulting pattern is referred to as ventricular trigeminy.</div><div id=\"graphicVersion\">Graphic 64181 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"64182":{"type":"graphic_figure","displayName":"Surv rates appendix CA","title":"Observed survival rates for 931 cases with carcinoma of the appendix","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Observed survival rates for 931 cases with carcinoma of the appendix</div><div class=\"cntnt\"><img style=\"width:552px; height:455px;\" src=\"images/ONC/64182_Surv_rates_appendix_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the SEER 1973-2005 Public Use File diagnosed in years 1991-2000. Stage I includes 150; Stage II, 369; Stage III, 76; and Stage IV, 346.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 64182 Version 12.0</div></div></div>"},"64183":{"type":"graphic_table","displayName":"Toxic blood lead levels children","title":"Blood lead levels considered toxic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood lead levels considered toxic</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Prior to 1971</strong></td> <td>&#8805;60 mcg/dL (2.88 micromol/L)</td> </tr> <tr> <td><strong>1972-1975</strong></td> <td>&#8805;40 mcg/dL (1.93 micromol/L)</td> </tr> <tr> <td><strong>1975-1985</strong></td> <td>&#8805;30 mcg/dL (1.45 micromol/L)</td> </tr> <tr> <td><strong>1985-1991</strong></td> <td>&#8805;25 mcg/dL (1.20 micromol/L)</td> </tr> <tr> <td><strong>1991-present</strong></td> <td>&#8805;10 mcg/dL (0.48 micromol/L)</td> </tr> <tr> <td><strong>2010-present</strong></td> <td>&#8805;5 mcg/dL (0.24 micromol/L)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">mcg: micrograms; dL: deciliter; micromol: micromoles; L: liter.</div><div id=\"graphicVersion\">Graphic 64183 Version 5.0</div></div></div>"},"64185":{"type":"graphic_table","displayName":"Factors affecting exhaled NO","title":"Factors affecting exhaled and nasal nitric oxide measurement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors affecting exhaled and nasal nitric oxide measurement</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Increased nitric oxide</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Drugs</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Papaverin</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Sodium nitroprusside</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">L-arginine </td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Enalapril</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">Air pollution exposure</td></tr>\n\t\t\t\t\t\t<tr><td>Ingestion of arginine or nitrite/nitrate rich foods</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Chemical exposure</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Fluoride</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Ozone</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Chlorine dioxide</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Latex</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Formaldehyde</td></tr>\n\t\t\t\t\t\t<tr><td>Upper respiratory tract infections</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Decreased nitric oxide</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Drugs</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Oxymetazoline</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">NOS inhibitors</td></tr>\n\t\t\t\t\t\t<tr><td>Repeated spirometry</td></tr>\n\t\t\t\t\t\t<tr><td>Exercise</td></tr>\n\t\t\t\t\t\t<tr><td>Menses</td></tr>\n\t\t\t\t\t\t<tr><td>Sputum induction</td></tr>\n\t\t\t\t\t\t<tr><td>Reduction in body temperature</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Chemical exposure</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Water vapor</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Nitrous oxide</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Heptane</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Carbon dioxide</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">100% oxygen</td></tr>\n\t\t\t\t\t\t<tr><td>Smoking</td></tr>\n\t\t\t\t\t\t<tr><td>Caffeine</td></tr>\n\t\t\t\t\t\t<tr><td>Alcohol ingestion</td></tr>\n\t\t\t\t\t\t<tr><td>Moderate altitude</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Kharitonov, SA, Barnes, PJ, Am J Respir Crit Care Med 2001; 163:1693.</div><div id=\"graphicVersion\">Graphic 64185 Version 1.0</div></div></div>"},"64186":{"type":"graphic_diagnosticimage","displayName":"Diabetic neuroarthropathy I","title":"Diabetic neuroarthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diabetic neuroarthropathy</div><div class=\"cntnt\"><img style=\"width:358px; height:236px;\" src=\"images/RHEUM/64186_Diabetic_neuroarthropathy_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longstanding Charcot's disease of the left ankle characterized by deformity and sclerosis (arrow). The patient had been diabetic for 20 years.</div><div class=\"graphic_reference\">Courtesy of LD Hordon, MD and Verna Wright, MD.</div><div id=\"graphicVersion\">Graphic 64186 Version 3.0</div></div></div>"},"64187":{"type":"graphic_picture","displayName":"Grade II nipple inversion","title":"Grade II nipple inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grade II nipple inversion</div><div class=\"cntnt\"><img style=\"width:388px; height:514px;\" src=\"images/SURG/64187_Grade_II_nipple_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with grade II nipple inversion, forceful manipulation is required to pull the nipple out, and retraction recurs quickly.</div><div id=\"graphicVersion\">Graphic 64187 Version 1.0</div></div></div>"},"64188":{"type":"graphic_picture","displayName":"Chest stretch","title":"Flexibility exercise: Chest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexibility exercise: Chest</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/64188_Chest_stretch_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise, which stretches the chest muscles, is also good for your posture. <ol> <li>You can do this stretch while standing or sitting in a sturdy, armless chair. </li> <li>Keep your feet flat on the floor, shoulder-width apart. </li> <li>Hold arms to your sides at shoulder height, with palms facing forward. </li> <li>Slowly move your arms back, while squeezing your shoulder blades together. Stop when you feel a stretch or slight discomfort. </li> <li>Hold the position for 10 to 30 seconds. </li> <li>Repeat at least three to five times. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 64188 Version 2.0</div></div></div>"},"64189":{"type":"graphic_table","displayName":"Indications for paracentesis","title":"Indications for abdominal paracentesis in a patient with ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for abdominal paracentesis in a patient with ascites</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>New onset ascites</td>\n\n    </tr>\n\n    <tr>\n\n      <td>At the time of each admission to the hospital</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Clinical deterioration, either inpatient or outpatient</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Fever</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Abdominal pain</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Abdominal tenderness</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Mental status change</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Ileus</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Hypotension</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Laboratory abnormalities that may indicate infection</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Peripheral leukocytosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Acidosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Worsening of renal function</td>\n    </tr>\n    <tr>\n\n      <td>Gastrointestinal bleeding (a high risk time for infection)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reference: Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57:1651.</div><div id=\"graphicVersion\">Graphic 64189 Version 3.0</div></div></div>"},"64190":{"type":"graphic_diagnosticimage","displayName":"Extensive primary TB x-ray","title":"Extensive primary tuberculosis in a toddler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensive primary tuberculosis in a toddler</div><div class=\"cntnt\"><img style=\"width:396px; height:333px;\" src=\"images/ID/64190_Extensive_primary_TB_x-ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is extensive primary tuberculosis in a toddler. There is right-sided hilar adenopathy, narrowing of the right mainstem bronchus, and collapse-consolidation of the right lower lobe.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 64190 Version 2.0</div></div></div>"},"64191":{"type":"graphic_figure","displayName":"Changes in PD transport over time","title":"Changes in peritoneal dialysis transport over time","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Changes in peritoneal dialysis transport over time</div><div class=\"cntnt\"><img style=\"width:458px; height:237px;\" src=\"images/NEPH/64191_PD_transport_changes_with_t.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of significant changes in peritoneal transport rates--increased D/P creatinine, decreased D/Do glucose--characteristic of rapid transport in patients on maintenance peritoneal dialysis. Conversion to slower transport was much less common:&nbsp;8 percent for creatinine and 15 percent for glucose at two years.</div><div class=\"graphic_reference\">Data from Blake PG, Abraham G, Sombolos K,&nbsp;et al. Changes in peritoneal membrane transport rates in patients on long&nbsp;term CAPD.&nbsp;Adv Perit Dial 1989; 5:3.</div><div id=\"graphicVersion\">Graphic 64191 Version 4.0</div></div></div>"},"64192":{"type":"graphic_figure","displayName":"B-LUVS and balloon","title":"Combined Bakri balloon, plus Bilateral Looped Uterine Vessels Sutures (B-LUVS) technique in case of cesarean delivery.","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Combined Bakri balloon, plus Bilateral Looped Uterine Vessels Sutures (B-LUVS) technique in case of cesarean delivery.</div><div class=\"cntnt\"><img style=\"width:595px; height:564px;\" src=\"images/OBGYN/64192_BLUVS_balloon_edt_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The double loop suture technique should include the full thickness of the lateral uterine wall. For the first stitch, the needle is brought through the eye of the loop, thus eliminating the need for a knot.<br> (B) The looped sutures are placed stepwise up the side of the uterus bilaterally, including both lower and upper uterine segments. The loop is cut prior to the last stitch, the last stitch is taken and the two ends are tied. The balloon catheter is inserted at this time.</div><div class=\"graphic_reference\">Courtesy of Younes N Bakri, MD.</div><div id=\"graphicVersion\">Graphic 64192 Version 4.0</div></div></div>"},"64194":{"type":"graphic_table","displayName":"Caloric balance PN preterm","title":"Caloric balance PN preterm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Caloric balance PN preterm</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Concentration, percent</td> <td class=\"subtitle1\">g/kg/day</td> <td class=\"subtitle1\">kcal/kg/day</td> <td class=\"subtitle1\">kcals, percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Infusion rate at 135 mL/kg/day</td> </tr> <tr> <td class=\"indent1\">Glucose</td> <td>12.5</td> <td>16.9</td> <td>57.5</td> <td>56</td> </tr> <tr> <td class=\"indent1\">Amino acids</td> <td>2.6</td> <td>3.5</td> <td>14</td> <td>14</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Infusion rate at 15 mL/kg/day</td> </tr> <tr> <td class=\"indent1\">Lipid</td> <td>20</td> <td>3.0</td> <td>30</td> <td>30</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Suggested distribution of energy sources in parenteral nutrition solutions for premature infants based upon an assumed total fluid intake of 150 mL/kg per day and total calorie intake is 102 kcal/kg per day.</div><div id=\"graphicVersion\">Graphic 64194 Version 2.0</div></div></div>"},"64196":{"type":"graphic_algorithm","displayName":"Guideline C-spine clearance unreliable child","title":"Guideline for clearing the cervical spine in the unreliable pediatric patient","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Guideline for clearing the cervical spine in the unreliable pediatric patient</div><div class=\"cntnt\"><img style=\"width:486px; height:536px;\" src=\"images/EM/64196_Guide_cspine_clear_unrel.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">C-spine: cervical spine; MRI: magnetic resonance imaging; CT: computed tomography; LOC: level of consciousness.<br />* Unconscious or decreased level of consciousness with Glasgow coma scale &lt;15.<br />Â¶ Change to long-term cervical spine collar as soon as appropriate.<br />Î Consider thoracolumbar spine injury in those with a documented cervical spine injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Chung S, Mikrogianakis A, Wales PW, et al. Trauma Association of Canada Pediatric Subcommittee National Pediatric Cervical Spine Evaluation Pathway: Consensus Guidelines. J Trauma 2011; 70:873. Copyright Â© 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64196 Version 11.0</div></div></div>"},"64197":{"type":"graphic_diagnosticimage","displayName":"Cholangiogram cuboidal bile duct stones","title":"Cholangiogram showing common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cholangiogram showing common bile duct stones</div><div class=\"cntnt\"><img style=\"width:504px; height:502px;\" src=\"images/GAST/64197_Cholang_cuboidal_stones_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram showing multiple cuboidal-shaped stones in the common bile duct.</div><div id=\"graphicVersion\">Graphic 64197 Version 2.0</div></div></div>"},"64198":{"type":"graphic_figure","displayName":"TGDC excision","title":"Excision of thyroglossal duct cyst and tract","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Excision of thyroglossal duct cyst and tract</div><div class=\"cntnt\"><img style=\"width:522px; height:331px;\" src=\"images/ENDO/64198_TGDC_excision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The standard operation for thyroglossal duct cyst is to resect the cyst in continuity witih the midportion of the hyoid bone and a core of tissue from the hyoid upwards toward the foramen cecum, an operation known as the Sistrunk procedure.</div><div id=\"graphicVersion\">Graphic 64198 Version 2.0</div></div></div>"},"64199":{"type":"graphic_picture","displayName":"Gastritis intestinal metaplasia","title":"Incomplete intestinal metaplasia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incomplete intestinal metaplasia</div><div class=\"cntnt\"><img style=\"width:394px; height:259px;\" src=\"images/GAST/64199_Gastritisintestinalmetapl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view (H&amp;E stain) of chronic atrophic&nbsp;gastritis with incomplete intestinal metaplasia showing metaplastic goblet cells in the surface and foveolar epithelium (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 64199 Version 3.0</div></div><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Normal gastric antrum</div><div class=\"cntnt\"><img style=\"width:520px; height:223px;\" src=\"images/GAST/79895_Normal_gastric_antrum_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Normal surface (SE) and foveolar epithelium (FE) and glands (G). Right panel: Higher power view of the glands shows mucous cells (M) and gastrin-secreting endocrine cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 79895 Version 1.0</div></div></div>"},"64200":{"type":"graphic_diagnosticimage","displayName":"Holoprosencephaly sonogram","title":"Holoprosencephaly on sonogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Holoprosencephaly on sonogram</div><div class=\"cntnt\"><img style=\"width:378px; height:247px;\" src=\"images/PEDS/64200_Holoprosencephaly_sonogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Antenatal sonogram of a single ventricle in a fetus with holoprosencephaly.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 64200 Version 4.0</div></div></div>"},"64202":{"type":"graphic_picture","displayName":"TM perforation","title":"Tympanic membrane perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane perforation</div><div class=\"cntnt\"><img style=\"width:396px; height:417px;\" src=\"images/PC/64202_TM_perforation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tympanic membrane perforation with surrounding myringosclerosis.</div><div class=\"graphic_reference\">Courtesy of Nikolas H Blevins, MD.</div><div id=\"graphicVersion\">Graphic 64202 Version 1.0</div></div></div>"},"64203":{"type":"graphic_figure","displayName":"Daytime vs nocturnal PCO2 COPD","title":"Effect of nocturnal assisted ventilation on daytime versus nocturnal PCO2 in COPD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of nocturnal assisted ventilation on daytime versus nocturnal PCO2 in COPD</div><div class=\"cntnt\"><img style=\"width:324px; height:292px;\" src=\"images/PULM/64203_Daytime_vs_nocturnal_PCO2_C.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There was a close correlation between change in daytime arterial tension of carbon dioxide (vertical axis) and change in mean overnight transcutaneous tension of carbon dioxide (horizontal axis) for individual patients with COPD after three months of nocturnal assisted ventilation.</div><div class=\"graphic_footnotes\">PaCO<SUB>2</SUB>: arterial tension of carbon dioxide; PtCO<SUB>2</SUB>: transcutaneous tension of carbon dioxide.</div><div class=\"graphic_reference\">Redrawn from Meecham-Jones DJ, Paul EA, Jones PW, Wedzicha JA. Am J Respir Crit Care 1995; 152:538.</div><div id=\"graphicVersion\">Graphic 64203 Version 2.0</div></div></div>"},"64204":{"type":"graphic_figure","displayName":"Survival after transplant idiopathic interstitial pneumonia","title":"Survival after lung transplantation for recipients with idiopathic interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Survival after lung transplantation for recipients with idiopathic interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:485px; height:286px;\" src=\"images/PULM/64204_SurvivalafttransplantIPF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival after lung transplantation for recipients with idiopathic&nbsp;interstitial pneumonia for transplantations performed between January 1990 and June 2014, stratified by procedure type.</div><div class=\"graphic_reference\">Reproduced from: The Registry of the International Society for Heart and Lung Transplantation: Thirty-Second Annual Report. J Heart Lung Transplant 2016; 35:1149. Illustration used with the permission of Elsevier Inc. All rights reserved. For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Adult Lung Transplantation Statistics,\" at: <a href=\"http://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\" target=\"_blank\">http://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry</a>.</div><div id=\"graphicVersion\">Graphic 64204 Version 7.0</div></div></div>"},"64205":{"type":"graphic_picture","displayName":"Pathology aortic intramural hematoma","title":"Pathology aortic intramural hematoma","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Pathology aortic intramural hematoma</div><div class=\"cntnt\"><img style=\"width:535px; height:174px;\" src=\"images/CARD/64205_Path_aortic_intramural_hema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autopsy specimen from a patient with an intramural hematoma of the ascending aorta. Left panel: Transverse section through the aorta shows the surrounding the aortic intima (*); the intima itself is intact. Right panel: Longitudinal section through the aorta.</div><div class=\"graphic_reference\">From Maraj R, Rekpattanapipat P, Jacobs LE, et al. Am J Cardiol 2000; 86:664, with permission from Excerpta Medica, Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 64205 Version 4.0</div></div></div>"},"64207":{"type":"graphic_figure","displayName":"Glucose induced hyperkalemia","title":"Glucose-induced hyperkalemia in diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glucose-induced hyperkalemia in diabetes</div><div class=\"cntnt\"><img style=\"width:411px; height:240px;\" src=\"images/NEPH/64207_Glucose_induced_hyperkalemi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of a glucose load on the plasma potassium concentration in diabetics (solid line) and nondiabetics (dashed line). Glucose led to a fall in the plasma potassium concentration in nondiabetics due to stimulation of insulin release but a rise in diabetics due to the elevation in plasma osmolality.</div><div class=\"graphic_reference\">Data from: Nicolis GL, Kahn T, Sanchez A,&nbsp;et al.&nbsp;Arch Intern Med 1981; 141:49.</div><div id=\"graphicVersion\">Graphic 64207 Version 2.0</div></div></div>"},"64209":{"type":"graphic_table","displayName":"Lumbosacral myotomes","title":"Lumbosacral myotomes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lumbosacral myotomes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1_single\">L1</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Femoral nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Iliopsoas (hip flexion)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">L2</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Femoral nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Iliopsoas (hip flexion)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Quadriceps (knee extension)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Obturator nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Hip adductors</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">L3</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Femoral nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Iliopsoas (hip flexion)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Quadriceps (knee extension)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Obturator nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Hip adductors</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">L4</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Femoral nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Iliopsoas (hip flexion)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Quadriceps (knee extension)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Obturator nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Hip adductors</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">L5</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Peroneal Nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Ankle dorsiflexion (tibialis anterior)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Ankle eversion (peroneus muscles)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Tibial nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Ankle inversion (tibialis posterior)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Superior gluteal nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Hip abduction (gluteus medius)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Leg internal rotation (tensor fascia latae)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">S1</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Inferior gluteal nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Hip extension (gluteus maximus)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Sciatic nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Knee flexion (hamstrings)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Tibial nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Ankle plantar flexion</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">S2</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Inferior gluteal nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Hip extension (Gluteus maximus)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Sciatic nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Knee flexion (hamstrings)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1_start\">Tibial nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist1\">Ankle plantar flexion</td>\n\t  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64209 Version 1.0</div></div></div>"},"64210":{"type":"graphic_table","displayName":"Differential diagnosis of a brain mass","title":"Differential diagnosis of a brain mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of a brain mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary brain tumors</td> </tr> <tr> <td>Glioma</td> </tr> <tr> <td>Meningioma</td> </tr> <tr> <td>Pituitary adenoma</td> </tr> <tr> <td>Vestibular schwannoma</td> </tr> <tr> <td>Primary central nervous system lymphoma</td> </tr> <tr> <td>Other</td> </tr> <tr> <td class=\"subtitle1_single\">Metastatic brain tumors</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular disease</td> </tr> <tr> <td class=\"subtitle2_single\">Cerebral hemorrhage</td> </tr> <tr> <td class=\"indent1 indent1\">Vascular anomaly</td> </tr> <tr> <td class=\"indent1 indent1\">Hypertensive</td> </tr> <tr> <td class=\"indent1 indent1\">Intratumoral</td> </tr> <tr> <td class=\"subtitle2_single\">Cerebral infarct</td> </tr> <tr> <td class=\"subtitle2_single\">Reversible posterior leukencephalopathy&nbsp;syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Abscess (bacterial, fungal)</td> </tr> <tr> <td>Viral infection</td> </tr> <tr> <td>Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td>Multiple sclerosis</td> </tr> <tr> <td>Post-infectious encephalomyelitis</td> </tr> <tr> <td>Granulomatous disease&nbsp;</td> </tr> <tr> <td>Vasculitis&nbsp;</td> </tr> <tr> <td>Textiloma&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64210 Version 2.0</div></div></div>"},"64212":{"type":"graphic_table","displayName":"TRALI diagnostic criteria","title":"Diagnostic criteria for transfusion-related acute lung injury (TRALI) and possible TRALI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for transfusion-related acute lung injury (TRALI) and possible TRALI</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">TRALI</td> <td class=\"subtitle1\">Possible TRALI</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)</strong></td> <td> <ul> <li>Acute onset (during or within six hours of transfusion) </li> <li>Hypoxemia* </li> <li>Bilateral infiltrates on frontal chest radiograph </li> <li>No evidence of circulatory overload/left atrial hypertension </li> <li>No pre-existing ALI/ARDS before transfusion&nbsp; </li> </ul> </td> <td>Same as for TRALI</td> </tr> <tr> <td><strong>ALI/ARDS risk factor<sup>&#916;</sup> at time of transfusion</strong></td> <td>Must be <em>absent</em></td> <td>Must&nbsp;be <em>present</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The diagnostic criteria for TRALI and possible TRALI share the following features: acute onset of hypoxemia, bilateral infiltrates on frontal chest radiograph, and absence of circulatory overload as the primary etiology of respiratory insufficiency. For a diagnosis of TRALI to be made, all of these features must be present. In addition, there should be no preexisting ALI/ARDS risk factors at the time of transfusion. If&nbsp;ALI/ARDS risk factors are present, the diagnostic terminology \"possible TRALI\" is appropriate.</div><div class=\"graphic_footnotes\">PaO2: arterial oxygen tension; FiO2: fraction of inspired oxygen; SpO2: hemoglobin oxygen saturation.<BR>* Hypoxemia is defined as PaO2/FiO2 â¤300 or SpO2 &lt;90 percent on room air or other clinical evidence of hypoxemia. <BR>Î Risk factors for ALI/ARDS include the following: aspiration, toxic inhalation, pneumonia, toxic contusion, near drowning, shock states, severe sepsis, multiple trauma, burn injury, acute pancreatitis, cardiopulmonary bypass, or drug overdose.</div><div class=\"graphic_reference\">Modified from: Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44:1774.</div><div id=\"graphicVersion\">Graphic 64212 Version 3.0</div></div></div>"},"64214":{"type":"graphic_figure","displayName":"First step ladder","title":"First step algorithm: The seven-level criterion ladder","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">First step algorithm: The seven-level criterion ladder</div><div class=\"cntnt\"><img style=\"width:655px; height:830px;\" src=\"images/DERM/64214_First_step_ladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>Level 1:</STRONG> Melanocytic lesions criteria. a) Pigment network (exception: dermatofibroma); b) Negative network; c) Angulated lines; d) Streaks; e) Aggregated globules; f) Peripheral globules; g) Homogeneous blue pigmentation; h) Pseudonetwork (facial skin); i) Parallel pigment pattern (palms and soles).<br /><STRONG>Level 2:</STRONG> Basal cell carcinoma criteria. a) Arborizing blood vessels; b) Spoke wheel-like structures; c) Leaf-like areas; d) Large blue-gray ovoid nests; e) Multiple nonaggregated blue-gray globules; f) Ulceration; g) Shiny white blotches and strands.<br /><STRONG>Level 3:</STRONG> Squamous cell carcinoma criteria. a) Focal glomerular vessels; b) Rosettes; c) Keratin pearls (white circles); d) Yellow scale; e) Brown dots aligned radially at the periphery.<br /><STRONG>Level 4:</STRONG> Seborrheic keratosis criteria. a) Multiple (three or more) milia-like cysts; b) Comedo-like openings; c) Gyri and sulci (fissures and ridges); d) Fingerprint-like structures; e) Moth-eaten borders.<br /><STRONG>Level 5:</STRONG> Hemangioma/angioma/angiokeratoma. a) Red lacunae; b) Blue lacunae; c) Black lacunae.<br /><STRONG>Level 6:</STRONG> Blood vessels as seen in nonmelanocytic tumors. a) Arborizing vessels; b) Glomerular vessels; c) Hairpin vessels with white halo; d) Crown vessels; e) Serpiginous or string of pearls; f) \"Strawberry\" pattern.<br /><STRONG>Level 7:</STRONG> Blood vessels as seen in melanocytic tumors. a) Comma-shaped vessels; b) Dotted vessels; c) Serpentine vessels (or linear irregular); d) Corkscrew vessels; e) Polymorphous vessels; f) Milky-red areas and milky-red globules.<br /><STRONG>Level 8:</STRONG> Structureless/featureless lesions or lesions with nonspecific/nondiagnostic features. No vessels noted.</div><div class=\"graphic_reference\">Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 64214 Version 4.0</div></div></div>"},"64215":{"type":"graphic_picture","displayName":"Acanthamoeba trophozoites","title":"<EM>Acanthamoeba</EM> trophozoites","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\"><EM>Acanthamoeba</EM> trophozoites</div><div class=\"cntnt\"><img style=\"width:514px; height:259px;\" src=\"images/ID/64215_Acanthamoeba_throph_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Trophozoite of <em>Acanthamoeba</em> spp in tissue, stained with hematoxylin and eosin (H&amp;E).<br> (B) Trophozoites of <em>Acanthamoeba</em> spp in a corneal scraping, stained with H&amp;E.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Free living amebic infections. Available at: <A href=\"http://www.cdc.gov/dpdx/freeLivingAmebic/index.html\">http://www.cdc.gov/dpdx/freeLivingAmebic/index.html</A>.</div><div id=\"graphicVersion\">Graphic 64215 Version 3.0</div></div></div>"},"64216":{"type":"graphic_table","displayName":"First generation antipsychotic Rx poisoning - Rapid overview","title":"First generation antipsychotic medication poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">First generation antipsychotic medication poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Rapid overview</td> </tr> <tr> <td class=\"subtitle2_single\">Clinical and laboratory features</td> </tr> <tr> <td class=\"indent1\">Cardinal feature of this overdose is CNS depression</td> </tr> <tr> <td class=\"indent1\">Most patients have mild tachycardia; occasional patients have additional features of the anticholinergic toxidrome</td> </tr> <tr> <td class=\"indent1\">Acute extrapyramidal syndromes (eg, acute dystonic reactions, akathisia) are uncommon in overdose</td> </tr> <tr> <td class=\"indent1\">Pupils may be any size</td> </tr> <tr> <td class=\"indent1\">QT prolongation is common but Torsade de Pointes (TdP) is rare</td> </tr> <tr> <td class=\"subtitle2_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"indent1\">No specific laboratory testing is required</td> </tr> <tr> <td class=\"indent1\">Obtain an ECG to evaluate for QT prolongation</td> </tr> <tr> <td class=\"indent1\">Rule out other causes of depressed mental status (eg, hypoglycemia, intracranial lesion) as clinically indicated</td> </tr> <tr> <td class=\"indent1\">Rule out common coingestions (eg, aspirin, acetaminophen) and others as clinically indicated</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment</td> </tr> <tr> <td class=\"indent1\">No specific antidote exists; treatment is supportive</td> </tr> <tr> <td class=\"indent1\">Acute extrapyramidal syndromes can be treated with antimuscarinic medications (diphenhydramine or benztropine) or benzodiazepines</td> </tr> <tr> <td class=\"sublist2_start\">For patients with significant QT prolongation:</td> </tr> <tr> <td class=\"sublist2\">Monitor the ECG until the QTc is &#60;500 msec and trending toward improvement</td> </tr> <tr> <td class=\"sublist2\">Correct significant electrolyte abnormalities, particularly hypokalemia</td> </tr> <tr> <td class=\"sublist2\">Avoid giving medications that further prolong the QT interval</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64216 Version 8.0</div></div></div>"},"64217":{"type":"graphic_waveform","displayName":"12 lead ECG atrial fibrillation","title":"12 lead ECG of atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">12 lead ECG of atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:536px; height:276px;\" src=\"images/CARD/64217_12_lead_ECG_atrial_fibrilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead ECG shows atrial fibrillation. The QRS complex is narrow, P waves are absent, and the baseline between successive QRS complexes shows irregular coarse &quot;fibrillatory waves.&quot; The QRS complexes occur at irregularly irregular intervals.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 64217 Version 2.0</div></div></div>"},"64218":{"type":"graphic_table","displayName":"Diet and stoma function","title":"Dietary influences on stoma function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary influences on stoma function</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1\">Increase odor</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\t\n\t\t\t\t\t\t<td>Beans</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Asparagus</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Broccoli</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Brussel sprouts</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cauliflower</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cabbage</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Eggs</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Fish</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Onions</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Some spices</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1\">Increase gas</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Beans</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Beer, carbonated soda</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Broccoli</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Brussel sprouts</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cauliflower</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cabbage</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Corn</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cucumbers</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Mushrooms</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Peas</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Radishes</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Spinach</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Dairy products</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1\">Thicken stool</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Apple sauce</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Bananas</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Cheese</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Boiled milk</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Marshmallows</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Pasta</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Creamy peanut butter</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Pretzels</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Rice</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Bread</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Tapioca</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Toast</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Yogurt</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1\">Loosen stool</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Green beans</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Beer</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Broccoli</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Fresh fruits</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Grape juice</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Raw vegetables</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Prunes</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Spicy foods</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Fried foods</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Chocolate</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Leafy green vegetables</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Spinach</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64218 Version 1.0</div></div></div>"},"64219":{"type":"graphic_picture","displayName":"Blastomycosis granuloma","title":"Blastomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blastomycosis</div><div class=\"cntnt\"><img style=\"width:278px; height:188px;\" src=\"images/PULM/64219_Blastomycosis_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows necrotizing granulomatous inflammation in a patient with blastomycosis. Neutrophils frequently are prominent within the necrotic centers. The outer portions of the granulomata are composed largely of epithelioid and multinucleated histiocytes.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 64219 Version 2.0</div></div></div>"},"64221":{"type":"graphic_diagnosticimage","displayName":"Baker cyst MRI","title":"Baker's cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Baker's cyst</div><div class=\"cntnt\"><img style=\"width:351px; height:415px;\" src=\"images/RHEUM/64221_Baker_cyst_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal short tau inversion recovery (STIR) magnetic resonance image of the knee shows a high signal fluid structure posterior and medial to the knee joint (arrow) consistent with a Baker's (popliteal) cyst.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD, and Celia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 64221 Version 2.0</div></div></div>"},"64223":{"type":"graphic_picture","displayName":"Disseminated granuloma annulare on trunk","title":"Disseminated granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:305px;\" src=\"images/DERM/64223_Disseminated_granuloma_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 64 year-old woman with disseminated granuloma annulare displays solitary papules and incomplete annular lesions composed of discrete papules at the periphery of the rings.</div><div id=\"graphicVersion\">Graphic 64223 Version 1.0</div></div></div>"},"64224":{"type":"graphic_figure","displayName":"Displaced transverse distal phalanx shaft fracture","title":"Displaced transverse distal phalanx shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Displaced transverse distal phalanx shaft fracture</div><div class=\"cntnt\"><img style=\"width:514px; height:196px;\" src=\"images/SURG/64224_Displ_trans_dist_phal_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse fracture that passes between the terminal insertions of the extensor and flexor tendons is an unstable fracture pattern due to the opposing deforming forces and usually has an apex dorsal angulation due to the greater pull of the flexor tendon.</div><div id=\"graphicVersion\">Graphic 64224 Version 2.0</div></div></div>"},"64225":{"type":"graphic_picture","displayName":"Pubic lice PI","title":"Pubic lice","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pubic lice</div><div class=\"cntnt\"><img style=\"width:386px; height:264px;\" src=\"images/PI/64225_Pubic_lice_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous lice and nits located around the pubic hair.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 64225 Version 1.0</div></div></div>"},"64226":{"type":"graphic_figure","displayName":"Ely test","title":"Ely test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ely test</div><div class=\"cntnt\"><img style=\"width:384px; height:267px;\" src=\"images/PEDS/64226_Ely_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Ely test detects contracture of the rectus femoris component of the quadriceps muscle. With the patient prone, the examiner gently flexes the knee to 130 degrees. Contracture of the rectus femoris is indicated by simultaneous flexion of the hip, which causes the buttocks to rise off the table.</div><div class=\"graphic_reference\">Adapted from Aronsson, DD. The pediatric orthopedic examination. In: Lovell and Winter's Pediatric Orthopedics, 5th ed, Morrissy, RT, Weinstein, SL (Eds), Lippincott Williams &amp;Wilkins, Philadelphia, 2001. p. 99.</div><div id=\"graphicVersion\">Graphic 64226 Version 2.0</div></div></div>"},"64227":{"type":"graphic_figure","displayName":"Temporomandibular joint anatomy","title":"Temporomandibular joint anatomy","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Temporomandibular joint anatomy</div><div class=\"cntnt\"><img style=\"width:525px; height:456px;\" src=\"images/EM/64227_Temporomandibularjointanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The temporomandibular joint (TMJ) is the articulation of the temporal and mandibular bones.</div><div id=\"graphicVersion\">Graphic 64227 Version 3.0</div></div></div>"},"64228":{"type":"graphic_picture","displayName":"Fungal endothelial plaque","title":"Fungal keratitis: Fungal endothelial plaque and hypopyon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fungal keratitis: Fungal endothelial plaque and hypopyon</div><div class=\"cntnt\"><img style=\"width:306px; height:227px;\" src=\"images/PC/64228_Fungal_endothelial_plaque.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64228 Version 3.0</div></div></div>"},"64230":{"type":"graphic_figure","displayName":"Precorneal tear film","title":"Precorneal tear film","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Precorneal tear film</div><div class=\"cntnt\"><img style=\"width:502px; height:675px;\" src=\"images/PC/64230_Precorneal_tear_film.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Pflugfelder, SC, Solomon, A, Stern, ME. The Diagnosis and Management of Dry Eye: A Twenty-Five Year Review. Cornea 2000; 19:644.</div><div id=\"graphicVersion\">Graphic 64230 Version 1.0</div></div></div>"},"64231":{"type":"graphic_figure","displayName":"Antioxidants and atherosclerosis","title":"Schematic representation of antioxidant actions","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Schematic representation of antioxidant actions</div><div class=\"cntnt\"><img style=\"width:532px; height:654px;\" src=\"images/CARD/64231_Antioxidants_and_atherosclerosis_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incorporation of antioxidants into low-density lipoprotein (LDL) protects against oxidation of LDL particles. Additionally, the incorporation of antioxidants into vascular cells may inhibit the vascular response to oxidized LDL.</div><div id=\"graphicVersion\">Graphic 64231 Version 7.0</div></div></div>"},"64233":{"type":"graphic_movie","displayName":"Mitral valve vegetation","title":"Mitral valve vegetation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve vegetation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64233_mitralvalvevegetconv.mp4\" style=\"width:320px;height:244px\"></div><img style=\"width:319px; height:228px;\" src=\"images/CARD/64233_mitralvalvevegetation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dan Sexton, MD. Duke University.</div><div id=\"graphicVersion\">Graphic 64233 Version 2.0</div></div></div>"},"64234":{"type":"graphic_movie","displayName":"TEE LA and prosthetic MV thrombus","title":"Left atrial thrombus and thrombus adjacent to a prosthetic mitral valve seen on TEE","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial thrombus and thrombus adjacent to a prosthetic mitral valve seen on TEE</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64234_teelatt3conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:275px; height:217px;\" src=\"images/CARD/64234_teelatt3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a thrombus within the left atrium as well as adjacent to a prosthetic mitral valve. There is a suggestion that the prosthetic valve also contains thrombus.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 64234 Version 4.0</div></div></div>"},"64237":{"type":"graphic_figure","displayName":"Paracervical block","title":"Paracervical block ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paracervical block </div><div class=\"cntnt\"><img style=\"width:421px; height:582px;\" src=\"images/OBGYN/64237_Paracervicalblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paracervical block is placed by injecting a total dose of 10 to 20 mL of anesthetic agent (usually 1% lidocaine or 2-chloroprocaine) about 10 mm into the cervical stroma at the 4 and 8 o'clock positions (some operators&nbsp;inject at the 2, 4, 8, and 10&nbsp;o'clock positions)&nbsp;at the cervicovaginal junction. </div><div class=\"graphic_reference\">Adapted from an illustration in: Shulman LP, Ling FW. Surgical termination of pregnancy. In: Gynecologic surgery, Mann WJ, Stovall TG (Eds), Churchill Livingstone, Inc, 1996.</div><div id=\"graphicVersion\">Graphic 64237 Version 8.0</div></div></div>"},"64238":{"type":"graphic_table","displayName":"Normal RBC parameters (adult)","title":"Normal values for red blood cell parameters in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal values for red blood cell parameters in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">RBC parameter</td> <td class=\"subtitle1\">Men</td> <td class=\"subtitle1\">Women</td> </tr> <tr> <td>Hemoglobin, g/dL</td> <td>15.7 (14.0 to 17.5)</td> <td>13.8 (12.3 to 15.3)</td> </tr> <tr> <td>Hematocrit, percent</td> <td>46 (42 to 50)</td> <td>40 (36 to 45)</td> </tr> <tr> <td>RBC count, million/microL</td> <td>5.2 (4.5 to 5.9)</td> <td>4.6 (4.1 to 5.1)</td> </tr> <tr> <td>Reticulocyte count, cells/microL</td> <td>20,000 to 110,000</td> <td>20,000 to 110,000</td> </tr> <tr> <td>Reticulocyte percentage</td> <td>1.6 &#177; 0.5</td> <td>1.4 &#177; 0.5</td> </tr> <tr> <td>Mean corpuscular volume (MCV), femtoliters (fL)</td> <td>88 (80 to 96)</td> <td>88 (80 to 96)</td> </tr> <tr> <td>Mean cell hemoglobin (MCH), pg/RBC</td> <td>30 (28 to 33)</td> <td>30 (28 to 33)</td> </tr> <tr> <td>Mean cell hemoglobin concentration (MCHC), g/dL of RBC</td> <td>34 (33 to 36)</td> <td>34 (33 to 36)</td> </tr> <tr> <td>Red cell distribution width (RDW), CV, percent</td> <td>13 (12 to 15)</td> <td>13 (12 to 15)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Values represent the mean and reference intervals (normal range, based on nonparametric 95% confidence interval) for each sex. Reference ranges may vary slightly in different laboratories. There are no sex differences in absolute reticulocyte count, MCV, MCH, MCHC, or RDW. Values for children are presented separately in UpToDate. Refer to UpToDate topics on anemia for further details.</div><div class=\"graphic_footnotes\">RBC: red blood cell; CV: coefficient of variation method.</div><div class=\"graphic_reference\">Adapted with permission from: Williams' Hematology, 7th ed, Lichtman MA, Beutler E, Kipps TJ, et al. (Eds), McGraw-Hill, New York 2006, p. 12. Copyright Â© 2006 McGraw-Hill Education. âMcGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 64238 Version 7.0</div></div></div>"},"64239":{"type":"graphic_figure","displayName":"Trigger event vs LQTS genotype","title":"Triggers for cardiac events in long QT syndrome are related to genotype","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Triggers for cardiac events in long QT syndrome are related to genotype</div><div class=\"cntnt\"><img style=\"width:565px; height:468px;\" src=\"images/CARD/64239_Trggr_evnt_vs_LQTS_genotype.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 670 patients with long QT syndrome and known genotype, all symptomatic (syncope, aborted cardiac arrest, or sudden death), the occurrence of a lethal cardiac event (n = 110) provoked by a specific trigger (exercise, emotion, and sleep/rest without arousal) differed according to genotype. LQT1 patients experienced most of their events (90%) during exercise or emotion. These percentages were almost reversed among LQT2 and LQT3 patients who had most of their events during rest or sleep (63 and 80%, respectively); by contrast, they were at almost no risk of major events during exercise (arrows), which is explained by their having a normal I<SUB>Ks</SUB> current.</div><div class=\"graphic_footnotes\">ACA: aborted cardiac arrest; SCD: sudden cardiac death.</div><div class=\"graphic_reference\">Modified from: Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89.</div><div id=\"graphicVersion\">Graphic 64239 Version 3.0</div></div></div>"},"64240":{"type":"graphic_table","displayName":"Differential diagnosis of hallucinogen intoxication","title":"Differential diagnosis of hallucinogen intoxication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hallucinogen intoxication</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Toxicologic </td> </tr> <tr> <td>Amphetamine/methamphetamine intoxication</td> </tr> <tr> <td>Anticholinergic delirium</td> </tr> <tr> <td>Cocaine intoxication</td> </tr> <tr> <td>Ethanol or sedative-hypnotic withdrawal</td> </tr> <tr> <td>Neuroleptic malignant syndrome</td> </tr> <tr> <td>Serotonin syndrome</td> </tr> <tr> <td>Synthetic cannabinoids (eg, spice; K2)</td> </tr> <tr> <td>Synthetic cathinones (eg, \"bath salts\")</td> </tr> <tr> <td class=\"subtitle1_single\">Non-toxicologic </td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>CNS infection (encephalitis, meningitis)</td> </tr> <tr> <td>Head trauma (intracranial hemorrhage)</td> </tr> <tr> <td>Sepsis</td> </tr> <tr> <td>Schizophrenia (other psychiatric illness)</td> </tr> <tr> <td>Thyroid storm</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64240 Version 3.0</div></div></div>"},"64241":{"type":"graphic_figure","displayName":"Initial trauma management in the severely injured child","title":"Initial trauma management in children with severe multiple trauma","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Initial trauma management in children with severe multiple trauma</div><div class=\"cntnt\"><img style=\"width:606px; height:1120px;\" src=\"images/EM/64241_Initial_trauma_mng_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">pCO2: partial pressure of carbon dioxide; O2: oxygen; GCS: Glasgow coma scale; FAST: focused abdominal sonography for trauma.<br />* Clinicians should always perform actions in <FONT color=#ff0000>RED</FONT>.<br /><FONT class=bullet>â¢</FONT> Administer 20 mL/kg of warmed normal saline or Ringer's lactate over 10 to 20 minutes. In children with severe head injury, the aim is to ensure normal but not excessive circulating volume. <br />Î Signs of herniation include coma, unilateral pupillary dilation with outward eye deviation followed by hemiplegia, hyperventilation, Cheyne-Stokes respirations, and/or decerebrate or decorticate posturing. Refer to UpToDate topics on severe traumatic brain injury in children for more specific guidance.&nbsp; </div><div id=\"graphicVersion\">Graphic 64241 Version 4.0</div></div></div>"},"64244":{"type":"graphic_figure","displayName":"Modified Martius fat pad graft","title":"Modified Martius labial fat pad graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Martius labial fat pad graft</div><div class=\"cntnt\"><img style=\"width:415px; height:381px;\" src=\"images/OBGYN/64244_Modified_Martius_fat_pad_gr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A vertical incision is made over the labia majora.</div><div id=\"graphicVersion\">Graphic 64244 Version 1.0</div></div></div>"},"64246":{"type":"graphic_table","displayName":"Interventions cent obstruction","title":"Indication for endoscopic therapy in the treatment of the three basic types of endobronchial stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indication for endoscopic therapy in the treatment of the three basic types of endobronchial stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Endobronchial lesion</td> <td class=\"subtitle1\">Extrinsic lesion</td> <td class=\"subtitle1\">Mixed lesion</td> </tr> <tr> <td>Laser</td> <td>+</td> <td>- </td> <td>+</td> </tr> <tr> <td>Electrocautery</td> <td>+</td> <td>-</td> <td>+</td> </tr> <tr> <td>Cryotherapy</td> <td>+*</td> <td>-</td> <td>+*</td> </tr> <tr> <td>Brachytherapy</td> <td>+*</td> <td>-</td> <td>+*</td> </tr> <tr> <td>APC</td> <td>+</td> <td>-</td> <td>+</td> </tr> <tr> <td>PDT</td> <td>+*</td> <td>-</td> <td>+*</td> </tr> <tr> <td>Stents</td> <td>-</td> <td>+</td> <td>+<sup>â&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">APC: argon plasma coagulator; PDT: photodynamic therapy.<br />* Contraindicated in impending respiratory failure.<br />Â¶ Indicated if postinterventional airway lumen is &lt;50 percent of normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 19:368. Copyright &copy; 2002 European Respiratory Society Journals Ltd.</div><div id=\"graphicVersion\">Graphic 64246 Version 3.0</div></div></div>"},"64248":{"type":"graphic_diagnosticimage","displayName":"Saprophytic aspergillus CT I","title":"Aspergilloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspergilloma</div><div class=\"cntnt\"><img style=\"width:363px; height:350px;\" src=\"images/PULM/64248_Saprophytic_aspergillus_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small fungus ball due to saprophytic Aspergillus fumigatus. Incidental note is made of an aortic arch aneurysm. CT scan shows a thin-walled left upper lobe cavity with a small nodular mass in the dorsal aspect of the cavity.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64248 Version 3.0</div></div></div>"},"64249":{"type":"graphic_figure","displayName":"Groin hernias PI","title":"Groin hernias","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Groin hernias</div><div class=\"cntnt\"><img style=\"width:501px; height:602px;\" src=\"images/PI/64249_Groin_hernia_exam_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hernia is a weakening or a tear in a tissue layer. When a person has a hernia, internal organs or tissues can bulge at the hernia.</div><div id=\"graphicVersion\">Graphic 64249 Version 3.0</div></div></div>"},"64251":{"type":"graphic_algorithm","displayName":"Evaluation and management of chemotherapy-induced diarrhea","title":"Evaluation and management of chemotherapy-induced diarrhea","html":"<div class=\"graphic\"><div style=\"width: 1266px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of chemotherapy-induced diarrhea</div><div class=\"cntnt\"><img style=\"width:1246px; height:1038px;\" src=\"images/ONC/64251_Eval_mngmnt_chemo_diarrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living; CBC: complete blood count; SubQ: subcutaneously; DTO: deodorized tincture of opium; CT: computed tomography; DPD: dyhydropyrimidine dehydrogenase; FU: fluorouracil; IV: intravenous; GI: gastroenterology.<br />* Doses that exceed the daily maximum of 16 mg (8 tablets) should be used as needed for severe diarrhea or mild to moderate diarrhea that persists after 24 hours. Patients should be reassured that the risk of loperamide overdose is low in this setting.<br />&para; Stool workup for infectious cause of diarrhea: Testing for Clostridium difficile, stool culture (Salmonella species, Shigella species, Escherichia coli, Campylobacter); patients with bloody diarrhea should be evaluated for enterohemorragic E. coli infection and Entamoeba.<br />&Delta; Consider CT scan for signs of peritonitis.<br /><span class=\"lozenge\">&loz;</span> Titration up to 2000 micrograms SubQ every 8 hours or use of an IV infusion may be needed in nonresponders (refer to topic).</div><div class=\"graphic_reference\">Adapted with permission from: Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Onc 2004; 22:2918. Copyright &copy; 2004 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 64251 Version 5.0</div></div></div>"},"64252":{"type":"graphic_algorithm","displayName":"Healthcare delivery mods","title":"Models of healthcare delivery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Models of healthcare delivery</div><div class=\"cntnt\"><img style=\"width:338px; height:401px;\" src=\"images/ONC/64252_Healthcare_delivery_mods.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from National Consensus Project for Quality Palliative Care (2004). Clinical practice guidelines for quality palliative care. http://www.nationalconsensusproject.org.</div><div id=\"graphicVersion\">Graphic 64252 Version 1.0</div></div></div>"},"64253":{"type":"graphic_picture","displayName":"Arthritis mutilans PI","title":"Arthritis mutilans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arthritis mutilans</div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/PI/64253_Arthritis_mutilans_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a patient with arthritis mutilans caused by psoriatic arthritis.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 64253 Version 1.0</div></div></div>"},"64254":{"type":"graphic_algorithm","displayName":"Osmotic diarrhea child","title":"Algorithm for evaluation of a child with osmotic diarrhea","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of a child with osmotic diarrhea</div><div class=\"cntnt\"><img style=\"width:476px; height:648px;\" src=\"images/PEDS/64254_Osmoticdiarrheachild.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.</div><div class=\"graphic_footnotes\">tTG-IgA: tissue transglutaminase immunoglobulin A antibody.<br />* As defined by Rome IV criteria.<sup>[1]</sup></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Benninga MA, Faure C, Hyman PE, et al. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology 2016.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64254 Version 8.0</div></div></div>"},"64258":{"type":"graphic_table","displayName":"Rx EC IE (R to PCN and S to vanc and gent) ","title":"Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains resistant to penicillin and susceptible to vancomycin and aminoglycosides*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains resistant to penicillin and susceptible to vancomycin and aminoglycosides*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)<sup>&#182;</sup></td> <td class=\"subtitle1\">European Society of Cardiology (ESC)</td> <td class=\"subtitle1\">British Society for Antimicrobial Therapy (BSAC)</td> </tr> <tr> <td class=\"subtitle2\">Adult dose</td> <td class=\"subtitle2\">Pediatric dose</td> <td class=\"subtitle2\">Adult dose</td> <td class=\"subtitle2\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Strains with intrinsic penicillin resistance<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in two divided doses for six weeks</p> <p><strong>plus</strong></p> Gentamicin<sup>&#167;</sup> 3 mg/kg per 24 hours IV or IM in three divided doses for six weeks</td> <td class=\"indent1\"> <p>Vancomycin<sup>&#9674;</sup> 40 mg/kg per 24 hours IV (maximum dose: 2 g per 24 hours unless levels are inappropriately low) in two or three divided doses for six weeks</p> <p><strong>plus</strong></p> Gentamicin<sup>&#167;</sup> 3 to 6 mg/kg per 24 hours IV in three divided doses for six weeks</td> <td class=\"indent1\"> <p>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in two divided doses for six weeks</p> <p><strong>plus</strong></p> Gentamicin<sup>&#167;</sup> 3 mg/kg per 24 hours IV or IM in one dose for six weeks</td> <td class=\"indent1\"> <p>Vancomycin<sup>&#9674;</sup> 1 g IV every 12 hours for&nbsp;four to six&nbsp;weeks<sup>&#134;</sup></p> <p><strong>or</strong></p> <p>Teicoplanin<sup>&#165;</sup> 10 mg/kg IV once daily for&nbsp;four to six&nbsp;weeks<sup>&#134;</sup></p> <p><strong>plus</strong></p> Gentamicin<sup>&#167;</sup> 1 mg/kg IV every 8 to 12 hours for&nbsp;four to six&nbsp;weeks<sup>&#134;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Beta-lactamase-producing strains</td> </tr> <tr> <td class=\"indent1\"> <p>Ampicillin-sulbactam<sup>&#135;</sup> 3 g every 6 hours IV for six weeks</p> <p><strong>or</strong></p> <p>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in two divided doses for six weeks</p> <p><strong>plus</strong></p> Gentamicin<sup>&#167;</sup> 3 mg/kg per 24 hours IV or IM in three divided doses for six weeks</td> <td class=\"indent1\">See above</td> <td class=\"indent1\"> <p>Ampicillin-sulbactam<sup>&#135;</sup> 12 g per 24 hours (or 300 mg/kg per 24 hours) IV in four equally divided doses for four to six weeks<sup>&#134;</sup></p> <p><strong>or</strong></p> <p>Amoxicillin-clavulanate<sup>&#135;</sup> 200 mg/kg (amoxicillin component) per 24 hours IV in six equally divided doses for four to six weeks<sup>&#134;</sup></p> <p><strong>or</strong></p> <p>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in two divided doses for six weeks</p> <p><strong>plus</strong></p> Gentamicin<sup>&#167;</sup> 3 mg/kg per 24 hours IV or IM in one dose for four to six weeks<sup>&#134;</sup></td> <td class=\"indent1\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">IV: intravenously; IM: intramuscularly; MIC: minimum inhibitory concentration; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; HLAR: high-level aminoglycoside resistance.<br />* Patients with isolates susceptible to penicillin who are unable to tolerate beta-lactams should receive treatment as for infection due to isolates with intrinsic penicillin resistance.<br />Â¶&nbsp;Duration of treatment for prosthetic valve or other prosthetic material&nbsp;infective&nbsp;endocarditis&nbsp;is a minimum of six weeks.<br />Î Intrinsic penicillin resistance defined as penicillin or ampicillin MIC â¥32 mcg/mL; consultation with infectious disease specialist recommended.<br /><FONT class=lozenge>â</FONT> Vancomycin therapy is recommended only in the setting of intrinsic penicillin resistance or for patients unable to tolerate beta-lactams (refer to&nbsp;text regarding beta-lactam intolerance). Vancomycin dose should be adjusted for serum trough concentration 10 to 20 mcg/mL; some favor trough concentration 15 to 20 mcg/mL. In adults, vancomycin is dosed based on actual body weight. The dose may need to be increased beyond 30 mg/kg and frequency may need to be increased to three divided doses.<br />Â§ Renal function and gentamicin serum concentrations should be monitored at least once per week. In non-obese and non-underweight adults, aminoglycosides are dosed based on ideal body weight. Gentamicin dosage adjusted for peak serum concentrations 3 to 4 mcg/mL, trough &lt;1 mcg/mL when two to three divided doses used. When given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per ESC guidelines, post-dose (peak, one hour after injection) serum concentrations should be approximately 10 to 12 mcg/mL (per AHA guidelines, there is no role for measuring peak gentamicin concentration following single daily dosing).<br />Â¥ Alternative for penicillin-allergic patient provided isolate is teicoplanin susceptible (MIC â¤8 mcg/mL).<br />â¡ If strain is gentamicin resistant, then &gt;6 weeks of ampicillin-sulbactam or amoxicillin-clavulanate therapy&nbsp;may be needed. Refer to local product information for optimal dosing and frequency of intravenous amoxicillin-clavulanate.&nbsp;Strain should be evaluated for HLAR to streptomycin.<br />â  Patients with NVE and symptoms &lt;3 months may be treated for 4 weeks; patients with PVE or NVE with symptoms &gt;3 months should be treated for at least 6 weeks.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI>&#xD;&#xA;<LI>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</LI></OL></div><div id=\"graphicVersion\">Graphic 64258 Version 10.0</div></div></div>"},"64261":{"type":"graphic_waveform","displayName":"ECG complete HB with Mobitz type II","title":"Electrocardiogram (ECG) showing complete heart block in a patient with syncopal episodes who previously had shown Mobitz II type AV block","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing complete heart block in a patient with syncopal episodes who previously had shown Mobitz II type AV block</div><div class=\"cntnt\"><img style=\"width:512px; height:75px;\" src=\"images/CARD/64261_Complete_HB_with_Mobitz_typ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first two beats are paced. After the pacemaker is turned off, a normally conducted beat followed with a PR interval of 0.19 sec and a LBBB morphology. The next eight P waves fail to conduct and no lower pacemaker appears to assume control of the ventricles. Restarting the artificial pacemaker led to the QRS complex at the end of the rhythm strip.</div><div class=\"graphic_footnotes\">LBBB: left bundle branch block.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 64261 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"64262":{"type":"graphic_diagnosticimage","displayName":"Brain MRI cerebral gumma","title":"Brain MRI of a cerebral gumma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a cerebral gumma</div><div class=\"cntnt\"><img style=\"width:418px; height:256px;\" src=\"images/NEURO/64262_Cerebral_gumma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI showing a cerebral gumma in an HIV-infected patient with recent secondary syphilis.<br />(A) Coronal contrast-enhanced T1-weighted MRI shows focal meningeal enhancement in the left frontal lobe with surrounding edema.<br />(B) Axial FLAIR MRI shows significant edema in the left posterior frontal lobe.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; HIV: human immunodeficiency virus; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Dr. Christina M. Marra, MD.</div><div id=\"graphicVersion\">Graphic 64262 Version 5.0</div></div></div>"},"64264":{"type":"graphic_picture","displayName":"XRT proctitis APC Endosc","title":"Radiation telangiectasias","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Radiation telangiectasias</div><div class=\"cntnt\"><img style=\"width:457px; height:224px;\" src=\"images/GAST/64264_XRT_proctitis_APC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Endoscopy shows hemorrhagic areas in the rectum in a patient with radiation telangiectasias and chronic hematochezia. Right panel: The hemorrhagic areas have been treated with argon plasma coagulation.</div><div class=\"graphic_reference\">Courtesy of Jonathan Cohen, MD.</div><div id=\"graphicVersion\">Graphic 64264 Version 2.0</div></div></div>"},"64265":{"type":"graphic_picture","displayName":"Vulvar cancer 4","title":"Vulvar cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar cancer</div><div class=\"cntnt\"><img style=\"width:350px; height:501px;\" src=\"images/OBGYN/64265_Vulvar_cancer_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exophytic vulvar carcinoma involving posterior fourchette.</div><div class=\"graphic_reference\">Reproduced with permission from: Scott, JR, Gibbs, RS. Danforth's Obstetrics and Gynecology, Ninth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64265 Version 1.0</div></div></div>"},"64267":{"type":"graphic_picture","displayName":"Blood smear, iron deficiency","title":"Peripheral blood smear in iron deficiency anemia showing microcytic, hypochromic red blood cells","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear in iron deficiency anemia showing microcytic, hypochromic red blood cells</div><div class=\"cntnt\"><img style=\"width:404px; height:586px;\" src=\"images/HEME/64267_Microcytichypchrmcanemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The same peripheral blood smear from a patient with iron deficiency is&nbsp;shown&nbsp;at two different magnifications.&nbsp;Small (microcytic) red blood cells are shown, many of which have a thin rim of pink hemoglobin (hypochromia). Occasional \"pencil\"-shaped cells are also present. A small lymphocyte is shown for size comparison (arrow). Normal red blood cells are similar in size to the nucleus of a small lymphocyte (arrow), and central pallor in normal red blood cells should equal approximately one-third of&nbsp;the cell&nbsp;diameter.</div><div class=\"graphic_reference\">Kindly supplied by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 64267 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"64268":{"type":"graphic_picture","displayName":"RTT pseudostationary","title":"Rett syndrome, pseudostationary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, pseudostationary</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/64268_RS_stage_III_pseudostationa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Between ages two and 10 years in RTT, there is a period of behavioral improvement that follows rapid deterioration. Note the change from an irritable to pleasant appearance, but continued repetitious finger rubbing movement.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright Â© 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 64268 Version 5.0</div></div></div>"},"64269":{"type":"graphic_figure","displayName":"IL17a expression","title":"Defective IL-17a expression in HIES","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Defective IL-17a expression in HIES</div><div class=\"cntnt\"><img style=\"width:476px; height:233px;\" src=\"images/ALLRG/64269_IL17a_expression_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood mononuclear cells (PBMCs) from a healthy individual and an individual with HIES are stimulated to induce IL-17a expression. IL-17 is severely reduced in patients with HIES.</div><div class=\"graphic_footnotes\">IL-17a: interleukin-17A; HIES: hyperimmunoglobulin E syndrome.</div><div id=\"graphicVersion\">Graphic 64269 Version 3.0</div></div></div>"},"64270":{"type":"graphic_picture","displayName":"Polymorphous light eruption forearms","title":"Polymorphous light eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphous light eruption</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64270_PMLE_forearms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows a 35-year-old woman with a symmetrical papulovesicular eruption on the forearms. Lesions were also present on the neck and lower legs.</div><div class=\"graphic_reference\">Copyright Â© Eric Ehrsam, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 64270 Version 7.0</div></div></div>"},"64272":{"type":"graphic_table","displayName":"Rapid sequence intubation induction agents for adults  ","title":"Rapid sequence intubation induction agents for adultsÂ ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid sequence intubation induction agents for adults&nbsp;</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug name</td> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Benefits</td> <td class=\"subtitle1\">Contraindications</td> <td class=\"subtitle1\">Notes</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td>Etomidate</td> <td>Imidazole derivative</td> <td>Excellent sedation with little hypotension</td> <td>Known to suppress adrenal cortisol production</td> <td>Use cautiously if patient has sepsis; initial dose of glucocorticoid may be needed</td> <td>0.3 mg/kg</td> </tr> <tr class=\"divider_top\"> <td>Ketamine</td> <td>Phencyclidine derivative, dissociative anesthetic</td> <td> <p>Stimulates catecholamine release</p> <p>Bronchodilation</p> </td> <td>Use in patients with elevated ICP or elevated blood pressure is controversial</td> <td>May be an excellent induction agent for patients with bronchospasm, septic shock, <strong>AND</strong> hemodynamic compromise</td> <td>1 to 2 mg/kg</td> </tr> <tr class=\"divider_top\"> <td>Midazolam</td> <td>Benzodiazepines</td> <td>Potent dose-related amnesic properties</td> <td>Dose-related myocardial depression can result in hypotension</td> <td>Frequently underdosed</td> <td>0.2 to 0.3 mg/kg</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Propofol</td> <td rowspan=\"2\">Alkylphenol derivative</td> <td rowspan=\"2\">Bronchodilation</td> <td>No absolute contraindications</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">1.5 to 3 mg/kg</td> </tr> <tr> <td>Dose-related hypotension</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Thiopental sodium</td> <td rowspan=\"3\">Ultrashort-acting barbiturate</td> <td rowspan=\"3\">Cerebroprotective and anti-convulsive properties</td> <td>Potent venodilator and myocardial depressant; can cause hypotension</td> <td rowspan=\"3\">May not be commercially available. Rarely used.</td> <td rowspan=\"3\">3 to 5 mg/kg</td> </tr> <tr> <td>Relatively contraindicated in reactive airway disease due to histamine release</td> </tr> <tr> <td>Acute intermittent and variegate porphyrias</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64272 Version 10.0</div></div></div>"},"64273":{"type":"graphic_diagnosticimage","displayName":"Cushings disease CT","title":"CT scan in Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan in Cushing's disease</div><div class=\"cntnt\"><img style=\"width:308px; height:324px;\" src=\"images/ENDO/64273_Cushings_disease_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal CT image of the sella in a 59-year-old man with Cushing's disease. No lesion is visible within the sella (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia 1996.</div><div id=\"graphicVersion\">Graphic 64273 Version 5.0</div></div></div>"},"64274":{"type":"graphic_table","displayName":"Tests for lung maturity","title":"Tests for determining fetal lung maturity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tests for determining fetal lung maturity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Positive discriminating value</td> <td class=\"subtitle1\">Predictive value for pulmonary maturity when test is mature*</td> <td class=\"subtitle1\">Predictive value for pulmonary immaturity when test is immature*</td> <td class=\"subtitle1\">Pros and cons</td> </tr> <tr> <td>Lamellar body count</td> <td>30,000 to 40,000<sup>&#182;</sup></td> <td>97 to 98 percent</td> <td>29 to 35 percent</td> <td>Results affected by blood but not by meconium. Cannot use a vaginal pooled sample.</td> </tr> <tr> <td>Phosphatidylglycerol</td> <td>Present (typically greater than&nbsp;2 percent of total phospholipids when performed by thin-layer chromatography, at least 0.5 mg/L&nbsp;when performed by slide agglutination)</td> <td>95 to 100 percent</td> <td>23 to 53 percent</td> <td>Time-consuming, complex test if performed using thin-layer chromatography, but a rapid and simple immunological method (slide agglutination) that uses antisera to phosphatidylglycerol is available. Not affected by blood, meconium. Bacteria can give a false positive in vaginal pool samples.</td> </tr> <tr> <td>Lecithin sphingomyelin ratio</td> <td>Greater than or equal to 2</td> <td>95 to 100 percent</td> <td>33 to 50 percent</td> <td>Time-consuming, complex test with large laboratory variation. Results affected by blood and meconium. Avoid use of a vaginal pooled sample.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The predictive value for each test is influenced by the prevalence of respiratory distress syndrome in the population, thus it varies with gestational age.<br />Â¶ â¥50,000 is the current threshold for maturity (refer to text).</div><div class=\"graphic_reference\">Adapted from: ACOG Practice Bulletin No. 97: Fetal Lung Maturity. Obstet Gynecol 2008; 112:717.</div><div id=\"graphicVersion\">Graphic 64274 Version 8.0</div></div></div>"},"64277":{"type":"graphic_figure","displayName":"Deep retinal hemorrhages","title":"Deep retinal hemorrhages","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep retinal hemorrhages</div><div class=\"cntnt\"><img style=\"width:416px; height:416px;\" src=\"images/PEDS/64277_Deep_retinal_hemorrhages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep retinal hemorrhages are small, rounded, slightly irregular red spots that are sometimes called dot or blot hemorrhages. They occur in a deeper layer of the retina than flame-shaped hemorrhages.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley, LS and Szilagyi, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64277 Version 1.0</div></div></div>"},"64278":{"type":"graphic_diagnosticimage","displayName":"Hand arteriogram in thromboangiitis obliterans","title":"Hand arteriogram in thromboangiitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand arteriogram in thromboangiitis obliterans</div><div class=\"cntnt\"><img style=\"width:222px; height:459px;\" src=\"images/CARD/64278_Hand_angiogram_Buergers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The angiogram shows multiple occlusions of the digital arteries, with collateralization &quot;corkscrew collaterals&quot; around the areas of occlusion (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Olin JW, Lie JT. Thromboagiitis (Buerger's disease). In: Current management of hypertensive and vascular disease, Cookie JP, Frohlich ED (Eds), Mosby-Year Book, St Louis 1992. p.265. Copyright Â© Elsevier Science.</div><div id=\"graphicVersion\">Graphic 64278 Version 4.0</div></div></div>"},"64279":{"type":"graphic_waveform","displayName":"ECG Idiopathic left ventricular tachycardia","title":"12-lead electrocardiogram (ECG) showing idiopathic left ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing idiopathic left ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:524px; height:355px;\" src=\"images/CARD/64279_IdiopathicVTleftventricl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The typical ECG features of an idiopathic left ventricular tachycardia are QRS complexes that are relatively narrow (0.12 sec) and have a right bundle branch morphology (tall R waves in V1 and V2 and a terminal S wave in V5 and V6); the frontal plane axis is extremely leftward (negative QRS complexes in leads II, III, and aVF), suggesting a left anterior fascicular block. The tachycardia was localized to the inferior apical left ventricular septum, accounting for the extreme leftward axis.</div><div id=\"graphicVersion\">Graphic 64279 Version 4.0</div></div></div>"},"64284":{"type":"graphic_figure","displayName":"Incidence of absence epilepsy","title":"Relative incidence of human absence epilepsy syndromes during first two decades of life","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relative incidence of human absence epilepsy syndromes during first two decades of life</div><div class=\"cntnt\"><img style=\"width:446px; height:310px;\" src=\"images/PEDS/64284_Incidence_absence_epilepsy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The five syndromes show developmental variation in the ages of seizure onset and duration of clinical seizure activity.</div><div class=\"graphic_footnotes\">In temporal order of peak incidence: MAE: myoclonic astatic epilepsy; EMA: epilepsy with myoclonic absences; CAE: childhood absence epilepsy; JAE: juvenile absence epilepsy; JME: juvenile myoclonic epilepsy.</div><div class=\"graphic_reference\">Data from Noebels, JL, Tharp, BR, In: Brain Development in Epilepsy, Schwartzkroin, P, MoshÃ©, SL, Noebels, J, Swann, J (Eds), Oxford University Press 1995, p.73.</div><div id=\"graphicVersion\">Graphic 64284 Version 3.0</div></div></div>"},"64285":{"type":"graphic_picture","displayName":"Exostosis of the external auditory canal","title":"Exostosis of the external auditory canal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exostosis of the external auditory canal</div><div class=\"cntnt\"><img style=\"width:324px; height:294px;\" src=\"images/PC/64285_Exostosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exostoses are multiple benign bony growths of the external auditory canal that most commonly occur in individuals who have had repeated exposure to cold water.</div><div class=\"graphic_reference\">Reprinted with permission from Nikolas H Blevins, MD</div><div id=\"graphicVersion\">Graphic 64285 Version 2.0</div></div></div>"},"64286":{"type":"graphic_table","displayName":"Non-SCID combined immunodeficiencies","title":"Non-SCID combined immunodeficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-SCID combined immunodeficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Gene</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">T cell receptor signaling defects</td> </tr> <tr> <td class=\"indent1\">TCR alpha deficiency</td> <td><em>TRAC</em></td> </tr> <tr> <td class=\"indent1\">CD3 gamma deficiency</td> <td><em>CD3G</em></td> </tr> <tr> <td class=\"indent1\">CD8 alpha deficiency</td> <td><em>CD8A</em></td> </tr> <tr> <td class=\"indent1\">Zeta-associated protein 70 kD (ZAP-70) deficiency</td> <td><em>ZAP70</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lck deficiency</td> <td><em>LCK</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Calcium channel defects</td> </tr> <tr> <td class=\"indent1\">Orai-1 deficiency</td> <td><em>ORAI1</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Stromal interaction molecule-1 (Stim-1) deficiency</td> <td><em>STIM1</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Magnesium channel defect</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MAGT1 deficiency</td> <td><em>MAGT1</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">MHC class I deficiency</td> </tr> <tr> <td class=\"indent1\">Transporters of antigenic peptides 1 and 2 deficiency</td> <td><em>TAP1/TAP2</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">TAP binding protein (tapasin) deficiency</td> <td><em>TAPBP</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">MHC class II deficiency</td> </tr> <tr> <td class=\"indent1\">CIITA</td> <td><em>MHC2TA</em></td> </tr> <tr> <td class=\"indent1\">RFX5</td> <td><em>RFX5</em></td> </tr> <tr> <td class=\"indent1\">RFXAP</td> <td><em>RFXAP</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">RFXANK</td> <td><em>RFXANK</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Transcription factor defects</td> </tr> <tr> <td class=\"indent1\">Winged helix deficiency (nude)</td> <td><em>FOXN1</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Signal transducer and activators of transcription 5b (STAT5b) deficiency</td> <td><em>STAT5B</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nucleic acid metabolic defects</td> </tr> <tr> <td class=\"indent1\">Purine nucleoside phosphorylase deficiency</td> <td><em>PNP</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cytidine triphosphate synthase 1 deficiency</td> <td><em>CTPS1</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hyper-IgM syndromes</td> </tr> <tr> <td class=\"indent1\">Tumor necrosis factor superfamily member 5 (CD40L) deficiency</td> <td><em>TNFSF5</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tumor necrosis factor receptor superfamily member 5 (CD40) deficiency</td> <td><em>TNFRSF5</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">RhoH deficiency</td> <td><em>RHOH</em></td> </tr> <tr> <td class=\"indent1\">MST1 deficiency</td> <td><em>STK4</em></td> </tr> <tr> <td class=\"indent1\">MALT1 deficiency</td> <td><em>MALT1</em></td> </tr> <tr> <td class=\"indent1\">IL-21R deficiency</td> <td><em>IL21R</em></td> </tr> <tr> <td class=\"indent1\">CARD11 deficiency</td> <td><em>CARD11</em></td> </tr> <tr> <td class=\"indent1\">OX40 deficiency</td> <td><em>OX40</em></td> </tr> <tr> <td class=\"indent1\">IKBKB deficiency</td> <td><em>IKBKB</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD: cluster of differentiation; MAGT1: magnesium transporter 1; MHC: major histocompatibility complex; TAP: transporter associated with antigen processing; CIITA: class II, major histocompatibility complex, transactivator; RFX5: regulatory factor X, 5; RFXAP: regulatory factor X-associated protein; RFXANK: regulatory factor X-associated ankyrin-containing protein; MST1: mammalian sterile 20-like protein 1; TCR: T cell receptor; Lck: lymphocyte-specific protein-tyrosine kinase; <FONT color=black>MALT1</FONT><FONT color=black>:</FONT> mucosa-associated lymphoid tissue lymphoma translocation gene 1; IL-21R: interleukin 21 receptor; CARD11: caspase recruitment domain family, member 11; <FONT color=black>OX40</FONT><FONT color=black>: also </FONT>known as tumor necrosis factor receptor superfamily, member 4 (TNFRSF4) or CD134; IKBKB: inhibitor of kappa light polypeitide gene enhancer in B cells, kinase beta; ARPC1B: actin-related protein complex-1B.</div><div class=\"graphic_reference\">Adapted from: Bonilla, FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</div><div id=\"graphicVersion\">Graphic 64286 Version 19.0</div></div></div>"},"64287":{"type":"graphic_diagnosticimage","displayName":"Hepatic hydrothorax nuclear","title":"Hepatic hydrothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic hydrothorax</div><div class=\"cntnt\"><img style=\"width:432px; height:327px;\" src=\"images/GAST/64287_Hepatic_hydrothorax_nuclear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraperitoneal injection of 500 MBq 99mTc-tagged nannocolloids, followed by scintigrams taken between 5 minutes and 24 hours post injection, demonstrated a transdiaphragmatic tracer flow into the right pleural cavity.</div><div class=\"graphic_reference\">Reproduced with permission from: Truninger K, Frey LD. Hepatic hydrothorax without ascites. Schweiz Med Wochenschr 2000; 130:1706.</div><div id=\"graphicVersion\">Graphic 64287 Version 3.0</div></div></div>"},"64291":{"type":"graphic_table","displayName":"Predictors of stroke in atrial fibrillation","title":"Clinical and echocardiographic predictors of stroke in atrial fibrillation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and echocardiographic predictors of stroke in atrial fibrillation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n      <td colspan=\"2\" class=\"subtitle1_single\">Clinical factors</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\">History of hypertension</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\">Recent (within 3 months) HF</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\">Previous cerebrovascular event (stroke or TIA)</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\" class=\"subtitle1_single\">Echocardiographic factors</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\">Global left ventricular dysfunction</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\">Dilated atrium on M-mode (&#8805;4.7 cm or 2.4 cm/m2)</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\" class=\"subtitle1_single\">Stroke risk (per year) based on clinical factors</td>\n    </tr>\n\n    <tr>\n      <td>No risk factors</td>\n      <td>2.5 percent</td>\n    </tr>\n\n    <tr>\n      <td>1 risk factor</td>\n      <td>7.2 percent</td>\n    </tr>\n\n    <tr>\n      <td>1 or 2 risk factors </td>\n      <td>17.6 percent</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\" class=\"subtitle1_single\">Stroke risk (per year) based on clinical and echocardiographic factors</td>\n    </tr>\n\n    <tr>\n      <td>No risk factors</td>\n      <td>1.0 percent</td>\n    </tr>\n\n    <tr>\n      <td>1 risk factor</td>\n      <td>6.0 percent</td>\n    </tr>\n\n    <tr>\n      <td>2 or 3 risk factors</td>\n      <td>18.6 percent</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116:1 and 1992; 116:6.</div><div id=\"graphicVersion\">Graphic 64291 Version 3.0</div></div></div>"},"64292":{"type":"graphic_table","displayName":"Etiology of arrhythmias in congenital heart disease","title":"Etiology of arrhythmias in congenital heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of arrhythmias in congenital heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bradycardia</td> <td class=\"subtitle1_single\">Examples</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Congenital</td> </tr> <tr> <td class=\"indent1\">Congenital sinus node dysfunction</td> <td>Situs inversus</td> </tr> <tr> <td class=\"indent1\">Congenital AV block</td> <td>AV canal defects; cc-TGA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acquired</td> </tr> <tr> <td class=\"indent1\">Acquired sinus node dysfunction</td> <td>s/p repair of Mustand/Senning, Fontan, Glenn or sinus venosus ASD</td> </tr> <tr> <td class=\"indent1\">Acquired AV node dysfunction</td> <td>s/p VSD/LVOT/aortic valve operation</td> </tr> <tr> <td class=\"subtitle1_single\">Tachycardia</td> <td class=\"subtitle1_single\">Examples</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Congenital</td> </tr> <tr> <td class=\"indent1\">Twin AV nodes</td> <td>Heterotaxy syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acquired</td> </tr> <tr> <td class=\"indent1\">Atrial tachycardia/flutter</td> <td>Atrial baffles; post-MAZE</td> </tr> <tr> <td class=\"indent1\">Atrial fibrillation</td> <td>ASD's, mitral valve disease</td> </tr> <tr> <td class=\"indent1\">Ectopic atrial tachycardia</td> <td>Fontan</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular; cc-TGA: congenitally corrected transposition of the great arteries; ASD: atrial septal defect; VSD: ventricular septal defect; LVOT: left ventricular outflow tract.</div><div id=\"graphicVersion\">Graphic 64292 Version 3.0</div></div></div>"},"64293":{"type":"graphic_algorithm","displayName":"Testing for iron overload and HH","title":"Algorithm for the testing for iron overload and hereditary hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Algorithm for the testing for iron overload and hereditary hemochromatosis</div><div class=\"cntnt\"><img style=\"width:588px; height:470px;\" src=\"images/HEME/64293_Testing_treat_HH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An algorithm can provide some further direction regarding testing and treatment for iron overload and hereditary hemochromatosis (HH). The algorithm is modified from the version used in the previous American Association for the Study of Liver Diseases (AASLD) guidelines. For screening purposes, the serum ferritin is considered elevated if it is &gt;200 ng/mL in men or &gt;150 ng/mL in women.</div><div class=\"graphic_footnotes\">HH: hereditary hemochromatosis; TS: transferrin saturation; HIC: hepatic iron concentration.</div><div class=\"graphic_reference\">From: Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328. Copyright Â© 2011 American Association for the Study of Liver Diseases. Reproduced with permission of John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 64293 Version 9.0</div></div></div>"},"64294":{"type":"graphic_table","displayName":"Tricyclic antidepressant intoxication - Rapid overview","title":"Tricyclic antidepressant intoxication: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tricyclic antidepressant intoxication: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span class=\"red\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span class=\"red\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Sedation, coma, seizures</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Tachycardia, hypotension, conduction abnormalities</td> </tr> <tr> <td class=\"subtitle2_single\">Anticholinergic</td> </tr> <tr> <td class=\"indent1\">Dilated pupils, dry mouth, absent bowel sounds, urinary retention</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"subtitle2_single\">Electrocardiographic changes in severe poisoning:</td> </tr> <tr> <td class=\"indent1\">QRS duration &#62;100 msec</td> </tr> <tr> <td class=\"indent1\">Rightward deflection of the terminal 40 msec of the QRS complex</td> </tr> <tr> <td class=\"indent1\">Deep S wave in leads I, AVL; tall R wave in lead AVR</td> </tr> <tr> <td class=\"indent1\">R wave in AVR &#62;3 mm; R/S ratio in AVR &#62;0.7</td> </tr> <tr> <td class=\"subtitle2_single\">Serum TCA concentrations do not help to guide therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Airway</td> </tr> <tr> <td class=\"indent1\">Manage as indicated; many patients require tracheal intubation</td> </tr> <tr> <td class=\"subtitle2_single\">Breathing</td> </tr> <tr> <td class=\"indent1\">Administer supplemental oxygen</td> </tr> <tr> <td class=\"subtitle2_single\">Circulation</td> </tr> <tr> <td class=\"indent1\">Hypotension: Treat with intravenous boluses of isotonic crystalloid. If patient remains hypotensive despite aggressive volume resuscitation, can treat with a vasopressor. Alpha-adrenergic agonists (eg, neosynephrine, norepinephrine) are preferred.</td> </tr> <tr> <td class=\"indent1\">Conduction disturbances: If QRS &#62;100 msec, challenge with intravenous sodium bicarbonate (2 to 3 mEq/kg up to 150 mEq IV push) and assess for QRS narrowing. If QRS narrows, begin continuous infusion (150 mEq of sodium bicarbonate in 1 liter of D5W to run at 250 mL/hour in adults or twice the maintenance fluid rate in children).</td> </tr> <tr> <td class=\"subtitle2_single\">Gastrointestinal decontamination</td> </tr> <tr> <td class=\"indent1\">Administer activated charcoal if patient presents within 2 hours of ingestion, unless gastrointestinal complication (ileus, obstruction) suspected. Dose is 1 g/kg (maximum dose 50 g).</td> </tr> <tr> <td class=\"subtitle2_single\">Seizures</td> </tr> <tr> <td class=\"indent1\">Treat with benzodiazepines (eg, diazepam 5 mg IV or lorazepam 2 mg IV)</td> </tr> <tr> <td class=\"indent1\">Do <strong>NOT</strong> treat with phenytoin</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64294 Version 14.0</div></div></div>"},"64295":{"type":"graphic_figure","displayName":"Natural history neurosyphilis","title":"Natural history of neurosyphilis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Natural history of neurosyphilis</div><div class=\"cntnt\"><img style=\"width:517px; height:355px;\" src=\"images/NEURO/64295_Natural_history_neurosyphil.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div class=\"graphic_reference\">Courtesy of Christina M. Marra, MD.</div><div id=\"graphicVersion\">Graphic 64295 Version 2.0</div></div></div>"},"64296":{"type":"graphic_table","displayName":"Diff dx preeclampsia","title":"Frequency of various signs and symptoms among imitators of preeclampsia-eclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of various signs and symptoms among imitators of preeclampsia-eclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Signs and symptoms</td> <td class=\"subtitle1\">HELLP syndrome, percent</td> <td class=\"subtitle1\">AFLP, percent</td> <td class=\"subtitle1\">TTP, percent</td> <td class=\"subtitle1\">HUS, percent</td> <td class=\"subtitle1\">Exacerbation of SLE, percent</td> </tr> <tr> <td>Hypertension</td> <td>85</td> <td>50</td> <td>20 to 75</td> <td>80 to 90</td> <td>80 with APA, nephritis</td> </tr> <tr> <td>Proteinuria</td> <td>90 to 95</td> <td>30 to 50</td> <td>With hematuria</td> <td>80 to 90</td> <td>100 with nephritis</td> </tr> <tr> <td>Fever</td> <td>Absent</td> <td>25 to 32</td> <td>20 to 50</td> <td>NR</td> <td>Common during flare</td> </tr> <tr> <td>Jaundice</td> <td>5 to 10</td> <td>40 to 90</td> <td>Rare</td> <td>Rare</td> <td>Absent</td> </tr> <tr> <td>Nausea and vomiting</td> <td>40</td> <td>50 to 80</td> <td>Common</td> <td>Common</td> <td>Only with APA</td> </tr> <tr> <td>Abdominal pain</td> <td>60 to 80</td> <td>35 to 50</td> <td>Common</td> <td>Common</td> <td>Only with APA</td> </tr> <tr> <td>Central nervous system</td> <td>40 to 60</td> <td>30 to 40</td> <td>60 to 70</td> <td>NR</td> <td>50 with APA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HELLP: hemolysis, elevated liver enzymes, low platelets; AFLP: acute fatty liver of pregnancy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; SLE: systemic lupus erythematosus; APA: antiphospholipid antibodies with or without catastrophic antiphospholipid syndrome; NR: values not reported; common: reported as the most common presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007; 109:956. Copyright Â© 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64296 Version 10.0</div></div></div>"},"64297":{"type":"graphic_table","displayName":"LEVO LV dose adjustment","title":"Recommendations for dose adjustment with LEVOleucovorin (l-isomer of leucovorin) for prolonged methotrexate excretion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for dose adjustment with LEVOleucovorin (l-isomer of leucovorin) for prolonged methotrexate excretion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical situation</td> <td class=\"subtitle1\">Laboratory findings</td> <td class=\"subtitle1\">Levoleucovorin injection dosage and duration</td> </tr> <tr class=\"divider_bottom\"> <td>Normal methotrexate elimination</td> <td>Serum methotrexate level approximately 10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours</td> <td>7.5 mg IV every 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion)</td> </tr> <tr class=\"divider_bottom\"> <td>Delayed late methotrexate elimination</td> <td>Serum methotrexate level remaining above 0.2 micromolar at 72 hours and more than 0.05 micromolar at 96 hours after administration</td> <td>Continue 7.5 mg IV every 6 hours until methotrexate level is less than 0.05 micromolar</td> </tr> <tr> <td>Delayed early methotrexate elimination and/or evidence of acute renal injury</td> <td>Serum methotrexate level of 50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration; OR a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration (eg, an increase from 0.5 mg/dL to a level of 1 mg/dL or more)</td> <td>75 mg IV every 3 hours until methotrexate level is less than 1 micromolar; then 7.5 mg IV every 3 hours until methotrexate level is less than 0.05 micromolar</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous</div><div id=\"graphicVersion\">Graphic 64297 Version 2.0</div></div></div>"},"64298":{"type":"graphic_picture","displayName":"Small cell carcinoma prostate","title":"Small cell (neuroendocrine) carcinoma of the prostate","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Small cell (neuroendocrine) carcinoma of the prostate</div><div class=\"cntnt\"><img style=\"width:543px; height:224px;\" src=\"images/ONC/64298_Small_cell_carcinoma_prosta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: high-power photomicrograph of an hematoxylin- and eosin-stained tissue section of the prostate gland showing a small cell cancer. In contrast to prostate adenocarcinoma (a Gleason grade 4 adenocarcinoma is pictured in the right panel for comparison), small cell carcinoma of the prostate is composed of small tumor cells with neuroendocrine differentiation and the absence of glandular structures.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 64298 Version 2.0</div></div></div>"},"64300":{"type":"graphic_table","displayName":"LD definition Natl Joint Comm","title":"National Joint Committee on Learning Disabilities definition of learning disabilities, 1994","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">National Joint Committee on Learning Disabilities definition of learning disabilities, 1994</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td>\"Learning Disabilities is a generic term that refers to\na heterogeneous group of disorders manifested by significant\ndifficulties in the acquisition and use of listening, speaking,\nreading, writing, reasoning, or mathematical abilities. These disorders\nare intrinsic to the individual and presumed to be due to central\nnervous system dysfunction. Even though a learning disability may occur\nconcomitantly with other handicapping conditions (eg, sensory\nimpairment, mental retardation, social and emotional disturbance) or\nenvironmental influences (eg, cultural differences, insufficient or\ninappropriate instruction, psychogenic factors), it is not the direct\nresult of those conditions or influences.\"</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">American Speech-Language Hearing Association; Association for Children and Adults with Learning Disabilities; Council for Learning Disabilities; Division for Children with Communication Disorders, Council for Exceptional Children; Division for Learning Disabilities, Council for Exceptional Children; International Reading Association; National Association for School Psychologists; The Orton Dyslexia Society.</div><div id=\"graphicVersion\">Graphic 64300 Version 1.0</div></div></div>"},"64301":{"type":"graphic_table","displayName":"Classification of syncope","title":"Classification of syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Reflex (neurally mediated) syncope</td> </tr> <tr> <td class=\"subtitle2_single\">Vasovagal:</td> </tr> <tr> <td class=\"indent1\">Mediated by emotional distress: fear, pain, instrumentation, blood phobia</td> </tr> <tr> <td class=\"indent1\">Mediated by orthostatic stress</td> </tr> <tr> <td class=\"subtitle2_single\">Situational:</td> </tr> <tr> <td class=\"indent1\">Cough, sneeze</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal stimulation (swallow, defecation, visceral pain)</td> </tr> <tr> <td class=\"indent1\">Micturition (postmicturition)</td> </tr> <tr> <td class=\"indent1\">Post-exercise</td> </tr> <tr> <td class=\"indent1\">Postprandial</td> </tr> <tr> <td class=\"indent1\">Others (eg, laughter, brass instrument playing, weightlifting)</td> </tr> <tr> <td class=\"subtitle2_single\">Carotid sinus syncope</td> </tr> <tr> <td class=\"subtitle2_single\">Atypical forms (without apparent triggers and/or atypical presentation)</td> </tr> <tr> <td class=\"subtitle1_single\">Syncope due to orthostatic hypotension</td> </tr> <tr> <td class=\"subtitle2_single\">Primary autonomic failure:</td> </tr> <tr> <td class=\"indent1\">Pure autonomic failure, multiple system atrophy, Parkinson's disease with autonomic failure, Lewy body dementia</td> </tr> <tr> <td class=\"subtitle2_single\">Secondary autonomic failure:</td> </tr> <tr> <td class=\"indent1\">Diabetes, amyloidosis, uraemia, spinal cord injuries</td> </tr> <tr> <td class=\"subtitle2_single\">Drug-induced orthostatic hypotension:</td> </tr> <tr> <td class=\"indent1\">Alcohol, vasodilators, diuretics, phenothiazines, antidepressants</td> </tr> <tr> <td class=\"subtitle2_single\">Volume depletion:</td> </tr> <tr> <td class=\"indent1\">Hemorrhage, diarrhoea, vomiting, etc</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac syncope (cardiovascular)</td> </tr> <tr> <td class=\"subtitle2_single\">Arrhythmia as primary cause:</td> </tr> <tr> <td class=\"subtitle3_single\">Bradycardia:</td> </tr> <tr> <td class=\"indent2\">Sinus node dysfunction (including bradycardia/tachycardia syndrome)</td> </tr> <tr> <td class=\"indent2\">Atrioventricular conduction system disease</td> </tr> <tr> <td class=\"indent2\">Implanted device malfunction</td> </tr> <tr> <td class=\"subtitle3_single\">Tachycardia:</td> </tr> <tr> <td class=\"indent2\">Supraventricular</td> </tr> <tr> <td class=\"indent2\">Ventricular (idiopathic, secondary to structural heart disease or to channelopathies)</td> </tr> <tr> <td class=\"subtitle3_single\">Drug-induced bradycardia and tachyarrhythmias</td> </tr> <tr> <td class=\"subtitle2_single\">Structural disease:</td> </tr> <tr> <td class=\"indent1\">Cardiac: cardiac valvular disease, acute myocardial infarction/ischaemia, hypertrophic cardiomyopathy, cardiac masses (atrial myxoma, tumors, etc), pericardial disease/tamponade, congenital anomalies of coronary arteries, prosthetic valves dysfunction</td> </tr> <tr> <td class=\"indent1\">Others: pulmonary embolus, acute aortic dissection, pulmonary hypertension</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright Â© 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 64301 Version 14.0</div></div></div>"},"64302":{"type":"graphic_table","displayName":"Diagnostic criteria for acute and recurrent pericarditis","title":"Diagnostic criteria for acute and recurrent pericarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for acute and recurrent pericarditis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute pericarditis (at least 2 criteria of 4):</td> </tr> <tr> <td class=\"indent1\">Typical pleuritic chest pain</td> </tr> <tr> <td class=\"indent1\">Pericardial friction rub</td> </tr> <tr> <td class=\"indent1\">Suggestive electrocardiogram changes (typically widespread ST segment elevation, PR depression)</td> </tr> <tr> <td class=\"indent1\">New or worsening pericardial effusion</td> </tr> <tr> <td class=\"subtitle1_single\">Recurrent pericarditis</td> </tr> <tr> <td class=\"subtitle2_single\">Typical pleuritic chest pain plus at least one objective evidence of disease activity:</td> </tr> <tr> <td class=\"indent1\">Fever</td> </tr> <tr> <td class=\"indent1\">Pericardial rub</td> </tr> <tr> <td class=\"indent1\">ECG changes</td> </tr> <tr> <td class=\"indent1\">New or worsening pericardial effusion</td> </tr> <tr> <td class=\"indent1\">Elevation of markers of inflammation (elevation in white blood cell count, erythrocyte sedimentation rate, or C-reactive protein)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">2</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=82588&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 64302 Version 3.0</div></div></div>"},"64303":{"type":"graphic_picture","displayName":"ECD perirenal mass biopsy","title":"Infiltration of CD68 positive, S100 negative histiocytes in Erdheim-Chester disease","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Infiltration of CD68 positive, S100 negative histiocytes in Erdheim-Chester disease</div><div class=\"cntnt\"><img style=\"width:581px; height:209px;\" src=\"images/HEME/64303_ECD_perirenal_mass_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The biopsy obtained from perirenal tissue showed an infiltration of numerous histiocytes (H&amp;E, x100). The histiocytes were CD68-positive (B: x100) and S100-negative (C: x100).</div><div class=\"graphic_reference\">Reproduced with permission from: Kim MS, Kim CH, Choi SJ, et al. Erdheim-Chester disease. Ann Dermatol 2010; 22:439. Copyright &#169; 2010 Korean Dermatological Association.</div><div id=\"graphicVersion\">Graphic 64303 Version 1.0</div></div></div>"},"64304":{"type":"graphic_picture","displayName":"Trichomycosis axillaris","title":"Trichomycosis axillaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Trichomycosis axillaris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64304_Trichomyc_axillaris_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tan concretions are present on the hair shafts.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64304 Version 4.0</div></div></div>"},"64305":{"type":"graphic_table","displayName":"Vulvar abscess antibiotics","title":"Antibiotic therapy for vulvar abscess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic therapy for vulvar abscess</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose (adult)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Outpatient oral antibiotic therapy options for vulvar abscess*</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole)</td> <td>1 to 2 double-strength<sup>&#182;</sup> tablets twice daily</td> </tr> <tr> <td class=\"indent1\">Doxycycline<sup>&#916;</sup></td> <td>100 mg twice daily</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#916;</sup><sup>&#9674;</sup></td> <td>600 mg three times daily or 300 to 450 mg three times daily for mild uncomplicated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Linezolid</td> <td>600 mg twice daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inpatient intravenous antibiotic therapy options for severe vulvar abscess/infection<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> <td>15 to 20 mg/kg/dose every 8 to 12 hours (maximum 2 grams per dose)<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td>600 mg twice daily</td> </tr> <tr> <td class=\"indent1\">Daptomycin</td> <td>4 mg/kg once daily</td> </tr> <tr> <td class=\"indent1\">Telavancin</td> <td>10 mg/kg once daily</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#9674;</sup></td> <td>600 mg three times daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Antimicrobial for management of Bartholin's gland abscess is covered separately. Refer to the topic on disorders of Bartholin's gland.</div><div class=\"graphic_footnotes\">* Outpatient antibiotic therapy for vulvar abscess is recommended for 5 to 10 days.<br />Â¶ One double-strength tablet is 160 mg trimethoprim and 800 mg sulfamethoxazole.<br />Î For empiric coverage combined with later generation oral cephalosporin (eg, cefuroxime axetil or cefprozil) or oral fluoroquinolone. Refer to the topic on vulvar abscess.<br /><FONT class=lozenge>â</FONT> Oral clindamycin is a reasonable choice for empiric coverage if local resistance is low. Data on parenteral use for methicillin-resistant <EM>Staphylococcus aureus</EM> are limited. Refer to the topics on treatment of methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />Â§ Due to the likelihood of methicillin-resistant <EM>Staphylococcus aureus</EM> infection in vulvar abscesses, these medications should be used in addition to broad-spectrum parenteral antibiotics for 7 to 14 days depending on response.<br />Â¥ For patients with renal insufficiency, serious infection, or who are obese, adjust dose for serum trough concentration of 15 to 20 mcg/mL. Refer to the topic on vancomycin dosing in adults.</div><div class=\"graphic_reference\">Data from: Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</div><div id=\"graphicVersion\">Graphic 64305 Version 3.0</div></div></div>"},"64306":{"type":"graphic_table","displayName":"Causes of palpitations","title":"Causes of palpitations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of palpitations</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Cardiac</td></tr>\n\t\t\t\t\t\t<tr><td>Any arrhythmia</td></tr>\n\t\t\t\t\t\t<tr><td>Cardiac and extracardiac shunts</td></tr>\n\t\t\t\t\t\t<tr><td>Valvular heart disease</td></tr>\n\t\t\t\t\t\t<tr><td>Pacemaker</td></tr>\n\t\t\t\t\t\t<tr><td>Atrial myxoma</td></tr>\n\t\t\t\t\t\t<tr><td>Cardiomyopathy</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Psychiatric disease</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Panic attack and disorder</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Generalized anxiety disorder</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Somatization</td></tr>\n\t\t\t\t\t\t<tr><td>Depression</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Medications</td></tr>\n\t\t\t\t\t\t<tr><td>Sympathomimetic agents</td></tr>\n\t\t\t\t\t\t<tr><td>Vasodilators</td></tr>\n\t\t\t\t\t\t<tr><td>Anticholinergic drugs</td></tr>\n\t\t\t\t\t\t<tr><td>Beta blocker withdrawal</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Habits</td></tr>\n\t\t\t\t\t\t<tr><td>Cocaine</td></tr>\n\t\t\t\t\t\t<tr><td>Amphetamines</td></tr>\n\t\t\t\t\t\t<tr><td>Caffeine</td></tr>\n\t\t\t\t\t\t<tr><td>Nicotine</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Metabolic disorders</td></tr>\n\t\t\t\t\t\t<tr><td>Hypoglycemia</td></tr>\n\t\t\t\t\t\t<tr><td>Thyrotoxicosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Pheochromocytoma</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Mastocytosis</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td>Scombroid food poisoning</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">High output states</td></tr>\n\t\t\t\t\t\t<tr><td>Anemia</td></tr>\n\t\t\t\t\t\t<tr><td>Pregnancy</td></tr>\n\t\t\t\t\t\t<tr><td>Paget's disease</td></tr>\n\t\t\t\t\t\t<tr><td>Fever</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Catecholamine excess</td></tr>\n\t\t\t\t\t\t<tr><td>Stress</td></tr>\n\t\t\t\t\t\t<tr><td>Exercise</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Data from Weber, BE, Kapoor, WN, Am J Med 1996; 100:138.</div><div id=\"graphicVersion\">Graphic 64306 Version 1.0</div></div></div>"},"64307":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa of the breast and axilla","title":"Hidradenitis suppurativa of the breast and axilla","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa of the breast and axilla</div><div class=\"cntnt\"><img style=\"width:504px; height:204px;\" src=\"images/PC/64307_Hidradenitis_assoc_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hidradenitis suppurativa of the lower breast.<br> (B) Hidradenitis suppurativa affecting the axilla.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 64307 Version 3.0</div></div></div>"},"64308":{"type":"graphic_diagnosticimage","displayName":"Calcified apical caps PA","title":"Bilateral calcified apical caps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral calcified apical caps</div><div class=\"cntnt\"><img style=\"width:324px; height:317px;\" src=\"images/PULM/64308_CalcifiedapicalcapsPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral calcified apical caps, unrelated to asbestos exposure. Pleural plaques usually spare the apices.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64308 Version 3.0</div></div></div>"},"64309":{"type":"graphic_figure","displayName":"Epoprostenol in HIV PAH","title":"Pulmonary vascular resistance at baseline and after long-term infusion of epoprostenol","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Pulmonary vascular resistance at baseline and after long-term infusion of epoprostenol</div><div class=\"cntnt\"><img style=\"width:537px; height:311px;\" src=\"images/PULM/64309_Epoprostenol_in_HIV_PAH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patients underwent right heart catheterization at the points cited and pulmonary vascular resistance was calculated.</div><div class=\"graphic_footnotes\">PVR: pulmonary vascular resistance.<br> * p &lt;0.05 compared with PVR at baseline.<br> &#8226; p &lt;0.05 compared with PVR after acute infusion of epoprostenol. There were not enough patients at 24 months to determine significance.</div><div class=\"graphic_reference\">Reproduced with permission from: Aguilar, RV, Farber, HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162:1846. Copyright &#169;2000 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 64309 Version 1.0</div></div></div>"},"64311":{"type":"graphic_table","displayName":"Clinical clues DISH","title":"Clinical clues to the presence of diffuse idiopathic skeletal hyperostosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical clues to the presence of diffuse idiopathic skeletal hyperostosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Generalized tenderness at peripheral entheses</td> </tr> <tr> <td>Recurrent Achilles tendinitis</td> </tr> <tr> <td>Recurrent shoulder \"bursitis\"</td> </tr> <tr> <td>Recurrent lateral or medial epicondylitis</td> </tr> <tr> <td>Palpable bony spurs (calcaneus, olecranon, patella)</td> </tr> <tr> <td>Soft tissue mass adherent to quadriceps, patella, or Achilles tendon</td> </tr> <tr> <td>Dysphagia</td> </tr> <tr> <td>Myelopathy</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Utsinger PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985; 11:325. Copyright &#169;1985 WB Saunders Company.</div><div id=\"graphicVersion\">Graphic 64311 Version 3.0</div></div></div>"},"64312":{"type":"graphic_table","displayName":"Hib conjugate vaccines US","title":"Comparison of conjugate vaccines against <em>Haemophilus influenzae</em> type b licensed in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of conjugate vaccines against <em>Haemophilus influenzae</em> type b licensed in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine<br /> (commercial name)</td> <td class=\"subtitle1\">Carrier protein</td> <td class=\"subtitle1\">Recommended age of administration*</td> <td class=\"subtitle1\">Allergy considerations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Monovalent Hib vaccines</td> </tr> <tr> <td class=\"indent1\"> <p>PRP-OMP<sup>&#182;</sup></p> <p>(PedvaxHIB)</p> </td> <td>Outer membrane protein complex of <em>Neisseria meningitidis</em></td> <td>2, 4, and 12 through 15 months</td> <td>Vial stoppers contain natural rubber latex</td> </tr> <tr> <td class=\"indent1\">PRP-T<br /> (ActHIB)</td> <td>Tetanus toxoid</td> <td>2, 4, 6, and 12 through 15 months</td> <td>Vial stoppers contain natural rubber latex</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PRP-T<br /> (Hiberix)</td> <td>Tetanus toxoid</td> <td>2, 4, 6, and 12 through&nbsp;15 months</td> <td>Vial stoppers do not contain natural rubber latex</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Combination Hib vaccine</td> </tr> <tr> <td class=\"indent1\">DTaP-IPV/PRP-T<br /> (Pentacel)</td> <td>Tetanus toxoid</td> <td>2, 4, 6, and 15 through 18 months<sup>&#916;</sup></td> <td>Vial stoppers do not contain natural rubber latex</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Hib: <EM>H. influenzae</EM> type b; PRP-OMP: polyribosylribitol phosphate conjugated to outer membrane protein complex of <EM>N. meningitidis</EM>; PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid; DTaP: diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine; IPV: inactivated polio vaccine.<br />* The first dose may be given as early as&nbsp;six weeks of age.<br />Â¶&nbsp;Preferred for Native Americans and Alaskan natives.<br />Î&nbsp;The booster (ie, fourth)&nbsp;dose may be given as early as 12 months of age, provided at least six months have elapsed since the third dose of DTaP.<br /></div><div class=\"graphic_reference\">Data from: <br />1. Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <A spellcheck=true href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6301a1.htm\" target=_blank>MMWR Recomm Rep 2014; 63:1</A>.<br />2. Hiberix [Haemophilus b conjugate vaccine (tetanus toxoid conjugate)]. US Food and Drug Administration (FDA) approved product information. Revised January 2016. US Food &amp; Drug Administration. Available online: <A spellcheck=true href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A> (Accessed January 21, 2016).<br />3. Briere EC. Food and Drug Administration approval for use of Hiberix as a 3-dose primary Haemophilus influenzae type b (Hib) vaccination series. MMWR Morb Mortal Wkly Rep 2016; 65:418.</div><div id=\"graphicVersion\">Graphic 64312 Version 15.0</div></div></div>"},"64313":{"type":"graphic_movie","displayName":"Central airway obstruction","title":"Central airway obstruction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central airway obstruction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64313_centairwayfbeconv.mp4\" style=\"width:320px;height:236px\"></div><img style=\"width:387px; height:263px;\" src=\"images/CARD/64313_centairwayfbe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Caused by aspiration of a large piece of meat. Foreign body forceps are used for extraction.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 64313 Version 2.0</div></div></div>"},"64314":{"type":"graphic_table","displayName":"Common misdiagnosis recluse spider bite","title":"A list of medical conditions that have been or could be misdiagnosed as cutaneous loxoscelism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A list of medical conditions that have been or could be misdiagnosed as cutaneous loxoscelism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Atypical mycobacteria</td> </tr> <tr> <td class=\"sublist1_start\">Bacterial</td> </tr> <tr> <td class=\"sublist1\">- Group A <em>Streptococcus</em></td> </tr> <tr> <td class=\"sublist1\">- <em>Staphylococcus aureus</em>&nbsp;(especially MRSA)</td> </tr> <tr> <td class=\"sublist1\">- Lyme disease</td> </tr> <tr> <td class=\"sublist1\">- Cutaneous anthrax</td> </tr> <tr> <td class=\"sublist1\">- Syphilis</td> </tr> <tr> <td class=\"sublist1\">- Gonococcemia</td> </tr> <tr> <td class=\"sublist1\">- Ricketsial disease</td> </tr> <tr> <td class=\"sublist1\">- Tularemia</td> </tr> <tr> <td class=\"sublist1_start\">Deep fungal</td> </tr> <tr> <td class=\"sublist1\">- Sporotrichosis</td> </tr> <tr> <td class=\"sublist1\">- Aspergillosis</td> </tr> <tr> <td class=\"sublist1\">- Cryptococcosis</td> </tr> <tr> <td>Ecthyma gangrenosum (<em>Pseudomonas aeruginosa</em>)</td> </tr> <tr> <td>Parasitic (Leishmaniasis)</td> </tr> <tr> <td>Viral (herpes simplex, herpes zoster [shingles]</td> </tr> <tr> <td class=\"subtitle1_single\">Topical and exogenous causes</td> </tr> <tr> <td>Burns (chemical, thermal)</td> </tr> <tr> <td>Toxic plant dermatitis (poison ivy, poison oak)</td> </tr> <tr> <td>Factitious injury (ie, self-induced)</td> </tr> <tr> <td>Pressure ulcers (ie, bed sores)</td> </tr> <tr> <td>Other arthropod bites</td> </tr> <tr> <td>Radiotherapy</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular occlusive or venous disease</td> </tr> <tr> <td>Antiphospholipid-antibody syndrome</td> </tr> <tr> <td>Livedoid vasculopathy</td> </tr> <tr> <td>Small-vessel occlusive arterial disease</td> </tr> <tr> <td>Venous stasis ulcer</td> </tr> <tr> <td class=\"subtitle1_single\">Necrotising vasculitis</td> </tr> <tr> <td>Leukocytoclastic vaculitis</td> </tr> <tr> <td>Polyarteritis nodosa</td> </tr> <tr> <td>Takayasu's arteritis</td> </tr> <tr> <td>Wegener's granulomatosis</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic disease</td> </tr> <tr> <td>Leukemia cutis</td> </tr> <tr> <td>Lymphoma (eg, mycosis fungoides)</td> </tr> <tr> <td>Primary skin neoplasms (basal cell carcinoma, malignant melanoma, squamous cell carcinoma)</td> </tr> <tr> <td>Lymphomatoid papulosis</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions</td> </tr> <tr> <td>Calcific uremic arteriolopathy</td> </tr> <tr> <td>Cryoglobulinemia</td> </tr> <tr> <td>Diabetic ulcer</td> </tr> <tr> <td>Langerhans' cell histiocytosis</td> </tr> <tr> <td>Pemphigus vegetans</td> </tr> <tr> <td>Pyoderma gangrenosum</td> </tr> <tr> <td>Septic embolism</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Vetter RS. Spiders of the genus Loxosceles (Araneae, Sicariidae): a review of biological, medical and psychological aspects regarding envenomations. Journal of Arachnology 2008; 36:150. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 64314 Version 8.0</div></div></div>"},"64316":{"type":"graphic_table","displayName":"Cong malformat and absent EDV","title":"Absent end diastolic velocity and congenital malformations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absent end diastolic velocity and congenital malformations</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Cardiovascular system</td></tr>\n\t\t\t\t\t\t<tr><td>Ventricular septal defect</td></tr>\n\t\t\t\t\t\t<tr><td>Hypoplastic left heart syndrome</td></tr>\n\t\t\t\t\t\t<tr><td>Double outlet right ventricle</td></tr>\n\t\t\t\t\t\t<tr><td>Ebstein's anomaly</td></tr>\n\t\t\t\t\t\t<tr><td>Arrhythmia - congenital heart block</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Central nervous system</td></tr>\n\t\t\t\t\t\t<tr><td>Hydrocephaly</td></tr>\n\t\t\t\t\t\t<tr><td>Holoprosencephaly</td></tr>\n\t\t\t\t\t\t<tr><td>Agenesis of corpus callosum</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Urogenital system</td></tr>\n\t\t\t\t\t\t<tr><td>Renal agenesis</td></tr>\n\t\t\t\t\t\t<tr><td>Hydronephrosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Gastrointestinal system/abdominal wall</td></tr>\n\t\t\t\t\t\t<tr><td>Esophageal atresia</td></tr>\n\t\t\t\t\t\t<tr><td>Omphaloccle</td></tr>\n\t\t\t\t\t\t<tr><td>Gastroschisis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Skeletal system</td></tr>\n\t\t\t\t\t\t<tr><td>Polydactyly</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Maulik, D. Absent end-diastolic velocity in the umbilical artery and its clinical significance. In: Maulik, D (ed) Doppler ultrasound in obstetrics and gynecology, 1997; 362, New York, Springer Verlag. Copyright &#169; 1997 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 64316 Version 1.0</div></div></div>"},"64317":{"type":"graphic_table","displayName":"CRS HIPEC MPM results","title":"Selected contemporary series of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with malignant peritoneal mesothelioma (MPM)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected contemporary series of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with malignant peritoneal mesothelioma (MPM)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"4\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Percent optimally cytoreduced*</td> <td class=\"subtitle1\">HIPEC agents</td> <td class=\"subtitle1\">Overall survival</td> <td class=\"subtitle1\">Favorable prognostic factors</td> <td class=\"subtitle1\">Preoperative morbidity and mortality</td> </tr> <tr class=\"divider_bottom\"> <td>Yan T, 2009</td> <td class=\"centered\">401</td> <td class=\"centered\">46</td> <td>Cisplatin and Dox; cisplatin, MMC, or both</td> <td> <p>Median 53 months (range 1 to 235)</p> Five-year: 47%</td> <td> <p>Epithelioid subtype</p> <p>Negative LNs</p> <p>Optimal CCR</p> HIPEC</td> <td>31%/2%</td> </tr> <tr class=\"divider_bottom\"> <td>Alexander HR, 2013</td> <td class=\"centered\">211</td> <td class=\"centered\">53</td> <td>Cisplatin or MMC</td> <td> <p>Median 38 months</p> Five-year: 41%</td> <td> <p>Histologic grade</p> <p>Optimal CCR</p> <p>Age &#60;60 y</p> Cisplatin HIPEC</td> <td>30%/2.3%</td> </tr> <tr class=\"divider_bottom\"> <td>Baratti D, 2013</td> <td class=\"centered\">108</td> <td class=\"centered\">66<br /> (estimated)</td> <td>Cisplatin and Dox</td> <td> <p>Median 63 months</p> Five-year estimated: 50%</td> <td> <p>Epithelioid subtype</p> <p>Neg LNs</p> Low mitotic rate</td> <td>39%/1.9%</td> </tr> <tr class=\"divider_bottom\"> <td>Schaub NP, 2013</td> <td class=\"centered\">104</td> <td class=\"centered\">66</td> <td>Cisplatin</td> <td> <p>Median 52 months (range 1 to 81)</p> Five-year: 46%</td> <td> <p>Epithelioid subtype</p> <p>Low PCI</p> Low pre-op CA-125</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td>Hommell-Fontaine J, 2013</td> <td class=\"centered\">28</td> <td class=\"centered\">70</td> <td>Cisplatin and MMC</td> <td>Median 37 months</td> <td>&#60;5% GLUT-1 expression</td> <td>N/A</td> </tr> <tr> <td>Magge D, 2014</td> <td class=\"centered\">65</td> <td class=\"centered\">86</td> <td>MMC (94%)</td> <td> <p>Median 46 months</p> Five-year: 39%</td> <td> <p>Younger age</p> <p>Low PCI</p> <p>Optimal CCR</p> <p>Histologic grade</p> No post-op sepsis</td> <td>35%/6%</td> </tr> <tr> <td>Shetty S, 2014</td> <td class=\"centered\">44</td> <td class=\"centered\">81</td> <td>Carboplatin or MMC</td> <td>Five-year: 53%</td> <td>Carboplatin versus MMC</td> <td>-/0%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CCR: Completeness of surgical cytoreduction score; Dox: doxorubicin; LNs: lymph nodes; MMC: mitomycin C; PCI: peritoneal cancer index; HIPEC: heated intraperitoneal chemotherapy.<br />*&nbsp;CCR score 0 or 1.</div><div id=\"graphicVersion\">Graphic 64317 Version 4.0</div></div></div>"},"64318":{"type":"graphic_diagnosticimage","displayName":"CTA segmental narrowing of intracranial vessels","title":"CTA showing segmental narrowing of intracranial vessels in a 33 year old woman with postpartum angiopathy (reversible cerebral vasoconstriction syndrome)","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">CTA showing segmental narrowing of intracranial vessels in a 33 year old woman with postpartum angiopathy (reversible cerebral vasoconstriction syndrome)</div><div class=\"cntnt\"><img style=\"width:515px; height:481px;\" src=\"images/NEURO/64318_Seg_narr_intracranial_vess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head CT angiography (CTA) six days after onset of postpartum occipital headache&nbsp;reveals segmental narrowing of the left middle cerebral artery and the A1 segment of the right anterior cerebral artery (panel A, arrows); in addition, there is segmental narrowing of the posterior cerebral and left distal vertebral arteries with broad narrowing of the basilar artery (panel B, arrows). Head magnetic resonance angiography (MRA) two months after discharge shows complete reversal of arterial pathology (panels C and D). The magnification is similar in all parts of the figure; the white vertical band denotes 5 cm.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Maalouf N, Harik SI. Clinical reasoning: A 33-year-old woman with severepostpartum occipital headaches. Neurology 2012; 78:366. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64318 Version 7.0</div></div></div>"},"64321":{"type":"graphic_table","displayName":"Mesenteric disease terms","title":"Nomenclature used in the medical literature for idiopathic primary inflammatory and fibrotic processes of the mesentery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nomenclature used in the medical literature for idiopathic primary inflammatory and fibrotic processes of the mesentery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sclerosing mesenteritis</td> </tr> <tr> <td>Mesenteric panniculitis</td> </tr> <tr> <td>Mesenteric lipodystrophy</td> </tr> <tr> <td>Retractile mesenteritis</td> </tr> <tr> <td>Mesenteric Weber-Christian disease</td> </tr> <tr> <td>Xanthogranulomatous mesenteritis</td> </tr> <tr> <td>Mesenteric lipogranuloma</td> </tr> <tr> <td>Liposclerotic mesenteritis</td> </tr> <tr> <td>Inflammatory pseudotumor</td> </tr> <tr> <td>Isolated lipodystrophy</td> </tr> <tr> <td>Retroperitoneal xanthogranuloma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64321 Version 2.0</div></div></div>"},"64322":{"type":"graphic_figure","displayName":"Omental flap for rectal anast","title":"Omental flap for rectal anastomosis during pelvic exenteration","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Omental flap for rectal anastomosis during pelvic exenteration</div><div class=\"cntnt\"><img style=\"width:457px; height:318px;\" src=\"images/OBGYN/64322_Omental_flap_for_rectal_ana.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64322 Version 2.0</div></div></div>"},"64323":{"type":"graphic_table","displayName":"Biliary disorders evaluated by ERCP","title":"Biliary disorders in children in which ERCP can be helpful","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biliary disorders in children in which ERCP can be helpful</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td>Biliary atresia</td> </tr> <tr> <td>Alagille syndrome*</td> </tr> <tr> <td>Caroli disease*</td> </tr> <tr> <td>Biliary cysts</td> </tr> <tr> <td>Biliary strictures</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td>Sclerosing cholangitis</td> </tr> <tr> <td>Ascariasis</td> </tr> <tr> <td>Choledocholithiasis</td> </tr> <tr> <td>Bile plug syndrome</td> </tr> <tr> <td>Malignant biliary strictures</td> </tr> <tr> <td>Common bile duct complications after liver transplantation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.<br> * ERCP is not generally needed for diagnosis of this disorder.</div><div id=\"graphicVersion\">Graphic 64323 Version 4.0</div></div></div>"},"64324":{"type":"graphic_picture","displayName":"Tube otorrhea","title":"Tympanostomy tube otorrhea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanostomy tube otorrhea</div><div class=\"cntnt\"><img style=\"width:260px; height:264px;\" src=\"images/PEDS/64324_Tubeotorrhea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Approximately 30 percent of children have at least one episode of tympanostomy tube otorrhea, depicted above, while the tube remains in place. When otorrhea is refractory to thorough cleaning and suctioning of the tube and topical steroid-antibiotic drops, treatment is based on culture and sensitivity of organisms from the ear canal.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 93, Pages 924-9, Copyright Â© 1994 by the AAP.</div><div id=\"graphicVersion\">Graphic 64324 Version 13.0</div></div></div>"},"64325":{"type":"graphic_figure","displayName":"Decreased SIMV support in ARDS","title":"Effect of decreased synchronized intermittent mandatory ventilation (SIMV) support in acute respiratory distress syndrome (ARDS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of decreased synchronized intermittent mandatory ventilation (SIMV) support in acute respiratory distress syndrome (ARDS)</div><div class=\"cntnt\"><img style=\"width:357px; height:271px;\" src=\"images/PULM/64325_Decreased_SIMV_support_in_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effects of decreasing synchronized intermittent mandatory ventilation (SIMV) support on the work of breathing per liter of ventilation in patients with acute respiratory distress syndrome. Inspiratory work per unit volume (work per liter Wp/L) done by the patient is shown during assisted cycles (blue bars) and spontaneous cycles (red bars). As machine support was withdrawn, the patients performed an increasing amount of inspiratory work per liter of ventilation. The increased work was significantly greater at all levels of machine support less than or equal to 60 percent (pâ¤0.01). Spontaneous breaths required 25 percent more work per liter of ventilation than assisted breaths at these levels of machine support. The pressure-time index exceeded a fatiguing level of work at all levels of machine support less than 80 percent. It was suggested that, when using the SIMV mode, the back-up rate should result in at least 80 percent of the minute ventilation coming from the machine in order to prevent fatigue.</div><div class=\"graphic_reference\">Redrawn from Marini JJ, Smith TC, Lamb V, Am Rev Respir Dis 1988; 138:1169.</div><div id=\"graphicVersion\">Graphic 64325 Version 2.0</div></div></div>"},"64328":{"type":"graphic_table","displayName":"Aeroallergen SCIT - One-day modified schedule - B","title":"Aeroallergen subcutaneous immunotherapy (SCIT) - One-day modified schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aeroallergen subcutaneous immunotherapy (SCIT) - One-day modified schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time (minutes)</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Dilution</td> <td class=\"subtitle1\">Color vial</td> </tr> <tr> <td>0</td> <td>0.3</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>30</td> <td>0.1</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>60</td> <td>0.3</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>90</td> <td>0.05</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>120</td> <td>0.15</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>180</td> <td>0.3</td> <td>1:10</td> <td>Yellow</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Protocol courtesy of Jay M Portnoy, MD.</div><div id=\"graphicVersion\">Graphic 64328 Version 4.0</div></div></div>"},"64329":{"type":"graphic_table","displayName":"Chromosomal locations","title":"Chromosomal locations of immunoglobulin genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chromosomal locations of immunoglobulin genes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Locus</td>\n<td class=\"subtitle1\">Chromosome</td>\n</tr>\n<tr>\n<td>Heavy chain</td>\n<td>14q32</td>\n</tr>\n<tr>\n<td>Kappa light chain</td>\n<td>2p12</td>\n</tr>\n<tr>\n<td>Lambda light chain</td>\n<td>22q12</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright Â© 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 64329 Version 2.0</div></div></div>"},"64330":{"type":"graphic_movie","displayName":"Cardiac amyloidosis parasternal long axis echocardiogram","title":"Cardiac amyloidosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac amyloidosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64330_laxcaramconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:278px; height:447px;\" src=\"images/CARD/64330_laxcaram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis view from a 2-D echocardiogram showing concentric left ventricular hypertrophy, thickened mitral and aortic valve leaflets, and left atrial dilatation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 64330 Version 3.0</div></div></div>"},"64333":{"type":"graphic_table","displayName":"Contraindications cryo cut SCC","title":"Contraindications to cryosurgical treatment of cutaneous squamous cell cancer (SCC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to cryosurgical treatment of cutaneous squamous cell cancer (SCC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Patients with abnormal cold tolerance, cold urticaria, cryoglobulinemia, cryofibrinogenemia, or Raynaud's disease/phenomenon</td> </tr> <tr> <td>High-risk SCCs or tumors located in high-risk, critical sites (nose, lips, ears, periocular and periauricular areas, and genitals)</td> </tr> <tr> <td>SCCs located on the lower legs or scalp</td> </tr> <tr> <td>SCCs located on free margins such as the eyelid, nasal alae, or helical rim</td> </tr> <tr> <td>SCCs located near the external auditory canal</td> </tr> <tr> <td>Tumors overlying nerves</td> </tr> <tr> <td>Recurrent or ill-defined tumors</td> </tr> <tr> <td>Deeply invasive SCCs (invading muscle, bone, or cartilage)</td> </tr> <tr> <td>Tumors in darkly pigmented patients</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Holt PJ, et al, Br J Dermatol 1988;119:231, Kuflik EG, Gage AA, J Am Acad Dermatol 1991;24:1002, Zacarian SA, J Am Acad Dermatol 1983;9:947, Graham GF, Cutis 1993;52:365.</div><div id=\"graphicVersion\">Graphic 64333 Version 2.0</div></div></div>"},"64334":{"type":"graphic_diagnosticimage","displayName":"Contrast study in duodenal atresia","title":"Contrast study in duodenal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast study in duodenal atresia</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/PEDS/64334_UGI_duodenal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast study of the upper gastrointestinal tract demonstrates dilation of the stomach and proximal duodenum.</div><div id=\"graphicVersion\">Graphic 64334 Version 3.0</div></div></div>"},"64335":{"type":"graphic_picture","displayName":"Erythema induratum 2","title":"Erythema induratum (nodular vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema induratum (nodular vasculitis)</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/64335_Erythema_indur_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nodules are present on the posterior lower legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64335 Version 3.0</div></div></div>"},"64336":{"type":"graphic_table","displayName":"LEMON mnemonic","title":"The LEMONÂ© mnemonic for predicting the difficult emergency airway","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The LEMONÂ© mnemonic for predicting the difficult emergency airway</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>L</strong>ook externally</td> </tr> <tr> <td><strong>E</strong>valuate 3-3-2</td> </tr> <tr> <td><strong>M</strong>allampati</td> </tr> <tr> <td><strong>O</strong>bstruction/<strong>O</strong>besity</td> </tr> <tr> <td><strong>N</strong>eck mobility</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12037&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Adapted from: Brown III CA, Walls RM. Identification of the difficult and failed airway. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia 2018.</div><div id=\"graphicVersion\">Graphic 64336 Version 5.0</div></div></div>"},"64337":{"type":"graphic_figure","displayName":"Pathogenesis PCOS","title":"Potential mechanisms underlying the development of PCOS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential mechanisms underlying the development of PCOS</div><div class=\"cntnt\"><img style=\"width:331px; height:421px;\" src=\"images/ENDO/64337_Pathogenesis_PCOS_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inherited factors act to create a susceptible genotype, most commonly identifiable by a positive family history for PCOS or related features. This susceptible genotype, in isolation or in association with environmental or acquired factors, may result in intermediate forms of functional hyperandrogenism. Continued exposure to environmental factors, or an increasing load of genetic variants favoring its occurrence, leads to the development of clinically evident PCOS.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; CNS: central nervous system; LH: luteinizing hormone; FSH: follicle stimulating hormone; IR: insulin resistance;&nbsp;AA: adrenal androgen; PCOM: polycystic ovarian morphology; HA: hyperandrogenemia.</div><div class=\"graphic_reference\">Courtesy of Ricardo Azziz, MD.</div><div id=\"graphicVersion\">Graphic 64337 Version 3.0</div></div></div>"},"64338":{"type":"graphic_picture","displayName":"Mantle cell lymphoma Endosc","title":"Mantle cell lymphoma polypoid lesions on colonoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mantle cell lymphoma polypoid lesions on colonoscopy</div><div class=\"cntnt\"><img style=\"width:222px; height:221px;\" src=\"images/GAST/64338_Mantle_cell_lymphoma_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic view of multiple polypoid lesions in the proximal colon. Histology was consistent with a mantle cell lymphoma.</div><div id=\"graphicVersion\">Graphic 64338 Version 2.0</div></div></div>"},"64341":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CT V","title":"Cystic hygroma in infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma in infant</div><div class=\"cntnt\"><img style=\"width:360px; height:256px;\" src=\"images/PULM/64341_Cystic_hygroma_CT_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a cystic mass in the anterior mediastinum, which displaces the trachea and esophagus against the spine.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64341 Version 3.0</div></div></div>"},"64343":{"type":"graphic_picture","displayName":"Inflammatory cells surrounding non-necrotic myofiber in IBM","title":"Inflammatory cells surrounding non-necrotic myofiber in IBM","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Inflammatory cells surrounding non-necrotic myofiber in IBM</div><div class=\"cntnt\"><img style=\"width:480px; height:361px;\" src=\"images/RHEUM/64343_Imflam_nonnecrotic_IBM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory cells surrounding and invading a non-necrotic myofiber in inclusion body myositis seen in a hematoxylin and eosin-stained section.</div><div class=\"graphic_reference\">Courtesy of Seven A Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 64343 Version 2.0</div></div></div>"},"64344":{"type":"graphic_table","displayName":"Young child hip imaging overview","title":"Overview of the use of various imaging modalities in the evaluation and management of common hip problems in young children (toddlers to 10 years)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of the use of various imaging modalities in the evaluation and management of common hip problems in young children (toddlers to 10 years)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Plain radiograph</td> <td class=\"subtitle1\">Ultrasonography</td> <td class=\"subtitle1\">Computed tomography</td> <td class=\"subtitle1\">MRI</td> <td class=\"subtitle1\">Radionuclide bone scan</td> <td class=\"subtitle1\">Arthrography</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Acute transient synovitis</strong></td> <td>May demonstrate effusion<sup>&#182;</sup></td> <td>May demonstrate effusion<sup>&#182;</sup></td> <td>NA</td> <td>May demonstrate joint effusion and synovial inflammation (with contrast enhancement)<sup>&#182;</sup></td> <td>NA</td> <td>NA</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Septic arthritis</strong></td> <td>May demonstrate effusion<sup>&#182;</sup></td> <td> <p>May demonstrate effusion<sup>&#182;</sup></p> May guide aspiration</td> <td>NA</td> <td> <p>May demonstrate joint effusion and synovial inflammation (with contrast enhancement)<sup>&#182;</sup></p> <p>Bone marrow edema is suggestive of septic arthritis but not always present</p> May identify adjacent osteomyelitis</td> <td>May suggest adjacent osteomyelitis</td> <td>NA</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Osteomyelitis</strong></td> <td> <p>Usually normal in the early stages</p> Bone destruction and/or joint effusion in advanced cases</td> <td>NA</td> <td>NA</td> <td>May demonstrate bone marrow edema and joint effusion</td> <td>May facilitate diagnosis in children with normal plain films and poorly localized symptoms</td> <td>NA</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Developmental coxa vara</strong></td> <td>Demonstrates decreased femoral neck-shaft angle (&#60;120&#176;), vertical orientation, and widening of the physis</td> <td>NA</td> <td>NA</td> <td>Preoperative planning (demonstrates the relationship between the acetabulum and femoral head, neck, and shaft)</td> <td>NA</td> <td>NA</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Legg-Calv&#233;-Perthes disease</strong></td> <td> <p>Diagnosis, classification, and follow-up</p> May be normal early in disease, but subsequently demonstrates sclerosis, fragmentation, and subchondral collapse of the ossification center of the femoral head</td> <td>Adjunct to other imaging modalities</td> <td>Early diagnosis of bone collapse and definition of anatomy<sup>&#916;</sup></td> <td> <p>Facilitates early diagnosis (bone marrow edema)</p> <p>Evaluation of complications (femoral head subluxation; physeal abnormalities)</p> Contrast enhanced MRI facilitates staging (avascular or revascularization and reparative)</td> <td>May facilitate early diagnosis if plain films are normal; scintigraphic changes (decreased uptake in the femoral head) precede plain radiographic findings by about&nbsp;three months</td> <td> <p>Conventional arthrography: Surgical planning in advanced disease</p> MRA: Assessment for complications</td> </tr> <tr> <td><strong>Neuromuscular hip dysplasia</strong></td> <td>Demonstrates valgus deformity, abnormal shape and location of the femoral head, and dysplastic changes in acetabulum</td> <td>NA</td> <td>Preoperative planning</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable; MRI: magnetic resonance imaging; MRA: magnetic resonance arthrography.<br />* This age range is approximate; these problems may occur in children outside this age group.<br />Â¶ Cannot differentiate between acute transient synovitis and septic arthritis of the hip.<br />Î Use of computed tomography is limited because of the risk of radiation exposure.</div><div id=\"graphicVersion\">Graphic 64344 Version 5.0</div></div></div>"},"64345":{"type":"graphic_table","displayName":"Etiologies of nasal septal perforation","title":"Etiologies of nasal septal perforation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of nasal septal perforation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Intranasal cocaine use (both cocaine and adulterants, such as borax or talcum powder)</td> </tr> <tr> <td>Piercings</td> </tr> <tr> <td class=\"sublist1_start\">Rheumatologic disease</td> </tr> <tr> <td class=\"sublist1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"sublist1\">Psoriatic arthritis</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"sublist1\">Progressive systemic sclerosis</td> </tr> <tr> <td class=\"sublist1\">Mixed connective tissue disease</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td>Foreign body</td> </tr> <tr> <td>Bevacizumab</td> </tr> <tr> <td>Head and neck tumors</td> </tr> <tr> <td>Industrial exposure to metal plating solutions (chrome)</td> </tr> <tr> <td>Mucocutaneous leishmaniasis, tuberculosis, syphilis</td> </tr> <tr> <td>Intranasal glucocorticoid sprays</td> </tr> <tr> <td>Atrophic rhinitis (primary)</td> </tr> <tr> <td>Complication of septal surgery or cautery for epistaxis </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64345 Version 3.0</div></div></div>"},"64346":{"type":"graphic_picture","displayName":"Early liver biopsy Wilson disease","title":"Wilson disease","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Wilson disease</div><div class=\"cntnt\"><img style=\"width:540px; height:175px;\" src=\"images/GAST/64346_Early_liver_bx_Wilsons_dise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy from a 4-year-old girl whose 10-year-old sister presented with liver failure and cirrhosis secondary to previously unrecognized Wilson disease. Liver biopsy was performed because her serum ceruloplasmin was low (4.0 mg/dL) and serum aminotransferases were repeatedly two to three times normal. Left panel: Low power shows portal fibrosis, mild portal inflammation, and fatty infiltration (Masson trichrome). Right panel: High power view shows fatty infiltration of hepatocytes and two glycogen nuclei (Masson trichrome).</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 64346 Version 2.0</div></div></div>"},"64348":{"type":"graphic_figure","displayName":"Depression cardiovasc events","title":"Survival free of a cardiovascular event is lower in recently depressed elderly men","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival free of a cardiovascular event is lower in recently depressed elderly men</div><div class=\"cntnt\"><img style=\"width:389px; height:237px;\" src=\"images/CARD/64348_Depression_cardiovasc_event.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In men over 70 years of age, the recent onset of depression, but not chronic depression, was associated with an increased risk of a cardiovascular disease event and all cause mortality. This association was not seen in women over 70 years.</div><div class=\"graphic_reference\">Data from Penninx, BWJH, Guralnik, J, Mendes de Leon, CF, et al, Am J Cardiol 1998; 81:988.</div><div id=\"graphicVersion\">Graphic 64348 Version 1.0</div></div></div>"},"64349":{"type":"graphic_figure","displayName":"Depth invasion esophageal cancer","title":"Subclassification of the depth of superficial esophageal cancer (number of patients)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subclassification of the depth of superficial esophageal cancer (number of patients)</div><div class=\"cntnt\"><img style=\"width:362px; height:215px;\" src=\"images/ONC/64349_Depth_invasion_esophag_ca.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subclassification of the depth of superficial esophageal cancer (number of patients) in a series of 160 patients with superficial esophageal cancer.</div><div class=\"graphic_footnotes\">Ep: epithelial layer; lpm: lamina propria; mm: muscularis mucosa; sm: submucosa; mp: muscularis propria.</div><div class=\"graphic_reference\">Reproduced with permission from: Shimada H, Nabeya Y, Matsubara H, et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 2006; 191:250. Copyright &copy; 2006 Excerpta Medica Inc.</div><div id=\"graphicVersion\">Graphic 64349 Version 5.0</div></div></div>"},"64350":{"type":"graphic_figure","displayName":"Lymph nodes body PI","title":"Lymph node groups","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Lymph node groups</div><div class=\"cntnt\"><img style=\"width:559px; height:574px;\" src=\"images/PI/64350_Lymph_nodes_body_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the lymph node groups and sub-areas. Note that popliteal nodes are palpable behind the knee.</div><div class=\"graphic_reference\">Modified with permission from: Celigny, P, Roy, P, Colombat, P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258. Copyright Â© 2004. American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 64350 Version 3.0</div></div></div>"},"64352":{"type":"graphic_figure","displayName":"Physical activity with age","title":"Decreased physical activity with age","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Decreased physical activity with age</div><div class=\"cntnt\"><img style=\"width:506px; height:273px;\" src=\"images/ENDO/64352_Physical_activity_with_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Surgeon General's report on Physical Activity suggested that the percent of time Americans spend in physical activity decreased as their age increased.</div><div class=\"graphic_reference\">Data from: US Department of Health and Human Services. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996.</div><div id=\"graphicVersion\">Graphic 64352 Version 2.0</div></div></div>"},"64354":{"type":"graphic_picture","displayName":"H pylori gastritis Light","title":"Helicobacter pylori gastritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Helicobacter pylori gastritis</div><div class=\"cntnt\"><img style=\"width:288px; height:454px;\" src=\"images/GAST/64354_H_pylori_gastritis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a gastric biopsy obtained at endoscopy shows infiltration of glands with neutrophils (arrow) and increased mononuclear cell infiltration typical of Helicobacter pylori gastritis.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 64354 Version 1.0</div></div><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Normal gastric antrum</div><div class=\"cntnt\"><img style=\"width:520px; height:223px;\" src=\"images/GAST/79895_Normal_gastric_antrum_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Normal surface (SE) and foveolar epithelium (FE) and glands (G). Right panel: Higher power view of the glands shows mucous cells (M) and gastrin-secreting endocrine cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 79895 Version 1.0</div></div></div>"},"64355":{"type":"graphic_diagnosticimage","displayName":"Malignant antral ulcer UGI","title":"Malignant gastric ulcer","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant gastric ulcer</div><div class=\"cntnt\"><img style=\"width:251px; height:338px;\" src=\"images/GAST/64355_Malignant_antral_ulcer_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast upper GI study demonstrates a large barium-filled ulcer crater (arrow) surrounded by edematous mucosa. The ulcer is extending from the stomach, across the pylorus and into the duodenum, features that are not seen with benign ulcers.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 64355 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"64356":{"type":"graphic_picture","displayName":"Palpation lateral epicondyle","title":"Palpation of the lateral epicondyle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the lateral epicondyle</div><div class=\"cntnt\"><img style=\"width:442px; height:364px;\" src=\"images/EM/64356_Palpation_lateral_epicondyl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral epicondyle is palpated for tenderness and swelling with the elbow flexed at 90 degrees. Local tenderness is a hallmark feature of lateral epicondylitis (tennis elbow).</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 64356 Version 4.0</div></div></div>"},"64357":{"type":"graphic_table","displayName":"Prevalence of disease","title":"Prevalence of infectious diseases, Texas Department of Criminal Justice, 1999 to 2000","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of infectious diseases, Texas Department of Criminal Justice, 1999 to 2000</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Prevalence of disease per 100,000</td> </tr> <tr> <td>Latent tuberculosis infection</td> <td>16,511 to 24,600*</td> </tr> <tr> <td>Hepatitis C</td> <td>8377</td> </tr> <tr> <td>HIV/AIDS</td> <td>1458</td> </tr> <tr> <td>Syphillis</td> <td>655</td> </tr> <tr> <td>MRSA</td> <td>328</td> </tr> <tr> <td>Herpes zoster</td> <td>206</td> </tr> <tr> <td>Hepatitis B</td> <td>84</td> </tr> <tr> <td>Active tuberculosis</td> <td>39</td> </tr> <tr> <td>Pneumonia</td> <td>27</td> </tr> <tr> <td>Gonorrhea</td> <td>15</td> </tr> <tr> <td>Encephalitis</td> <td>3.6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; MRSA: methicillin-resistant Staphylococcus aureus.<br />* Estimate of latent tuberculosis infection from six different correctional institutions in United States, 1990 to 1991.</div><div class=\"graphic_reference\">Data from: Baillargeon, J, Black, SA, Leach, CT, et al. The infectious disease profile of Texas prison inmates. Prev Med 2004; 38:607 and Centers for Disease Control and Prevention. Tuberculosis prevention in drug-treatment centers and correctional facilities--selected US sites, 1990-1991. MMWR Morb Mortal Wkly Rep 1993; 42:210.</div><div id=\"graphicVersion\">Graphic 64357 Version 2.0</div></div></div>"},"64358":{"type":"graphic_diagnosticimage","displayName":"CT reconstruction of trachea","title":"Focal tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:338px; height:302px;\" src=\"images/PULM/64358_CT_reconstruction_of_trache.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaded surface display reconstruction of a high resolution chest computed tomographic data set reveals a focal area of tracheal stenosis (red arrows) just above the thoracic inlet.</div><div id=\"graphicVersion\">Graphic 64358 Version 2.0</div></div></div>"},"64359":{"type":"graphic_picture","displayName":"Olecranon bursitis","title":"Olecranon bursitis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Olecranon bursitis</div><div class=\"cntnt\"><img style=\"width:590px; height:364px;\" src=\"images/RHEUM/64359_Olecranon_bursitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fluctuant mass is visible over the olecranon process.</div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 64359 Version 4.0</div></div></div>"},"64361":{"type":"graphic_figure","displayName":"CYP11B1 deficiency","title":"11Î²-hydroxylase (CYP11B1) deficiency","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">11Î²-hydroxylase (CYP11B1) deficiency</div><div class=\"cntnt\"><img style=\"width:609px; height:383px;\" src=\"images/ENDO/64361_CYP11B1_deficiency_edt2.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64361 Version 1.0</div></div></div>"},"64363":{"type":"graphic_movie","displayName":"Flail mitral leaflet apical long axis echocardiogram","title":"Flail mitral valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flail mitral valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64363_aplaflmvconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:252px; height:435px;\" src=\"images/CARD/64363_aplaflmv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical long axis view from a 2-D echocardiogram shows a flail posterior leaflet of the mitral valve. It has exaggerated motion in diastole and prolapses into the left atrium with diastole. The bright echo seen at the tip suggests that a ruptured papillary muscle as the etiology. The presence of left atrial enlargement suggests that there is significant mitral regurgitation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 64363 Version 2.0</div></div></div>"},"64364":{"type":"graphic_figure","displayName":"CW Doppler computer MV area","title":"Mitral valve area from continuous wave Doppler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve area from continuous wave Doppler</div><div class=\"cntnt\"><img style=\"width:385px; height:263px;\" src=\"images/CARD/64364_CW_Doppler_computer_MV_area.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A computer system, incorporated into current echocardiographic equipment, can automatically measure the P 1/2 time on the continuous wave Doppler tracing and compute the mitral valve area (MVA). In this case the P 1/2 time is 255 msec and the MVA is 220/255 or 0.86 cm<SUP>2</SUP>.</div><div id=\"graphicVersion\">Graphic 64364 Version 2.0</div></div></div>"},"64365":{"type":"graphic_diagnosticimage","displayName":"Radiographic features of CRS without NP","title":"Radiographic features of CRS without NP","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Radiographic features of CRS without NP</div><div class=\"cntnt\"><img style=\"width:528px; height:300px;\" src=\"images/ALLRG/64365_CRS_S_NP_pre_post_tx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus CT scan of a 35-year-old female with CRS without NP before and immediately following intensive medical treatment. The pretreatment sinus CT scan shows near total opacification of both maxillary and anterior ethmoid sinuses. The posttreatment sinus CT scan shows complete resolution of these findings. The patient's CRS symptoms completely resolved.</div><div class=\"graphic_footnotes\">CRS: chronic rhinosinusitis; NP: nasal polyposis; CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Subramanian HN, Schechtman KB, Hamilos DL. A retrospective analysis of treatment outcomes and time to relapse after intensive medical treatment for chronic sinusitis. Am J Rhinol 2002; 16:303. Copyright &copy; 2002 Oceanside Publications.</div><div id=\"graphicVersion\">Graphic 64365 Version 5.0</div></div></div>"},"64366":{"type":"graphic_table","displayName":"Cutaneous SCC high-risk features","title":"Features of squamous cell carcinoma that correlate with high risk for recurrence and metastasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of squamous cell carcinoma that correlate with high risk for recurrence and metastasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Five-year recurrence rate (percent)</td> <td class=\"subtitle1\">Five-year metastatic rate (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Size &#8805;2 cm in diameter</td> <td class=\"centered\">15.2</td> <td class=\"centered\">30.3</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Location</td> </tr> <tr> <td class=\"sublist2\">Ear</td> <td class=\"sublist_other_centered\">18.7</td> <td class=\"sublist_other_centered\">11.0</td> </tr> <tr> <td class=\"sublist2\">Lip</td> <td class=\"sublist_other_centered\">10.5</td> <td class=\"sublist_other_centered\">13.7</td> </tr> <tr> <td class=\"sublist2\">Genitals</td> <td class=\"sublist_other_centered\">&ndash;</td> <td class=\"sublist_other_centered\">20-60</td> </tr> <tr> <td class=\"indent1\">Arising within scar, sinus tract, chronic ulcer, or burn</td> <td class=\"centered\">NA</td> <td class=\"centered\">37.9</td> </tr> <tr> <td class=\"indent1\">Locally recurrent</td> <td class=\"centered\">23.3</td> <td class=\"centered\">30.3</td> </tr> <tr> <td class=\"indent1\">Immunosuppressed patient</td> <td class=\"centered\">NA</td> <td class=\"centered\">12.9</td> </tr> <tr> <td class=\"indent1\">Rapid growth</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Histologic features</td> </tr> <tr> <td class=\"indent1\">Depth &#8805;4 mm/Clark's level IV, V</td> <td class=\"centered\">17.2</td> <td class=\"centered\">45.7</td> </tr> <tr> <td class=\"indent1\">Poorly differentiated</td> <td class=\"centered\">28.6</td> <td class=\"centered\">32.8</td> </tr> <tr> <td class=\"indent1\">Perineural involvement</td> <td class=\"centered\">47.2</td> <td class=\"centered\">47.3</td> </tr> <tr> <td class=\"indent1\">Intravascular invasion</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">87.5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable.</div><div class=\"graphic_reference\">Data from: Rowe DE, et al, J Am Acad Dermatol 1992; 26:1, Kwa RE, et al, J Am Acad Dermatol 1992; 26:976, Dinehart SM, et al, J Am Acad Dermatol 1989; 21:241, Johnson TM, et al, J Am Acad Dermatol 1992; 26:467, Alam M, et al, N Engl J Med 2001; 344:975, Staubitz WJ, et al, Cancer 1955; 8:371, Dean AL, J Urol 1948; 60:508, Srinivas V, et al, J Urol 1987; 137:880, Binder SW, et al, Gynecol Oncol 1990; 37:9, Ray B, et al, J Urol 1977; 117:741.</div><div id=\"graphicVersion\">Graphic 64366 Version 4.0</div></div></div>"},"64367":{"type":"graphic_picture","displayName":"Inflamed tophaceous gout PI","title":"Inflamed tophaceous gout","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflamed tophaceous gout</div><div class=\"cntnt\"><img style=\"width:383px; height:266px;\" src=\"images/PI/64367_Inflamed_tophaceous_gout_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three inflamed tophi over the proximal interphalangeal joints in a patient with chronic tophaceous gout. Several of the lesions ruptured spontaneously over the next three days, exuding a pasty material composed of urate crystals and inflammatory cells but no organisms. The inflammation largely subsided over one week after the administration of a nonsteroidal antiinflammatory drug.</div><div class=\"graphic_reference\">Courtesy of Michael A Becker, MD.</div><div id=\"graphicVersion\">Graphic 64367 Version 1.0</div></div></div>"},"64368":{"type":"graphic_figure","displayName":"Prevalence of gynecomastia","title":"Bimodal prevalence of gynecomastia after infancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bimodal prevalence of gynecomastia after infancy</div><div class=\"cntnt\"><img style=\"width:373px; height:270px;\" src=\"images/ENDO/64368_Prevalence_of_gynecomastia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of gynecomastia at various chronologic ages showing peaks at puberty and in older men. The data are derived from multiple population studies.</div><div class=\"graphic_reference\">Data from Braunstein GD. Gynecomastia. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (Eds), Lippincott-Raven, Philadelphia 1996. p.54.</div><div id=\"graphicVersion\">Graphic 64368 Version 3.0</div></div></div>"},"64369":{"type":"graphic_diagnosticimage","displayName":"Stereotactic radiosurgery I","title":"Stereotactic radiosurgery for Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stereotactic radiosurgery for Cushing's disease</div><div class=\"cntnt\"><img style=\"width:360px; height:312px;\" src=\"images/ENDO/64369_Stereotactic_radiosurgery_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal section CT image through the sella turcica and anterior pituitary gland of a patient with Cushing's disease. The brown areas represent brain or other tissue; the black areas represent cerebrospinal fluid (eg, the upper center vertical space is the third ventricle) or air-filled sinuses (eg, the space just below center is the sphenoid sinus); the white areas represent bone (eg, the highest points represent the clinoid processes). A computer-assisted stereotactic &quot;photon knife&quot; treatment plan is superimposed on the CT image; it employs two isocenters of 15 Gy radiation delivered by a linear accelerator, one in each half of the anterior pituitary. Each concentric circle is an isorad 1 Gy less than the next inner circle. The optic chiasm will be exposed to less than 8 cGy of radiation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of David N Orth, MD.</div><div id=\"graphicVersion\">Graphic 64369 Version 3.0</div></div></div>"},"64371":{"type":"graphic_figure","displayName":"Loading the wire II","title":"Completion of precut sphincterotomy with blended current","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Completion of precut sphincterotomy with blended current</div><div class=\"cntnt\"><img style=\"width:389px; height:255px;\" src=\"images/GAST/64371_Loading_the_wire_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After an initial 2 to 3 mm incision is made with the &quot;loaded wire&quot; method, the endoscope slightly withdrawn, and the dials are adjusted as necessary to &quot;load the wire&quot; once more at the top of the freshly made incision. The cut is then continued in small increments.</div><div class=\"graphic_reference\">Courtesy of Douglas A Howell, MD and David J Desilets, MD.</div><div id=\"graphicVersion\">Graphic 64371 Version 2.0</div></div></div>"},"64372":{"type":"graphic_picture","displayName":"Acne fulminans","title":"Acne fulminans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne fulminans</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/DERM/64372_Acne_fulminans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy adolescent with severe nodulocystic acne developed ulcerations and crusts shortly after starting oral 13-cis retinoic acid. Oral corticosteroids were added to his regimen and slowly tapered over&nbsp;two months.</div><div class=\"graphic_reference\">Copyright Â© Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 64372 Version 8.0</div></div></div>"},"64373":{"type":"graphic_picture","displayName":"Passive neck rotation","title":"Passive neck rotation","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Passive neck rotation</div><div class=\"cntnt\"><img style=\"width:452px; height:435px;\" src=\"images/PC/64373_Passive_neck_rotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of rotation is the universal sign of neck pathology. The patient is asked to relax. The examiner places one hand on the shoulder and one hand on the chin. The neck is passively rotated to the affected side and compared with rotation to the opposite side. Rotation less than 90 degrees is abnormal.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 64373 Version 2.0</div></div></div>"},"64374":{"type":"graphic_table","displayName":"Precipitating factors DKA and HHS","title":"Predisposing or precipitating factors for diabetic ketoacidosis and hyperosmolar hyperglycemic state","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predisposing or precipitating factors for diabetic ketoacidosis and hyperosmolar hyperglycemic state</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">DKA</td> </tr> <tr> <td class=\"subtitle2_single\">Inadequate insulin treatment or noncompliance</td> </tr> <tr> <td class=\"subtitle2_single\">New onset diabetes (20 to 25 percent)</td> </tr> <tr> <td class=\"subtitle2_single\">Acute illness </td> </tr> <tr> <td class=\"indent1\">Infection (30 to 40 percent)</td> </tr> <tr> <td class=\"indent1\">Cerebral vascular accident</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction</td> </tr> <tr> <td class=\"indent1\">Acute pancreatitis</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Clozapine or olanzapine</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"indent1\">SGLT2 inhibitors</td> </tr> <tr> <td class=\"indent1\">Terbutaline</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">HHS</td> </tr> <tr> <td class=\"subtitle2_single\">Inadequate insulin treatment or noncompliance (21 to 41 percent) </td> </tr> <tr> <td class=\"subtitle2_single\">Acute illness</td> </tr> <tr> <td class=\"sublist2_start\">Infection (32 to 60 percent)</td> </tr> <tr> <td class=\"sublist2\">Pneumonia</td> </tr> <tr> <td class=\"sublist2\">Urinary tract infection</td> </tr> <tr> <td class=\"sublist2\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Cerebral vascular accident</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction</td> </tr> <tr> <td class=\"indent1\">Acute pancreatitis</td> </tr> <tr> <td class=\"indent1\">Acute pulmonary embolus</td> </tr> <tr> <td class=\"indent1\">Intestinal obstruction</td> </tr> <tr> <td class=\"indent1\">Dialysis, peritoneal</td> </tr> <tr> <td class=\"indent1\">Mesenteric thrombosis</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">Heat stroke</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> </tr> <tr> <td class=\"indent1\">Subdural hematoma</td> </tr> <tr> <td class=\"indent1\">Severe burns</td> </tr> <tr> <td class=\"subtitle2_single\">Endocrine</td> </tr> <tr> <td class=\"indent1\">Acromegaly</td> </tr> <tr> <td class=\"indent1\">Thyrotoxicosis</td> </tr> <tr> <td class=\"indent1\">Cushing's syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs/therapy</td> </tr> <tr> <td class=\"indent1\">Beta-Adrenergic blockers</td> </tr> <tr> <td class=\"indent1\">Calcium-channel blockers</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> </tr> <tr> <td class=\"indent1\">Chlorthalidone</td> </tr> <tr> <td class=\"indent1\">Cimetidine</td> </tr> <tr> <td class=\"indent1\">Clozepine</td> </tr> <tr> <td class=\"indent1\">Diazoxide</td> </tr> <tr> <td class=\"indent1\">Ethacrynic acid</td> </tr> <tr> <td class=\"indent1\">Immunosuppressive agents</td> </tr> <tr> <td class=\"indent1\">L-asparaginase</td> </tr> <tr> <td class=\"indent1\">Loxapine</td> </tr> <tr> <td class=\"indent1\">Olanzapine</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Propranolol</td> </tr> <tr> <td class=\"indent1\">Steroids</td> </tr> <tr> <td class=\"indent1\">Thiazide diuretics</td> </tr> <tr> <td class=\"indent1\">Total parenteral nutrition</td> </tr> <tr> <td class=\"subtitle2_single\">Previously undiagnosed diabetes</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; HHS: hyperosmolar hyperglycemic state; SGLT2: sodium-glucose co-transporter 2.</div><div class=\"graphic_reference\">Data from: Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes mellitus (Technical Review). Diabetes Care 2001; 24:131.</div><div id=\"graphicVersion\">Graphic 64374 Version 4.0</div></div></div>"},"64375":{"type":"graphic_diagnosticimage","displayName":"Chylothorax CT","title":"Chylothorax after esophagectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chylothorax after esophagectomy</div><div class=\"cntnt\"><img style=\"width:321px; height:319px;\" src=\"images/PULM/64375_Chylothorax_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT shows large low attenuation right pleural effusion with inversion of the right hemidiaphragm and cardiomediastinal shift to the left.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64375 Version 3.0</div></div></div>"},"64377":{"type":"graphic_picture","displayName":"Invasive diarrhea","title":"Invasive diarrhea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Invasive diarrhea</div><div class=\"cntnt\"><img style=\"width:422px; height:316px;\" src=\"images/ID/64377_Invasive_diarrhea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The appearance of frank blood in the stool constitutes invasive diarrhea.<br> (A) Melenic stool with abundant mucous.<br> (B) Watery stool with blood and mucous.<br> (C) Bloody, mucoid stool.</div><div id=\"graphicVersion\">Graphic 64377 Version 1.0</div></div></div>"},"64378":{"type":"graphic_picture","displayName":"Acute ISN Light I","title":"High power light micrograph of kidney biopsy of a patient with acute interstitial nephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High power light micrograph of kidney biopsy of a patient with acute interstitial nephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:252px;\" src=\"images/NEPH/64378_Acute_ISN_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power light micrograph of acute interstitial nephritis showing diffuse interstitial infiltrate of inflammatory cells on the right and an uninvolved glomerulus on the left.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 64378 Version 2.0</div></div></div>"},"64380":{"type":"graphic_diagnosticimage","displayName":"Banana sign","title":"The \"banana\" sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The \"banana\" sign</div><div class=\"cntnt\"><img style=\"width:389px; height:288px;\" src=\"images/OBGYN/64380_Banana_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cerebellum as it herniates through the foramen magnum takes up the shape of a banana (arrows). When both the lemon and banana signs are seen together, an open spinal defect is present.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 64380 Version 2.0</div></div></div>"},"64381":{"type":"graphic_waveform","displayName":"ECG in flash pulmonary edema","title":"Electrocardiogram in a patient with flash pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in a patient with flash pulmonary edema</div><div class=\"cntnt\"><img style=\"width:504px; height:259px;\" src=\"images/CARD/64381_ECG_in_flash_pulmonary_edem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ECG tracing reveals left ventricular hypertrophy (LVH) assoicated with ST segment depression and T wave inversions; these ST-T wave changes (arrows) may also represent subendocardial ischemia, which along with the LVH may be responsible for the episode of flash pulmonary edema.</div><div id=\"graphicVersion\">Graphic 64381 Version 2.0</div></div></div>"},"64382":{"type":"graphic_picture","displayName":"Type 2 breast lobule","title":"Type 2 breast lobule","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Type 2 breast lobule</div><div class=\"cntnt\"><img style=\"width:464px; height:386px;\" src=\"images/SURG/64382_Breast_lobule_type2_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whole mount preparation of breast tissue of a 24-year-old nulliparous woman showing type 2 breast lobules as viewed by light microscopy.<br />(Left panel) Tissue section stained with toluidine blue. 2.5x.<br />(Right panels) Histological section of lobule type 2 stained with hematoxylin and eosin (H&amp;E). Photographs at 10x and 40x respectively.</div><div class=\"graphic_reference\">Reproduced with permission from: Russo J, Hu Y-F, Silva IDCG, and Russo IH. Cancer risk related to mammary gland structure and development. Microscopy Research and Technique 2001; 52:204. Copyright &copy; 2001 American Cancer Society.</div><div id=\"graphicVersion\">Graphic 64382 Version 5.0</div></div></div>"},"64383":{"type":"graphic_figure","displayName":"PCR technique","title":"Polymerase chain reaction (PCR)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymerase chain reaction (PCR)</div><div class=\"cntnt\"><img style=\"width:425px; height:609px;\" src=\"images/PC/64383_PCR_technique.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the polymerase chain reaction (PCR), unamplified target DNA (red and black strands at top) is separated into two single strands by heating. Next, primers (green and blue arrows) anneal to the opposite DNA strands of the desired target sequence. The complementary strand is then synthesized (longer blue and green arrows). Subsequent cycles of strand separation (denaturing), primer hybridization (annealing), and strand synthesis (extension) ensure exponential amplification of the target sequence by using the amplified sequences of the previous cycle as a new template (as shown in the Second PCR cycle). The target PCR product, which consists of approximately 10(6) copies after 30 cycles, is shown at the bottom of the figure.</div><div id=\"graphicVersion\">Graphic 64383 Version 1.0</div></div></div>"},"64384":{"type":"graphic_figure","displayName":"Organization of the human T cell receptor-delta chain locus","title":"Organization of the human T cell receptor-delta chain locus","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Organization of the human T cell receptor-delta chain locus</div><div class=\"cntnt\"><img style=\"width:614px; height:159px;\" src=\"images/ALLRG/64384_Human_TCR_delta_chain.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is one V delta gene within the V alpha region. There are also five genes in V alpha that may rearrange with either J alpha or J delta. There is an additional V delta gene between V alpha and D delta, and one more 3' (to the right) of C delta. There are three D delta, and four J delta genes. There is a single C delta gene.</div><div class=\"graphic_footnotes\">V: variable; D: diversity; J: joining; C: constant; 3': three prime end of the DNA strand.</div><div class=\"graphic_reference\">Adapted from: Moss PA, Rosenberg WM, Bell JL. The human T cell receptor in health and disease. Ann Rev Immunol 1992; 10:71.</div><div id=\"graphicVersion\">Graphic 64384 Version 2.0</div></div></div>"},"64385":{"type":"graphic_figure","displayName":"Anterior compartment forearm muscles","title":"Muscles of the anterior compartment of the forearm","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior compartment of the forearm</div><div class=\"cntnt\"><img style=\"width:560px; height:732px;\" src=\"images/EM/64385_Forearmmusclesantpict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagrams above show the location of the muscles of the forearm's anterior compartment. Red represents a muscle's origin and blue a muscle's insertion.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64385 Version 12.0</div></div></div>"},"64386":{"type":"graphic_table","displayName":"Opioid receptors","title":"Opioid effects by receptor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid effects by receptor</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Traditional*</td>\n\t\t\t<td class=\"subtitle1\">IUPHAR*</td>\n\t\t\t<td class=\"subtitle1\">Clinical Effects</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"5\">&#181;1</td>\n\t\t\t<td rowspan=\"5\">MOP</td>\n\t\t\t<td>Supraspinal analgesia</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Peripheral analgesia</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Sedation</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Euphoria</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Prolactin release</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"7\">&#181;2</td>\n\t\t\t<td rowspan=\"7\">&nbsp;</td>\n\t\t\t<td>Spinal analgesia</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Respiratory depression</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Physical dependence</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Gastrointestinal dysmotility</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Pruritus</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Bradycardia</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Growth hormone release</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"3\">&#954;1</td>\n\t\t\t<td rowspan=\"3\">KOP</td>\n\t\t\t<td>Spinal analgesia</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Miosis</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Diuresis</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"2\">&#954;2</td>\n\t\t\t<td rowspan=\"2\">&nbsp;</td>\n\t\t\t<td>Psychotomimesis</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Dysphoria</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>&#954;3</td>\n\t\t\t<td>&nbsp;</td>\n\t\t\t<td>Supraspinal analgesia</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"2\">&#948;&nbsp;</td>\n\t\t\t<td rowspan=\"2\">DOP</td>\n\t\t\t<td>Spinal and supraspinal analgesia</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Modulations of &#181;-receptor function</td>\n\t\t</tr>\n \t\t<tr>\n\t\t\t<td rowspan=\"2\">Nociceptin/orphanin</td>\n\t\t\t<td rowspan=\"2\">NOP</td>\n\t\t\t<td>Anxiolysis</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Analgesia</td>\n\t\t</tr>\n\t\t</table></div><div class=\"graphic_footnotes\">* International Union of Pharmacology Committee on Receptor Nomenclature has recommended new naming schema to replace traditional Greek nomenclature.</div><div id=\"graphicVersion\">Graphic 64386 Version 1.0</div></div></div>"},"64387":{"type":"graphic_diagnosticimage","displayName":"Shrinkage of a macroadenoma","title":"Effect of octreotide on the size of a somatotroph adenoma before (A) and after 12 weeks (B) and 24 weeks (C) of treatment with short-acting octreotide","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Effect of octreotide on the size of a somatotroph adenoma before (A) and after 12 weeks (B) and 24 weeks (C) of treatment with short-acting octreotide</div><div class=\"cntnt\"><img style=\"width:504px; height:116px;\" src=\"images/ENDO/64387_Shrinkage_of_a_macroadenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bevan, JS, Atkin, SL, Atkinson, AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octeotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002: 87:4554. Copyright Â© 2002. The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 64387 Version 2.0</div></div></div>"},"64389":{"type":"graphic_picture","displayName":"Pulmonary LAM lung biopsy Low","title":"Gross features of pulmonary lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross features of pulmonary lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:206px; height:242px;\" src=\"images/PULM/64389_Pulmonary_LAM_gross_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of open lung biopsy from a patient with early lymphangioleiomyomatosis. The main change is the presence of scattered cystic spaces in what is otherwise unremarkable lung tissue.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 64389 Version 2.0</div></div></div>"},"64392":{"type":"graphic_diagnosticimage","displayName":"Lipoma arborescens knee MRI","title":"Lipoma arborescents of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lipoma arborescents of the knee</div><div class=\"cntnt\"><img style=\"width:396px; height:398px;\" src=\"images/RHEUM/64392_Lipoma_arbor_knee_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal proton density MRI of the knee shows lipomatous proliferation of the synovium in the suprapatellar space (arrows), surrounded by a small joint effusion.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 64392 Version 6.0</div></div></div>"},"64393":{"type":"graphic_waveform","displayName":"ECG right bundle branch block 2","title":"Electrocardiogram (ECG) showing common right bundle branch block (RBBB)","html":"<div class=\"graphic normal\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing common right bundle branch block (RBBB)</div><div class=\"cntnt\"><img style=\"width:478px; height:293px;\" src=\"images/CARD/64393_Rightbundlebranchblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing characteristic changes in the precordial leads in common RBBB. The asynchronous activation of the two ventricles increases the QRS duration (0.13 sec). The terminal forces are rightward and anterior due to&nbsp;the delayed activation of the right ventricle, resulting in an rsR' pattern in the anterior-posterior lead V1 and a wide negative S wave in the left-right lead V6 (and, not shown, in lead I).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 64393 Version 5.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"64395":{"type":"graphic_movie","displayName":"Laser coagulation TTTS","title":"Laser coagulation twin-twin transfusion syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laser coagulation twin-twin transfusion syndrome</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64395_tttsconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:288px; height:288px;\" src=\"images/CARD/64395_ttts.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64395 Version 3.0</div></div></div>"},"64396":{"type":"graphic_waveform","displayName":"ECG digoxin toxicity in AF 1","title":"Single-lead electrocardiogram (ECG) showing atrial fibrillation (AF) with junctional escape beats suggesting digoxin toxicity","html":"<div class=\"graphic normal\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing atrial fibrillation (AF) with junctional escape beats suggesting digoxin toxicity</div><div class=\"cntnt\"><img style=\"width:538px; height:80px;\" src=\"images/CARD/64396_Digitalis_toxicity_in_AF_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 4 electrocardiograms in this sequence demonstrate increasing severity of digoxin toxicity in a patient with atrial fibrillation.<br />This ECG shows atrial fibrillation with an irregularly irregular ventricular response. However, the longest recurring R-R intervals are constant, suggesting junctional escape beats due to AV nodal block. The escape interval of 680 msec indicates an accelerated automatic pacemaker with a rate of 88 beats/min.</div><div class=\"graphic_reference\">The four electrocardiograms are adapted from: Childers R, Med Clin North Am 1976; 60:3.</div><div id=\"graphicVersion\">Graphic 64396 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"64398":{"type":"graphic_table","displayName":"Echo for MI complications","title":"Mechanical complications of myocardial infarction recognized by two dimensional echocardiography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanical complications of myocardial infarction recognized by two dimensional echocardiography</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Aneurysm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intracavitary thrombus</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Cardiac rupture (cardiorrhexis)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> Contained rupture (pseudoaneurysm)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> Ventricular septal defect</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> Free wall rupture with tamponade</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Papillary muscle rupture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mitral regurgitation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right ventricular infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pericardial effusion</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64398 Version 1.0</div></div></div>"},"64399":{"type":"graphic_table","displayName":"Cancer pain interventions","title":"Common interventional therapies for cancer pain management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common interventional therapies for cancer pain management</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Celiac plexus/splanchnic nerve blocks for abdominal pain</td> </tr> <tr> <td>Hypogastric plexus/ganglion impar block for pelvic pain</td> </tr> <tr> <td>Intercostal blocks for rib fractures</td> </tr> <tr> <td>Kyphoplasty and vertebroplasty for vertebral compression fractures</td> </tr> <tr> <td>Lumbar sympathetic block for rectal tenesmus</td> </tr> <tr> <td>Myofascial injections for muscle spasm</td> </tr> <tr> <td>Neuraxial infusions</td> </tr> <tr> <td>Suprascapular block for shoulder pain</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64399 Version 3.0</div></div></div>"},"64402":{"type":"graphic_diagnosticimage","displayName":"Oblique fractures of the lateral and posterior malleoli","title":"Oblique fractures of the lateral and posterior malleoli","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Oblique fractures of the lateral and posterior malleoli</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/64402_Oblique_lateral_post_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While the fracture of the lateral malleolus (arrow) is clearly seen on both views, the posterior malleolar fracture (arrowhead) is only seen on the lateral view. This combination of injuries is unstable and requires orthopedic referral regardless of whether widening of the medial joint line (dashed arrow) is apparent.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 64402 Version 5.0</div></div></div>"},"64403":{"type":"graphic_table","displayName":"Secondary causes of osteoporosis in premenopausal women","title":"Secondary causes of osteoporosis in premenopausal women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary causes of osteoporosis in premenopausal women</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Anorexia nervosa</td> </tr> <tr> <td>Gastrointestinal malabsorption (eg, celiac disease, postoperative states)</td> </tr> <tr> <td>Vitamin D and/or calcium deficiency</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Hyperparathyroidism</td> </tr> <tr> <td>Cushing's syndrome</td> </tr> <tr> <td>Hypogonadism (hypogonadotropic or hypergonadotropic)</td> </tr> <tr> <td>Hypercalciuria</td> </tr> <tr> <td>Rheumatoid arthritis and other inflammatory conditions</td> </tr> <tr> <td>Alcoholism</td> </tr> <tr> <td>Renal disease</td> </tr> <tr> <td>Liver disease</td> </tr> <tr> <td>Osteogenesis imperfecta</td> </tr> <tr> <td>Systemic mastocytosis</td> </tr> <tr> <td>Marfan's syndrome and Ehlers-Danlos syndrome</td> </tr> <tr> <td>Homocystinuria</td> </tr> <tr> <td class=\"sublist1_start\">Hereditary hemochromatosis</td> </tr> <tr> <td class=\"sublist1_start\">Thalassemia major</td> </tr> <tr> <td class=\"sublist1_start\">Gaucher disease</td> </tr> <tr> <td class=\"sublist1_start\">HIV infection and/or medications</td> </tr> <tr> <td class=\"sublist1_start\">Diabetes (types 1 and 2)</td> </tr> <tr> <td class=\"sublist1_start\">Medications</td> </tr> <tr> <td class=\"sublist1\">Glucocorticoids</td> </tr> <tr> <td class=\"sublist1\">Immunosuppressants (cyclosporine)</td> </tr> <tr> <td class=\"sublist1\">Antiseizure medications (particularly phenobarbital and phenytoin)</td> </tr> <tr> <td class=\"sublist1\">GnRH agonists (when used to suppress ovulation)</td> </tr> <tr> <td class=\"sublist1\">Heparin</td> </tr> <tr> <td class=\"sublist1\">Chemotherapy leading to amenorrhea</td> </tr> <tr> <td class=\"sublist1\">Thiazolidinediones</td> </tr> <tr> <td class=\"sublist1\">Depot medroxyprogesterone acetate</td> </tr> <tr> <td class=\"sublist1_start\">Possible contributors</td> </tr> <tr> <td class=\"sublist1\">Excess thyroid hormone</td> </tr> <tr> <td class=\"sublist1\">Depression and/or SSRI use</td> </tr> <tr> <td class=\"sublist1\">Proton pump inhibitors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; GnRH: gonadotropin-releasing hormone; SSRI: selective serotonin reuptake inhibitor.</div><div class=\"graphic_reference\">Courtesy of Carolyn Becker, MD and Adi Cohen, MD.</div><div id=\"graphicVersion\">Graphic 64403 Version 9.0</div></div></div>"},"64404":{"type":"graphic_picture","displayName":"Coccidioidomycosis granulomata","title":"Coccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:277px; height:183px;\" src=\"images/PULM/64404_Coccidioidomycosis_granulom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows multiple necrotizing and nonnecrotizing granulomas in a patient with coccidioidomycosis.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 64404 Version 2.0</div></div></div>"},"64406":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM PA gram IV","title":"Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/64406_Pulm_AVM_PA_gram_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A left selective pulmonary arteriogram shows abnormally dilated and tortuous segmental and subsegmental pulmonary arteries without early venous drainage.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64406 Version 2.0</div></div></div>"},"64407":{"type":"graphic_picture","displayName":"Knee chest stretch PI","title":"Knee chest stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee chest stretch</div><div class=\"cntnt\"><img style=\"width:432px; height:218px;\" src=\"images/PI/64407_Knee_chest_stretch_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lie on the back on a bed or on a towel on the floor. Bring knees up to chest. Place the hands behind the knees and pull toward the chest until you feel a stretch in the lower back and buttocks. Hold for 5 seconds. Rest. Repeat 10 times.</div><div id=\"graphicVersion\">Graphic 64407 Version 4.0</div></div></div>"},"64409":{"type":"graphic_figure","displayName":"Removable cast walker","title":"Removable cast walker","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Removable cast walker</div><div class=\"cntnt\"><img style=\"width:457px; height:607px;\" src=\"images/SURG/64409_Removable-cast-walker.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64409 Version 2.0</div></div></div>"},"64411":{"type":"graphic_picture","displayName":"Type I MPGN EM","title":"Electron microscopy in type I membranoproliferative glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron microscopy in type I membranoproliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/64411_MPGN_EM_Type_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in type I membranoproliferative glomerulonephritis shows marked thickening of the glomerular capillary wall by immune deposits (arrowhead) and by interposition of mesangial cell processes (arrow). There are two layers of the glomerular basement membrane (GBM) surrounding the mesangial interposition that account for the double-contour appearance on light microscopy.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 64411 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"64412":{"type":"graphic_algorithm","displayName":"Algorithm for expectantly managed PPROM reaching 34 weeks","title":"Algorithm for expectantly managed pregnancies with PPROM that reach 34 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Algorithm for expectantly managed pregnancies with PPROM that reach 34 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:530px; height:342px;\" src=\"images/OBGYN/64412_Algo_mngd_PPROM_34wks.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The American College of Obstetricians and Gynecologists considers pregnancies \"suboptimally dated\" in the absence of an ultrasound examination before 22+0 weeks of gestation confirming or revising the estimated date of delivery.<br />Â¶ Refer to UpToDate topic on preterm premature rupture of membranes for discussion of the components of expectant management. Terminate expectant management and deliver before 37 weeks if patient develops a standard indication for delivery (eg, chorioamnionitis, abruption, nonreassuring fetal testing, etc).<br />Î Labor is induced if there are no contraindications to vaginal delivery; cesarean delivery is performed for standard indications. Misoprostol or another prostaglandin can be used for cervical ripening if the cervix is unfavorable and there are no contraindications to its use.<br /><FONT class=lozenge>â</FONT> Refer to UpToDate topic on preterm premature rupture of membranes for discussion of the advantages and disadvantages of expectant management versus delivery.</div><div id=\"graphicVersion\">Graphic 64412 Version 8.0</div></div></div>"},"64413":{"type":"graphic_picture","displayName":"Chronic villitis ","title":"Chronic villitis (VUE)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic villitis (VUE)</div><div class=\"cntnt\"><img style=\"width:393px; height:260px;\" src=\"images/OBGYN/64413_Chronicvillitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is increased cellularity of the villi with sclerosis of the villi due to collapse of the villous vessels and clumping of the involved villi.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 64413 Version 4.0</div></div></div>"},"64415":{"type":"graphic_table","displayName":"Diagnostic value of findings in suspected FBA","title":"Diagnostic value of specific findings in children with suspected foreign body aspiration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic value of specific findings in children with suspected foreign body aspiration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"28%\"></colgroup><colgroup span=\"4\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Positive predictive value</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> <td class=\"subtitle1\">Negative predictive value</td> </tr> <tr> <td><strong>History of choking</strong></td> <td class=\"centered\">50/63/78</td> <td class=\"centered\">85/79/81</td> <td class=\"centered\">21/46/33</td> <td class=\"centered\">60/64/38</td> </tr> <tr> <td><strong>Unilateral decrease in breath sounds</strong></td> <td class=\"centered\">84/84/-</td> <td class=\"centered\">65/67/-</td> <td class=\"centered\">88/85/-</td> <td class=\"centered\">73/68/-</td> </tr> <tr> <td><strong>Wheezing</strong></td> <td class=\"centered\">65/47/74</td> <td class=\"centered\">33/10/60</td> <td class=\"centered\">84/87/40</td> <td class=\"centered\">57/45/26</td> </tr> <tr> <td><strong>Radiopaque foreign body</strong></td> <td class=\"centered\">100/100/-</td> <td class=\"centered\">20/7/-</td> <td class=\"centered\">100/100/-</td> <td class=\"centered\">57/47/-</td> </tr> <tr> <td><strong>Unilateral obstructive emphysema</strong></td> <td class=\"centered\">81/86/-</td> <td class=\"centered\">53/55/-</td> <td class=\"centered\">88/89/-</td> <td class=\"centered\">67/63/-</td> </tr> <tr> <td><strong>Abnormal inspiratory radiograph</strong></td> <td class=\"centered\">72/-/83</td> <td class=\"centered\">70/-/82</td> <td class=\"centered\">74/-/44</td> <td class=\"centered\">73/-/41</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diagnostic value of specific findings in children with foreign body aspiration, as estimated in three different case series in which the diagnosis was confirmed or excluded by bronchoscopy. Each value is given as Ref 1/Ref 2/Ref 3. A hyphen (-) is used where no data was provided by the reference.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Martinot A, Closset M, Marquette CH, et al. Indications for flexible versus rigid bronchoscopy in children with suspected foreign-body aspiration. Am J Respir Crit Care Med 1997; 155:1676. </li>&#xD;&#xA;    <li>Francois M, Thach-Toan, Maisani D, et al. [Endoscopy for exploration for foreign bodies of the lower respiratory tract of the child. Apropos of 668 cases.] Ann Otolaryngol Chir Cervicofac 1985; 102:433.</li>&#xD;&#xA;    <li>Hoeve LJ, Rombout J, Pot DJ. Foreign body aspiration in children. The diagnostic value of signs, symptoms, and pre-operative examination. Clin Otolaryngol 1993; 18:55.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64415 Version 3.0</div></div></div>"},"64416":{"type":"graphic_diagnosticimage","displayName":"Tetralogy Fallot PA angio I","title":"Main pulmonary artery angiogram in tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Main pulmonary artery angiogram in tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:344px; height:304px;\" src=\"images/CARD/64416_Tetralogy_Fallot_PA_angio_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angled angiogram performed in the main pulmonary artery demonstrates severe proximal left pulmonary artery (LPA) stenosis (*). There is discrepancy in size between the proximal right pulmonary artery (RPA) and the proximal LPA.</div><div class=\"graphic_reference\">Photo courtesy of Thomas Doyle, MD.</div><div id=\"graphicVersion\">Graphic 64416 Version 2.0</div></div></div>"},"64417":{"type":"graphic_figure","displayName":"Hallux valgus measurement","title":"Angles relevant to hallux valgus deformity","html":"<div class=\"graphic\"><div style=\"width: 753px\" class=\"figure\"><div class=\"ttl\">Angles relevant to hallux valgus deformity</div><div class=\"cntnt\"><img style=\"width:733px; height:574px;\" src=\"images/SM/64417_Hallux_valgus_measrmnt_edt1.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HA: hallux abductus angle (hallux valgus); IM: intermetatarsal angle.</div><div id=\"graphicVersion\">Graphic 64417 Version 3.0</div></div></div>"},"64418":{"type":"graphic_figure","displayName":"Needle technique for fish-hook removal","title":"Needle technique of fish-hook removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Needle technique of fish-hook removal</div><div class=\"cntnt\"><img style=\"width:309px; height:475px;\" src=\"images/EM/64418_Needletechnique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Anesthetize the skin adjacent to the embedded fish-hook barb. B) Advance a large gauge needle through the skin so that it covers the barb (see inset). C) Back the fish-hook and needle out of the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Diekema DS. Fishhook removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64418 Version 11.0</div></div></div>"},"64419":{"type":"graphic_picture","displayName":"Benign macrofollicular thyroid lesion high-power view","title":"Benign macrofollicular thyroid lesion: Findings on fine-needle aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign macrofollicular thyroid lesion: Findings on fine-needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ENDO/64419_Macrofollicular_lesion_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a fine-needle aspirate of a thyroid nodule. The follicular cells are small, uniform in size, flat, and noncrowded, with smeared colloid in the background. These findings can be seen in a normal thyroid gland, benign sporadic goiter, or a true benign macrofollicular monoclonal tumor.</div><div id=\"graphicVersion\">Graphic 64419 Version 5.0</div></div></div>"},"64420":{"type":"graphic_table","displayName":"PEF in children","title":"Predicted average peak expiratory flowÂ values for normal children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predicted average peak expiratory flow&nbsp;values for normal children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Height</td> <td class=\"subtitle1\">PEFR</td> <td class=\"subtitle1\" colspan=\"2\">Height</td> <td class=\"subtitle1\">PEFR</td> </tr> <tr> <td>(inches)</td> <td>(cm)</td> <td>(L/min)</td> <td>(inches)</td> <td>(cm)</td> <td>(L/min)</td> </tr> <tr> <td>43</td> <td>109</td> <td>147</td> <td>56</td> <td>142</td> <td>320</td> </tr> <tr> <td>44</td> <td>112</td> <td>160</td> <td>57</td> <td>145</td> <td>334</td> </tr> <tr> <td>45</td> <td>114</td> <td>173</td> <td>58</td> <td>147</td> <td>347</td> </tr> <tr> <td>46</td> <td>117</td> <td>187</td> <td>59</td> <td>150</td> <td>360</td> </tr> <tr> <td>47</td> <td>119</td> <td>200</td> <td>60</td> <td>152</td> <td>373</td> </tr> <tr> <td>48</td> <td>122</td> <td>214</td> <td>61</td> <td>155</td> <td>387</td> </tr> <tr> <td>49</td> <td>124</td> <td>227</td> <td>62</td> <td>157</td> <td>400</td> </tr> <tr> <td>50</td> <td>127</td> <td>240</td> <td>63</td> <td>160</td> <td>413</td> </tr> <tr> <td>51</td> <td>130</td> <td>254</td> <td>64</td> <td>163</td> <td>427</td> </tr> <tr> <td>52</td> <td>132</td> <td>267</td> <td>65</td> <td>165</td> <td>440</td> </tr> <tr> <td>53</td> <td>135</td> <td>280</td> <td>66</td> <td>168</td> <td>454</td> </tr> <tr> <td>54</td> <td>137</td> <td>293</td> <td>67</td> <td>170</td> <td>467</td> </tr> <tr> <td>55</td> <td>140</td> <td>307</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEFR: peak expiratory flow rate.</div><div class=\"graphic_reference\">Reproduced with permission from: Polger G, Promedhat V. Pulmonary function testing in children: techniques and standards. WB Saunders, Philadelphia 1971. Copyright &copy; 1971 Elsevier Science (USA).</div><div id=\"graphicVersion\">Graphic 64420 Version 5.0</div></div></div>"},"64421":{"type":"graphic_diagnosticimage","displayName":"Posterior junction line CT","title":"Posterior pleural junction line on chest CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior pleural junction line on chest CT scan</div><div class=\"cntnt\"><img style=\"width:324px; height:320px;\" src=\"images/PULM/64421_Posterior_junction_line_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows the posterior junction line formed by four layers of pleura that join posterior to the esophagus.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64421 Version 4.0</div></div></div>"},"64422":{"type":"graphic_table","displayName":"Protocol for noninvasive vent","title":"Protocol for noninvasive nocturnal ventilation for patients with COPD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for noninvasive nocturnal ventilation for patients with COPD</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Device\n   </td>\n   <td>Bilevel positive pressure device</td>\n   </tr>\n   <tr>\n   <td>Portable home ventilator</td>\n   </tr>\n   <tr>\n   <td>Location</td>\n   <td>Chronic ventilator or step-down unit versus intensive care unit</td>\n   </tr>\n   <tr>\n   <td>Monitors</td>\n   <td>\t<p>Trend pulse oximetry (SpO2) </p>\n\t<p>Heart rate</p>\n\t<p>Respiratory rate</p>\n</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"4\">\n   Initial setup\n   </td>\n   <td>Select/adjust nasal mask</td>\n   </tr>\n   <tr>\n   <td>Connect patient to bilevel positive pressure device (BPAP) in spontaneous mode</td>\n   </tr>\n   <tr>\n   <td>Start IPAP = 6; EPAP = 2 cmH2O</td>\n   </tr>\n   <tr>\n   <td>Supplemental oxygen at 0-3 LPM for SpO2 less than 89 percent</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"6\">\n   Observe\n   </td>\n   <td>Tolerance (log patient's complaints)</td>\n   </tr>\n   <tr>\n   <td>Dyspnea (Borg scale)</td>\n   </tr>\n   <tr>\n   <td>Synchrony (rib cage/abdominal excursion with IPAP onset)</td>\n   </tr>\n   <tr>\n   <td>SpO2</td>\n   </tr>\n   <tr>\n   <td>Vital signs</td>\n   </tr>\n   <tr>\n   <td>Arterial blood gas in the morning</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"4\">\n   Nasal mask titration\n   </td>\n   <td>Increase IPAP by 2 cmH2O as tolerated up to a maximum of 20 cmH2O</td>\n   </tr>\n   <tr>\n   <td>Increase EPAP to 4 to 6 cmH2O as needed to improve SpO2 or decrease work of breathing in COPD patients</td>\n   </tr>\n   <tr>\n   <td>FiO2 increased only after ventilation improved. Goal is to achieve SpO2 90 to 93 percent</td>\n   </tr>\n   <tr>\n   <td>Switch to spontaneous/timed (S/T) mode at 12 breaths/min if indicated</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Face mask titration\n   </td>\n   <td>Patients failing nasal mask will proceed to full face mask and above titration will be repeated</td>\n   </tr>\n   <tr>\n   <td>Patients failing full face mask and BPAP will proceed to volume ventilator (See Failure of nocturnal noninvasive ventilatory support below)</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"6\">\n   Volume ventilator\n   </td>\n   <td>Full face mask</td>\n   </tr>\n   <tr>\n   <td>Mode - assist control</td>\n   </tr>\n   <tr>\n   <td>Flow - start 60 LPM</td>\n   </tr>\n   <tr>\n   <td>Rate - set 2 to 4 bpm below patient spontaneous rate</td>\n   </tr>\n   <tr>\n   <td>Volume - as tolerated but target minute ventilation &#62;10 LPM</td>\n   </tr>\n   <tr>\n   <td>FiO2 increased only after ventilation improved. Goal is to achieve SpO2 90 to 93 percent</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"4\">\n   Failure of nocturnal noninvasive ventilatory support\n   </td>\n   <td>Patient refuses to accept either the nasal or face mask (anytime during the trial)</td>\n   </tr>\n   <tr>\n   <td>Unacceptable deterioration in mental status (anytime)</td>\n   </tr>\n   <tr>\n   <td>Intolerable dyspnea at any time or Borg scale &#62;15 with no improvement</td>\n   </tr>\n   <tr>\n   <td>Consider tracheostomy or other more acute treatment</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">IPAP: Inspiratory positive airway pressure; EPAP: Expiratory positive airway pressure; LPM: Liters per minute; FIO2: Fractional concentration of inspired oxygen; SpO2: Oxygen saturation.</div><div id=\"graphicVersion\">Graphic 64422 Version 1.0</div></div></div>"},"64424":{"type":"graphic_picture","displayName":"Interstitial pneumonitis in RA","title":"Interstitial pneumonitis in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Interstitial pneumonitis in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:580px; height:233px;\" src=\"images/RHEUM/64424_Interstitial_pneumonitis_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stages of interstitial pneumonitis in rheumatoid arthritis. Left panel: The histopathologic finding of permeation of the interaveolar septae by a lymphocytic infiltrate is consistent with lymphocytic interstitial pneumonitis in rheumatoid arthritis. Right panel: A more advanced stage of lymphocytic interstitial pneumonitis reveals germinal center formation and a focus of angiocentric granulomatous inflammation.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 64424 Version 1.0</div></div></div>"},"64425":{"type":"graphic_waveform","displayName":"Sinus bradycardia tutorial","title":"Sinus bradycardia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus bradycardia</div><div class=\"cntnt\"><img style=\"width:440px; height:100px;\" src=\"images/CARD/64425_Sinus_bradycardia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus bradycardia is defined as a sinus rhythm with a rate less than 60 beats per minute. This rhythm strip shows a sinus rate of 50 beats per minute.</div><div id=\"graphicVersion\">Graphic 64425 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"64426":{"type":"graphic_figure","displayName":"Nomogram to estimate KtV","title":"Nomogram to estimate Kt/V","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nomogram to estimate Kt/V</div><div class=\"cntnt\"><img style=\"width:286px; height:292px;\" src=\"images/NEPH/64426_KtV_nomogram.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nomogram to estimate Kt/V from the ratio (R) of the postdialysis to predialysis BUN and the fraction of body weight removed by ultrafiltration (UF/W), ranging from 0 to 0.09 (0 to 9 percent). Drawing the postdialysis blood sample should be delayed for 30 minutes after short-duration, high-efficiency hemodialysis to permit reequilibration with intracellular stores.</div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen.</div><div class=\"graphic_reference\">Data from Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error.&nbsp;J Am Soc Nephrol 1993; 4:1205.</div><div id=\"graphicVersion\">Graphic 64426 Version 4.0</div></div></div>"},"64427":{"type":"graphic_diagnosticimage","displayName":"Calyceal brush in medullary sponge kidney","title":"Calyceal brush in medullary sponge kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calyceal brush in medullary sponge kidney</div><div class=\"cntnt\"><img style=\"width:239px; height:360px;\" src=\"images/NEPH/64427_Medullary_sponge_kidney_bru.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retrograde pyelogram of the right kidney demonstrates reflux of contrast material into distended tubules in medullary pyramids, producing the characteristic brush lesion of medullary sponge kidney.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 64427 Version 5.0</div></div></div>"},"64429":{"type":"graphic_table","displayName":"CGG repeats mutation status","title":"How CGG repeats influence mutation status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How CGG repeats influence mutation status</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Maternal repeats</td> <td class=\"subtitle1\">Percent of offspring with expansion to full mutation (&#62;200 repeats)</td> </tr> <tr> <td>55 to 59</td> <td>4</td> </tr> <tr> <td>60 to 69</td> <td>5</td> </tr> <tr> <td>70 to 79</td> <td>31</td> </tr> <tr> <td>80 to 89</td> <td>58</td> </tr> <tr> <td>90 to 99</td> <td>80</td> </tr> <tr> <td>100 to 200</td> <td>Approximately 100</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CGG: cytosine-guanine-guanine.</div><div class=\"graphic_reference\">Data from: Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 2003; 72:454.</div><div id=\"graphicVersion\">Graphic 64429 Version 6.0</div></div></div>"},"64430":{"type":"graphic_table","displayName":"Education at subsequent visits","title":"Delivery of asthma education by clinicians during patient care visits: recommendations for all subsequent visits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Delivery of asthma education by clinicians during patient care visits: recommendations for all subsequent visits</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Assessment questions</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Focus on:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Expectations of visit</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Goals of treatment</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Medications</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Quality of life</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Ask relevant questions from previous visit and also ask:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"How have you tried to control things that make your asthma worse?\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"Please show me how you use your inhaled medication.\"</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Information</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Teach or review in simple language:</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Review and reinforce all:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Educational messages</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Environmental control strategeis at home, work, or school</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Medications</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Review and interpret from daily diary:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Peak flow measures</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Symptom scores</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Skills</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Teach or review and demonstrate:</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"indent1\">Inhaler/spacer/holding chamber techique.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Peak flow monitoring technique.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Use of daily self-management plan. Review and adjust as needed.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Review use of action plan. Confirm that patient knows what to do if\nasthma gets worse. Periodically review and adjust written action plan.</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n    \n    \n    \n\n    \n\n    \n\n    \n\n\n    \n\n    \n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64430 Version 1.0</div></div></div>"},"64431":{"type":"graphic_figure","displayName":"Periph nodule sampling II","title":"Endobronchial ultrasound (EBUS) peripheral nodule sampling II","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) peripheral nodule sampling II</div><div class=\"cntnt\"><img style=\"width:543px; height:491px;\" src=\"images/PULM/64431_Periph_nodule_sampling_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The radial probe is placed in a guide sheath and then both are advanced through the bronchoscope until they reach&nbsp;the airway. B) The radial probe and guide sheath are advanced until the peripheral pulmonary nodule is visualized. C) The probe is removed, leaving the guide sheath in position. D) Biopsy forceps or a bronchial brush are inserted through the guide sheath and the nodule is sampled.</div><div id=\"graphicVersion\">Graphic 64431 Version 2.0</div></div></div>"},"64433":{"type":"graphic_picture","displayName":"Glottic view with and without external laryngeal manipulation","title":"View of glottis with and without external laryngeal manipulation","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">View of glottis with and without external laryngeal manipulation</div><div class=\"cntnt\"><img style=\"width:488px; height:246px;\" src=\"images/EM/64433_GlottisnoELM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ELM improves the glottic view in more than 50 percent of patients with inadequate initial views. The photos show the view of the glottis without (A) and with (B) ELM.<br /></div><div class=\"graphic_footnotes\">ELM: external laryngeal manipulation.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 64433 Version 13.0</div></div></div>"},"64434":{"type":"graphic_diagnosticimage","displayName":"Jefferson C1 arch fracture lateral xray","title":"C1 arch fractures: Jefferson fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">C1 arch fractures: Jefferson fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:508px;\" src=\"images/EM/64434_Jefferson_fx_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph shows increased predental space between C1 and the odontoid (red arrow). Also note the soft tissue swelling anterior to the site of injury.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 64434 Version 3.0</div></div></div>"},"64435":{"type":"graphic_algorithm","displayName":"Monocular vision loss algorithm","title":"Monocular vision loss algorithm","html":"<div class=\"graphic\"><div style=\"width: 912px\" class=\"figure\"><div class=\"ttl\">Monocular vision loss algorithm</div><div class=\"cntnt\"><img style=\"width:892px; height:840px;\" src=\"images/EM/64435_Mnclr_vsn_lss_alg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EOM: extraocular movement; IIH: idiopathic intracranial hypertension; IOP: intraocular pressure.<br />* Eccentric pupil, prolapse of uvea or other structure, decreased anterior chamber size, and/or tenting of cornea/sclera.<br />&para; Injuries anterior and posterior to the lens often coexist.<br />&Delta; Causes include rapidly expanding infectious, vascular, or neoplastic masses.</div><div id=\"graphicVersion\">Graphic 64435 Version 5.0</div></div></div>"},"64441":{"type":"graphic_figure","displayName":"SPECT imaging and outcome","title":"SPECT imaging predicts cardiac death and myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">SPECT imaging predicts cardiac death and myocardial infarction</div><div class=\"cntnt\"><img style=\"width:531px; height:307px;\" src=\"images/CARD/64441_SPECT_imaging_and_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 5183 patients who underwent myocardial perfusion imaging, the presence and severity of an abnormal scan was predictive of cardiac death or a myocardial infarction during a two year follow-up.</div><div class=\"graphic_reference\">Data from Hachamovitch, R, Berman, DS, Shaw, LJ, et al, Circulation 1998; 97:535.</div><div id=\"graphicVersion\">Graphic 64441 Version 1.0</div></div></div>"},"64447":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic carcinoma CT III","title":"Locally advanced bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Locally advanced bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:385px; height:271px;\" src=\"images/PULM/64447_Bronchogenic_carcinoma_CT2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: CT scan of an advanced bronchogenic carcinoma shows right lower lobe atelectasis with accompanying right pleural effusion.<br />Right panel: Barium esophagram from this patient demonstrates an esophagopulmonary fistula (arrow) that indicates mediastinal extension and invasion by this T4 tumor.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64447 Version 4.0</div></div></div>"},"64448":{"type":"graphic_table","displayName":"Newer antiplatelet ASGE","title":"Recommendations regarding management of newer antiplatelet agents prior to endoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations regarding management of newer antiplatelet agents prior to endoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute GI hemorrhage in the patient taking a P2Y12 receptor blocker (eg, clopidogrel, ticlopidine, prasugrel, ticagrelor)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">The P2Y12 receptor blocker should be discontinued. The decision to reverse the antiplatelet effect, risking ischemic consequences, must be weighed against the risk of continued bleeding by maintaining the state of impaired platelet aggregation. If quick reversal is required, platelet transfusion may be appropriate.</td> </tr> <tr> <td class=\"subtitle1_single\">Elective endoscopic procedures in the patient taking a P2Y12 receptor blocker</td> </tr> <tr> <td class=\"indent1\">A decision regarding discontinuation of therapy before endoscopy has to be weighed against the patient's risk for developing an adverse ischemic event, including coronary stent occlusion. Endoscopic procedures previously have been categorized as low risk or high risk for bleeding.</td> </tr> <tr> <td class=\"indent2\"><strong>Low-risk procedures</strong></td> </tr> <tr> <td class=\"indent3\">No adjustments in antiplatelet regimen need to be made.</td> </tr> <tr> <td class=\"indent2\"><strong>High-risk procedures</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">Whether to discontinue these agents has not been determined. If discontinued, the recommended duration for discontinuing the agent prior to the procedure is as follows: 5 days (clopidogrel), 3 to 5 days (ticagrelor), 7 days (prasugrel), or 10 to 14 days (ticlopidine). Following the procedure, the P2Y12 platelet receptor blocker should be restarted, with or without a loading dose, as soon as it is deemed safe, taking into account the patient's indication for taking it and any therapy performed during the endoscopy that may increase the risk for bleeding (such as removal of a large polyp). In patients who receive a P2Y12 platelet receptor blocker plus aspirin, consider reversion to a single agent (preferably aspirin) before elective endoscopy.</td> </tr> <tr> <td class=\"subtitle1_single\">Patients taking dipyridamole</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">In the absence of a preexisting bleeding disorder, endoscopic procedures may be performed in patients who take dipyridamole or combination dipyridamole-aspirin in standard doses. However, the safety in patients undergoing high-risk procedures is unknown.</td> </tr> <tr> <td class=\"subtitle1_single\">Patients taking a Gp IIb/IIIa inhibitor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Patients being considered for elective endoscopy are not typically exposed to this class of drug. For patients requiring emergency endoscopy for acute GI hemorrhage, the Gp II/b/IIIa infusion should be discontinued. Eptifibatide and tirofiban have a relatively short duration (4 hours of action and 1 to 2 seconds, respectively), whereas abciximab may last up to 24 hours. Transfusion of platelets or use of DDAVP may play a role in the setting of major bleeding.</td> </tr> <tr> <td class=\"subtitle1_single\">Patients taking PAR-1 inhibitors</td> </tr> <tr> <td class=\"indent1\">PAR-1 inhibitors should be discontinued 5 to 13 days prior to elective procedures. They should also be held in patients requiring urgent endoscopy.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">DDAVP: I-desamino-8-d-arginine vasopressin (desmopressin); Gp: glycoprotein; PAR: protease activated receptor.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE). Gastrointest Endosc 2005; 61:189.</li>&#xD;&#xA;    <li>Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368:2113.</li>&#xD;&#xA;    <li>Baron TH, Kamath PS, McBane RD. New Anticoagulant and Antiplatelet Agents: A Primer for the Gastroenterologist. Clin Gastroenterol Hepatol 2014; 12:187.</li>&#xD;&#xA;    <li>ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83:3.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64448 Version 3.0</div></div></div>"},"64449":{"type":"graphic_picture","displayName":"Peripheral blood smear in sickle cell anemia","title":"Peripheral blood smear in sickle cell anemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear in sickle cell anemia</div><div class=\"cntnt\"><img style=\"width:360px; height:247px;\" src=\"images/HEME/64449_Sickle_cell_anemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with sickle cell anemia. This smear shows multiple sickle cells (blue arrows). There are also findings consistent with functional asplenia, including a nucleated red blood cell (upper left), a red blood cell containing a Howell-Jolly body (black arrow), and target cells (red arrow).</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 64449 Version 9.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"64450":{"type":"graphic_picture","displayName":"Facial musculoskeletal asym","title":"Facial asymmetry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Facial asymmetry</div><div class=\"cntnt\"><img style=\"width:271px; height:349px;\" src=\"images/RHEUM/64450_Facial_musculoskeletal_asym.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left side of this patient's face is smaller than the right. Temporomandibular joint dysfunction is more common in patients with facial asymmetry. Other associated features may include scoliosis and a short leg.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 64450 Version 3.0</div></div></div>"},"64451":{"type":"graphic_picture","displayName":"Complete uterine prolapse","title":"Evaluation of uterine prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of uterine prolapse</div><div class=\"cntnt\"><img style=\"width:348px; height:465px;\" src=\"images/OBGYN/64451_Uterine_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: RG Rogers, MD, Division of Female Pelvic Medicine and Reconstructive Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM.</div><div id=\"graphicVersion\">Graphic 64451 Version 2.0</div></div></div>"},"64453":{"type":"graphic_figure","displayName":"TDE pericarditis restrictive CM","title":"Doppler M-mode distinguishes between restrictive cardiomyopathy and constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Doppler M-mode distinguishes between restrictive cardiomyopathy and constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:500px; height:357px;\" src=\"images/CARD/64453_TDEpericarditisrestrictiv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler M-mode echocardiographic&nbsp;imaging of the left ventricular posterior wall is seen in row 1, the calculated Doppler myocardial velocity gradient (MVG) is in row 2, and the corresponding transmitral pulsed-wave Doppler blood flow is seen in row 3. Panel A is from a patient with a restrictive cardiomyopathy (RCM), panel B is from a patient with constrictive pericarditis (CP) who has marked respiratory variation of blood flow (&gt;25 percent E-wave reduction in inspiration), and panel C is from a patient with constrictive pericarditis and absent respiratory variation (nondiagnostic E-wave reduction in inspiration). Arrows seen in row 2 indicate peak values of the MVG in the predetermined phases of the cardiac cycle. The rapid ventricular filling (RVF) MVG was 3 times higher in both CP patients (* in row 2, panels B and C) compared with RCM patient (panel A), and the isovolumic relaxation (IR) MVG was positive in RCM patient and negative in both CP patients (# in row 2, panels B and C).</div><div class=\"graphic_reference\">Reproduced with permission from Palka P, Lange A, Donnelly JE, Nihoyannopoulos P. Circulation 2000; 102:655. Copyright Â© 2000 Lippincott Williams &amp;Wilkins.</div><div id=\"graphicVersion\">Graphic 64453 Version 3.0</div></div></div>"},"64454":{"type":"graphic_table","displayName":"Causes of hemolytic anemia in children","title":"Causes of hemolytic anemia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hemolytic anemia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Intrinsic red blood cell defects</td> </tr> <tr> <td class=\"indent1\">Hemoglobinopathies (eg, sickle cell disease, thalassemias)</td> </tr> <tr> <td class=\"indent1\">Membrane defects (eg, hereditary spherocytosis, elliptocytosis)</td> </tr> <tr> <td class=\"indent1\">Enzyme deficiencies (eg, G6PD, pyruvate kinase deficiencies)</td> </tr> <tr> <td class=\"subtitle1_single\">Extrinsic hemolytic processes</td> </tr> <tr> <td class=\"indent1\">Autoimmune hemolytic anemia (AIHA)<br /> <ul class=\"decimal_heading\"> <li>Warm-reactive </li> <li>Cold agglutinin disease </li> <li>Paroxysmal cold hemoglobinuria </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Hypersplenism</p> </td> </tr> <tr> <td class=\"indent1\"> <p>Systemic disease</p> <ul> <li>Infection (eg, malaria, <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\"><em>Clostridium perfringens)</em></span></li> <li><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Liver disease</span></li> <li><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Renal disease</span></li> </ul> </td> </tr> <tr> <td class=\"indent1\">Drugs and toxins*</td> </tr> <tr> <td class=\"indent1\">Microangiopathies<br /> <ul class=\"decimal_heading\"> <li>Hemolytic uremic syndrome (HUS) </li> <li>Thrombotic thrombocytopenic purpura (congenital or acquired)&nbsp; </li> <li>Disseminated intravascular coagulation (DIC)&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mechanical damage (eg, artificial heart valves, Kasabach-Merritt phenomena)</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> <tr> <td class=\"subtitle1_single\">Combined mechanism (intrinsic and extrinsic)</td> </tr> <tr> <td class=\"indent1\">Paroxysmal nocturnal hemoglobinuria (PNH)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate dehydrogenase.<br />*&nbsp;For details of specific agents, refer to separate UpToDate content on hemolytic anemia due to drugs and toxins.</div><div class=\"graphic_reference\">Courtesy of Michael Recht, MD, PhD.</div><div id=\"graphicVersion\">Graphic 64454 Version 11.0</div></div></div>"},"64460":{"type":"graphic_diagnosticimage","displayName":"Echogenic bowel cystic fibrosis","title":"Echogenic bowel, cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echogenic bowel, cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:407px; height:251px;\" src=\"images/OBGYN/64460_Echogenic_bowel_cystic_fibr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this longitudinal image, there is a very echogenic portion of fetal bowel seen in the mid abdomen that is as echodense as fetal bone. Both parents were known carriers of the ÎF508 cystic fibrosis mutation, and the newborn was found to be homozygous for this mutation.</div><div class=\"graphic_reference\">Courtesy of Stephen Chasen, MD.</div><div id=\"graphicVersion\">Graphic 64460 Version 2.0</div></div></div>"},"64461":{"type":"graphic_picture","displayName":"Dislocated tooth PI","title":"Avulsed incisors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Avulsed incisors</div><div class=\"cntnt\"><img style=\"width:432px; height:379px;\" src=\"images/PI/64461_Dislocated_tooth_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Permanent teeth that are knocked out should be handled carefuly on the top (crown, see arrows) to avoid damaging them.</div><div class=\"graphic_reference\">Courtesy of Dennis J McTigue, MD.</div><div id=\"graphicVersion\">Graphic 64461 Version 1.0</div></div></div>"},"64462":{"type":"graphic_figure","displayName":"Transperineal fistula repair4","title":"Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex</div><div class=\"cntnt\"><img style=\"width:430px; height:447px;\" src=\"images/OBGYN/64462_Transperineal_fistula_rep3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior rectal wall defect is closed longitudinally with interrupted 4-0 delayed absorbable sutures.</div><div id=\"graphicVersion\">Graphic 64462 Version 1.0</div></div></div>"},"64464":{"type":"graphic_picture","displayName":"Chronic GVHD - subcutaneous","title":"Chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:504px; height:224px;\" src=\"images/DERM/64464_Chron_GVHD_subcutaneous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cellulite-like plaque is present on the upper arm in this patient with subcutaneous fibrosis secondary to chronic graft-versus-host disease.</div><div id=\"graphicVersion\">Graphic 64464 Version 1.0</div></div></div>"},"64466":{"type":"graphic_diagnosticimage","displayName":"Midshaft fracture 4","title":"Midshaft forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Midshaft forearm fracture</div><div class=\"cntnt\"><img style=\"width:399px; height:489px;\" src=\"images/EM/64466_Distal_third_forearm_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radius and ulna fractures with minimal posterior angulation and no displacement in a 1-year-old child.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 64466 Version 3.0</div></div></div>"},"64467":{"type":"graphic_figure","displayName":"Mean serum melatonin","title":"Mean serum melatonin profiles","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Mean serum melatonin profiles</div><div class=\"cntnt\"><img style=\"width:466px; height:341px;\" src=\"images/ENDO/64467_Mean_serum_melatonin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean serum melatonin profiles of 20 subjects sampled at intervals after ingesting 0.1, 0.3, 1.0, and 10 mg of melatonin or placebo at 11:45 am.</div><div class=\"graphic_reference\">Reproduced from: Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, bodytemperature, and performance. Proc Natl Acad Sci 1994; 91:1824. Copyright &#169; 1994 National Academy of Sciences, USA.</div><div id=\"graphicVersion\">Graphic 64467 Version 2.0</div></div></div>"},"64472":{"type":"graphic_table","displayName":"Drug and toxin related movement disorders","title":"Drug- and toxin-induced movement disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced movement disorders</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Seizures</td> </tr> <tr> <td>Propranolol</td> </tr> <tr> <td>Insecticides (eg, organophosphates, carbamates)</td> </tr> <tr> <td>Lidocaine and other local anesthetics</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Nicotine</td> </tr> <tr> <td>Drug withdrawal states</td> </tr> <tr> <td class=\"sublist1_start\">Antidepressants</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td class=\"sublist1\">Bupropion</td> </tr> <tr> <td class=\"sublist1\">Citalopram</td> </tr> <tr> <td class=\"sublist1\">Escitalopram</td> </tr> <tr> <td class=\"sublist1\">Fluvoxamine</td> </tr> <tr> <td class=\"sublist1\">Venlafaxine</td> </tr> <tr> <td class=\"sublist1\">Amoxapine</td> </tr> <tr> <td class=\"sublist1\">Maprotiline</td> </tr> <tr> <td class=\"sublist1_start\">Antipsychotics</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines</td> </tr> <tr> <td class=\"sublist1\">Clozapine</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Camphor</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Chemical nerve agents (eg, soman, VX)</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Hypoglycemic agents</td> </tr> <tr> <td>Cyanide</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td>Meperidine</td> </tr> <tr> <td>Propoxyphene</td> </tr> <tr> <td>Orphenadrine</td> </tr> <tr> <td>Antihistamines (rare)</td> </tr> <tr> <td>Lindane</td> </tr> <tr> <td>Gyromitra-containing mushrooms</td> </tr> <tr> <td>Heavy metals</td> </tr> <tr> <td class=\"sublist1_start\">Antimicrobials</td> </tr> <tr> <td class=\"sublist1\">Imipenem</td> </tr> <tr> <td class=\"sublist1\">Penicillins</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Tremors/myoclonus</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Albuterol</td> </tr> <tr> <td class=\"sublist1\">Methylphenidate</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td>Drug withdrawal states</td> </tr> <tr> <td>Heavy metals</td> </tr> <tr> <td class=\"subtitle1_single\">Rigidity/parkinsonism</td> </tr> <tr> <td>Antipsychotics (neuroleptics)</td> </tr> <tr> <td>Metoclopramide</td> </tr> <tr> <td>Amoxapine</td> </tr> <tr> <td>Carbon monoxide (delayed)</td> </tr> <tr> <td>Methanol</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td>Phencyclidine</td> </tr> <tr> <td>MAOIs</td> </tr> <tr> <td>Serotonin syndrome</td> </tr> <tr> <td>Black widow spider bite</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Methaqualone</td> </tr> <tr> <td>MPTP (designer meperidine)</td> </tr> <tr> <td>Manganese</td> </tr> <tr> <td>Strychnine</td> </tr> <tr> <td>Carbon disulfide</td> </tr> <tr> <td>Cyanide</td> </tr> <tr> <td>Malignant hyperthermia</td> </tr> <tr> <td>Neuroleptic malignant syndrome</td> </tr> <tr> <td>Postanoxic injury from any agent</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Choreoathetosis</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">TCAs</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1_start\">Antiepileptics</td> </tr> <tr> <td class=\"sublist1\">Phenytoin</td> </tr> <tr> <td class=\"sublist1\">Carbamazepine</td> </tr> <tr> <td class=\"subtitle1_single\">Weakness/paralysis</td> </tr> <tr> <td>Barium (hypokalemia)</td> </tr> <tr> <td>Magnesium</td> </tr> <tr> <td class=\"sublist1_start\">Solvent abuse</td> </tr> <tr> <td class=\"sublist1\">Toluene</td> </tr> <tr> <td class=\"sublist1\">Gasoline</td> </tr> <tr> <td class=\"sublist1_start\">Heavy metals</td> </tr> <tr> <td class=\"sublist1\">Mercury</td> </tr> <tr> <td class=\"sublist1\">Thallium</td> </tr> <tr> <td class=\"sublist1_start\">Insecticides</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td>Nicotine</td> </tr> <tr> <td>Botulism</td> </tr> <tr> <td>Neurotoxic snake envenomation</td> </tr> <tr> <td>Tick paralysis</td> </tr> <tr> <td class=\"sublist1_start\">Seafood poisoning</td> </tr> <tr> <td class=\"sublist1\">Paralytic shellfish</td> </tr> <tr> <td class=\"sublist1\">Pufferfish (fugu)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64472 Version 9.0</div></div></div>"},"64474":{"type":"graphic_picture","displayName":"Quarter squat PI","title":"Quarter squat","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Quarter squat</div><div class=\"cntnt\"><img style=\"width:290px; height:504px;\" src=\"images/PI/64474_Quarter_squat_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand 12 to 18 inches away from a wall (facing away from the wall). Place feet shoulder-width apart. Lean back against the wall and slide the back down the wall while bending the knees. Do not bend the knees more than 30 to 45&#176; (this should not hurt the knees). Hold for a count of 5. Stand up. Repeat 10 times.</div><div id=\"graphicVersion\">Graphic 64474 Version 3.0</div></div></div>"},"64475":{"type":"graphic_table","displayName":"Epidemiology of ehrlichiosis","title":"Epidemiology of ehrlichiosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiology of ehrlichiosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Feature</td>\n\n      <td class=\"subtitle1\">HME</td>\n\n      <td class=\"subtitle1\">HGA</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Etiologic agent</td>\n\n      <td>E. chaffeensis</td>\n\n      <td>A. phagocytophilum</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Percent with tick exposure</td>\n\n      <td>80-90</td>\n\n      <td>45-85</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Percent with tick bite</td>\n\n      <td>68</td>\n\n      <td>67</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Vectors</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Amblyomma americanum</td>\n\n      <td>Ixodes scapularis</td>\n\n    </tr>\n\n    <tr>\n      \n      \n      <td>Ixodes pacificus</td>\n    </tr>\n    <tr>\n\n      <td>Suspected animal reserve</td>\n\n      <td>Deer</td>\n\n      <td>White-footed mouse</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Median age of patient</td>\n\n      <td>44</td>\n\n      <td>67</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64475 Version 1.0</div></div></div>"},"64476":{"type":"graphic_figure","displayName":"Temperature pattern in relapsing fever","title":"Temperature pattern in two patients with relapsing fever","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Temperature pattern in two patients with relapsing fever</div><div class=\"cntnt\"><img style=\"width:401px; height:316px;\" src=\"images/ID/64476_Temp_pattern_in_relapsing_f.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64476 Version 2.0</div></div></div>"},"64478":{"type":"graphic_table","displayName":"Incid LN mets superf esoph CA","title":"Incidence of lymph node metastases in superficial esophageal cancers according to depth of invasion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of lymph node metastases in superficial esophageal cancers according to depth of invasion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author,<br /> year</td> <td class=\"subtitle1\" rowspan=\"2\">Histology</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" colspan=\"3\">Percent LN Mets,<br /> mucosal lesion</td> <td class=\"subtitle1\" colspan=\"3\">Percent LN Mets,<br /> submucosal lesion</td> </tr> <tr> <td class=\"subtitle2\">M1</td> <td class=\"subtitle2\">M2</td> <td class=\"subtitle2\">M3</td> <td class=\"subtitle2\">SM1</td> <td class=\"subtitle2\">SM2</td> <td class=\"subtitle2\">SM3</td> </tr> <tr> <td>Endo M; 2000</td> <td>Squam</td> <td>236</td> <td>0</td> <td>0</td> <td>8</td> <td>11</td> <td>30</td> <td>61</td> </tr> <tr> <td>Fujita H; 2001</td> <td>Squam</td> <td>150</td> <td>0</td> <td>0</td> <td>4</td> <td>25</td> <td>22</td> <td>40</td> </tr> <tr> <td>Westerterp M; 2005</td> <td>Adeno</td> <td>120</td> <td>0</td> <td>0</td> <td>4</td> <td>0</td> <td>26</td> <td>67</td> </tr> <tr> <td>Eguchi T; 2006</td> <td>Squam</td> <td>464</td> <td>0</td> <td>6</td> <td>18</td> <td>53</td> <td>54*</td> <td>54*</td> </tr> <tr> <td>Shimada H; 2006</td> <td>Squam</td> <td>160</td> <td>0</td> <td>0</td> <td>6</td> <td>32</td> <td>31</td> <td>42</td> </tr> <tr> <td>Ancona E; 2008</td> <td> <p>Adeno</p> Squam</td> <td> <p>31</p> 67</td> <td>0</td> <td>0</td> <td>0</td> <td>8</td> <td>29</td> <td>54</td> </tr> <tr> <td>H&#246;lscher A; 2011</td> <td> <p>Adeno </p> Squam</td> <td> <p>121</p> 50</td> <td>0</td> <td>0</td> <td>0</td> <td>13</td> <td>19</td> <td>56</td> </tr> <tr> <td>Yamashina T; 2013</td> <td>Squam</td> <td>402</td> <td>0.4<sup>&#182;</sup></td> <td>0.4<sup>&#182;</sup></td> <td>9</td> <td>8</td> <td>36</td> <td>NR</td> </tr> <tr> <td>Akutsu Y; 2013</td> <td>Squam</td> <td>295</td> <td>0<sup>&#916;</sup></td> <td>0<sup>&#916;</sup></td> <td>9<sup>&#916;</sup></td> <td>16<sup>&#916;</sup></td> <td>35<sup>&#916;</sup></td> <td>62<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LN: lymph node; Squam: squamous cell cancer; Adeno: adenocarcinoma; NR: not reported.<br />* SM2/SM3 combined.<br />&para; M1 and M2 combined; metastasis rate combined for nodal and distant spread.<br />&Delta; Risks for lymph node metastases (surgically treated patients) or lymph node recurrences (non-surgically treated patients).</div><div id=\"graphicVersion\">Graphic 64478 Version 8.0</div></div></div>"},"64479":{"type":"graphic_table","displayName":"ESC 2008 CM familial","title":"Familial types of cardiomyopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Familial types of cardiomyopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">HCM</td> <td class=\"subtitle1\">DCM</td> <td class=\"subtitle1\">ARVC</td> <td class=\"subtitle1\">Arrhythmogenic CM</td> <td class=\"subtitle1\">RCM</td> <td class=\"subtitle1\">Unclassified</td> </tr> <tr> <td> <p>Familial, unknown gene</p> Sarcomeric protein mutations <ul> <li>&#914; myosin heavy chain </li> <li>Cardiac myosin binding protein C </li> <li>Cardiac troponin I </li> <li>Troponin-T </li> <li>&#945;-tropomyosin </li> <li>Essential myosin light chain </li> <li>Regulatory myosin light chain </li> <li>Cardiac actin </li> <li>&#945;-myosin heavy chain </li> <li>Titin </li> <li>Troponin C </li> <li>Muscle LIM protein </li> </ul> <p>Glycogen storage disease (eg, Pompe; PRKAG2, Forbes', Danon)</p> <p>Lysosomal storage diseases (eg, Anderson-Fabry, Hurler's)</p> <p>Disorders of fatty acid metabolism</p> <p>Carnitine deficiency</p> <p>Phosphorylase B kinase deficiency</p> <p>Mitochondrial cytopathies</p> Syndromic HCM <ul> <li>Noonan's syndrome </li> <li>LEOPARD syndrome </li> <li>Friedreich's ataxia </li> <li>Beckwith-Wiedemann syndrome </li> <li>Swyer's syndrome </li> </ul> Other <ul> <li>Phospholamban promoter </li> <li>Familial amyloid </li> </ul> </td> <td> <p>Familial, unknown gene</p> <p>Sarcomeric protein mutations (see HCM)</p> Z-band <ul> <li>Muscle LIM protein </li> <li>TCAP </li> </ul> Cytoskeletal genes <ul> <li>Titin </li> <li>Dystrophin </li> <li>Desmin </li> <li>Metavinculin </li> <li>Sarcoglycan complex </li> <li>CRYAB </li> <li>Epicardin </li> </ul> Nuclear membrane <ul> <li>Lamin A/C </li> <li>Emerin </li> </ul> <p>Mildly dilated CM</p> <p>Intercalated disc protein mutations (see ARVC)</p> Mitochondrial cytopathy</td> <td> <p>Familial, unknown gene</p> Intercalated disc protein mutations <ul> <li>Plakoglobin </li> <li>Desmoplakin </li> <li>Plakophilin 2 </li> <li>Desmoglein 2 </li> <li>Desmocollin 2 </li> </ul> <p>&nbsp;Transforming growth factor-&#946;3 (TGF-&#946;3)<br /> Transmembrane protein 43 (TMEM43)</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> <td> <p>Familial, unknown gene</p> <p>Intercalated disc protein mutations (see ARVC)</p> <p>Lamin A/C</p> <p>SCN5A</p> <p>Phospholamban</p> </td> <td> <p>Familial, unknown gene</p> Sarcomeric protein mutations <ul> <li>Troponin I (RCM +/- HCM) </li> <li>Essential light chain of myosin </li> </ul> Familial amyloidosis <ul> <li>Transthyretin (RCM + neuropathy) </li> <li>Apolipoprotein (RCM + nephropathy) </li> </ul> <p>Desminopathy</p> <p>Pseuxanthoma elasticum</p> <p>Haemochromatosis</p> <p>Anderson-Fabry disease</p> Glycogen storage disease</td> <td>Left ventricular non-compaction <ul> <li>Barth syndrome </li> <li>Lamin A/C </li> <li>ZASP </li> <li>&#945;-dystrobrevin </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; ARVC: arrhythmogenic right ventricular cardiomyopathy; RCM: restrictive cardiomyopathy.</div><div class=\"graphic_reference\">Modified with permission from: Elliott P, Anderson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial disease. Eur Heart J 2008; 29:270. Copyright &copy; 2008 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 64479 Version 11.0</div></div></div>"},"64481":{"type":"graphic_table","displayName":"Procedure table child endotracheal intubation","title":"Procedure summary: Endotracheal intubation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedure summary: Endotracheal intubation in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preparation </td> </tr> <tr> <td class=\"indent1\">1. Preoxygenate the patient with 100 percent inspired oxygen.</td> </tr> <tr> <td class=\"indent1\">2. Provide bag-mask ventilation as needed.</td> </tr> <tr> <td class=\"indent1\">3. Initiate continuous monitoring of heart rate, respiratory, pulse oximetry, and cycled noninvasive or intraarterial blood pressure.</td> </tr> <tr> <td class=\"indent1\">4. Assemble appropriately sized equipment*.</td> </tr> <tr> <td class=\"indent1\">5. Test the laryngoscope blade light.</td> </tr> <tr> <td class=\"indent1\">6. If applicable, inflate and deflate the cuff of the endotracheal tube to ensure no leak.</td> </tr> <tr> <td class=\"indent1\">7. Place a stylet in the endotracheal tube and put a slight \"hockey stick\" bend at the tip.</td> </tr> <tr> <td class=\"indent1\">8. If no concern for cervical spine trauma, position the patient in the sniffing position<sup>&#182;</sup>.</td> </tr> <tr> <td class=\"indent1\">9. Have an assistant provide manual inline stabilization for patients with concern for cervical spine trauma<sup>&#916;</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\">Direct laryngoscopy </td> </tr> <tr> <td class=\"indent1\">1. Open the patient's mouth using the scissor technique or, in patients without cervical spine restrictions, extending the head.</td> </tr> <tr> <td class=\"indent1\">2. Insert the laryngoscope blade into the right side of the mouth along the base of the tongue while following the natural contour of the oropharynx.</td> </tr> <tr> <td class=\"indent1\">3. Sweep the tongue to the left side by advancing the laryngoscope into the midline of the hypopharynx.</td> </tr> <tr> <td class=\"indent1\">4. Advance the laryngoscope blade and identify the epiglottis.</td> </tr> <tr> <td class=\"sublist2_start\">5. Visualize the glottic opening and vocal cords: </td> </tr> <tr> <td class=\"sublist2\">Straight blade - Position the tip of the blade under the epiglottis </td> </tr> <tr> <td class=\"sublist2\">Curved blade - Position the tip of the blade in the deepest portion of the vallecula </td> </tr> <tr> <td class=\"indent1\">6. Pull upward on the laryngoscope handle at a 45 degree angle to expose the glottic opening. <strong>DO NOT</strong> rock the laryngoscope handle backward as this will limit the ability to pass the endotracheal tube and typically causes injury to the upper gums, teeth, or lip.</td> </tr> <tr> <td class=\"subtitle1_single\">Endotracheal tube placement </td> </tr> <tr> <td class=\"indent1\">1. While maintaining visualization of the glottic opening and vocal cords, advance the endotracheal tube horizontally from the right side of the mouth.</td> </tr> <tr> <td class=\"indent1\">2. Once the endotracheal tube has passed approximately 1 to 2 cm through the vocal cords, remove the stylet.</td> </tr> <tr> <td class=\"indent1\">3. Confirm tracheal placement with capnography and clinical findings.</td> </tr> <tr> <td class=\"indent1\">4. Assess proper depth of insertion (eg, centimeter mark equal to 3 times the internal diameter of the endotracheal tube).</td> </tr> <tr> <td class=\"indent1\">5. Secure the endotracheal tube.</td> </tr> <tr> <td class=\"indent1\">6. Obtain chest radiograph to document proper endotracheal tube placement.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* See table \"Equipment sizing for pediatric endotracheal intubation\" and see table \"Age based formula for selecting endotracheal tube size (internal diameter in mm)\".<br />&para; See figure \"Proper positioning for ventilation and intubation for children older than two years of age\".<br />&Delta; See figure \"Manual stabilization of the pediatric spine\".</div><div id=\"graphicVersion\">Graphic 64481 Version 3.0</div></div></div>"},"64482":{"type":"graphic_figure","displayName":"Trabecular BMD hypogonadism","title":"Reduced trabecular bone mineral density (BMD) in men with hypogonadism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reduced trabecular bone mineral density (BMD) in men with hypogonadism</div><div class=\"cntnt\"><img style=\"width:366px; height:274px;\" src=\"images/ENDO/64482_Trabecular_BMD_hypogonadism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trabecular bone density (determined by QCT) in 36 men with acquired hypogonadism are shown in the open circles. The solid line refers to the mean values in normal men and the dashed lines are Â±SD. Forty-six percent of hypogonadal men had trabecular BMD values more than 1.0 SD below the mean for normal men. Trabecular BMD correlated negatively with age (r = -0.54; p = 0.003), but the relationship was not significant when corrected for serum testosterone concentration.</div><div class=\"graphic_reference\">Reproduced with permission from: Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.&nbsp;J Clin Endocrinol Metab 1996; 81:4358.</div><div id=\"graphicVersion\">Graphic 64482 Version 2.0</div></div></div>"},"64484":{"type":"graphic_picture","displayName":"Zephyr Endobronchial Valve side view","title":"ZephyrÂ® Endobronchial Valve, side view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Zephyr&#174; Endobronchial Valve, side view</div><div class=\"cntnt\"><img style=\"width:338px; height:432px;\" src=\"images/PULM/64484_Zephyr_Endobronchial_Valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Strange, C, Herth, FJ, Kovitz, KL, et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med 2007; 7:10. Copyright &#169; 2010 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 64484 Version 3.0</div></div></div>"},"64485":{"type":"graphic_movie","displayName":"B lines and lung sliding","title":"B lines and lung sliding","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">B lines and lung sliding</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/64485_Blineslungslidingconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:442px; height:364px;\" src=\"images/PULM/64485_Blineslungsliding.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64485 Version 2.0</div></div></div>"},"64486":{"type":"graphic_figure","displayName":"High resolution manometry defecation patterns","title":"High resolution manometry images showing patterns of defecation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High resolution manometry images showing patterns of defecation</div><div class=\"cntnt\"><img style=\"width:400px; height:656px;\" src=\"images/GAST/64486_High_res_manometry_defeca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution manometry images showing (A) normal pattern of defecation in a healthy subject and (B) an incoordinated or dyssynergic pattern of defecation in a subject with constipation and dyssynergic defecation. In the normal subject the anal pressure decreases (Green color: Pressure = 20 mmHg), whereas in the dyssynergic subject there is paradoxical increase in anal sphincter pressure (Red color: Pressure = 100 mmHg). The rectal pressure increases in both subjects.</div><div class=\"graphic_reference\">Reproduced from: Rao SSC, Meduri K. What is necessary to diagnose constipation? Best Pract Res Clin Gastroenterol 2011; 25:127. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64486 Version 1.0</div></div></div>"},"64487":{"type":"graphic_table","displayName":"Clinicopathological criteria for NSF","title":"Clinicopathological criteria for NSF","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinicopathological criteria for NSF</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical findings: Major criteria</td> </tr> <tr> <td>Patterned plaques</td> </tr> <tr> <td>Joint contractures</td> </tr> <tr> <td>\"Cobblestoning\"</td> </tr> <tr> <td>Marked induration/Peau d'orange</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical findings: Minor criteria</td> </tr> <tr> <td>Puckering/linear banding</td> </tr> <tr> <td>Superficial plaque/patch</td> </tr> <tr> <td>Dermal papules</td> </tr> <tr> <td>Scleral plaques (age &#60;45 years)</td> </tr> <tr> <td class=\"subtitle1_single\">Histologic findings</td> </tr> <tr> <td>Increased dermal cellularity (score +1)</td> </tr> <tr> <td>CD34<sup>+</sup> cells with tram-tracking (score +1)</td> </tr> <tr> <td>Thick and thin collagen bundles (score +1)</td> </tr> <tr> <td>Preserved elastic fibers (score -1 if <em>absent</em>)</td> </tr> <tr> <td>Septal involvement (score +1)</td> </tr> <tr> <td>Osseous metaplasia (score +3)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64487 Version 2.0</div></div></div>"},"64489":{"type":"graphic_table","displayName":"Lab abnormalities in alcoholic liver disease","title":"Laboratory abnormalities in alcoholic liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory abnormalities in alcoholic liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Diagnostic characteristics*</td> </tr> <tr> <td>Serum AST&#62;ALT (ratio usually &#62;2.0, both usually &#60;300 international units/L, and almost never &#62;500 international units/L)</td> <td>Sensitivity and specificity have not been well studied, but may vary with the magnitude of the ratio</td> </tr> <tr> <td rowspan=\"2\">Elevated serum AST</td> <td>Sensitivity 50 percent</td> </tr> <tr> <td>Specificity 82 percent</td> </tr> <tr> <td rowspan=\"2\">Elevated serum ALT</td> <td>Sensitivity 35 percent </td> </tr> <tr> <td>Specificity 86 percent</td> </tr> <tr> <td rowspan=\"2\">Elevated serum GGT</td> <td>Sensitivity approximately 70 percent</td> </tr> <tr> <td>Specificity approximately 60 to 80 percent</td> </tr> <tr> <td rowspan=\"2\">High MCV</td> <td>Sensitivity approximately 30 to 50 percent</td> </tr> <tr> <td>Specificity approximately 85 to 90 percent</td> </tr> <tr> <td rowspan=\"2\">Elevated carbohydrate-deficient transferrin</td> <td>Sensitivity approximately 60 to 70 percent&nbsp;(lower values have been reported)</td> </tr> <tr> <td>Specificity approximately 80 to 90 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase; MCV: mean corpuscular volume.<br />* The sensitivity and specificity figures all assume chronic alcohol use, although the definitions have varied among studies.</div><div id=\"graphicVersion\">Graphic 64489 Version 2.0</div></div></div>"},"64491":{"type":"graphic_figure","displayName":"Infections after autologous HCT","title":"Typical timing of infections among autologous hematopoietic cell recipients receiving antimicrobial prophylaxis","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Typical timing of infections among autologous hematopoietic cell recipients receiving antimicrobial prophylaxis</div><div class=\"cntnt\"><img style=\"width:506px; height:527px;\" src=\"images/ID/64491_Infections_after_autologous_HCT.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64491 Version 5.0</div></div></div>"},"64492":{"type":"graphic_picture","displayName":"Vessel changes in optic fundi","title":"Vessel changes in optic fundi","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Vessel changes in optic fundi</div><div class=\"cntnt\"><img style=\"width:532px; height:321px;\" src=\"images/ID/64492_Vessel_cxs_in_optic_fundi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vessel changes in the optic fundi of patients with cerebral malaria. Vessels&nbsp;that are normally red in color become orange or yellow because they contain parasitized red cells. The parasite consumes some of the hemoglobin in solution, so those red cells become less red. In the image on the left, all three features of malarial retinopathy are present (white-centered hemorrhages, vessel changes, and whitening in areas of the retina).</div><div class=\"graphic_reference\">Courtesy of Susan Lewallen and Nicholas Beare.</div><div id=\"graphicVersion\">Graphic 64492 Version 4.0</div></div></div>"},"64493":{"type":"graphic_figure","displayName":"Classification exercise","title":"Classification of sports","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Classification of sports</div><div class=\"cntnt\"><img style=\"width:756px; height:482px;\" src=\"images/CARD/64493_Classificationexercise.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This classification is based on peak static and dynamic components achieved during competition. It should be noted, however, that higher values may be reached during training. The increasing dynamic component is defined in terms of the estimated percent of Max O<sub>2</sub> achieved and results in an increasing cardiac output. The increasing static component is related to the estimated percent of MVC reached and results in an increasing blood pressure load. The lowest total cardiovascular demands (cardiac output and blood pressure) are shown in green and the highest in red. Blue, yellow, and orange depict low moderate, moderate, and high moderate total cardiovascular demands.</div><div class=\"graphic_footnotes\">Max O<sub>2</sub>: maximal oxygen uptake; MVC: maximal voluntary contraction.<br />* Danger of bodily collision.<br />&#182; Increased risk if syncope occurs.</div><div class=\"graphic_reference\">Reproduced with permission from: Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364. Copyright &copy; 2005 American College of Cardiology Foundation.</div><div id=\"graphicVersion\">Graphic 64493 Version 7.0</div></div></div>"},"64494":{"type":"graphic_diagnosticimage","displayName":"Face holoprosencephaly","title":"At 19 postmenstrual weeks, this fetus with trisomy 13 and alobar holoprosencephaly also displays abnormal facies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">At 19 postmenstrual weeks, this fetus with trisomy 13 and alobar holoprosencephaly also displays abnormal facies</div><div class=\"cntnt\"><img style=\"width:271px; height:421px;\" src=\"images/OBGYN/64494_Face_holoprosencephaly_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The orbits are very close together (hypotelorism).<br />(B) There is disruption of the hard palate consistent with a midline cleft lip and palate (arrow).</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 64494 Version 5.0</div></div></div>"},"64495":{"type":"graphic_table","displayName":"GI peptide modes of action","title":"Classification of gastrointestinal peptides based upon mode of action","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of gastrointestinal peptides based upon mode of action</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Hormone</td> </tr> <tr> <td>Gastrin</td> </tr> <tr> <td>Cholecystokinin</td> </tr> <tr> <td>Secretin</td> </tr> <tr> <td>Gastric inhibitory peptide*</td> </tr> <tr> <td>Pancreatic polypeptide</td> </tr> <tr> <td>Motilin</td> </tr> <tr> <td>Insulin</td> </tr> <tr> <td>Glucagon</td> </tr> <tr> <td>Enteroglucagon</td> </tr> <tr> <td>Peptide YY</td> </tr> <tr> <td>Somatostatin</td> </tr> <tr> <td class=\"subtitle1\">Paracrine</td> </tr> <tr> <td>Somatostatin</td> </tr> <tr> <td>Peptide YY</td> </tr> <tr> <td class=\"subtitle1\">Neurocrine</td> </tr> <tr> <td>Cholecystokinin</td> </tr> <tr> <td>Secretin</td> </tr> <tr> <td>Gastrin-releasing peptide</td> </tr> <tr> <td>Neuropeptide Y</td> </tr> <tr> <td>Peptide YY</td> </tr> <tr> <td>Vasoactive intestinal peptide</td> </tr> <tr> <td>Neurotensin</td> </tr> <tr> <td>Peptide histidine-isoleucine</td> </tr> <tr> <td>Substance P</td> </tr> <tr> <td>Substance K</td> </tr> <tr> <td>Enkephalin</td> </tr> <tr> <td>Dynorphin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Also called glucose-dependent insulinotropic polypeptide.</div><div id=\"graphicVersion\">Graphic 64495 Version 2.0</div></div></div>"},"64496":{"type":"graphic_table","displayName":"Fetal age by foot length","title":"Gestational age based upon fetal foot length","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gestational age based upon fetal foot length</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Foot length, mm</td>\n\n\n      <td class=\"subtitle1\">Gestational age, weeks</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6</td>\n\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>9</td>\n\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>14</td>\n\n\n      <td>14</td>\n\n    </tr>\n\n    <tr>\n\n      <td>20</td>\n\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td>27</td>\n\n\n      <td>18</td>\n\n    </tr>\n\n    <tr>\n\n      <td>33</td>\n\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>39</td>\n\n\n      <td>22</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 64496 Version 1.0</div></div></div>"},"64500":{"type":"graphic_figure","displayName":"Proportion IPD due to vaccine serotypes in children 0 to 5 yrs","title":"Proportion of invasive pneumococcal disease in children ","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Proportion of invasive pneumococcal disease in children </div><div class=\"cntnt\"><img style=\"width:500px; height:272px;\" src=\"images/PEDS/64500_Prop_IPD_sero_child_0_5yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Assumes serotype 6A/6B cross-protection, globally and by region. Error bars indicate the 95% confidence intervals.</div><div class=\"graphic_footnotes\">PCV7: 7-valent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, 23F); PCV10: 10-valent pneumococcal conjugate vaccine (PCV7 serotypes plus 1, 5, 7F); PCV13: 13-valent pneumococcal conjugate vaccine (PCV10 serotypes plus 3, 6A, 19A).</div><div class=\"graphic_reference\">Reproduced with permission from: Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Med 2010; 7: e1000348. Copyright Â© 2010.</div><div id=\"graphicVersion\">Graphic 64500 Version 3.0</div></div></div>"},"64501":{"type":"graphic_table","displayName":"Genetic diseases with NK def","title":"Genetic diseases associated with a natural killer (NK) cell deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic diseases associated with a natural killer (NK) cell deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Gene(s)</td> <td class=\"subtitle1\">NK cell defect</td> <td class=\"subtitle1\">Infectious susceptibility</td> </tr> <tr> <td>X-linked SCID</td> <td><em>IL2RG</em></td> <td>Development</td> <td>Multiple infections</td> </tr> <tr> <td rowspan=\"2\">Autosomal recessive SCID</td> <td><em>JAK3</em></td> <td>Development</td> <td rowspan=\"2\">Multiple infections</td> </tr> <tr> <td><em>ADA</em></td> <td>Survival</td> </tr> <tr> <td>Bloom syndrome</td> <td><em>BLM</em></td> <td>Survival</td> <td>Fungi, bacteria</td> </tr> <tr> <td>Fanconi's anemia</td> <td><em>FANCA-G</em></td> <td>Survival</td> <td>Multiple infections</td> </tr> <tr> <td>Familial erythrophagocytic lymphohistiocytosis</td> <td><em>PFP1, UNC13D, STX11, MUNC13-4, MUNC18-2</em></td> <td>Function: Cytotoxicity</td> <td>Herpesviruses</td> </tr> <tr> <td>Chediak-Higashi syndrome</td> <td><em>LYST</em></td> <td>Function: Cytotoxicity</td> <td>EBV, fungi</td> </tr> <tr> <td>Griscelli syndrome</td> <td><em>RAB27A</em></td> <td>Function: Cytotoxicity</td> <td>Herpesviruses, bacteria</td> </tr> <tr> <td>X-linked lymphoproliferative syndrome</td> <td><em>SH2D1A, BIRC4 (XIAP)</em></td> <td>Function: Cytotoxicity</td> <td>EBV</td> </tr> <tr> <td>Bare lymphocyte syndrome</td> <td><em>TAP1, TAP2</em></td> <td>Function: Specific cytotoxicity</td> <td>Bacteria</td> </tr> <tr> <td>Leukocyte adhesion deficiency</td> <td><em>ITGB2</em></td> <td>Function: Target binding</td> <td>Picornaviruses, bacteria, HSV</td> </tr> <tr> <td>X-linked hyper-IgM-I</td> <td><em>TNFSF5</em></td> <td>Development, function: Cytotoxicity</td> <td>Enteroviruses, bacteria, pneumocystis</td> </tr> <tr> <td>Paroxysmal nocturnal hemoglobinuria</td> <td><em>PIGA</em></td> <td>Function: Cytotoxicity</td> <td>Multiple infections</td> </tr> <tr> <td>Wiskott-Aldrich syndrome</td> <td><em>WASP</em></td> <td>Function: Cytotoxicity</td> <td>Multiple infections</td> </tr> <tr> <td>IL-12 receptor beta-1 deficiency</td> <td><em>IL12RB1</em></td> <td>Function: Cytokine response and production</td> <td>Mycobacteria, salmonella</td> </tr> <tr> <td>Ectodermal dysplasia with immunodeficiency</td> <td><em>NEMO</em></td> <td>Function: Cytotoxicity</td> <td>Mycobacteria, bacteria, CMV</td> </tr> <tr> <td>Autoimmune lymphoproliferative syndrome with immunodeficiency</td> <td><em>CASP8</em></td> <td>Function: Activation receptor-induced stimulation</td> <td> <p>Sinopulmonary bacterial</p> Mucocutaneous herpesviruses</td> </tr> <tr> <td>Familial erythrophagocytic lymphohistiocytosis - type 3</td> <td><em>UNC13D</em></td> <td>Function: Cytotoxicity</td> <td>Herpesviruses</td> </tr> <tr> <td>Familial erythrophagocytic lymphohistiocytosis - type 4</td> <td><em>STX11</em></td> <td>Function: Cytotoxicity</td> <td>Herpesviruses</td> </tr> <tr> <td>Hermansky-Pudlak syndrome</td> <td><em>AP3B1</em></td> <td>Function: Cytotoxicity</td> <td> <p>Sinopulmonary bacterial</p> Herpesviruses</td> </tr> <tr> <td>Papillon-Lefevre syndrome</td> <td><em>CTSC</em></td> <td>Function: Cytotoxicity</td> <td>Periodontitis (herpesvirus)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCID: severe combined immunodeficiency; EBV: Epstein Barr virus; HSV: herpes simplex virus; CMV: cytomegalovirus.</div><div id=\"graphicVersion\">Graphic 64501 Version 4.0</div></div></div>"},"64502":{"type":"graphic_picture","displayName":"Gyromitra esculenta - false morel ","title":"Gyromitra esculenta (false morel) and edible species, Morchella esculenta (morel, sponge mushroom, or honeycomb mushroom) and Morchella elata (black morel)","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Gyromitra esculenta (false morel) and edible species, Morchella esculenta (morel, sponge mushroom, or honeycomb mushroom) and Morchella elata (black morel)</div><div class=\"cntnt\"><img style=\"width:514px; height:425px;\" src=\"images/EM/64502_Gyromitra_morch_escul_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The toxic Gyromitra esculenta (&quot;false morel&quot;, panel A) is often mistaken for the edible mushrooms, Morchella esculenta (&quot;morel&quot;, panel B) and Morchella elata (&quot;black morel&quot;, panel C) leading to delayed onset seizures, gastroenteritis, renal, and liver toxicity caused by the toxin, gyromitra which is metabolized to monomethylhydrazine after ingestion. Gyromitra esculenta mushrooms are found in North America and parts of Europe. Gyromitra mushrooms may be eaten if parboiled. In parboiling the mushroom is boiled and the water discarded before further preparation. Some evidence suggests that even parboiling does not render the Gyromitra completely safe.</div><div class=\"graphic_reference\">Photo A is reproduced courtesy of Severine Mei&#223;ner. Copyright &#169; 2005. Photos B and C are reproduced courtesy of William Hollenbaugh. Copyright &#169; 2011.</div><div id=\"graphicVersion\">Graphic 64502 Version 4.0</div></div></div>"},"64503":{"type":"graphic_diagnosticimage","displayName":"Electron beam computed tomography scan of aortic dissection","title":"Electron beam computed tomography scan of aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron beam computed tomography scan of aortic dissection</div><div class=\"cntnt\"><img style=\"width:385px; height:208px;\" src=\"images/CARD/64503_EBCT_in_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single electron beam computed tomography scan of the ascending and descending aorta showing a clear &quot;flap&quot; in the ascending aorta. This finding is consistent with a type A aortic dissection.</div><div id=\"graphicVersion\">Graphic 64503 Version 3.0</div></div></div>"},"64504":{"type":"graphic_table","displayName":"Chemo regimens met CRC","title":"Irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen*</td> <td class=\"subtitle1\">Irinotecan</td> <td class=\"subtitle1\">Oxaliplatin</td> <td class=\"subtitle1\">Leucovorin<sup>&#182;</sup></td> <td class=\"subtitle1\">Fluorouracil/capecitabine</td> <td class=\"subtitle1\">Schedule</td> </tr> <tr> <td>FOLFIRI<sup>[1]</sup></td> <td>180 mg/m<sup>2</sup> day 1</td> <td>&nbsp;</td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus day 1, followed by 2400 to 3000 mg/m<sup>2</sup><sup>&#916;</sup> over 46 hours, continuous infusion</td> <td>Every two weeks</td> </tr> <tr> <td>Douillard regimen<sup>[2]</sup></td> <td>180 mg/m<sup>2</sup> day 1</td> <td>&nbsp;</td> <td>200 mg/m<sup>2</sup> leucovorin over two hours days 1 and 2 before fluorouracil</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus then 600 mg/m<sup>2</sup> over 22 hours days 1 and 2</td> <td>Every two weeks</td> </tr> <tr> <td>FOLFOX 4<sup>[3]</sup></td> <td>&nbsp;</td> <td>85 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours days 1 and 2 before fluorouracil<sup>&#9674;</sup></td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus then 600 mg/m<sup>2</sup> over 22 hours days 1 and 2</td> <td>Every two weeks</td> </tr> <tr> <td>FOLFOX 6<sup>[1]</sup></td> <td>&nbsp;</td> <td>100 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus day 1, followed by 2400 to 3000 mg/m<sup>2</sup><sup>&#916;</sup> over 46 hours, continuous infusion</td> <td>Every two weeks</td> </tr> <tr> <td>Modified FOLFOX 6<sup>[4,5]</sup></td> <td>&nbsp;</td> <td>85 mg/m<sup>2</sup> day 1</td> <td>350 mg total dose over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus day 1, followed by 2400 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>FOLFOX 7<sup>[6]</sup></td> <td>&nbsp;</td> <td>130 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 400 mg/m<sup>2</sup> bolus, then 2400 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>Modified FOLFOX 7<sup>[7]</sup> (Optimox)</td> <td>&nbsp;</td> <td>100 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 3000 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>Modified FOLFOX 7<sup>[8]</sup> (CONcePT)<sup>&#167;</sup></td> <td>&nbsp;</td> <td>85 mg/m<sup>2</sup> day 1</td> <td>200 mg/m<sup>2</sup> over two hours day 1</td> <td>Fluorouracil 2400 mg/m<sup>2</sup> over 46 hours</td> <td>Every two weeks</td> </tr> <tr> <td>XELOX<sup>[5]</sup></td> <td>&nbsp;</td> <td>130 mg/m<sup>2</sup> day 1</td> <td>&nbsp;</td> <td>Capecitabine 1000 mg/m<sup>2</sup> orally twice per day on days 1 to 14</td> <td>Every three weeks</td> </tr> <tr> <td>FOLFOXIRI<sup>[9]</sup></td> <td>165 mg/m<sup>2</sup> day 1</td> <td>85 mg/m<sup>2</sup> day 1</td> <td>400 mg/m<sup>2</sup> leucovorin over two hours day 1</td> <td>Fluorouracil 3200 mg/m<sup>2</sup> over 48 hours</td> <td>Every two weeks</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All doses shown are for intravenous (IV) administration, except capecitabine.<br />Â¶ Leucovorin doses given for the d,l racemic mixture.<br />Î 2400 mg/m<SUP>2</SUP> dose is commonly used.<br /><FONT class=lozenge>â</FONT> The original trial report indicated a leucovorin dose of 200 mg/m<SUP>2</SUP> daily, but this was an error, and the correct dose used in the protocol was 400 mg/m<SUP>2</SUP> (R Goldberg, personal communication).<br />Â§ FOLFOX7 was administered with bevacizumab (5 mg/kg every two weeks) in the CONCePT trial.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tournigand C, AndrÃ© T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229. </LI>&#xD;&#xA;<LI>Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041. </LI>&#xD;&#xA;<LI>Goldberg R, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23. </LI>&#xD;&#xA;<LI>Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87:393.</LI>&#xD;&#xA;<LI>Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523.</LI>&#xD;&#xA;<LI>Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37:1000. </LI>&#xD;&#xA;<LI>Chibaudel B,&nbsp;Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27:5727. </LI>&#xD;&#xA;<LI>Grothey A, Hart L, Rowland K, et al. Intermittent oxaliplatin administration improves time to-treatment failure in metastatic colorectal cancer: final results of the Phase III of the CONcePT Trial. J Clin Oncol 2008; 26(Suppl):Abstract 4010. </LI>&#xD;&#xA;<LI>Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670. </LI></OL></div><div id=\"graphicVersion\">Graphic 64504 Version 13.0</div></div></div>"},"64505":{"type":"graphic_table","displayName":"FOLFIRI plus bevacizumab","title":"FOLFIRI plus bevacizumab chemotherapy for metastatic colorectal cancer<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOLFIRI plus bevacizumab chemotherapy for metastatic colorectal cancer<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 14 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Bevacizumab</strong></td> <td>5 mg/kg IV</td> <td>Dilute into a total volume of 100 mL normal saline (NS)*. The first dose should be administered over 90 minutes following chemotherapy. If well tolerated, the second infusion may be administered over 60 minutes after irinotecan and leucovorin. If well tolerated, all subsequent doses may be administered over 10 to 30 minutes before chemotherapy<sup>&#916;[3,4]</sup>.</td> <td>Day 1</td> </tr> <tr> <td><strong>Irinotecan</strong></td> <td>180<sup>&#9674;</sup> mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5 percent dextrose in water (D5W) and administer over 90 minutes (can be administered concurrently with leucovorin via y-site connection).</td> <td>Day 1</td> </tr> <tr> <td><strong>Leucovorin</strong><sup>&#167;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL D5W and administer over two hours.</td> <td>Day 1</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Slow intravenous push over five minutes (administer immediately after leucovorin).</td> <td>Day 1</td> </tr> <tr> <td><strong>FU</strong></td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL to 1000 mL D5W and administer over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There is no standard premedication regimen for prophylaxis of infusion reactions.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia approximately 5 percent<sup>[2]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> A lower starting dose of FU and irinotecan may be needed for patients with liver impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Obtain CBC with differential and platelet count prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes and liver and renal function prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess changes in blood pressure, urine protein concentration, and risk for bleeding prior to each treatment.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Each treatment should be delayed until absolute neutrophil count is &#62;1500 cells/microL and the platelet count is &#62;100,000/microL. United States Prescribing Information suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity (including febrile neutropenia) during treatment<sup>[5]</sup>. A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m<sup>2</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Withhold treatment until resolution of diarrhea for at least 24 hours off all antidiarrheal medications. The United States Prescribing Information suggests decreasing the irinotecan dose for patients with grade 2 or higher diarrhea in the prior cycle<sup>[5]</sup>. Withhold FU for grade 2 or worse diarrhea and restart at a lower dose after complete resolution<sup>[6]</sup>. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other toxicity:</strong> For other non-hematologic toxicities, hold treatment until less than or equal to grade 1, if grade 2; hold treatment until less than or equal to grade 2, if grade 3 or 4. The United States Prescribing Information suggests decreasing the irinotecan dose for patients with grade 3 or higher non-hematologic toxicity other than diarrhea in the prior cycle. Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS)<sup>[3]</sup>. Bevacizumab should not be administered within 28 days of surgery, and it should be suspended prior to elective surgery. Refer to UpToDate topics on \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Î For the 5 mg/kg dose, many clinicians <FONT color=black>administer the first dose over 60 minutes and if well tolerated, subsequent doses are administered over 10 minutes<SUP>[4]</SUP>.<br /><FONT class=lozenge>â</FONT> A lower initial starting dose of irinotecan&nbsp;may be considered for patients with&nbsp;poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels<SUP>[5]</SUP>. Whether a reduced starting dose is needed in patients who are homozygous for the </FONT>UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".<br />Â§ Leucovorin dose is given for d,l-racemic mixture<SUP>[7]</SUP>. Use half the dose for LEVOleucovorin (l-leucovorin).</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Tournigand C, et al. J Clin Oncol 2004; 22:229. </LI>&#xD;&#xA;<LI>Fuchs CS, et al. J Clin Oncol 2007; 25:4779. </LI>&#xD;&#xA;<LI>Bevacizumab injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI>&#xD;&#xA;<LI>Reidy DL, et al. J Clin Oncol 2007; 25:2691. </LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016). </LI></OL></div><div id=\"graphicVersion\">Graphic 64505 Version 23.0</div></div></div>"},"64506":{"type":"graphic_figure","displayName":"Blocked sinus passage 2 PI","title":"Chronic sinusitis with polyps","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Chronic sinusitis with polyps</div><div class=\"cntnt\"><img style=\"width:540px; height:483px;\" src=\"images/PI/64506_Blocked_sinus_passage_2_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a person who has chronic rhinosinusitis with polyps (abnormal growths inside the nose or sinuses). Scientists do not know why polyps develop.</div><div id=\"graphicVersion\">Graphic 64506 Version 4.0</div></div></div>"},"64507":{"type":"graphic_table","displayName":"Intellectual disability and associated impairments","title":"Intellectual disability and associated impairments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intellectual disability and associated impairments</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>MILD (IQ 50 to 69):</strong> Capable of personal independence with a little guidance and assistance.</td> </tr> <tr> <td><strong>MODERATE (IQ 35 to 49):</strong> Require assistance with more complex activities; communicate with simple sentences.</td> </tr> <tr> <td><strong>SEVERE (IQ 20 to 34):</strong> Require assistance with most ADLs; communicate with words and gestures.</td> </tr> <tr> <td><strong>PROFOUND (IQ &#60;20):</strong> Require comprehensive care and assistance; usually non-verbal; high incidence of secondary disabilities.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADLs: activities of daily living.</div><div id=\"graphicVersion\">Graphic 64507 Version 3.0</div></div></div>"},"64508":{"type":"graphic_table","displayName":"Risk factors breast cancer","title":"Risk and protective factors for developing breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk and protective factors for developing breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Risk group</td> </tr> <tr> <td class=\"subtitle2\">Low risk</td> <td class=\"subtitle2\">High risk</td> <td class=\"subtitle2\">Relative risk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Risk factors</td> </tr> <tr> <td class=\"indent1\">Deleterious <em>BRCA1</em>/<em>BRCA2</em> genes</td> <td>Negative</td> <td>Positive</td> <td>3.0 to 7.0</td> </tr> <tr> <td class=\"indent1\">Mother or sister with breast cancer</td> <td>No</td> <td>Yes</td> <td>2.6</td> </tr> <tr> <td class=\"indent1\">Age</td> <td>30 to 34</td> <td>70 to 74</td> <td>18.0</td> </tr> <tr> <td class=\"indent1\">Age at menarche</td> <td>&#62;14</td> <td>&#60;12</td> <td>1.5</td> </tr> <tr> <td class=\"indent1\">Age at first birth</td> <td>&#60;20</td> <td>&#62;30</td> <td>1.9 to 3.5</td> </tr> <tr> <td class=\"indent1\">Age at menopause</td> <td>&#60;45</td> <td>&#62;55</td> <td>2.0</td> </tr> <tr> <td class=\"indent1\">Use of contraceptive pills</td> <td>Never</td> <td>Past/current use</td> <td>1.07 to 1.2</td> </tr> <tr> <td class=\"indent1\">Hormone replacement therapy&nbsp;(estrogen + progestin) </td> <td>Never</td> <td>Current</td> <td>1.2</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> <td>None</td> <td>Two to five&nbsp;drinks/day</td> <td>1.4</td> </tr> <tr> <td class=\"indent1\">Breast density on mammography (percents)</td> <td>0</td> <td>&#8805;75</td> <td>1.8 to 6.0</td> </tr> <tr> <td class=\"indent1\">Bone density</td> <td>Lowest quartile</td> <td>Highest quartile</td> <td>2.7 to 3.5</td> </tr> <tr> <td class=\"indent1\">History of a benign breast biopsy</td> <td>No</td> <td>Yes</td> <td>1.7</td> </tr> <tr> <td class=\"indent1\">History of atypical hyperplasia on biopsy</td> <td>No</td> <td>Yes</td> <td>3.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Protective factors</td> </tr> <tr> <td class=\"indent1\">Breast feeding (months) </td> <td>&#8805;16</td> <td>0</td> <td>0.73</td> </tr> <tr> <td class=\"indent1\">Parity</td> <td>&#8805;5</td> <td>0</td> <td>0.71</td> </tr> <tr> <td class=\"indent1\">Recreational exercise</td> <td>Yes</td> <td>No</td> <td>0.70</td> </tr> <tr> <td class=\"indent1\">Postmenopause body mass index (kg/m<sup>2</sup>)</td> <td>&#60;22.9</td> <td>&#62;30.7</td> <td>0.63</td> </tr> <tr> <td class=\"indent1\">Oophorectomy before age 35 years </td> <td>Yes</td> <td>No</td> <td>0.3</td> </tr> <tr> <td class=\"indent1\">Aspirin</td> <td>&#8805;Once/week for &#8805;6 months</td> <td>Nonusers</td> <td>0.79 </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344:276.</div><div id=\"graphicVersion\">Graphic 64508 Version 3.0</div></div></div>"},"64509":{"type":"graphic_table","displayName":"Contraindications elective surgery in patients liver disease","title":"Contraindications to elective surgery in patients with liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to elective surgery in patients with liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acute alcoholic hepatitis</td> </tr> <tr> <td>Acute viral hepatitis</td> </tr> <tr> <td>Child-Pugh&nbsp;class C cirrhosis</td> </tr> <tr> <td>Fulminant hepatic failure</td> </tr> <tr> <td>Severe chronic hepatitis</td> </tr> <tr> <td>Severe coagulopathy (prolongation of the prothrombin time &#62;3 seconds despite vitamin K administration; platelet count &#60;50,000/mm<sup>3</sup>)</td> </tr> <tr> <td class=\"sublist1_start\">Severe extrahepatic complications</td> </tr> <tr> <td class=\"sublist1\">Acute renal failure </td> </tr> <tr> <td class=\"sublist1\">Cardiomyopathy, heart failure</td> </tr> <tr> <td class=\"sublist1\">Hypoxemia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999; 29:1617. Copyright Â© 1999 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 64509 Version 4.0</div></div></div>"},"64510":{"type":"graphic_waveform","displayName":"ECG Brugada syndrome type I pattern","title":"12-lead electrocardiogram (ECG) from a patient with the Brugada syndrome shows downsloping ST elevation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) from a patient with the Brugada syndrome shows downsloping ST elevation</div><div class=\"cntnt\"><img style=\"width:429px; height:432px;\" src=\"images/CARD/64510_Brugada_syndrome_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ST segment elevation and T wave inversion in the right precordial leads V1 and V2 (arrows); the QRS is normal. The widened S wave in the left lateral leads (V5 and V6) that is characteristic of right bundle branch block is absent.</div><div class=\"graphic_reference\">Courtesy of Rory Childers, MD, University of Chicago.</div><div id=\"graphicVersion\">Graphic 64510 Version 10.0</div></div></div>"},"64511":{"type":"graphic_diagnosticimage","displayName":"Hangmans fracture","title":"Hangman's fracture","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Hangman's fracture</div><div class=\"cntnt\"><img style=\"width:480px; height:312px;\" src=\"images/PEDS/64511_Hangmans_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the marked prevertebral soft tissue swelling and the displacement of the posterior aspect of C2.</div><div class=\"graphic_reference\">Reproduced with permission from: Graber, MA, Kathol, M. Cervical Spine Radiographs in the Trauma Patient. Am Fam Physician 1999; 59:331. A: Copyright Â© 1999 Mark Graber, MD. B: Copyright Â© 1999 David Klemm.</div><div id=\"graphicVersion\">Graphic 64511 Version 2.0</div></div></div>"},"64512":{"type":"graphic_diagnosticimage","displayName":"Subglottic edema","title":"Subglottic edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subglottic edema</div><div class=\"cntnt\"><img style=\"width:358px; height:286px;\" src=\"images/PEDS/64512_Subglottic_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view demonstrates ballooning of the supralaryngeal structures and marked narrowing of the subglottic trachea secondary to subglottic edema. This finding cannot be simulated in the normal child.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 64512 Version 2.0</div></div></div>"},"64514":{"type":"graphic_picture","displayName":"Pneumatic retinopexy","title":"Pneumatic retinopexy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatic retinopexy</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/PC/64514_Pneumatic_retinopexy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pneumatic retinopexy involves cryoretinopexy of the retinal break followed by injection of an intravitreal gas bubble.</div><div class=\"graphic_reference\">Reproduced with permission from: Wilkinson CP, Rice TA. Mitchel's Retinal Detachment, 2nd ed, Mosby-Year Book, Inc., Louis 1997. Copyright &#169; Charles P Wilkinson, MD.</div><div id=\"graphicVersion\">Graphic 64514 Version 2.0</div></div></div>"},"64515":{"type":"graphic_figure","displayName":"Transection of redundant sigmoid colon sagittal view","title":"Transection of redundant sigmoid colon sagittal view","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Transection of redundant sigmoid colon sagittal view</div><div class=\"cntnt\"><img style=\"width:518px; height:659px;\" src=\"images/SURG/64515_Trans_Red_sig_col_sag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the sagittal view of a transected redundant sigmoid colon. A suture rectopexy is shown between the presacral fascia and the seromuscular layer of posterior rectal wall.</div><div id=\"graphicVersion\">Graphic 64515 Version 3.0</div></div></div>"},"64516":{"type":"graphic_table","displayName":"Materials for OFCs","title":"Examples of materials for creating food challenge substances","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of materials for creating food challenge substances</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common allergens </td> </tr> <tr> <td>Peanut flour, peanut butter</td> </tr> <tr> <td>Powdered egg white</td> </tr> <tr> <td>Powdered/fresh milk</td> </tr> <tr> <td>Soy milk, soy flour</td> </tr> <tr> <td>Wheat breads, flour</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Useful carrier agents </td> </tr> <tr> <td>Proprietary formulas (hydrolyzed casein, amino acid)</td> </tr> <tr> <td>Baby foods (squash, carrot, potato)</td> </tr> <tr> <td>Applesauce</td> </tr> <tr> <td>Cornmeal, instant oats, instant mashed potatoes</td> </tr> <tr> <td>Juices</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64516 Version 2.0</div></div></div>"},"64517":{"type":"graphic_figure","displayName":"Ileal pouch anal anastomosis","title":"Ileal pouch-anal anastamosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileal pouch-anal anastamosis</div><div class=\"cntnt\"><img style=\"width:419px; height:305px;\" src=\"images/GAST/64517_Ileal_pouch_anal_anast_edt_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of the J, W, and S ileal pouches used for anastomosis to the anal canal (ileal pouch-anal anastomosis).</div><div class=\"graphic_reference\">By permission of Mayo Foundation for Medical Education and Research. All rights reserved. This figure has been modified for this publication.</div><div id=\"graphicVersion\">Graphic 64517 Version 4.0</div></div></div>"},"64518":{"type":"graphic_diagnosticimage","displayName":"Intrauterine adhesions","title":"Saline sonohysterogram image, transverse view, demonstrating adhesive bands between anterior and posterior uterine walls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saline sonohysterogram image, transverse view, demonstrating adhesive bands between anterior and posterior uterine walls</div><div class=\"cntnt\"><img style=\"width:426px; height:285px;\" src=\"images/OBGYN/64518_Intrauterine_adhesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Marcelle Cedars, MD.</div><div id=\"graphicVersion\">Graphic 64518 Version 3.0</div></div></div>"},"64519":{"type":"graphic_figure","displayName":"Resectoscope metroplasty","title":"Resectoscope metroplasty","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Resectoscope metroplasty</div><div class=\"cntnt\"><img style=\"width:479px; height:611px;\" src=\"images/OBGYN/64519_Resectoscope_metroplasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) After a Foley catheter is placed in one cavity of the complete septate uterus, the resectoscope is inserted into the opposite cavity. The septum is then incised with the resectoscope until the Foley catheter is visualized. The septum is removed in small portions until both oses are visible. (B) In a similar fashion, the septate uterus may be repaired with stepwise resectoscopic excision of the septum.</div><div id=\"graphicVersion\">Graphic 64519 Version 1.0</div></div></div>"},"64520":{"type":"graphic_waveform","displayName":"Osborn waves","title":"Electrocardiogram in hypothermia","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in hypothermia</div><div class=\"cntnt\"><img style=\"width:540px; height:285px;\" src=\"images/CARD/64520_Osborn_waves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ECG reveals marked sinus bradycardia (about 40 beats/min) with first degree atrioventricular block (PR interval = 0.23 sec). The slow heart rate in this patient is due to hypothermia (90ÂºF, 32.2ÂºC), which also produces prominent convex deflections at the J point (junction of QRS and ST segments) that are best seen in the precordial leads. The J waves or Osborn waves (arrows) are characteristic of severe hypothermia and resolve with rewarming.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 64520 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"64522":{"type":"graphic_picture","displayName":"Single incision laparoscopic surgery","title":"Single incision laparoscopic surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single incision laparoscopic surgery</div><div class=\"cntnt\"><img style=\"width:432px; height:337px;\" src=\"images/SURG/64522_Single-access_laparoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three instruments have been introduced through a single umbilical port.</div><div class=\"graphic_reference\">Courtesy of Dr. Aurora Pryor.</div><div id=\"graphicVersion\">Graphic 64522 Version 1.0</div></div></div>"},"64523":{"type":"graphic_picture","displayName":"Nasogastric tube removal","title":"Nasogastric tube removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasogastric tube removal</div><div class=\"cntnt\"><img style=\"width:374px; height:575px;\" src=\"images/SURG/64523_NG_tube_removal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After placing an absorbant pad, gently remove the tape fixing the tube to the patient's nose. Use a catheter-tip syringe to flush the tube with 10 mL of air or normal saline solution to ensure the tube doesn't contain stomach contents that could irritate tissues during tube removal. Clamp the tube by folding it in your hand, then gently and steadily pull the tube out. Provide a tissue to the patient with which to clean and blow their nose, if needed.</div><div class=\"graphic_reference\">Reproduced with permission from: Springhouse. Lippincott's Visual Encyclopedia of Clinical Skills. Philadelphia: Wolters Kluwer Health, 2009. Copyright &#169; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64523 Version 2.0</div></div></div>"},"64524":{"type":"graphic_picture","displayName":"Pretibial myxedema II","title":"Pretibial myxedema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pretibial myxedema</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/64524_Pretibial_myxedema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin&nbsp;is edematous and has a waxy, \"orange peel\" appearance. A large nodular plaque is visible on the anterior aspect of the ankle.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64524 Version 5.0</div></div></div>"},"64525":{"type":"graphic_picture","displayName":"Adult atopic dermatitis 1","title":"Adult atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Adult atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:517px; height:439px;\" src=\"images/DERM/64525_Adultatopicdermatitis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic atopic dermatitis with lichenification (skin thickening and enhancement of skin markings) of the knee flexures in a 22-year-old woman.</div><div class=\"graphic_reference\">Copyright Â© Monica Standish, RN, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 64525 Version 4.0</div></div></div>"},"64526":{"type":"graphic_algorithm","displayName":"Treatment of acute cholecystitis","title":"Treatment of acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Treatment of acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:508px; height:406px;\" src=\"images/GAST/64526_Acute_cholecystitis_algorit.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Salam Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 64526 Version 3.0</div></div></div>"},"64529":{"type":"graphic_table","displayName":"Grades salivary gland cancer","title":"Histologic grades of salivary gland cancers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic grades of salivary gland cancers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High-grade</td> </tr> <tr> <td class=\"indent1\">High-grade mucoepidermoid carcinoma</td> </tr> <tr> <td class=\"indent1\">Salivary duct carcinoma</td> </tr> <tr> <td class=\"indent1\">Adenoid cystic carcinoma</td> </tr> <tr> <td class=\"indent1\">Carcinoma ex-pleomorphic adenoma</td> </tr> <tr> <td class=\"indent1\">Squamous cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Anaplastic or undifferentiated carcinoma</td> </tr> <tr> <td class=\"indent1\">Malignant mixed carcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Low- to intermediate-grade</td> </tr> <tr> <td class=\"indent1\">Low-grade mucoepidermoid carcinoma</td> </tr> <tr> <td class=\"indent1\">Acinic cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Polymorphous low-grade adenocarcinoma (PLGA)</td> </tr> <tr> <td class=\"indent1\">Epithelial-myoepithelial carcinoma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Stenner M, Klussmann JP. Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved. Eur Arch Otorhinolaryngol 2009; 266:333.</li>&#xD;&#xA;    <li>Terhaard CH. Salivary glands. In: Principles and Practice of Radiation Oncology, 5th edition, Halperin EC, Perez CA, Brady LW (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.407.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64529 Version 4.0</div></div></div>"},"64530":{"type":"graphic_picture","displayName":"Accessory lacrimal duct","title":"Accessory lacrimal duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Accessory lacrimal duct</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/PEDS/64530_Accessory_lacrimal_duct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Accessory lacrimal ducts are anomalous lacrimal ducts that exit to the skin (arrow).</div><div class=\"graphic_reference\">Adapted with permission from: Paysse EA, Coats DK, Cassidy M. Refinements Volume III/ Number 2. San Francisco: American Academy of Opthalmology, 1999.</div><div id=\"graphicVersion\">Graphic 64530 Version 3.0</div></div></div>"},"64533":{"type":"graphic_picture","displayName":"Botulinum toxin injection sites for platysmal bands","title":"Botulinum toxin injection sites for platysmal bands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection sites for platysmal bands</div><div class=\"cntnt\"><img style=\"width:307px; height:271px;\" src=\"images/DERM/64533_Botulinum_toxin_inject_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of botulinum toxin injection sites for the treatment of platysmal bands.</div><div id=\"graphicVersion\">Graphic 64533 Version 3.0</div></div></div>"},"64534":{"type":"graphic_picture","displayName":"FAST suprapubic probe position sagittal","title":"FAST: Suprapubic probe position in sagittal orientation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Suprapubic probe position in sagittal orientation</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/EM/64534_FAST_suprapubic_probe_sagit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows probe position for obtaining a sagittal view of the bladder and retrovesical structures.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 64534 Version 1.0</div></div></div>"},"64535":{"type":"graphic_table","displayName":"Coexisting emotional and behavioral disorders in ADHD","title":"Emotional and behavioral disorders that commonly coexist with attention deficit hyperactivity disorder in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emotional and behavioral disorders that commonly coexist with attention deficit hyperactivity disorder in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Conduct disorder</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Repetitive and persistent violation of age-appropriate societal norms, rules, or basic rights of others; includes: <ul class=\"decimal_heading\"> <li>Aggression to people and animals</li> <li>Destruction of property</li> <li>Deceitfulness or theft</li> <li>Serious violations of rules</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Anxiety disorder</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Persistent, excessive, difficult to control worry about events or activities; associated with: <ul class=\"decimal_heading\"> <li>Restlessness</li> <li>Easy fatigability</li> <li>Difficulty concentrating</li> <li>Irritability</li> <li>Muscle tension</li> <li>Sleep disturbance</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Depression</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Persistent disturbance in emotions, ideation, or somatic symptoms as indicated by &#8805;5 of the following symptoms; at least one of the symptoms in bold must be present: <ul class=\"decimal_heading\"> <li><strong>Depressed or irritable mood</strong></li> <li><strong>Markedly diminished interest or pleasure in almost all activities</strong></li> <li>Change in appetite or weight</li> <li>Insomnia or hypersomnia</li> <li>Psychomotor agitation or retardation</li> <li>Fatigue or loss of energy</li> <li>Feelings of worthlessness or guilt</li> <li>Impaired concentration, indecisiveness</li> <li>Recurring thoughts of death or suicide</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Learning disability</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intrinsic cognitive difficulty that results in lower academic achievement than expected for intellectual potential; examples include: <ul class=\"decimal_heading\"> <li>Reading disorder</li> <li>Disorder of written language</li> <li>Mathematics disorder</li> <li>Learning disorder, not otherwise specified</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Oppositional defiant disorder</td> </tr> <tr> <td class=\"indent1\">Recurrent negative, defiant, disobedient, and hostile behavior toward authority figures, including: <ul class=\"decimal_heading\"> <li>Losing temper</li> <li>Arguing with adults</li> <li>Actively defying or refusing to comply with adults' requests or rules</li> <li>Deliberately annoying people</li> <li>Blaming others for his or her mistakes or misbehavior</li> <li>Being touchy or easily annoyed by others</li> <li>Being angry and resentful</li> <li>Being spiteful or vindictive</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4<SUP>th</SUP> ed, American Psychiatric Association, Washington, DC 2000. p.85.</LI>&#xD;&#xA;<LI>Anxiety disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4<SUP>th</SUP> ed, American Psychiatric Association, Washington, DC 2000. p.429.</LI>&#xD;&#xA;<LI>Mood disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4<SUP>th</SUP> ed, American Psychiatric Association, Washington, DC 2000. p.345.</LI>&#xD;&#xA;<LI>Oppositional defiant disorder. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4<SUP>th</SUP> ed, American Psychiatric Association, Washington, DC 2000. p.100.</LI>&#xD;&#xA;<LI>Conduct disorder. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4<SUP>th</SUP> ed, American Psychiatric Association, Washington, DC 2000. p.93.</LI></OL></div><div id=\"graphicVersion\">Graphic 64535 Version 3.0</div></div></div>"},"64538":{"type":"graphic_table","displayName":"Healthy vulval hygiene practice","title":"Healthy vulval hygiene practices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Healthy vulval hygiene practices</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Avoid </td> <td class=\"subtitle1\">Substitute </td> </tr> <tr> <td rowspan=\"2\">Pantyhose </td> <td>Stockings with a garter belt</td> </tr> <tr> <td>Thigh-high or knee-high stockings</td> </tr> <tr> <td>Synthetic underwear</td> <td>Cotton underwear or no underwear</td> </tr> <tr> <td>Jeans and other tight pants</td> <td>Loose pants, skirts, dresses</td> </tr> <tr> <td>Swimsuits, leotards, thongs, lycra garments</td> <td>Loose-fitting cotton garments</td> </tr> <tr> <td>Panty liners</td> <td>Tampons or cotton pads</td> </tr> <tr> <td>Scented soaps or shampoos</td> <td>Fragrance-free pH neutral soap (eg,&nbsp;Neutrogena fragrance free, pure olive oil soap, Cetaphil gentle skin cleanser or equivalent ingredients)</td> </tr> <tr> <td>Bubble bath</td> <td>Tub baths in the morning and at night without additives and at a comfortable temperature</td> </tr> <tr> <td>Scented detergents</td> <td>Unscented detergents</td> </tr> <tr> <td>Washcloths</td> <td>Use fingertips for washing; pat dry, don't rub dry</td> </tr> <tr> <td>Baby wipes or flushable wipes</td> <td>Rinse with water using sports water bottle or perineal irrigation bottle&nbsp;</td> </tr> <tr> <td>Feminine sprays, douches, powders</td> <td>These are not necessary products and can be omitted from personal practices</td> </tr> <tr> <td>Dyed toilet articles</td> <td>Toilet articles without dyes</td> </tr> <tr> <td>Hair dryers to dry vulva skin without contact</td> <td>Dry vulva by gentle patting</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64538 Version 6.0</div></div></div>"},"64539":{"type":"graphic_picture","displayName":"Megameatus intact prepuce","title":"Megameatus intact prepuce: Hypospadias variation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megameatus intact prepuce: Hypospadias variation</div><div class=\"cntnt\"><img style=\"width:350px; height:390px;\" src=\"images/PEDS/64539_Megameatus_intact_prepuce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Megameatus intact prepuce is a hypospadias variant with a normal foreskin. After circumcision, the abnormal large urethral meatus at the coronal margin is apparent.</div><div class=\"graphic_reference\">Courtesy of Dr. Laurence Baskin.</div><div id=\"graphicVersion\">Graphic 64539 Version 4.0</div></div></div>"},"64540":{"type":"graphic_picture","displayName":"Anterior blepharitis","title":"Anterior blepharitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior blepharitis</div><div class=\"cntnt\"><img style=\"width:432px; height:278px;\" src=\"images/PC/64540_Anterior_blepharitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower lid with inflammation with characteristic scales on the eyelashes.</div><div id=\"graphicVersion\">Graphic 64540 Version 4.0</div></div></div>"},"64543":{"type":"graphic_figure","displayName":"Anatomy and innervation of the diaphragm","title":"Anatomy and innervation of the diaphragm","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Anatomy and innervation of the diaphragm</div><div class=\"cntnt\"><img style=\"width:554px; height:612px;\" src=\"images/SURG/64543_Diaphragm_surface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The diaphragm is dome-shaped and attaches to the chest and abdominal walls circumferentially. The diaphragm is composed of two muscle groups, costal and crural. The costal muscle group forms the diaphragmatic leaflets. The right and left crus of the diaphragm are thick but contribute minimally to the displacement of the diaphragm. The median arcuate ligament anterior to the aortic hiatus is formed by the continuation of the medial tendinous margins of the crura. The costal and crural fibers insert into the central tendon. The anterior portion of the central tendon attaches to the posterior aspect of the xiphisternal junction. The posterior portion of the central tendon attaches to L1 to L3.<br> (B) The phrenic nerve originates in the neck and traverses the mediastinum before inserting into the diaphragm centrally. The outer rim of the diaphragmatic muscle is innervated laterally from the T7 through T12. The crural group of muscles receive innervation from the vagus nerve.</div><div class=\"graphic_reference\">Adapted and reproduced with permission from:<br> (A) Anderson JE. Grant's Atlas of Anatomy, 7th Edition. Baltimore, Williams &amp; Wilkins Co., 1978. Copyright &#169; 1978 Lippincott Williams &amp; Wilkins.<br> (B) Moore KL, Dalley AF. Clinically Oriented Anatomy, 4th Edition. Baltimore, Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64543 Version 3.0</div></div></div>"},"64544":{"type":"graphic_figure","displayName":"Anatomy of the nipple","title":"Anatomy of the nipple","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the nipple</div><div class=\"cntnt\"><img style=\"width:312px; height:307px;\" src=\"images/SURG/64544_Anatomy_nipple_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64544 Version 1.0</div></div></div>"},"64545":{"type":"graphic_waveform","displayName":"Basic case 9","title":"Basic case 9","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Basic case 9</div><div class=\"cntnt\"><img style=\"width:540px; height:80px;\" src=\"images/CARD/64545_Basic_case_9.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64545 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"64546":{"type":"graphic_picture","displayName":"Large tonsils","title":"Large tonsils","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large tonsils</div><div class=\"cntnt\"><img style=\"width:432px; height:304px;\" src=\"images/PEDS/64546_Large_tonsils.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large tonsils often accompany obstructive sleep apnea in children. This photograph shows tonsils that would be graded as 4+ and could easily cause airway obstruction during sleep.</div><div class=\"graphic_reference\">Courtesy of Dr. Ron Mitchell.</div><div id=\"graphicVersion\">Graphic 64546 Version 3.0</div></div></div>"},"64547":{"type":"graphic_diagnosticimage","displayName":"Takayasu arteritis","title":"Takayasu arteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Takayasu arteritis</div><div class=\"cntnt\"><img style=\"width:360px; height:374px;\" src=\"images/PEDS/64547_Takayasus_arteritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram of a child with Takayasu arteritis showing massive bilateral carotid dilation, stenosis, and poststenotic dilation.</div><div class=\"graphic_reference\">Reproduced with permission from: Behrman RE. Nelson textbook of pediatrics, 16th ed, WB Saunders, Philadelphia 2000. Copyright Â©2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 64547 Version 4.0</div></div></div>"},"64550":{"type":"graphic_picture","displayName":"Pustular psoriasis - palms","title":"Pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:163px; height:254px;\" src=\"images/DERM/64550_Pustular_psoriasis_palms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustular collections are present on the palms of this patient with pustular psoriasis.</div><div id=\"graphicVersion\">Graphic 64550 Version 1.0</div></div></div>"},"64551":{"type":"graphic_figure","displayName":"Laparoscopy LUQ entry","title":"Left upper quadrant laparoscopy entry sites","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Left upper quadrant laparoscopy entry sites</div><div class=\"cntnt\"><img style=\"width:540px; height:567px;\" src=\"images/OBGYN/64551_Laparoscopy_LUQ_entry.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64551 Version 1.0</div></div></div>"},"64552":{"type":"graphic_table","displayName":"Measures to reduce the risk and duration of postoperative ileus","title":"Measures to reduce the risk and duration of postoperative ileus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Measures to reduce the risk and duration of postoperative ileus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Effective strategies</td> </tr> <tr> <td class=\"indent1\">Epidural use</td> </tr> <tr> <td class=\"subtitle1_single\">Potentially effective strategies</td> </tr> <tr> <td class=\"indent1\">Reducing postoperative opioid use</td> </tr> <tr> <td class=\"indent1\">Minimally traumatic surgical techniques</td> </tr> <tr> <td class=\"indent1\">Minimally-invasive surgery</td> </tr> <tr> <td class=\"indent1\">Multimodal fast-track programs</td> </tr> <tr> <td class=\"indent1\">Alvimopan</td> </tr> <tr> <td class=\"indent1\">Postoperative gum chewing</td> </tr> <tr> <td class=\"subtitle1_single\">Unproven, investigational, or ineffective strategies</td> </tr> <tr> <td class=\"indent1\">Ambulation</td> </tr> <tr> <td class=\"indent1\">Routine replacement of electrolytes</td> </tr> <tr> <td class=\"indent1\">Delayed postoperative feeding</td> </tr> <tr> <td class=\"indent1\">Preoperative bran diet</td> </tr> <tr> <td class=\"indent1\">Metoclopramide</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> </tr> <tr> <td class=\"indent1\">Preoperative \"visceral learning\"</td> </tr> <tr> <td class=\"indent1\">Neostigmine</td> </tr> <tr> <td class=\"indent1\">Propanolol</td> </tr> <tr> <td class=\"indent1\">Coffee</td> </tr> <tr> <td class=\"indent1\">COX-2 inhibitors</td> </tr> <tr> <td class=\"subtitle1_single\">Harmful strategies</td> </tr> <tr> <td class=\"indent1\">Routine use of nasogastric tubes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64552 Version 5.0</div></div></div>"},"64553":{"type":"graphic_algorithm","displayName":"C1INH deficiency diagnostic algorithm","title":"C1INH deficiency diagnostic algorithm","html":"<div class=\"graphic\"><div style=\"width: 824px\" class=\"figure\"><div class=\"ttl\">C1INH deficiency diagnostic algorithm</div><div class=\"cntnt\"><img style=\"width:804px; height:576px;\" src=\"images/ALLRG/64553_C1INH_deficiency_diagnostic.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FXII: factor XII.</div><div class=\"graphic_reference\">Modified with permission from: Bowen T, Cicardi M, Farkas H, et al. 2010 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Allergy, Asthma, and Clinical Immunology 2010; 6:24. Copyright &copy; 2010 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 64553 Version 8.0</div></div></div>"},"64554":{"type":"graphic_table","displayName":"Revised IPI","title":"Revised International Prognostic Index (R-IPI) for diffuse large B-cell lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised International Prognostic Index (R-IPI) for diffuse large B-cell lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Revised International Prognostic Index (R-IPI)</td> </tr> <tr> <td colspan=\"4\">Age &#62;60</td> </tr> <tr> <td colspan=\"4\">Serum lactate dehydrogenase concentration above normal</td> </tr> <tr> <td colspan=\"4\">ECOG performance status &#8805;2</td> </tr> <tr> <td colspan=\"4\">Ann Arbor stage III or IV</td> </tr> <tr> <td colspan=\"4\">Number of extranodal disease sites &#62;1</td> </tr> <tr> <td colspan=\"4\">One point is given for each of the above characteristics present in the patient, for a total score ranging from zero to five. When applied to patients with DLBCL who were treated with R-CHOP, 4 year overall survival (OS) and progression free survival (PFS) rates according to the score were as follows:</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">Risk group</td> <td class=\"subtitle2\">4-yr OS, percent</td> <td class=\"subtitle2\">4-yr PFS</td> </tr> <tr> <td>0</td> <td>Very good</td> <td>94</td> <td>94</td> </tr> <tr> <td>1 or 2</td> <td>Good</td> <td>79</td> <td>80</td> </tr> <tr> <td>3 or more</td> <td>Poor</td> <td>55</td> <td>53</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109:1857.</div><div id=\"graphicVersion\">Graphic 64554 Version 3.0</div></div></div>"},"64555":{"type":"graphic_table","displayName":"Clinical spectrum of fusariosis","title":"Clinical spectrum of fusariosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical spectrum of fusariosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Immunocompetent hosts</td> </tr> <tr> <td class=\"subtitle2_single\">Non-infectious</td> </tr> <tr> <td class=\"indent1\">Mycotoxicosis</td> </tr> <tr> <td class=\"indent1\">Allergic bronchopulmonary fusariosis</td> </tr> <tr> <td class=\"subtitle2_single\">Infectious</td> </tr> <tr> <td class=\"indent1\"><em>Common:</em></td> </tr> <tr> <td class=\"indent2\">Onychomycosis</td> </tr> <tr> <td class=\"indent2\">Keratitis*</td> </tr> <tr> <td class=\"indent1\"><em>Uncommon:</em></td> </tr> <tr> <td class=\"indent2\">Cutaneous (burns, wounds)<sup>[1]</sup></td> </tr> <tr> <td class=\"indent2\">Peritonitis (patients receiving CAPD)<sup>[2-4]</sup></td> </tr> <tr> <td class=\"indent2\">Endocarditis</td> </tr> <tr> <td class=\"indent2\">Pneumonia</td> </tr> <tr> <td class=\"indent2\">Sinusitis</td> </tr> <tr> <td class=\"indent2\">Endophthalmitis</td> </tr> <tr> <td class=\"indent2\">Thrombophlebitis</td> </tr> <tr> <td class=\"indent2\">Fungemia</td> </tr> <tr> <td class=\"indent2\">Arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Immunocompromised hosts<sup>[5]</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Invasive infection</td> </tr> <tr> <td class=\"subtitle3_single\">Disseminated</td> </tr> <tr> <td class=\"indent2\">Multiorgan infection</td> </tr> <tr> <td class=\"indent2\">Isolated fungemia </td> </tr> <tr> <td class=\"subtitle3_single\">Localized</td> </tr> <tr> <td class=\"indent2\"><em>Common:</em></td> </tr> <tr> <td class=\"indent3\">Cellulitis</td> </tr> <tr> <td class=\"indent3\">Sinusitis</td> </tr> <tr> <td class=\"indent3\">Pneumonia</td> </tr> <tr> <td class=\"indent2\"><em>Less common:</em></td> </tr> <tr> <td class=\"indent3\">CNS infection</td> </tr> <tr> <td class=\"indent3\">Endophthalmitis</td> </tr> <tr> <td class=\"indent3\">Arthritis/osteomyelitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAPD: continuous ambulatory peritoneal dialysis; CNS: central nervous system.<br> * Outbreaks of fusarial keratitis have been reported among contact lens wearers<sup>[6]</sup>.</div><div class=\"graphic_reference\">References: <br> <ol> <li>Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909. </li> <li>Rippon JW, Larson RA, Rosenthal DM, Clayman J. Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature. Mycopathologia 1988; 101:105. </li> <li>Kerr CM, Perfect JR, Craven PC, et al. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med 1983; 99:334. </li> <li>Flynn JT, Meislich D, Kaiser BA, et al. Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Perit Dial Int 1996; 16:52. </li> <li>Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695. </li> <li>Patel A, Hammersmith K. Contact lens-related microbial keratitis: recent outbreaks. Curr Opin Ophthalmol 2008; 19:302. </li> </ol></div><div id=\"graphicVersion\">Graphic 64555 Version 2.0</div></div></div>"},"64556":{"type":"graphic_picture","displayName":"Diaper dermatitis candidiasis","title":"Diaper dermatitis complicated by <EM>Candida</EM> infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diaper dermatitis complicated by <EM>Candida</EM> infection</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64556_Diaper_derm_candidiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diaper dermatitis with superimposed candidiasis. The skin folds are involved and satellite lesions are typically present at the periphery of the involved area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64556 Version 4.0</div></div></div>"},"64557":{"type":"graphic_figure","displayName":"Glucagon injection sites child PI","title":"Where to give a child a glucagon shot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Where to give a child a glucagon shot</div><div class=\"cntnt\"><img style=\"width:379px; height:572px;\" src=\"images/PI/64557_Glucagon_injection_sites_child_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A glucagon shot can be given in the&nbsp;buttock,&nbsp;upper arm, or thigh&nbsp;(as shown by the shaded areas).</div><div id=\"graphicVersion\">Graphic 64557 Version 4.0</div></div></div>"},"64558":{"type":"graphic_figure","displayName":"Mastectomy closure and drain placement","title":"Mastectomy closure and drain placement","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Mastectomy closure and drain placement</div><div class=\"cntnt\"><img style=\"width:588px; height:192px;\" src=\"images/SURG/64558_Mastectomyclosure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Closure of the incision, with a JacksonâPratt drain exiting the skin of the low axilla and secured externally with a nylon suture. With the drain under the lower ï¬ap, it catches the ï¬uid dependently.<br> (A) The incision with a simple closure of the ellipse.<br> (B) With a Y-plasty modiï¬cation in the context of those larger individuals who have developed a ridge of tissue extending to the lateral thorax or back secondary to the weight of the breast over time. This closure results in reducing the excess tissue laterally, beyond the breast, which may stick out after closure. Closure of the skin-sparing incisions is not depicted, as it is generally used in the context of collaboration with a plastic surgeon who will reconstruct before closure.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright Â© 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64558 Version 7.0</div></div></div>"},"64559":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis - toxic epidermal necrolysis-like","title":"Linear IgA bullous dermatosis resembling toxic epidermal necrolysis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis resembling toxic epidermal necrolysis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64559_LineIgAbulldermaTEN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive bullae and skin sloughing are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64559 Version 5.0</div></div></div>"},"64561":{"type":"graphic_picture","displayName":"Crypto H and E","title":"Pleural biopsy with <EM>Cryptococcus</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural biopsy with <EM>Cryptococcus</EM></div><div class=\"cntnt\"><img style=\"width:432px; height:353px;\" src=\"images/ID/64561_Crypto_H_and_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin stain of a pleural biopsy specimen from a patient with cryptococcal pneumonia.</div><div class=\"graphic_reference\">Reproduced with permission from: Cartwright E, Rouphael N, Jain S, Ilksoy N. Pleural Effusion in a Patient with AIDS. Clin Infect Dis 2008; 46:1887. Copyright Â©2008 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 64561 Version 2.0</div></div></div>"},"64562":{"type":"graphic_picture","displayName":"Brown syndrome","title":"Brown syndrome left eye","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Brown syndrome left eye</div><div class=\"cntnt\"><img style=\"width:507px; height:399px;\" src=\"images/PEDS/64562_Brown_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Limited elevation of the left eye in adduction. B) Normal elevation in abduction. C) Because the eyes are straight in the primary position, there is no compensatory face turn. D) In straight upgaze, there is divergence of the eyes, a V pattern, as the left eye &quot;looks around&quot; the restricted area.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64562 Version 1.0</div></div></div>"},"64563":{"type":"graphic_diagnosticimage","displayName":"ILS chest radiograph","title":"Chest radiograph from a four-year-old child with an intralobar pulmonary sequestration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph from a four-year-old child with an intralobar pulmonary sequestration</div><div class=\"cntnt\"><img style=\"width:245px; height:422px;\" src=\"images/PEDS/64563_ILS_chest_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a four-year-old child with an intralobar pulmonary sequestration (ILS). A moderate sized triangular soft tissue mass is seen in the retrocardiac area of the left lower lobe, on top of the diaphragm (arrow).</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 64563 Version 4.0</div></div></div>"},"64564":{"type":"graphic_table","displayName":"Management organ donor","title":"Goals of pediatric organ donor management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Goals of pediatric organ donor management</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Correct electrolyte disturbances and maintain fluid and electrolyte balance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Maintenance of normal cardiac output and tissue perfusion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ensure adequate ventilation and pulmonary viability; minimize atelectasis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Prevent aspiration around endotracheal tube</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Prevent and treat infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Control diabetes insipidus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Maintain skin integrity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Maintain normothermia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Reduce inflammation</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 64564 Version 1.0</div></div></div>"},"64565":{"type":"graphic_table","displayName":"SLE presentation","title":"Frequency of presenting clinical features of children with systemic lupus erythematosus at tertiary care centers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of presenting clinical features of children with systemic lupus erythematosus at tertiary care centers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical features </td> <td class=\"subtitle1\">France, percent </td> <td class=\"subtitle1\">Toronto, percent </td> </tr> <tr> <td class=\"sublist1_start\">Hematologic </td> <td class=\"sublist_other_start\">72 </td> <td class=\"sublist_other_start\">55 </td> </tr> <tr> <td class=\"sublist1\">Anemia (Hgb level &#8804;12 g/dL) </td> <td class=\"sublist_other\">27 </td> <td class=\"sublist_other\">NA </td> </tr> <tr> <td class=\"sublist1\">Leukopenia (WBC 4000/mL) </td> <td class=\"sublist_other\">35 </td> <td class=\"sublist_other\">NA </td> </tr> <tr> <td class=\"sublist1\">Lymphopenia </td> <td class=\"sublist_other\">NA </td> <td class=\"sublist_other\">29 </td> </tr> <tr> <td class=\"sublist1\">Thrombocytopenia (150,000/mL) </td> <td class=\"sublist_other\">28 </td> <td class=\"sublist_other\">29 </td> </tr> <tr> <td class=\"sublist1_start\">Mucocutaneous (eg, rash and oral ulcers) </td> <td class=\"sublist_other_start\">70 </td> <td class=\"sublist_other_start\">NA </td> </tr> <tr> <td class=\"sublist1\">Malar rash </td> <td class=\"sublist_other\">39 </td> <td class=\"sublist_other\">61 </td> </tr> <tr> <td>Musculoskeletal (arthritis, arthralgia)</td> <td>64</td> <td>61</td> </tr> <tr> <td>Fever</td> <td>58</td> <td>39</td> </tr> <tr> <td class=\"sublist1_start\">Renal </td> <td class=\"sublist_other_start\">50 </td> <td class=\"sublist_other_start\">NA </td> </tr> <tr> <td class=\"sublist1\">Nephritis </td> <td class=\"sublist_other\">NA </td> <td class=\"sublist_other\">37 </td> </tr> <tr> <td class=\"sublist1\">Nephrotic syndrome </td> <td class=\"sublist_other\">NA </td> <td class=\"sublist_other\">22 </td> </tr> <tr> <td>Abdominal complaints</td> <td>26</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Hgb: hemoglobin; WBC: white blood count; NA: data not available.</div><div class=\"graphic_reference\">1. Bader-Meunier B, Armengaud JB, Haddad E, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr 2005; 146:648.<br />2. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152:550.</div><div id=\"graphicVersion\">Graphic 64565 Version 3.0</div></div></div>"},"64567":{"type":"graphic_picture","displayName":"Transient neonatal pustular melanosis 1","title":"Transient neonatal pustular melanosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transient neonatal pustular melanosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64567_Transneonatpustmel1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustules, collarettes of scales, and hyperpigmented macules in a neonate with transient pustular melanosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64567 Version 4.0</div></div></div>"},"64568":{"type":"graphic_picture","displayName":"Post-ERCP perforation","title":"Endoscopic view of a retroperitoneal duodenal perforation following biliary sphincterotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of a retroperitoneal duodenal perforation following biliary sphincterotomy</div><div class=\"cntnt\"><img style=\"width:288px; height:313px;\" src=\"images/GAST/64568_Post-ERCP_perforation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perforation site is visible above the bile duct.</div><div class=\"graphic_reference\">Photo courtesy of Luigi Familiari, MD.</div><div id=\"graphicVersion\">Graphic 64568 Version 2.0</div></div></div>"},"64569":{"type":"graphic_table","displayName":"Ovarian cancer survival","title":"Carcinoma of the ovary: FIGO stage and overall survival for patients treated in 1999-2001","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carcinoma of the ovary: FIGO stage and overall survival for patients treated in 1999-2001</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">FIGO stage</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" colspan=\"3\">Overall survival (percent)</td> </tr> <tr> <td class=\"subtitle2\">One year</td> <td class=\"subtitle2\">Two years</td> <td class=\"subtitle2\">Five years</td> </tr> <tr> <td class=\"centered\">IA</td> <td class=\"centered\">632</td> <td class=\"centered\">98.4</td> <td class=\"centered\">96.2</td> <td class=\"centered\">89.6</td> </tr> <tr> <td class=\"centered\">IB</td> <td class=\"centered\">69</td> <td class=\"centered\">100</td> <td class=\"centered\">93.9</td> <td class=\"centered\">86.1</td> </tr> <tr> <td class=\"centered\">IC</td> <td class=\"centered\">663</td> <td class=\"centered\">96.3</td> <td class=\"centered\">91.4</td> <td class=\"centered\">83.4</td> </tr> <tr> <td class=\"centered\">IIA</td> <td class=\"centered\">72</td> <td class=\"centered\">93.0</td> <td class=\"centered\">87.2</td> <td class=\"centered\">70.7</td> </tr> <tr> <td class=\"centered\">IIB</td> <td class=\"centered\">93</td> <td class=\"centered\">93.4</td> <td class=\"centered\">84.5</td> <td class=\"centered\">65.5</td> </tr> <tr> <td class=\"centered\">IIC</td> <td class=\"centered\">241</td> <td class=\"centered\">93.6</td> <td class=\"centered\">85.6</td> <td class=\"centered\">71.4</td> </tr> <tr> <td class=\"centered\">IIIA</td> <td class=\"centered\">128</td> <td class=\"centered\">88.1</td> <td class=\"centered\">72.6</td> <td class=\"centered\">46.7</td> </tr> <tr> <td class=\"centered\">IIIB</td> <td class=\"centered\">271</td> <td class=\"centered\">85.7</td> <td class=\"centered\">70.6</td> <td class=\"centered\">41.5</td> </tr> <tr> <td class=\"centered\">IIIC</td> <td class=\"centered\">2030</td> <td class=\"centered\">84.8</td> <td class=\"centered\">64.5</td> <td class=\"centered\">32.5</td> </tr> <tr> <td class=\"centered\">IV</td> <td class=\"centered\">626</td> <td class=\"centered\">72.4</td> <td class=\"centered\">48.4</td> <td class=\"centered\">18.6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics.</div><div class=\"graphic_reference\">Original table modified for this publication. From: Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2006; 95:S161. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64569 Version 13.0</div></div></div>"},"64570":{"type":"graphic_diagnosticimage","displayName":"Subchorionic bleeding","title":"Subchorionic bleeding in fetus at 5.5 weeks' gestational age","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Subchorionic bleeding in fetus at 5.5 weeks' gestational age</div><div class=\"cntnt\"><img style=\"width:514px; height:198px;\" src=\"images/OBGYN/64570_Subchorionic_bleeding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transverse transvaginal sonogram reveals intrauterine gestational sac with yolk sac. Note small amount of blood (arrow) adjacent to gestational sac. B, Transvaginal sagittal sonogram obtained 2 weeks after (A) because of vaginal bleeding shows subchorionic hematoma (arrow) with debris. Collection could be mistake for second gestational sac with embryonic demise.</div><div class=\"graphic_reference\">Reproduced with permission from Trop, I, Levine, D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright 2001 American.</div><div id=\"graphicVersion\">Graphic 64570 Version 2.0</div></div></div>"},"64572":{"type":"graphic_picture","displayName":"T PLL blood smear","title":"T cell prolymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">T cell prolymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:516px; height:231px;\" src=\"images/HEME/64572_T_PLL_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear from a patient with T cell prolymphocytic leukemia. The tumor cells are medium-sized lymphoid cells with moderately condensed chromatin and a prominent nucleolus. In T-PLL, the nucleus can be round or oval and the cytoplasm is slightly basophilic without granules. Cytoplasmic protrusions (blebs) are common.</div><div class=\"graphic_reference\">Kindly provided by Sarayu Chandrashekhar, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 64572 Version 1.0</div></div></div>"},"64573":{"type":"graphic_form","displayName":"Intake and void volume record","title":"24-hour intake and void volume record","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">24-hour intake and void volume record</div><div class=\"cntnt\"><img style=\"width:479px; height:688px;\" src=\"images/PC/64573_Intake_and_void_volume_reco.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64573 Version 2.0</div></div></div>"},"64575":{"type":"graphic_picture","displayName":"Fusarium skin lesions on lower extremities","title":"<EM>Fusarium </EM>skin lesions on lower extremities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium </EM>skin lesions on lower extremities</div><div class=\"cntnt\"><img style=\"width:420px; height:315px;\" src=\"images/ID/64575_Fusarium_skin_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower extremity involvement, with several <EM>Fusarium</EM> skin lesions of different types and ages. Small macular lesions, papular lesions of different sizes, and two target lesions: central necrosis surrounded by an erythematous base, an area of normal skin, and an outer rim of thin erythema (arrows). Patient was a 32-year-old woman with relapsed leukemia who had undergone allogeneic bone marrow transplantation and developed disseminated and fatal fusarial infection.</div><div class=\"graphic_reference\">Reproduced from: Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immuncompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35:909 by permission of Oxford University Press. Copyright Â© 2002.</div><div id=\"graphicVersion\">Graphic 64575 Version 3.0</div></div></div>"},"64576":{"type":"graphic_picture","displayName":"Bunny lines lateral view","title":"\"Bunny lines\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">&quot;Bunny lines&quot;</div><div class=\"cntnt\"><img style=\"width:248px; height:359px;\" src=\"images/DERM/64576_Bunny_lines_lat_view_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wrinkles on the dorsal and lateral nose can occur during contraction of the upper nasalis muscle.</div><div id=\"graphicVersion\">Graphic 64576 Version 2.0</div></div></div>"},"64577":{"type":"graphic_picture","displayName":"Perioral dermatitis lesions","title":"Perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64577_Perioral_dermatitis_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clustered small papules on the perioral skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64577 Version 4.0</div></div></div>"},"64578":{"type":"graphic_diagnosticimage","displayName":"MRI subependymal giant cell tumor","title":"Brain MRI of subependymal giant cell tumor in tuberous sclerosis complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of subependymal giant cell tumor in tuberous sclerosis complex</div><div class=\"cntnt\"><img style=\"width:442px; height:504px;\" src=\"images/NEURO/64578_MRI_SGCT_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative brain MRI axial FLAIR sequence showing a subependymal giant cell tumor, also known as a subependymal giant cell astrocytoma, located near the left foramen of Monro. There is minimal enlargement of the ipsilateral ventricle despite markedly increased intracranial pressure evident at surgery.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid attenuated inversion recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004; 63:1457. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64578 Version 9.0</div></div></div>"},"64583":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 7","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:372px; height:350px;\" src=\"images/OBGYN/64583_Tx_post_vaginal_wall_def_7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a transverse defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 64583 Version 2.0</div></div></div>"},"64584":{"type":"graphic_table","displayName":"Risk factors severe jaundice","title":"Risk factors for development of severe hyperbilirubinemia in infants of 35 or more weeks gestation (in approximate order of importance)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for development of severe hyperbilirubinemia in infants of 35 or more weeks gestation (in approximate order of importance)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major risk factors</td> </tr> <tr> <td class=\"indent1\">Predischarge TB or TcB level in the high-risk zone</td> </tr> <tr> <td class=\"indent1\">Jaundice observed in the first 24 hours</td> </tr> <tr> <td class=\"indent1\">Blood group incompatibility with positive direct antiglobulin test, other known hemolytic disease (eg, G6PD deficiency), elevated ETCOc</td> </tr> <tr> <td class=\"indent1\">Gestational age 35 to 36 weeks</td> </tr> <tr> <td class=\"indent1\">Previous sibling received phototherapy</td> </tr> <tr> <td class=\"indent1\">Cephalohematoma or significant bruising</td> </tr> <tr> <td class=\"indent1\">Exclusive breastfeeding, particularly if nursing is not going well and weight loss is excessive</td> </tr> <tr> <td class=\"indent1\">East Asian race*</td> </tr> <tr> <td class=\"subtitle1_single\">Minor risk factors</td> </tr> <tr> <td class=\"indent1\">Predischarge TB or TcB level in the high intermediate-risk zone</td> </tr> <tr> <td class=\"indent1\">Gestational age 37 to 38 weeks</td> </tr> <tr> <td class=\"indent1\">Jaundice observed before discharge</td> </tr> <tr> <td class=\"indent1\">Previous sibling with jaundice</td> </tr> <tr> <td class=\"indent1\">Macrosomic infant of a diabetic mother</td> </tr> <tr> <td class=\"indent1\">Maternal age &#8805;25 years</td> </tr> <tr> <td class=\"indent1\">Male gender</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased risk (these factors are associated with decreased risk of significant jaundice, listed in order of decreasing importance)</td> </tr> <tr> <td class=\"indent1\">TB or TcB level in the low-risk zone</td> </tr> <tr> <td class=\"indent1\">Gestational age &#8805;41 weeks</td> </tr> <tr> <td class=\"indent1\">Exclusive bottle feeding</td> </tr> <tr> <td class=\"indent1\">Black race*</td> </tr> <tr> <td class=\"indent1\">Discharge from hospital after 72 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: total serum or plasma bilirubin; TcB: transcutaneous bilirubin; G6PD: glucose-6-phosphate dehydrogenase; ETCOc: end-tidal carbon monoxide concentration.<br />* Race as defined by mother's description.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 114, Pages 297-316, Copyright Â© 2004 by the AAP.</div><div id=\"graphicVersion\">Graphic 64584 Version 17.0</div></div></div>"},"64586":{"type":"graphic_figure","displayName":"CO2 waveform COPD","title":"CO<sub>2</sub> waveform in obstructive lung disease","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">CO<sub>2</sub> waveform in obstructive lung disease</div><div class=\"cntnt\"><img style=\"width:608px; height:214px;\" src=\"images/EM/64586_CO2_waveform_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top waveform is from a patient with normal lung function and has a characteristic rectangular appearance. The bottom waveform is from a patient with severe chronic obstructive pulmonary disease and has a characteristic curved appearance and up-sloping of the alveolar plateau.</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second; FVC: forced vital capacity.</div><div class=\"graphic_reference\">Reproduced with permission from: Krauss B, Deykin A, Lam A, et al. Capnogram shape in obstructive lung disease. Anesth Analg 2005; 100:884. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64586 Version 10.0</div></div></div>"},"64588":{"type":"graphic_figure","displayName":"Detrusor BoNT injection","title":"Botulinum toxin detrusor injection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin detrusor injection</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/OBGYN/64588_Detrusor_BoNT_injection.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64588 Version 3.0</div></div></div>"},"64589":{"type":"graphic_figure","displayName":"Vaginscopy findings","title":"Commonly observed findings on vaginoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Commonly observed findings on vaginoscopy</div><div class=\"cntnt\"><img style=\"width:407px; height:404px;\" src=\"images/OBGYN/64589_Vaginscopy_findings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Petechiae (from swabs used to obtain cultures) and papillary excrescences (associated with inflammation).</div><div id=\"graphicVersion\">Graphic 64589 Version 1.0</div></div></div>"},"64591":{"type":"graphic_table","displayName":"Benefits pulmonary rehab COPD","title":"Benefits of pulmonary rehabilitation in COPD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benefits of pulmonary rehabilitation in COPD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Improves exercise capacity</td> </tr> <tr> <td>Reduces the perceived intensity of breathlessness</td> </tr> <tr> <td>Improves health-related quality of life</td> </tr> <tr> <td>Reduces the number of hospitalizations and days in the hospital</td> </tr> <tr> <td>Reduces anxiety and depression associated with COPD</td> </tr> <tr> <td>Strength and endurance training of the upper limbs improves arm function</td> </tr> <tr> <td>Benefits extend well beyond the immediate period of training</td> </tr> <tr> <td>Improves survival</td> </tr> <tr> <td>Respiratory muscle training is beneficial, especially when combined with general exercise training</td> </tr> <tr> <td>Improves recovery after hospitalization for an exacerbation<sup>[1]</sup></td> </tr> <tr> <td>Enhances the effect of long-acting bronchodilators</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Puhan MA, Gimeno-Santos E, Scharplatz M, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011.</LI></OL>Reproduced with permission from the Global Strategy for Diagnosis, Management and Prevention of COPD 2013,&nbsp;&#169; Global Initiative for Chronic Obstructive Lung Disease (GOLD), all rights reserved. Available from <A style=\"FONT-STYLE: italic\" href=\"http://www.goldcopd.org/\" target=_blank>http://www.goldcopd.org</A>. Unauthorized use of this material is strictly prohibited.</div><div id=\"graphicVersion\">Graphic 64591 Version 3.0</div></div></div>"},"64595":{"type":"graphic_figure","displayName":"Hypothetical pathology TDP-43 and FUS proteinopathy","title":"Hypothetical common pathology of TAR DNA-binding protein (TDP-43) proteinopathy and fused in sarcoma (FUS) proteinopathy","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Hypothetical common pathology of TAR DNA-binding protein (TDP-43) proteinopathy and fused in sarcoma (FUS) proteinopathy</div><div class=\"cntnt\"><img style=\"width:596px; height:457px;\" src=\"images/NEURO/64595_Hypo_path_TDP43_FUS_prot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nuclear import of TDP-43 is mediated by importin-Î±, importin-Î², and Ran-GTPase. p35iso (which is derived from an alternate initiation codon) and p35f (proteolytically cleaved by caspase-3) do not have a nuclear localization signal (NLS) and are mislocalized to the cytoplasm. Wild-type FUS protein is transferred to the nucleus via transportin-1, transportin-2, and Ran-dependent transport machinery. Amyotrophic lateral sclerosis (ALS)-linked mutants of FUS interfere with the interaction with transportin and lead to localization in the cytoplasm. Under certain pathologic stresses or aging-related nuclear leakiness, cytoplasmic accumulation of TDP-43 and FUS lead to a common pathologic process, the formation of stress granules (SGs), or dysregulation of the RNA quality control system that may then be associated with motor neuron degeneration. Similar to inclusions in other neurodegenerative diseases, whether SGs are cytotoxic or cytoprotective remains unclear. An alternative pathway suggests that neuronal intranuclear inclusions (NIIs) may be associated with pathogenesis in some types of frontotemporal lobar degeneration (FTLD)-TDP and -FUS, especially Paget disease of bone and frontotemporal dementia (IBMPFD).</div><div class=\"graphic_reference\">Reproduced with permission from: Ito D, Suzuki N. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 2011; 77:1636. Copyright Â© 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64595 Version 5.0</div></div></div>"},"64596":{"type":"graphic_table","displayName":"Treatment streptococcal pharyngitis in adults","title":"Treatment of pharyngitis due to group A <em>Streptococcus</em> in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of pharyngitis due to group A <em>Streptococcus</em> in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"12%\"></colgroup><colgroup span=\"3\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic class</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dosing in adults</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Penicillins</strong><br /> (preferred)</td> <td>Penicillin V</td> <td> <ul> <li>500 mg orally two to three times daily for 10 days </li> </ul> </td> <td> <ul> <li>Narrow spectrum </li> <li>No documented resistance </li> <li>Low cost </li> </ul> </td> <td> <ul> <li>Three-times-daily dosing; however, twice-daily regimen appears to be as effective as thrice daily<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td>Amoxicillin*</td> <td> <ul> <li>500 mg orally twice daily for 10 days </li> </ul> </td> <td> <ul> <li>Available as once-daily extended-release tablet<sup>&#182;</sup> </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Penicillin G benzathine*<br /> (Bicillin L-A)</td> <td> <ul> <li>1.2 million units IM as a single dose </li> </ul> </td> <td> <ul> <li>Can be given as a single dose </li> <li>Ensured adherence </li> <li>Only drug studied for prevention of acute rheumatic fever </li> </ul> </td> <td> <ul> <li>Variable availability </li> <li>High cost </li> <li>Injection site pain </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Cephalosporins</strong><br /> (potential alternatives for mild reactions to <span style=\"white-space: nowrap;\">penicillin<sup>&#916;</sup>)</span></td> <td>Cephalexin*<br /> (first generation)</td> <td> <ul> <li>500 mg orally twice daily for 10 days </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>Narrower spectrum than later-generation cephalosporins </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr> <td>Cefuroxime*<br /> (second generation)</td> <td> <ul> <li>250 mg orally twice daily for 10 days </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>Narrower spectrum than later-generation cephalosporins </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and first-generation cephalosporins </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr> <td>Cefpodoxime*<br /> (third generation)</td> <td> <ul> <li>100 mg orally twice daily for 5 to 10 days </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>FDA approved for 5-day course </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and earlier-generation cephalosporins </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cefdinir*<br /> (third generation)</td> <td> <ul> <li>300 mg orally twice daily for 5 to 10 days or 600 mg orally once daily for 10 days </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>FDA approved for 5-day course </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and earlier-generation cephalosporins </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Macrolides</strong><br /> (alternatives for patients with anaphylaxis or other IgE-mediated reactions or severe delayed reactions to <span style=\"white-space: nowrap;\">penicillin<sup>&#916;</sup>)</span></td> <td>Azithromycin</td> <td> <ul> <li>500 mg orally on day 1 followed by 250 mg orally on days 2 through 5 </li> </ul> </td> <td> <ul> <li>Can be given as a 5-day course due to extended half-life </li> </ul> </td> <td> <ul> <li>Growing rates of resistance </li> <li>Rarely associated with prolonged QT interval and TdP </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Clarithromycin*</td> <td> <ul> <li>250 mg orally twice daily for 10 days </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Growing rates of resistance </li> <li>Greater gastrointestinal side effects than azithromycin </li> <li>Causes CYP3A4 drug interactions </li> <li>Rarely associated with prolonged QT interval and TdP </li> </ul> </td> </tr> <tr> <td><strong>Lincosamides</strong><br /> (alternative when macrolide resistance is a concern and penicillins and cephalosporins cannot be used)</td> <td>Clindamycin</td> <td> <ul> <li>300 mg orally three times daily for 10 days </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Growing rates of resistance </li> <li>High side-effect profile (ie, gastrointestinal) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscularly; FDA: US Food and Drug Administration: TdP: torsades de pointes.<br />* Dose alteration needed for renal insufficiency.<br />&para; Once-daily extended-release amoxicillin is recommended by the 2009 American Heart Association (AHA) guidelines. It is noninferior to amoxicillin administered in multiple daily doses. The dose in adults is 775 mg orally once per day for 10 days.<br />&Delta; Approach to patients with penicillin allergy varies among experts and allergy severity; refer to the text for additional detail.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lan AJ, Colford JM, Colford JM Jr; The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A meta-analysis. Pediatrics; 2000 Feb; 105:E19.</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of Group A Streptococcal pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:e86.</li>&#xD;&#xA;    <li>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64596 Version 39.0</div></div></div>"},"64597":{"type":"graphic_figure","displayName":"Deep cervical infx extension","title":"Potential pathways of extension in deep cervical fascial space infections","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential pathways of extension in deep cervical fascial space infections</div><div class=\"cntnt\"><img style=\"width:435px; height:365px;\" src=\"images/ID/64597_Deep_cervical_infx_ext_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Chow, AW. Life-threatening infections of the head, neck, and upper respiratory tract. In: Principles of Critical Care, 2nd ed, Hall, JB, Schmidt, GA, Wood, LH (Eds), McGraw-Hill, New York 1998. p.891. Copyright &#169; 1998 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 64597 Version 4.0</div></div></div>"},"64598":{"type":"graphic_figure","displayName":"Direct indirect allorecognition","title":"Schematic representation showing direct and indirect allorecognition during graft rejection","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Schematic representation showing direct and indirect allorecognition during graft rejection</div><div class=\"cntnt\"><img style=\"width:510px; height:320px;\" src=\"images/NEPH/64598_Direct_indirect_allorecogni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T cell recognition of alloantigen occurs by one of two separate pathways. T cell activation by the &quot;direct&quot; pathway occurs when T cells encounter intact donor MHC on the surface of donor antigen-presenting cells (APC). This pathway is thought to be of dominant importance during early acute rejection as engrafted organs contain a large number of passenger leukocytes. Intact donor MHC molecules are also known to be continuously shed into the circulation where they may then be endocytosed by the recipient's antigen-presenting cells. Within the acidic endosomal compartment, the MHC proteins are fragmented into their constituent peptides. They are then transferred into the endoplasmic reticulum, loaded into the antigen binding cleft of MHC class II of the recipient and finally expressed on the cell surface of recipients APCs. This mechanism has been referred to as the &quot;indirect allorecognition.&quot; However, this is of course the normal route by which T cells normally encounter antigen.</div><div class=\"graphic_footnotes\">APC: antigen-presenting cell; MHC: major histocompatibility complex.</div><div id=\"graphicVersion\">Graphic 64598 Version 3.0</div></div></div>"},"64600":{"type":"graphic_diagnosticimage","displayName":"Bladder exstrophy prenatal ultrasound","title":"Bladder exstrophy fetal ultrasound at 31 weeks gestational age","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Bladder exstrophy fetal ultrasound at 31 weeks gestational age</div><div class=\"cntnt\"><img style=\"width:582px; height:263px;\" src=\"images/PEDS/64600_Bladder_exstrophy_prenat_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Carol E Barnewolt, MD.</div><div id=\"graphicVersion\">Graphic 64600 Version 5.0</div></div></div>"},"64602":{"type":"graphic_figure","displayName":"Fascia iliaca block","title":"Fascia iliaca block","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Fascia iliaca block</div><div class=\"cntnt\"><img style=\"width:462px; height:639px;\" src=\"images/ANEST/64602_Fasciailiacablock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is placed in a supine position. A line is drawn between the ASIS and pubic tubercle and divided into thirds. At the border between the lateral and medial thirds, a perpendicular line 2 cm in length is drawn caudally. A blunt needle is inserted and directed cephalad. Local anesthetic is injected when the operator appreciates two distinct \"pops,\" first through the fascia lata and then through fascia iliaca. Utrasound is commonly used to aid with the approach.</div><div class=\"graphic_footnotes\">n.: nerve; a.: artery; v.: vein; m.: muscle; ASIS: anterior superior iliac spine.</div><div id=\"graphicVersion\">Graphic 64602 Version 3.0</div></div></div>"},"64603":{"type":"graphic_picture","displayName":"Longitudinal melanonychia - thumbs","title":"Longitudinal melanonychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal melanonychia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64603_Long_melanonychia_thumbs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple pigmented linear streaks on the nail are common in individuals (adults &gt; children) with dark skin. The wart on the proximal nail fold of the thumb on the left is an unrelated finding.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64603 Version 6.0</div></div></div>"},"64604":{"type":"graphic_table","displayName":"Serotonin syndrome drugs","title":"Examples of drugs that can precipitate serotonin syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of drugs that can precipitate serotonin syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Drugs involved</td> </tr> <tr> <td>Increases serotonin formation</td> <td>Tryptophan</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Increases release of serotonin</td> <td>Amphetamines (including dextroamphetamine, methamphetamine)</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>MDMA (Ecstasy)</td> </tr> <tr> <td>Amphetamine derivatives (including fenfluramine, dexfenfluramine, phentermine)</td> </tr> <tr> <td>Levodopa, carbidopa-levodopa (indirectly causes release serotonin)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"18\">Impairs reuptake from the synaptic cleft into the presynaptic neuron</td> <td>Cocaine</td> </tr> <tr> <td>MDMA (Ecstasy)</td> </tr> <tr> <td>Meperidine</td> </tr> <tr> <td>Tramadol</td> </tr> <tr> <td>Pentazocine</td> </tr> <tr> <td>Selective serotonin reuptake inhibitors (SSRIs; including citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline)</td> </tr> <tr> <td>Serotonin-norepinephrine reuptake inhibitors (SNRIs; including desvenlafaxine, duloxetine, milnacipran, and venlafaxine)</td> </tr> <tr> <td>Dopamine-norepinephrine reuptake inhibitors (including bupropion)</td> </tr> <tr> <td>Serotonin modulators (including nefazodone, trazodone, and vilazodone)</td> </tr> <tr> <td>Tricyclic antidepressants (TCAs; including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine)</td> </tr> <tr> <td>St. John's wort (<em>Hypericum perforatum</em>)</td> </tr> <tr> <td>5-HT3 receptor antagonists (including dolasetron, granisetron, ondansetron, palonosetron)</td> </tr> <tr> <td>Metoclopramide</td> </tr> <tr> <td>Valproate</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Sibutramine</td> </tr> <tr> <td>Dextromethorphan</td> </tr> <tr> <td>Cyclobenzaprine</td> </tr> <tr class=\"divider_top\"> <td>Inhibits serotonin metabolism (ie, inhibits monoamine oxidase activity)</td> <td>Monoamine oxidase inhibitors (MAOIs; including phenelzine, tranylcypromine, isocarboxazid, moclobemide, safinamide, selegiline, rasagiline, linezolid, <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">tedizolid, </span>methylene blue, procarbazine, Syrian rue [<em>Peganum harmala</em>, harmine])</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Direct serotonin agonist</td> <td>Buspirone</td> </tr> <tr> <td>Triptans (including sumatriptan, rizatriptan, others)</td> </tr> <tr> <td>Ergot derivatives (including ergotamine, methylergonovine)</td> </tr> <tr> <td>Fentanyl</td> </tr> <tr> <td>Lysergic acid diethylamide (LSD)</td> </tr> <tr class=\"divider_top\"> <td>Increases sensitivity of postsynaptic receptor</td> <td>Lithium</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data courtesy of authors with additional data from: Boyer EW,&nbsp;Shannon M. The serotonin syndrome. NEJM 2005; 352:1112.</div><div id=\"graphicVersion\">Graphic 64604 Version 14.0</div></div></div>"},"64605":{"type":"graphic_figure","displayName":"Vulvar deep anatomy","title":"Deep anatomy of the vulva","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Deep anatomy of the vulva</div><div class=\"cntnt\"><img style=\"width:532px; height:460px;\" src=\"images/OBGYN/64605_Vulvar_deep_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64605 Version 4.0</div></div></div>"},"64606":{"type":"graphic_figure","displayName":"Lymph nodes body","title":"Lymph node groups","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Lymph node groups</div><div class=\"cntnt\"><img style=\"width:559px; height:574px;\" src=\"images/HEME/64606_Lymph_nodes_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the lymph node groups and sub-areas.</div><div class=\"graphic_reference\">Modified with permission from: Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258. Copyright Â© 2004. American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 64606 Version 2.0</div></div></div>"},"64607":{"type":"graphic_diagnosticimage","displayName":"Neonatal HSV brain CT","title":"Computed tomography scan of the brain of a four-week-old infant with central nervous system (CNS) herpes simplex virus (HSV) infection","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Computed tomography scan of the brain of a four-week-old infant with central nervous system (CNS) herpes simplex virus (HSV) infection</div><div class=\"cntnt\"><img style=\"width:500px; height:273px;\" src=\"images/PEDS/64607_Neonatal_HSV_brain_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography scan of the brain of a four-week-old infant with advanced destructive lesions of the brain associated with neonatal HSV infection of CNS. Infant presented with a one-week history of fever, seizures, and poor feeding. Cerebrospinal fluid showed mononuclear pleocytosis and elevated protein, and HSV DNA was detected by molecular polymerase chain reaction (PCR) assay.</div><div class=\"graphic_reference\">Courtesy of Gail Demmler-Harrison, MD, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 64607 Version 3.0</div></div></div>"},"64609":{"type":"graphic_figure","displayName":"Mortality VPBs during exercise","title":"Ventricular arrhythmia during exercise predicts an increased cardiac mortality","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Ventricular arrhythmia during exercise predicts an increased cardiac mortality</div><div class=\"cntnt\"><img style=\"width:482px; height:354px;\" src=\"images/CARD/64609_Mortality_VPBs_during_exerc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 6101 normal men who underwent exercise testing and were followed for 23 years, the occurrence of ventricular premature beats (VPBs) during exercise testing was associated with a significantly higher all-cause mortality (41 versus 26 percent for no VPBs) and death from cardiovascular disease (16 versus 6.4 percent). After adjusting for age, tobacco use, diabetic status, body-mass index, level of physical activity, systolic blood pressure, the heart rate at rest, and total cholesterol level the presence of VPBs prior to or during exercise was an independent predictor of cardiovascular mortality (relative risk 2.53) and had the same prognostic value as exercise induced ischemia (relative risk 2.63).</div><div class=\"graphic_reference\">Data from: Jouven X, Zureik M, Desnos M, et al. N Engl J Med 2000; 343:826.</div><div id=\"graphicVersion\">Graphic 64609 Version 2.0</div></div></div>"},"64610":{"type":"graphic_figure","displayName":"Helical scanning modes","title":"Single- and variable-mode CT scanning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single- and variable-mode CT scanning</div><div class=\"cntnt\"><img style=\"width:360px; height:221px;\" src=\"images/PULM/64610_Helical_scanning_modes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of single-mode helical scanning and variable-mode scanning.</div><div id=\"graphicVersion\">Graphic 64610 Version 2.0</div></div></div>"},"64611":{"type":"graphic_figure","displayName":"Model pathogenesis IPF","title":"Conceptual pathogenesis of idiopathic pulmonary fibrosis: Key role of the fibroblast","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Conceptual pathogenesis of idiopathic pulmonary fibrosis: Key role of the fibroblast</div><div class=\"cntnt\"><img style=\"width:528px; height:356px;\" src=\"images/PULM/64611_Model_pathogenesis_IPF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a genetically predisposed host (eg, telomerase mutation/deficiency), recurrent injury disrupts the alveolar epithelium and basement membrane, and activates cells within the alveolar wall to release proinflammatory cytokines and chemokines, including TNF-alpha, IL-1, and MCP-1. These soluble mediators may activate residential and/or recruit circulating cells including fibrocytes, thus perpetuating the response to recurrent insults. Profibrogenic molecules, such as PDGF and TGF-beta, are also secreted by inflammatory, epithelial, and endothelial cells. Fibroblasts respond to these changes in one of several ways: they may increase in number, they may differentiate into myofibroblasts and actively synthesize collagen; or they may undergo further differentiation, resulting in the expression of unique cell surface receptors. Increased collagen synthesis, coupled with decreased degradation, causes excessive and abnormal collagen deposition. The resulting aggregates, composed of mesenchymal cells and newly synthesized collagen, are called &quot;fibrotic foci&quot;. Progressive deposition of extracellular matrix leads to distorted pulmonary architecture with loss of capillary surface area and gas exchange units; the resulting honeycomb fibrotic lung has no potential for regeneration and repair.</div><div class=\"graphic_reference\">Courtesy of Ganesh Raghu, MD.</div><div id=\"graphicVersion\">Graphic 64611 Version 1.0</div></div></div>"},"64612":{"type":"graphic_table","displayName":"Parenteral rx elective PCI","title":"Parenteral antithrombotic drugs for elective percutaneous coronary intervention (PCI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antithrombotic drugs for elective percutaneous coronary intervention (PCI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Initiation relative to PCI</td> <td class=\"subtitle1\">Duration of therapy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Abciximab</td> <td>0.25 mg/kg IV bolus, then 0.125 mcg/kg/min IV (max 10 mcg/min).</td> <td class=\"divider_bottom\" rowspan=\"2\">10 to 60 min prior to PCI</td> <td class=\"divider_bottom\" rowspan=\"2\">12 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Renal adjustment: none.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Eptifibatide</td> <td>180 mcg/kg IV bolus x2, 10 min apart (max 22.6 mg each bolus). Start infusion of 2 mcg/kg/min (max 15 mg/hr) after first bolus.</td> <td class=\"divider_bottom\" rowspan=\"3\">Immediately prior to PCI</td> <td class=\"divider_bottom\" rowspan=\"3\">12 to 18 hours</td> </tr> <tr> <td>Renal adjustment of continuous infusion: CrCl* &#60;50 mL/min: 1 mcg/kg/min (max 7.5 mg/hr).</td> </tr> <tr class=\"divider_bottom\"> <td>Hemodialysis dependent: contraindicated.</td> </tr> <tr class=\"divider_bottom\"> <td>Tirofiban</td> <td>Not generally used in elective PCI.</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Unfractionated heparin</td> <td>60 to 100 units/kg IV bolus, titrate to ACT 250 to 300 sec (50 to 70 units/kg IV if GP IIb/IIIa used, titrate to ACT 200 to 250 sec).</td> <td class=\"divider_bottom\" rowspan=\"2\">Immediately prior to PCI</td> <td class=\"divider_bottom\" rowspan=\"2\">Heparin is discontinued at the end of the procedure</td> </tr> <tr class=\"divider_bottom\"> <td>Renal adjustment: none.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Enoxaparin</td> <td>Not generally started for elective PCI. For the occasional patient already on drug, it can be continued at prior dose with an additional 0.3 mg/kg IV if 8 to 12 hours since last dose.</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"2\">May continue for prior indication</td> </tr> <tr class=\"divider_bottom\"> <td>Renal adjustment: avoid use if CrCl* &#60;30 mL/min or dialysis dependent.</td> </tr> <tr> <td rowspan=\"3\">Bivalirudin</td> <td>0.75 mg/kg IV bolus, then 1.75 mg/kg/hr IV.</td> <td rowspan=\"3\">Immediately prior to PCI</td> <td rowspan=\"3\">Bivalirudin is discontinued at the end of the procedure</td> </tr> <tr> <td>Renal adjustment of continuous infusion: CrCl* 10 to 29 mL/min: 1 mg/kg/hr.</td> </tr> <tr> <td>Hemodialysis dependent: 0.25 mg/kg/hr.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACT: activated clotting time; CrCl: creatinine clearance; GP: glycoprotein; IV: intravenous; PCI: percutaneous coronary intervention.<br />* CrCl is estimated using Cockcroft-Gault equation. For discussion of Cockcroft-Gault equation,&nbsp;refer to topic&nbsp;\"Assessment of kidney function: Serum creatinine; BUN; and GFR\", section on Estimation equations.</div><div class=\"graphic_reference\">Adapted with permission from: Antiplatelet and anticoagulant drugs. The Medical Letter 2008; 6:29.</div><div id=\"graphicVersion\">Graphic 64612 Version 10.0</div></div></div>"},"64614":{"type":"graphic_picture","displayName":"Necrotizing gingivitis","title":"Necrotizing ulcerative gingivitis in a 3-year-old child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotizing ulcerative gingivitis in a 3-year-old child</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/ID/64614_Necrotizing_gingivitis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gingival lesion/inflammation involves the mandibular incisors in a malnourished child with poor oral hygiene.</div><div class=\"graphic_reference\">Reproduced with permission from: Enwonwu, CO, Phillips, RS, Savage, KO. Inflammatory cytokine profile and circulating cortisol levels in malnourished children with necrotizing ulcerative gingivitis. Eur Cytokine Netw 2005; 16:240. Copyright &#169; 2005 John Libbey Eurotext.</div><div id=\"graphicVersion\">Graphic 64614 Version 3.0</div></div></div>"},"64616":{"type":"graphic_picture","displayName":"Fully developed papilledema","title":"Fully developed papilledema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fully developed papilledema</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/NEURO/64616_Fully_developed_papilledema.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 64616 Version 1.0</div></div></div>"},"64617":{"type":"graphic_figure","displayName":"Surv by grade sarcs","title":"Survival according to grade, (n = 106, information unavailable on five patients)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival according to grade, (n = 106, information unavailable on five patients)</div><div class=\"cntnt\"><img style=\"width:409px; height:293px;\" src=\"images/ONC/64617_Surv_by_grade_sarcs.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cha C, Antonescu CR, Quan ML, et al. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239:903. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64617 Version 8.0</div></div></div>"},"64618":{"type":"graphic_diagnosticimage","displayName":"Enchondromatosis","title":"Multiple enchondromatosis (Ollier disease)","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Multiple enchondromatosis (Ollier disease)</div><div class=\"cntnt\"><img style=\"width:500px; height:383px;\" src=\"images/PEDS/64618_Enchondromatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Hand. Observe the geographic, expansile, soap-bubble lesions affecting nearly every bone visualized within the hand. Slight matrix calcification is noted in the metacarpal bones. <BR>B) Foot. Observe the multiple, geographic, expansile lesions scattered throughout the proximal phalanges of the foot. The first metatarsal and the diaphysis of the fourth metatarsal also contain expansile enchondromas. The expansion of bone has widened the diaphysis of most of the affected bones.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64618 Version 2.0</div></div></div>"},"64619":{"type":"graphic_figure","displayName":"Mobilization of the cervical esophagus","title":"Mobilization of the cervical esophagus and creation of an esophagostomy","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Mobilization of the cervical esophagus and creation of an esophagostomy</div><div class=\"cntnt\"><img style=\"width:452px; height:399px;\" src=\"images/SURG/64619_Moblize-cerv-eso.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the mobilization of the distal esophagus in preparation for a cervical esophagostomy. The proximal length should be preserved in order to facilitate placement of the esophagostomy on the anterior chest wall. The recurrent laryngeal nerve, which lies in the tracheo-esophageal groove, should be protected.</div><div id=\"graphicVersion\">Graphic 64619 Version 4.0</div></div></div>"},"64620":{"type":"graphic_picture","displayName":"New World CL ulceration ","title":"New World cutaneous leishmaniasis ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">New World cutaneous leishmaniasis ulcer</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/ID/64620_Ulcer_Leishmania.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcer with sporotrichoid extension into local lymphatics.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention and Drs. Martins Castro and Lucille K Georg.</div><div id=\"graphicVersion\">Graphic 64620 Version 4.0</div></div></div>"},"64621":{"type":"graphic_picture","displayName":"Straight leg raise patella fracture","title":"Straight leg raise for patella fracture","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Straight leg raise for patella fracture</div><div class=\"cntnt\"><img style=\"width:479px; height:283px;\" src=\"images/EM/64621_Straight_leg_raise_active.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the straight leg raise, elevate the&nbsp;leg to 20 to 25 degrees, hold for a few seconds, and return to the starting position. Repeat for a total of 10 repetitions per set.</div><div class=\"graphic_reference\">Courtesy of Jim Blount, MD.</div><div id=\"graphicVersion\">Graphic 64621 Version 2.0</div></div></div>"},"64622":{"type":"graphic_diagnosticimage","displayName":"EUS gallstone CBD","title":"Choledocholithiasis seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choledocholithiasis seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:324px; height:314px;\" src=\"images/GAST/64622_EUS_gallstone_CBD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic image of a gallstone in the common bile duct.</div><div class=\"graphic_reference\">Courtesy of Gavin C Harewood, MD and Mauritis J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 64622 Version 3.0</div></div></div>"},"64623":{"type":"graphic_picture","displayName":"Left vocal fold polyp A","title":"Left vocal fold polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left vocal fold polyp</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PC/64623_Left_vocal_fold_polyp_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These can occur secondary to acute vocal fold trauma (such as yelling) with hemorrhage into the vocal fold and subsequent edema and fibrosis. Excision is often required.</div><div id=\"graphicVersion\">Graphic 64623 Version 2.0</div></div></div>"},"64624":{"type":"graphic_figure","displayName":"Spleen preserving distal pancreatectomy","title":"Spleen preserving distal pancreatectomy","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Spleen preserving distal pancreatectomy</div><div class=\"cntnt\"><img style=\"width:517px; height:458px;\" src=\"images/SURG/64624_Splenic_preservation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Operative bed following distal pancreatectomy with splenic preservation.</div><div id=\"graphicVersion\">Graphic 64624 Version 4.0</div></div></div>"},"64625":{"type":"graphic_figure","displayName":"Myocarditis versus IDC","title":"Similar outcome in myocarditis and IDC","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Similar outcome in myocarditis and IDC</div><div class=\"cntnt\"><img style=\"width:463px; height:253px;\" src=\"images/CARD/64625_Myocarditis_versus_IDC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of survival in 27 patients with biopsy-proved myocarditis (definite or borderline) versus 58 patients with idiopathic dilated cardiomyopathy (IDC) who had a negative endomyocardial biopsy. The survival rates were equivalent in the two disorders.</div><div class=\"graphic_reference\">Data from Grogan, M, Redfield, MM, Bailey, KR, et al, J Am Coll Cardiol 1995; 26:80.</div><div id=\"graphicVersion\">Graphic 64625 Version 1.0</div></div></div>"},"64626":{"type":"graphic_algorithm","displayName":"Pacemaker algorithm","title":"Pacemaker algorithm","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Pacemaker algorithm</div><div class=\"cntnt\"><img style=\"width:479px; height:260px;\" src=\"images/CARD/64626_Pacemaker_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for the use of the different types of pacemakers depending upon the need for atrioventricular (AV) sequential pacing, the presence of sinoatrial (SA) node chronotropic competence, the AV conduction rate, and the need for rate-responsiveness.</div><div class=\"graphic_reference\">Courtesy of MD McGoon, MD.</div><div id=\"graphicVersion\">Graphic 64626 Version 2.0</div></div></div>"},"64627":{"type":"graphic_picture","displayName":"Swan neck deformity scleroderma","title":"Swan neck deformity and scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Swan neck deformity and scleroderma</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/RHEUM/64627_Swan_neck_deformity_sclerod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture showing hyperextension of the proximal interphalangeal joint resulting from the development of metocarpophalangeal joint subluxation in flexion. This condition is similar to the swan neck deformity observed in patients with rheumatoid arthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright Â© 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64627 Version 8.0</div></div></div>"},"64629":{"type":"graphic_table","displayName":"Rx of hepatic encephalopathy","title":"Efficacy of treatments of hepatic encephalopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Efficacy of treatments of hepatic encephalopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Rationale</td> <td class=\"subtitle1\" colspan=\"2\">Controlled studies</td> </tr> <tr> <td class=\"subtitle2\">vs lactulose</td> <td class=\"subtitle2\">vs placebo</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Ammonia hypothesis</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Decrease in ammoniagenic substrates</td> </tr> <tr> <td class=\"indent2\">Enemas with lactulose</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td class=\"indent2\">Restriction of dietary protein intake</td> <td>&nbsp;</td> <td>?</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Inhibition of ammonia production</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Antibiotics</td> </tr> <tr> <td class=\"sublist3\">Neomycin, paromomycin, metronidazole</td> <td class=\"sublist_other\">=</td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist3\">Rifaximin</td> <td class=\"sublist_other\">=</td> <td class=\"sublist_other\">+</td> </tr> <tr> <td class=\"sublist3\">Vancomycin</td> <td class=\"sublist_other\">=/+</td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Disaccharides</td> </tr> <tr> <td class=\"sublist3\">Lactulose</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">?</td> </tr> <tr> <td class=\"sublist3\">Lactitol</td> <td class=\"sublist_other\">=</td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"sublist3\">Lactose in lactase deficiency</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">+</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Modification of colonic flora</td> </tr> <tr> <td class=\"sublist3\">Lactobacillus SF 68</td> <td class=\"sublist_other\">=</td> <td class=\"sublist_other\">ND</td> </tr> <tr> <td class=\"indent2\">Correction of hypokalemia</td> <td>ND</td> <td>ND</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Metabolic ammonia removal</td> </tr> <tr> <td class=\"indent2\">Ornithine-aspartate</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td class=\"indent2\">Benzoate</td> <td>=</td> <td>ND</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">False neurotransmitter hypothesis</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Branched chain amino acid supplementation</td> </tr> <tr> <td class=\"indent2\">Modified amino acid solutions (FO80 type)</td> <td>=</td> <td>&#177;</td> </tr> <tr> <td class=\"indent2\">\"COMA\" solutions</td> <td>ND</td> <td>ND</td> </tr> <tr> <td class=\"indent2\">Dietary BCAA supplementation</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Increased dopamine</td> </tr> <tr> <td class=\"indent2\">L-DOPA, bromocriptine </td> <td>&nbsp;</td> <td>-</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">GABA hypothesis</td> </tr> <tr> <td class=\"indent1\">Flumazenil</td> <td>&nbsp;</td> <td>+</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Other</td> </tr> <tr> <td class=\"indent1\">Zinc</td> <td>&nbsp;</td> <td>&#177;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">+: superior to control; =: equal to lactulose; -: no effect; &#177;: conflicting results; ND: not done.</div><div id=\"graphicVersion\">Graphic 64629 Version 3.0</div></div></div>"},"64630":{"type":"graphic_picture","displayName":"Cardiac amyloidosis Light","title":"Cardiac amyloidosis","html":"<div class=\"graphic normal\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Cardiac amyloidosis</div><div class=\"cntnt\"><img style=\"width:521px; height:233px;\" src=\"images/CARD/64630_Cardiac_amyloidosis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endomyocardial biopsy in cardiac amyloidosis using hematoxylin and eosin stain (left panel) and a sulfated alcian blue stain (right panel). The left panel shows a prominent interstitium which is expanded by an acellular, eosinophilic substance (arrows). The myocardial cells are of uneven size and are often vacuolated. The massive amyloid deposits are identified by a positive affinity for sulfated alcian blue (producing a green color), a histochemical reaction equivalent to the Congo red stain.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 64630 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal endomyocardial biopsy</div><div class=\"cntnt\"><img style=\"width:358px; height:235px;\" src=\"images/CARD/61625_Normal_myocardium_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal endomyocardial biopsy in longitudinal section.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 61625 Version 1.0</div></div></div>"},"64632":{"type":"graphic_picture","displayName":"Unilateral KW disease Light","title":"Unilateral diabetic glomerulosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unilateral diabetic glomerulosclerosis</div><div class=\"cntnt\"><img style=\"width:378px; height:262px;\" src=\"images/NEPH/64632_Unilateral_KW_disease_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrographs from a postmortem examination of a diabetic patient with unilateral renal artery stenosis on the right side. Classic Kimmelstiel-Wilson nodules are seen in the glomeruli in the left kidney (left panel); in contrast, the glomeruli are normal in the &quot;protected&quot; right kidney (right panel).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 64632 Version 1.0</div></div></div>"},"64635":{"type":"graphic_picture","displayName":"Spider kukulcania","title":"Kukulcania spider","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kukulcania spider</div><div class=\"cntnt\"><img style=\"width:362px; height:504px;\" src=\"images/ALLRG/64635_Spider_kukulcania.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spider appears larger than actual size. Kukulcania males are approximately 6 to 9 mm long (body length, not including legs) and females are 12 to 20 mm long.</div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 64635 Version 2.0</div></div></div>"},"64636":{"type":"graphic_picture","displayName":"AIP Gross","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:288px; height:418px;\" src=\"images/GAST/64636_AIP_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen in a patient who underwent resection for autoimmune pancreatitis.</div><div class=\"graphic_reference\">Courtesy of Norton Greenberger, MD.</div><div id=\"graphicVersion\">Graphic 64636 Version 1.0</div></div></div>"},"64637":{"type":"graphic_table","displayName":"Cyclic changes cx secretions","title":"Example of cervical secretion variations during a menstrual cycle","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of cervical secretion variations during a menstrual cycle</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1_single\" colspan=\"10\">&nbsp;</td>\n    <td class=\"subtitle1\" colspan=\"9\">Fertile</td>\n    <td class=\"subtitle1_single\" colspan=\"12\">&nbsp;</td>\n  </tr>\n  <tr>\n    <td colspan=\"2\" align=\"right\"><strong>Cycle day</strong></td>\n    <td>&nbsp;1</td>\n    <td>&nbsp;2</td>\n    <td>&nbsp;3</td>\n    <td>&nbsp;4</td>\n    <td>&nbsp;5</td>\n    <td>&nbsp;6</td>\n    <td>&nbsp;7</td>\n    <td>&nbsp;8</td>\n    <td>&nbsp;9</td>\n    <td>10</td>\n    <td>11</td>\n    <td>12</td>\n    <td>13</td>\n    <td>14</td>\n    <td>15</td>\n    <td>16</td>\n    <td>17</td>\n    <td>18</td>\n    <td>19</td>\n    <td>20</td>\n    <td>21</td>\n    <td>22</td>\n    <td>23</td>\n    <td>24</td>\n    <td>25</td>\n    <td>26</td>\n    <td>27</td>\n    <td>28</td>\n    <td>29</td>\n  </tr>\n  <tr>\n    <td colspan=\"2\" align=\"right\"><strong>Date</strong></td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n  </tr>\n  <tr>\n    <td rowspan=\"5\"><p><strong>Cervical secretions</strong></p>\n    <p><strong>(Feel, look and touch)</strong></p></td>\n  </tr>\n  <tr>\n    <td>Wet, slippery, transparent or stretchy</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n  </tr>\n  <tr>\n    <td>Thick, cloudy or sticky</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n  </tr>\n  <tr>\n    <td>Dry, no secretions seen or felt</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n  </tr>\n  <tr>\n    <td>Period</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td class=\"subtitle1_left\">&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n    <td>&nbsp;</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Unprotected intercourse should be avoided during menses, on preovulatory days following days with intercourse, on all days with wet, slippery, transparent or stretchy secretions, and for four days past the last day with wet secretions.</div><div class=\"graphic_reference\">Modified with permission from: The Institute for Reproductive Health, Georgetown University.</div><div id=\"graphicVersion\">Graphic 64637 Version 1.0</div></div></div>"},"64638":{"type":"graphic_figure","displayName":"Chromosome 13 in myeloma","title":"Chromosome 13 deletions in multiple myeloma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chromosome 13 deletions in multiple myeloma</div><div class=\"cntnt\"><img style=\"width:504px; height:331px;\" src=\"images/HEME/64638_Chromosome_13_in_myeloma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional cytogenetic analysis with G banding was performed in 106 patients with multiple myeloma. Each vertical line to the right of the figure (the long arm of chromosome 13) indicates the part of chromosome 13 that was found to be deleted in one patient. With the exception of eight patients, the minimal region of deletion overlap appears to be in the 13q14 region (red arrow).</div><div class=\"graphic_reference\">Reprinted with permission from Shaughnessy, J, et al. Blood 2000; 96:1505. Copyright 2000, American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 64638 Version 1.0</div></div></div>"},"64639":{"type":"graphic_table","displayName":"Abnormalities reported in patients with hematospermia","title":"Abnormalities reported in patients with hematospermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abnormalities reported in patients with hematospermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infections </td> </tr> <tr> <td class=\"indent1\">Chlamydia</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\"><em>Enterococcus faecalis</em></td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> </tr> <tr> <td class=\"indent1\">Schistosomiasis</td> </tr> <tr> <td class=\"indent1\">Trichomoniasis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Ureaplasma urealyticum</em></td> </tr> <tr> <td class=\"subtitle1_single\">Malignant tumors (urogenital) </td> </tr> <tr> <td class=\"indent1\">Bladder cancer</td> </tr> <tr> <td class=\"indent1\">Prostate adenocarcinoma</td> </tr> <tr> <td class=\"indent1\">Prostate sarcoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Testicular tumors</td> </tr> <tr> <td class=\"subtitle1_single\">Malignant tumors (metastatic) </td> </tr> <tr> <td class=\"indent1\">Melanoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Renal cell carcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Prostatic disorders </td> </tr> <tr> <td class=\"indent1\">Benign prostatic hypertrophy</td> </tr> <tr> <td class=\"indent1\">Prostatic calculi</td> </tr> <tr> <td class=\"indent1\">Prostatic telangiectasia</td> </tr> <tr> <td class=\"indent1\">Prostatic urethral hemangiomas</td> </tr> <tr> <td class=\"indent1\">Prostatic urethral polyps</td> </tr> <tr> <td class=\"indent1\">Prostatic utricle (or m&#252;llerian duct) cysts</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Prostatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Seminal vesicle disorders </td> </tr> <tr> <td class=\"indent1\">Adenomyosis</td> </tr> <tr> <td class=\"indent1\">Amyloidosis</td> </tr> <tr> <td class=\"indent1\">Calculi</td> </tr> <tr> <td class=\"indent1\">Cancer</td> </tr> <tr> <td class=\"indent1\">Cysts</td> </tr> <tr> <td class=\"indent1\">Dilated seminal vesicles</td> </tr> <tr> <td class=\"indent1\">Ectopic prostate tissue</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hemorrhage</td> </tr> <tr> <td class=\"subtitle1_single\">Spermatic cord and ejaculatory system disorders </td> </tr> <tr> <td class=\"indent1\">Cavernous hemangiomas</td> </tr> <tr> <td class=\"indent1\">Ejaculation duct obstruction</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Epididymitis</td> </tr> <tr> <td class=\"subtitle1_single\">Urethral disorders </td> </tr> <tr> <td class=\"indent1\">Ectopic prostate tissue</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Papillary urethritis</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular disorders </td> </tr> <tr> <td class=\"indent1\">Genitourinary varices</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Malignant hypertension</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Aspirin therapy</td> </tr> <tr> <td class=\"indent1\">Hyperuricemia</td> </tr> <tr> <td class=\"indent1\">Prothrombin deficiency</td> </tr> <tr> <td class=\"indent1\">von Willebrand disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64639 Version 5.0</div></div></div>"},"64640":{"type":"graphic_figure","displayName":"Auto PEEP trigger threshold","title":"Trigger threshold for auto-PEEP","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Trigger threshold for auto-PEEP</div><div class=\"cntnt\"><img style=\"width:481px; height:211px;\" src=\"images/PULM/64640_Auto_PEEP_trigger_threshold.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of auto-PEEP on elevation of the triggering threshold in a mechanically ventilated patient with obstructive airways disease. This&nbsp;figure representation shows airway pressure over time. The solid blue line demonstrates the circuit pressure as measured by the ventilator manometer, and the dashed red line is the alveolar pressure. In the absence of auto-PEEP, the sensitivity setting of -1 cm H<SUB>2</SUB>O would be achieved by the patient making inspiratory efforts at the end of expiration, when airway pressure is at its minimum. In the presence of auto-PEEP, alveolar pressure remains positive. In this setting, the patient's inspiratory effort needs to decrease airway pressure not only by the -1 cm H<SUB>2</SUB>O sensitivity set on the machine, but also by the amount of positive alveolar pressure (auto-PEEP). In this figure, the patient's inspiratory efforts are insufficient to trigger the ventilator, and the patient is \"locked out,\" being unable to get a breath because of an inability to overcome the elevated effective triggering threshold rendered by auto-PEEP.</div><div class=\"graphic_footnotes\">PEEP: positive end-expiratory pressure.</div><div class=\"graphic_reference\">Adapted from Puritan-Bennett 1994, Form AA-1888.</div><div id=\"graphicVersion\">Graphic 64640 Version 4.0</div></div></div>"},"64642":{"type":"graphic_table","displayName":"Clinical effects of blood alcohol concentration","title":"Clinical effects of blood alcohol concentration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical effects of blood alcohol concentration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Blood alcohol concentration</td> <td class=\"subtitle1\">Clinical effects</td> </tr> <tr> <td>20-50 mg/dL (4.4-11 mmol/L)</td> <td>Diminished fine motor coordination</td> </tr> <tr> <td>50-100 mg/dL (11-22 mmol/L</td> <td>Impaired judgement; impaired coordination</td> </tr> <tr> <td>100-150 mg/dL (22-33 mmol/L)</td> <td>Difficulty with gait and balance</td> </tr> <tr> <td>150-250 mg/dL (33-55 mmol/L)</td> <td>Lethargy; difficulty sitting upright without assistance</td> </tr> <tr> <td>300 mg/dL (66 mmol/L)</td> <td>Coma in the non-habituated drinker</td> </tr> <tr> <td>400 mg/dL (88 mmol/L)</td> <td>Respiratory depression</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Marx JA. Rosen's emergency medicine: concepts and clinical practice, 5th ed, Mosby, Inc., St. Louis 2002. p. 2513. Copyright &#169; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 64642 Version 4.0</div></div></div>"},"64643":{"type":"graphic_table","displayName":"Laboratory testing for CHI","title":"Laboratory testing for congenital hyperinsulinemia of infancy (also known as persistent hyperinsulinemic hypoglycemia of infancy)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory testing for congenital hyperinsulinemia of infancy (also known as persistent hyperinsulinemic hypoglycemia of infancy)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Result suggestive of CHI<br /> (for samples taken during a period of hypoglycemia)</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Blood</td> </tr> <tr> <td class=\"indent1\">Glucose</td> <td class=\"centered\">&#8595;</td> <td>&#60;40 mg/dL (2.2 mmol/L)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Insulin</td> <td class=\"centered\">&#8593;</td> <td>&#8805;2 mcU/mL (14 pmol/L)</td> <td>Normal or elevated plasma insulin levels at the time of hypoglycemia support the diagnosis of CHI, but undetectable levels do not exclude the diagnosis.<sup>[1]</sup> </td> </tr> <tr> <td class=\"indent1\">C-peptide</td> <td class=\"centered\">&#8593;</td> <td>&#8805;0.2 nmol/L (0.6 ng/mL)</td> <td>If C-peptide is low despite hyperinsulinemia, the possibility of exogenous administration of insulin should be considered.</td> </tr> <tr> <td class=\"indent1\">Free fatty acids</td> <td class=\"centered\">&#8595;</td> <td>&#60;1.0 mmol/L</td> <td>Somewhat higher values do not exclude the possibility of&nbsp;CHI.<sup><span style=\"font-size: 13px;\">[1]</span></sup></td> </tr> <tr> <td class=\"indent1\">Beta-hydroxybutyrate</td> <td class=\"centered\">&#8595;</td> <td>&#60;1.8 mmol/L</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Lactic acid</td> <td class=\"centered\">Normal</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Carnitine</td> <td class=\"centered\">Normal</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ammonia</td> <td class=\"centered\">&#8593; in HIHA form of PHHI</td> <td>&nbsp;</td> <td>Normal in other forms of CHI</td> </tr> <tr> <td class=\"indent1\">Growth hormone</td> <td class=\"centered\">&#8593;</td> <td>Usually &#62;10 mcg/L</td> <td>Elevated due to hypoglycemia; this result excludes growth hormone deficiency as a cause of hypoglycemia. However, a normal or low value is NOT diagnostic of growth hormone deficiency.</td> </tr> <tr> <td class=\"indent1\">Cortisol</td> <td class=\"centered\">&#8593;</td> <td>&nbsp;</td> <td>Elevated due to hypoglycemia; this result excludes cortisol deficiency as a cause of hypoglycemia. However, a normal or low value is NOT diagnostic of cortisol deficiency.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Glucagon stimulation test&nbsp;</td> </tr> <tr> <td class=\"indent1\">Glucose</td> <td class=\"centered\">&#8593;</td> <td>&#62;30 mg/dL increase from baseline</td> <td>During an episode of hypoglycemia, administer <span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">0.03 mg/kg glucagon IV, and measure blood glucose at 10, 20, and 30 minutes. </span></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Urine</td> </tr> <tr> <td class=\"indent1\">Ketones</td> <td class=\"centered\">Negative</td> <td>&nbsp;</td> <td>In some cases of CHI, ketonuria may be present despite an abnormally low plasma concentration of ketones, because the renal threshold for ketones is low</td> </tr> <tr> <td class=\"indent1\">C-peptide</td> <td class=\"centered\">&#8593;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CHI:&nbsp;congenital hyperinsulinemia of infancy (also known as persistent hyperinsulinemic hypoglycemia of infancy); HIHA: hyperinsulinism-hyperammonemia.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Ferrara C, Patel P, Becker S, et al. Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children. J Pediatr 2016; 168:212.</LI></OL></div><div id=\"graphicVersion\">Graphic 64643 Version 10.0</div></div></div>"},"64644":{"type":"graphic_figure","displayName":"Anatomic zones","title":"Anatomic zones of the abdominal cavity","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomic zones of the abdominal cavity</div><div class=\"cntnt\"><img style=\"width:542px; height:350px;\" src=\"images/EM/64644_Anatomic_zones.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64644 Version 3.0</div></div></div>"},"64646":{"type":"graphic_table","displayName":"Drugs that cause uricosuria","title":"Drugs which increase uric acid excretion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs which increase uric acid excretion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Agent(s)</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Primary uricosurics</td> <td>Probenecid, sulfinpyrazone*, benzbromarone*, lesinurad </td> <td>&nbsp;</td> </tr> <tr> <td>Urate oxidase (uricolytics)</td> <td>Pegloticase, rasburicase</td> <td>Converts uric acid to allantoin (inactive water soluble metabolite).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Drugs with secondary uricosuric effect</td> </tr> <tr> <td class=\"indent1\">ACE inhibitors</td> <td>Enalapril, captopril</td> <td>Other ACE inhibitors do not seem to increase uric acid excretion.</td> </tr> <tr> <td class=\"indent1\">Angiotensin II receptor blocker</td> <td>Losartan</td> <td>Only ARB that significantly lowers serum uric acid. May counteract uric acid increase due to thiazide or cyclosporine.</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers, dihydropyridine</td> <td>Amlodipine, felodipine, nitrendipine, nicardipine</td> <td>Shown to decrease serum uric acid in patients taking cyclosporine following renal graft.</td> </tr> <tr> <td class=\"indent1\">Fibric acid derivative</td> <td>Fenofibrate (micronized)</td> <td>Significant uricosuric effect; data are lacking on effect of other fibrates.</td> </tr> <tr> <td class=\"indent1\">Statins</td> <td>Atorvastatin</td> <td>Modest effect; studies of other statins demonstrated inconsistent or no effect.</td> </tr> <tr> <td class=\"indent1\">Anti-infectives</td> <td>Trimethoprim-sulfamethoxazole, ampicillin, rifampin, isoniazid</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hormone replacement therapy</td> <td>Estrogen</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Salicylates (high doses), aspirin, selected NSAIDs</td> <td>Diflunisal, aspirin (high dose &#62;3 g/day and low dose 75 mg/day), sulindac, phenylbutazone*</td> <td>Moderate doses of aspirin can cause uric acid retention.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not available in US. Limited availability in other countries.</div><div class=\"graphic_reference\">Reference: <br /><OL>&#xD;&#xA;<LI>Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect of serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11:4161.</LI></OL></div><div id=\"graphicVersion\">Graphic 64646 Version 5.0</div></div></div>"},"64649":{"type":"graphic_table","displayName":"Risks of external cephalic version","title":"Risks of external cephalic version, pooled risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risks of external cephalic version, pooled risk</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Outcome</td>\n\t    <td class=\"subtitle1\">Percent</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Overall risk of complications</td>\n\t    <td>6.1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Transient fetal heart rate changes</td>\n\t    <td>4.7</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Fetomaternal transfusion</td>\n\t    <td>0.9</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Emergency cesarean delivery</td>\n\t    <td>0.4</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Vaginal bleeding</td>\n\t    <td>0.3</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Ruptured membranes</td>\n\t    <td>0.2</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Fetal death</td>\n\t    <td>0.2</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Placental abruption</td>\n\t    <td>0.2</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Cord prolapse</td>\n\t    <td>0.2</td>\n\t  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=44364&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Risk_of_ECV.htm</title></head></div><div class=\"graphic_reference\">Data from: Grootscholten K, Kok M, Oei SG, et al. External cephalic version-related risks. A meta-analysis. Obstet Gynecol 2008; 112:1143.</div><div id=\"graphicVersion\">Graphic 64649 Version 3.0</div></div></div>"},"64650":{"type":"graphic_table","displayName":"Tumor skull base synd","title":"Tumor-related base of skull syndromes in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumor-related base of skull syndromes in cancer patients</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Syndrome\n   </td>\n   <td  class=\"subtitle1\">\n   Characteristics\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Orbital syndrome\n   </td>\n   <td>Increasing pain in the retroorbital and supraorbital regions of the affected eye</td>\n   </tr>\n   <tr>\n   <td>Associated problems include blurred vision, diplopia, proptosis, chemosis (conjunctival edema), external ophthalmoplegia, ipsilateral papilledema, and decreased sensation in the ophthalmic division of the trigeminal nerve</td>\n   </tr>\n   <tr>\n   <td>Parasellar syndrome</td>\n   <td>Neoplastic invasion in the parasellar region can lead to unilateral supraorbital and frontal headache, as well as diplopia</td>\n   </tr>\n   <tr>\n   <td>Middle cranial fossa syndrome</td>\n   <td>Pain and sensory changes in the distribution of the mandibular and maxillary divisions of the trigeminal nerve. May be associated with headache, diplopia, dysarthria, dysphagia, facial numbness, paresthesias, or pain referred to the cheek or jaw.</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Jugular foramen and hypoglossal syndrome\n   </td>\n   <td>Afffects the glossopharyngeal, vagus, and accessory nerves. Throat pain, hoarseness, dysphasia, deep aching in the ipsilateral mastoid region, and glossopharyngeal neuralgia with or without bradycardia and syncope.</td>\n   </tr>\n   <tr>\n   <td>Neurological signs may include Horner's syndrome and weakness of the palatal muscles, sternocleidomastoid, or trapezius muscles</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Occipital condyle syndrome\n   </td>\n   <td>Presents with severe unilateral occipital pain that is worsened by neck flexion, neck stiffness</td>\n   </tr>\n   <tr>\n   <td>Almost always includes concomitant involvement of hypoglossal canal leading to paresis and atrophy of ipsilateral tongue</td>\n   </tr>\n   <tr>\n   <td>Physical examination may reveal head tilt, limited movement of neck, tenderness to palpation over occipito-nuchal junction</td>\n   </tr>\n   <tr>\n   <td>Clivus syndrome</td>\n   <td>Severe headache maximally experienced at vertex and worse with neck flexion, sixth nerve palsy</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Sphenoid sinus syndrome\n   </td>\n   <td>Bifrontal headache radiating to the temples and retroorbital areas</td>\n   </tr>\n   <tr>\n   <td>May present with associated nasal congestion and diplopia from sixth nerve palsy</td>\n   </tr>\n   <tr>\n   <td>Fracture of the odontoid process (dens)</td>\n   <td>Posterior headache, worse on neck flexion. Instability of the cervical spine or mass effect from tumor may cause spinal cord or brainstem compression.</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 64650 Version 1.0</div></div></div>"},"64651":{"type":"graphic_figure","displayName":"Positions of anterior dislocations of the shoulder","title":"Positions of anterior dislocations of the shoulder","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Positions of anterior dislocations of the shoulder</div><div class=\"cntnt\"><img style=\"width:541px; height:482px;\" src=\"images/EM/64651_Ant_shoulder_disloc_postns.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64651 Version 4.0</div></div></div>"},"64652":{"type":"graphic_picture","displayName":"Hands in acromegaly","title":"Hands in acromegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hands in acromegaly</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/ENDO/64652_Hands_in_acromegaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling of the hands in a patient with acromegaly, which resulted in an increase in glove size and the need to remove rings.</div><div class=\"graphic_reference\">Courtesy of Verna Wright, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 64652 Version 1.0</div></div></div>"},"64653":{"type":"graphic_picture","displayName":"Endosc gastric adenoma","title":"Gastric adenoma (noninvasive intraepithelial neoplasia)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric adenoma (noninvasive intraepithelial neoplasia)</div><div class=\"cntnt\"><img style=\"width:360px; height:309px;\" src=\"images/GAST/64653_Endosc_gastric_adenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large gastric adenoma on the lesser curve of the distal corpus.</div><div class=\"graphic_reference\">Courtesy of Jin-Seok Jang, MD.</div><div id=\"graphicVersion\">Graphic 64653 Version 1.0</div></div></div>"},"64655":{"type":"graphic_form","displayName":"Tinnitus handicap inventory","title":"Tinnitus handicap inventory questionnaire","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Tinnitus handicap inventory questionnaire</div><div class=\"cntnt\"><img style=\"width:542px; height:582px;\" src=\"images/PC/64655_Tinnitus_handicap_inventory.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Clinical Health Services, Inc. (http://www.clinicalhealthservices.com).</div><div id=\"graphicVersion\">Graphic 64655 Version 2.0</div></div></div>"},"64657":{"type":"graphic_figure","displayName":"Survival after lung transplant","title":"Improved survival after lung transplantation","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Improved survival after lung transplantation</div><div class=\"cntnt\"><img style=\"width:676px; height:401px;\" src=\"images/PULM/64657_Survival_aftr_lng_transplnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival following lung transplantation was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients.<br />The median survival is the estimated time point at which 50% of all of the recipients have died. For patients who were transplanted in 2005 or subsequently, the median survival is 6.1 years.<br />The conditional median survival is the estimated time point at which 50% of the recipients who survive to at least one year have died. Because the decline in survival is greatest during the first year following transplantation, the conditional survival provides a more realistic expectation of survival time for recipients who survive the early post-transplant period.<br />Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffe's method.</div><div class=\"graphic_reference\">Reproduced from: Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Adult Lung and Heart-Lung Transplant Report-2014; Focus Theme: Retransplantation. J Heart Lung Transplant 2014; 33:1009. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64657 Version 5.0</div></div></div>"},"64659":{"type":"graphic_table","displayName":"Causes of vaginal bleeding in children and adolescents","title":"Causes of vaginal bleeding in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of vaginal bleeding in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">At any time</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Before normal menarche</td> </tr> <tr> <td class=\"sublist2_start\">Hormonal</td> </tr> <tr> <td class=\"sublist2\">Neonatal hormonal withdrawal bleeding</td> </tr> <tr> <td class=\"sublist2\">Exogenous estrogen</td> </tr> <tr> <td class=\"sublist2\">Precocious puberty</td> </tr> <tr> <td class=\"sublist2_start\">Nonhormonal</td> </tr> <tr> <td class=\"sublist2\">Urethral prolapse</td> </tr> <tr> <td class=\"sublist2\">Genital warts</td> </tr> <tr> <td class=\"sublist2\">Lichen sclerosus</td> </tr> <tr> <td class=\"sublist2\">Infectious vaginitis</td> </tr> <tr> <td class=\"sublist2\">Foreign body</td> </tr> <tr> <td class=\"subtitle1_single\">After menarche</td> </tr> <tr> <td class=\"sublist2_start\">Pregnancy*</td> </tr> <tr> <td class=\"sublist2\">Ectopic pregnancy</td> </tr> <tr> <td class=\"sublist2\">Spontaneous abortion</td> </tr> <tr> <td class=\"sublist2\">Placenta previa</td> </tr> <tr> <td class=\"sublist2\">Abruptio placentae</td> </tr> <tr> <td class=\"indent1\">Abnormal uterine bleeding (most common conditions in adolescents: delayed pubertal maturation, polycystic ovary syndrome, or caused by hormonal contraception)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Pelvic infection</td> </tr> <tr> <td class=\"indent1\">Bleeding disorder (especially platelet dysfunction, von Willebrand disease, or factor deficiency)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on vaginal bleeding during pregnancy.<br />&para; Refer to UpToDate topics on abnormal uterine bleeding in the adolescent.</div><div class=\"graphic_reference\">Reproduced with permission from: Paradise JE. Vaginal bleeding. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 64659 Version 20.0</div></div></div>"},"64660":{"type":"graphic_figure","displayName":"Valvotomy in mitral stenosis","title":"Hemodynamic improvement after valvotomy in mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemodynamic improvement after valvotomy in mitral stenosis</div><div class=\"cntnt\"><img style=\"width:362px; height:240px;\" src=\"images/CARD/64660_Valvotomy_in_mitral_stenosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ventricular (LV) and left atrial (LA) pressures before and after balloon mitral valvotomy. After valvotomy, there is a fall in left atrial pressure and a substantial reduction in the transmitral pressure gradient (arrow). The cardiac output increased from 5.9 to 7.4 L/min.</div><div class=\"graphic_reference\">Courtesy of John D Carroll, MD.</div><div id=\"graphicVersion\">Graphic 64660 Version 1.0</div></div></div>"},"64661":{"type":"graphic_algorithm","displayName":"Management of plasma lactates","title":"Algorithm for the management of elevated plasma lactates","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for the management of elevated plasma lactates</div><div class=\"cntnt\"><img style=\"width:379px; height:304px;\" src=\"images/ID/64661_Management_of_plasma_lactat.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Kees Brinkman, MD.</div><div id=\"graphicVersion\">Graphic 64661 Version 2.0</div></div></div>"},"64665":{"type":"graphic_table","displayName":"Frequency signs symptoms HELLP","title":"Reported frequency of signs and symptoms of HELLP syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reported frequency of signs and symptoms of HELLP syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Sign/symptom </td> <td class=\"subtitle1\">Frequency, percent </td> </tr> <tr> <td>Proteinuria</td> <td>86 to 100</td> </tr> <tr> <td>Hypertension</td> <td>82 to 88</td> </tr> <tr> <td>Right upper quadrant/epigastric pain</td> <td>40 to 90</td> </tr> <tr> <td>Nausea, vomiting</td> <td>29 to 84</td> </tr> <tr> <td>Headache</td> <td>33 to 61</td> </tr> <tr> <td>Visual changes</td> <td>10 to 20</td> </tr> <tr> <td>Jaundice</td> <td>5</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64665 Version 2.0</div></div></div>"},"64666":{"type":"graphic_table","displayName":"Selected translocations in sarcomas","title":"Selected translocations associated with sarcomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected translocations associated with sarcomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Translocation </td> <td class=\"subtitle1\">Genes </td> <td class=\"subtitle1\" colspan=\"3\">Type of fusion gene </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ewing's sarcoma (OMIM#133450) </td> </tr> <tr> <td class=\"indent1\">t(11;22)(q24;q12) </td> <td><em>EWSR1-FLI1</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(21;22)(q22;q12) </td> <td><em>EWSR1-ERG</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(7;22)(p22;q12) </td> <td><em>EWSR1-ETV1</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(17;22)(q12;q12) </td> <td><em>EWSR1-ETV4</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(2;22)(q35;q12) </td> <td><em>EWSR1-FEV</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(2;16)(q35;p11)</td> <td><em>FUS-FEV</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(16;21)(p11;q24)</td> <td><em>FUS-ERG</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ewing-like undifferentiated sarcoma (OMIM#300485) </td> </tr> <tr> <td class=\"indent1\">t(X;X)(p11;p11)</td> <td><em>BCOR-CCNB3</em></td> <td colspan=\"3\">Cell cycle progression </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Clear cell sarcoma (OMIM#123803)</td> </tr> <tr> <td class=\"indent1\">t(12;22)(q13;q12) </td> <td><em>EWSR1-ATF1</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Desmoplastic small round&nbsp;cell tumor of the abdomen (OMIM#133450) </td> </tr> <tr> <td class=\"indent1\">t(11;22)(p13;q12) </td> <td><em>EWSR1-WT1</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Myxoid chondrosarcoma (OMIM#600542) </td> </tr> <tr> <td class=\"indent1\">t(9;22)(q22-31;q11-12) </td> <td><em>EWSR1-NR4A3</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Myxoid liposarcoma (OMIM#126337, #137070) </td> </tr> <tr> <td class=\"indent1\">t(12;16)(q13;p11) </td> <td><em>FUS-CHOP </em>(<em>FUS-DDIT3</em>)</td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\"><span class=\"indent1\"></span><span class=\"indent1\"></span><span class=\"indent2\"></span>t(12;22)(q13;q12)</td> <td><em>EWSR1-CHOP</em> (<em>EWSR1-DDIT3</em>)</td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Alveolar rhabdomyosarcoma (OMIM#268220) </td> </tr> <tr> <td class=\"indent1\">t(2;13)(q35;q14) </td> <td><em>PAX3-FOXO1A</em>*</td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(1;13)(p36;q14) </td> <td><em>PAX7-FOXO1A</em>*</td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Congenital infantile spindle cell rhabdomyosarcoma</td> </tr> <tr> <td class=\"indent1\">t(6;6)(q24.1;q22.1)</td> <td><em>VGLL2-CITED2</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(6;8)(q22.1;q13.3)&nbsp;</td> <td><em>VGLL2-NC0A2</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(11;8)(p15.3;q13.3)</td> <td><em>TEAD1-NCOA2</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(2;8)(q36;q13.3)</td> <td><em>PAX3-NCOA2</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"indent1\">t(6;8)(p21.1;q13.3)</td> <td><em>SRF-NCOA2</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Synovial sarcoma (OMIM#312820) </td> </tr> <tr> <td class=\"indent1\">t(X;18)(p11;q11) </td> <td><em>SS18-SSX1</em>, <em>SSX2</em>, or <em>SSX4</em></td> <td colspan=\"3\">Remodels chromatin to alter transcription</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Dermatofibrosarcoma protuberans (OMIM#607907) </td> </tr> <tr> <td class=\"indent1\">t(17;22)(q22;q13) </td> <td><em>COL1A1-PDGFB </em></td> <td colspan=\"3\">Growth factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Congenital fibrosarcoma (OMIM#191316) </td> </tr> <tr> <td class=\"indent1\">t(12;15)(p13;q25) </td> <td><em>ETV6-NTRK3</em></td> <td colspan=\"3\">Transcription factor receptor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inflammatory myofibroblastic tumor </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">2p23 rearrangements </td> <td><em>TMP3-ALK</em></td> <td colspan=\"3\">Growth factor receptor</td> </tr> <tr> <td><em>TMP4-ALK</em></td> <td colspan=\"3\">Growth factor receptor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Alveolar soft part sarcoma (OMIM#606243) </td> </tr> <tr> <td class=\"indent1\">t(X;17)(p11.2;q25) </td> <td><em>ASPL-TFE3</em></td> <td colspan=\"3\">Transcription factor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Solitary fibrous tumor&nbsp;(OMIM#602381)</td> </tr> <tr> <td class=\"indent1\">&nbsp;Inversion 12q13</td> <td><em>&nbsp;NAB2-STAT</em>6</td> <td colspan=\"3\">Transcription factor&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Epithelioid hemangioendothelioma</td> </tr> <tr> <td class=\"indent1\">&nbsp;t(1;3)(p36;q25)</td> <td><em>&nbsp;WWTR1-CAMTA1</em></td> <td colspan=\"3\">&nbsp;Transcription factor</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note that for some tumors, notably Ewing's sarcoma, multiple variant translocations have been observed involving related genes.</div><div class=\"graphic_footnotes\">OMIM: Online Mendelian Inheritance in Man, available at http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim.<br />* <EM>FOXO1A</EM> gene, also known as the<EM> FKHR</EM> gene.</div><div class=\"graphic_reference\">Adapted with permission from: Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nature Reviews: Cancer 2003; 3:685. Copyright Â© 2003 MacMillan Magazines Ltd.</div><div class=\"contractual\"><br/><a href=\"http://www.nature.com/\">http://www.nature.com</a></div><div id=\"graphicVersion\">Graphic 64666 Version 6.0</div></div></div>"},"64669":{"type":"graphic_table","displayName":"Antibiotic regimens endometritis","title":"Sample antibiotic regimens for endometritis alternatives to the \"Gold Standard\" gentamicin and clindamycin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample antibiotic regimens for endometritis alternatives to the &quot;Gold Standard&quot; gentamicin and clindamycin</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Ampicillin-sulbactam 3 grams IV Q 6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ticarcillin-clavulanate 3.1 grams IV Q 4 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cefoxitin 2 grams IV Q 6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ceftriaxone 2 grams IV Q 24 hours plus metronidazole 500 mg PO or IV Q 8 hours*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Levofloxacin 500 mg IV Q 24 hours plus metronidazole 500 mg PO or IV Q 8 hours*</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=21665&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Antibiotic_regimens_endomet.htm</title></head></div><div class=\"graphic_lgnd\">If chlamydia infection is suspected, azithromycin 1 gram PO for one dose should be added to the regimen.</div><div class=\"graphic_footnotes\">* Should not be given to breastfeeding mothers.</div><div id=\"graphicVersion\">Graphic 64669 Version 3.0</div></div></div>"},"64670":{"type":"graphic_figure","displayName":"Decision tree example","title":"Evaluation of a simple decision tree","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of a simple decision tree</div><div class=\"cntnt\"><img style=\"width:304px; height:265px;\" src=\"images/PC/64670_Decision_tree_example.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The expected value of any node is simply the probability-weighted average of the outcomes across all of the branches of the node. This is calculated by taking the sum of each branch's value times its probability. For Choice 1 above, the average life expectancy of a cohort of patients undergoing that therapy would consist of the combination of 45 percent who lived 10 years and 55 percent who lived 12 years, for an average of 11.1 years.</div><div id=\"graphicVersion\">Graphic 64670 Version 1.0</div></div></div>"},"64671":{"type":"graphic_picture","displayName":"Straight leg raise","title":"Straight leg raise maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Straight leg raise maneuver</div><div class=\"cntnt\"><img style=\"width:360px; height:284px;\" src=\"images/EM/64671_Straight_leg_raise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The straight leg raise maneuver is used to determine the presence of radiculopathy. The maneuver can be performed in the sitting or lying position. The leg is gradually moved to the fully extended position. Ankle dorsiflexion can be added in full extension to bring out subtle cases. A positive maneuver reproduces the patient's pain; the test is inconclusive if tightness or pain is felt only in the hamstring area.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 64671 Version 2.0</div></div></div>"},"64672":{"type":"graphic_table","displayName":"Criteria for extubation or decannulation to continuous NPPV","title":"Indications and criteria for extubation or decannulation of patients unable to sustain autonomous breathing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications and criteria for extubation or decannulation of patients unable to sustain autonomous breathing</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>The patient is mentally competent, cooperative, and not using heavy sedation or narcotics</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Supplemental oxygen therapy is avoided or minimized</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>SaO<sub>2</sub> is maintained above 95 percent by aggressive airway secretion elimination and assisted ventilation as necessary</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bulbar muscle function is sufficient so that aspiration of airway secretions does not cause O<sub>2</sub> desaturation below 95 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>There is no history of substance abuse or uncontrollable seizures</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pulmonary compliance is adequate for noninvasive IPPV to provide normal alveolar ventilation at interface pressures under 40 cm H<sub>2</sub>O</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>There are no conditions which interfere with the use of IPPV interfaces, ie, facial fractures, inadequate bite or neck rotation for mouthpiece entry, presence of a nasogastric tube or a beard that hampers airtight interface seal, etc</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 64672 Version 2.0</div></div></div>"},"64673":{"type":"graphic_figure","displayName":"NSCLC adrenal met PETCT","title":"Adrenal metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adrenal metastasis</div><div class=\"cntnt\"><img style=\"width:396px; height:290px;\" src=\"images/PULM/64673_NSCLC_adrenal_met_PETCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PET-CT showing intense metabolic activity in the right adrenal gland in a 76-year-old with a right paratracheal mass. CT guided adrenal biopsy confirmed stage IV non-small cell carcinoma of the lung.</div><div id=\"graphicVersion\">Graphic 64673 Version 1.0</div></div></div>"},"64674":{"type":"graphic_diagnosticimage","displayName":"Endomicroscopic image of neoplasia in Barretts esophagus","title":"Endomicroscopic image of neoplasia in Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endomicroscopic image of neoplasia in Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:286px; height:571px;\" src=\"images/GAST/64674_Endocyto_img_neopl_Barr_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endomicroscopic image of neoplasia arising from Barrett's esophagus (Panel A) and benign Barrett's metaplasia (Panel B). Cancerous tissue shows a loss of epithelial structures. The epithelium becomes dark and the vasculature is irregular with leakage of fluorescein. Benign mucosa is characterized by a more tubular shaped pattern with a regular and constant width of the epithelial layer. In addition, goblet cells (dark spots within the epithelial layer) can be clearly identified.</div><div class=\"graphic_reference\">Courtesy of Alexander Meining, MD.</div><div id=\"graphicVersion\">Graphic 64674 Version 3.0</div></div></div>"},"64675":{"type":"graphic_picture","displayName":"Plantar ecchymosis sign","title":"Plantar ecchymosis sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantar ecchymosis sign</div><div class=\"cntnt\"><img style=\"width:242px; height:396px;\" src=\"images/EM/64675_Plantar_ecchymosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ecchymosis along the plantar aspect of the midfoot is an important clinical finding in subtle Lisfranc tarsometatarsal injuries.</div><div class=\"graphic_reference\">Reproduced with permission from: Ross G, Cronin R, Hauzenblas J, Juliano P. Plantar ecchymosis sign: a clinical aid to diagnosis of occult Lisfranc tarsometatarsal injuries. J Orthop Trauma 1996; 10:119. Copyright Â© 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64675 Version 10.0</div></div></div>"},"64676":{"type":"graphic_picture","displayName":"Pink colonies Rhodococcus","title":"Salmon-pink colonies visible 4 days after incubation of the aspirated pus obtained from the patient's cavitary lung mass at 37Â°C on chocolate agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salmon-pink colonies visible 4 days after incubation of the aspirated pus obtained from the patient's cavitary lung mass at 37&#176;C on chocolate agar</div><div class=\"cntnt\"><img style=\"width:396px; height:384px;\" src=\"images/ID/64676_Pink_colonies_Rhodococcus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Mackowiak, PA. A 40-year-old man with cough and fever. Clin Infect Dis 2007; 44:1461. Copyright &#169;2007 The University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 64676 Version 1.0</div></div></div>"},"64677":{"type":"graphic_table","displayName":"Causes of lymphedema","title":"Causes of lymphedema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of lymphedema</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Primary lymphedema\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Congenital</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Precox (adolescence)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tarda (adulthood)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Secondary lymphedema\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Malignancy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Recurrent cellulitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Connective tissue disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Infection (filariasis)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Contact dermatitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lymphatic damage (surgery, radiation therapy, burns, etc)</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 64677 Version 1.0</div></div></div>"},"64678":{"type":"graphic_figure","displayName":"Preventive care by nephrologists","title":"Comparison of preventive care provided by nephrologists and internists","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Comparison of preventive care provided by nephrologists and internists</div><div class=\"cntnt\"><img style=\"width:501px; height:282px;\" src=\"images/NEPH/64678_Primary_care_by_nephrologis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A comparison of the results of two surveys suggests that nephrologists provide routine preventive primary care at a rate comparable to that reported by general internists.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Bender FH, Holley JL. Most nephrologists are primary care providers for chronic dialysis patients: Results of a national survey. Am J Kidney Dis 1996; 28:67</LI>&#xD;&#xA;<LI>Schwartz JS, Lewis CE, Clancy C, et al. Internists' practices in health promotion and disease prevention: A survey. Ann Intern Med 1991; 114:46.</LI></UL></div><div id=\"graphicVersion\">Graphic 64678 Version 4.0</div></div></div>"},"64679":{"type":"graphic_picture","displayName":"Nonorganic ptosis right lid","title":"Nonorganic ptosis of the right upper lid","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Nonorganic ptosis of the right upper lid</div><div class=\"cntnt\"><img style=\"width:468px; height:296px;\" src=\"images/NEURO/64679_Nonorg_ptosis_rt_lid_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrary to expected, the patient is raising the left eyebrow and depressing the right eyebrow.</div><div class=\"graphic_reference\">Courtesy of Michael S Lee, MD.</div><div id=\"graphicVersion\">Graphic 64679 Version 2.0</div></div></div>"},"64680":{"type":"graphic_picture","displayName":"Acquired ichthyosis","title":"Acquired ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Acquired ichthyosis</div><div class=\"cntnt\"><img style=\"width:472px; height:217px;\" src=\"images/ONC/64680_Acquired_ichthyosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe scaling of the skin with hyperkeratosis on the body (panel A) and soles of the feet (panel B) in a patient with Hodgkins disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Rizos E, Milionis RH, Pavlidis N Elisaf MS. Acquired icthyosis: A paraneoplastic skin manifestation of Hodgkin's disease.&nbsp;Lancet Oncol 2002; 3:727. Copyright Â© 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 64680 Version 3.0</div></div></div>"},"64682":{"type":"graphic_figure","displayName":"Dissection along the latissimus dorsi muscle","title":"Dissection along the latissimus dorsi muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection along the latissimus dorsi muscle</div><div class=\"cntnt\"><img style=\"width:418px; height:383px;\" src=\"images/SURG/64682_Dissect_lat_dorsi_musc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pectoralis muscle has been exposed and retracted medially, and dissection is carried out on the anterior surface of the latissimus dorsi muscle as it courses superiorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Harris JR, Lippman ME, MorrowM, Osborne CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64682 Version 2.0</div></div></div>"},"64683":{"type":"graphic_table","displayName":"Dyspnea onset","title":"Dyspnea onset","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dyspnea onset</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Acute onset dyspnea\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aspirated foreign body</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Airway trauma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Direct pulmonary injury</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anaphylaxis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Angioedema</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Flash pulmonary edema</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary embolism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary hemorrhage</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pneumothorax</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cardiac arrhythmia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute coronary syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cardiac tamponade*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Organophosphate poisoning</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hyperventilation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anxiety attack</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Gradual onset dyspnea\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pharyngeal/neck infections</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sepsis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>High output heart failure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>HF exacerbation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>COPD exacerbations</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Asthma exacerbations*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pleural effusion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lung tumor</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>ARDS</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Neuromuscular disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Carbon monoxide poisoning</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diabetic ketoacidosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Salicylate poisoning or other toxin-related acidosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pregnancy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cardiomyopathy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Valvular dysfunction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ascites</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute chest syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intraabdominal process (eg, infection, obstruction, ischemic bowel)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Massive obesity</td>\r\n  \r\n   </tr>\r\n  \r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">*May be acute or gradual in onset.</div><div id=\"graphicVersion\">Graphic 64683 Version 1.0</div></div></div>"},"64684":{"type":"graphic_table","displayName":"Cand genes function T2 DM","title":"Candidate genes and genetic polymorphisms associated with type 2 diabetes mellitus (ordered by chromosome (Chr))","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Candidate genes and genetic polymorphisms associated with type 2 diabetes mellitus (ordered by chromosome (Chr))</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t  <td class=\"subtitle1\">Marker</td>\n\t  <td class=\"subtitle1\">Chr</td>\n\t  <td class=\"subtitle1\">Description</td>\n\t  <td class=\"subtitle1\">Gene region</td>\n\t  <td class=\"subtitle1\">Function</td>\n\t </tr>\n\t <tr>\n\t  <td>rs10923931</td>\n\t  <td>1</td>\n\t  <td>Intronic</td>\n\t  <td><em>NOTCH2</em></td>\n\t  <td>Transmembrane receptor implicated in pancreatic organogenesis</td>\n\t </tr>\n\t <tr>\n\t  <td>rs7578597</td>\n\t  <td>2</td>\n\t  <td>Missense: T1187A</td>\n\t  <td><em>THADA</em></td>\n\t  <td>Thyroid adenoma; associates with PPAR<sub>&#915;</sub></td>\n\t </tr>\n\t <tr>\n\t  <td>rs4607103</td>\n\t  <td>3</td>\n\t  <td>38 kb upstream</td>\n\t  <td><em>ADAMTS9</em></td>\n\t  <td>Secreted metalloprotease expressed in muscle and pancreas</td>\n\t </tr>\n\t <tr>\n\t  <td>rs4402960</td>\n\t  <td>3</td>\n\t  <td>Intronic</td>\n\t  <td><em>IGF2BP2</em></td>\n\t  <td>Growth factor binding protein; pancreatic development</td>\n\t </tr>\n\t <tr>\n\t  <td>rs1801282</td>\n\t  <td>3</td>\n\t  <td>Missense: P12A</td>\n\t  <td><em>PPARG</em></td>\n\t  <td>Transcription factor involved in adipocyte development</td>\n\t </tr>\n\t <tr>\n\t  <td>rs10010131</td>\n\t  <td>4</td>\n\t  <td>Intron-exon junction</td>\n\t  <td><em>WFS1</em></td>\n\t  <td>Endoplasmic reticulum transmembrane protein</td>\n\t </tr>\n\t <tr>\n\t  <td>rs7754840</td>\n\t  <td>6</td>\n\t  <td>Intronic</td>\n\t  <td><em>CDKAL1</em></td>\n\t  <td>Homologous to CDK5RAP1, CDK5 inhibitor; islet glucotoxicity sensor</td>\n\t </tr>\n\t <tr>\n\t  <td>rs864745</td>\n\t  <td>7</td>\n\t  <td>Intronic</td>\n\t  <td><em>JAZF1</em></td>\n\t  <td>Transcriptional repressor; associated with prostate cancer</td>\n\t </tr>\n\t <tr>\n\t  <td>rs13266634</td>\n\t  <td>8</td>\n\t  <td>Missense: R325W</td>\n\t  <td><em>SLC30A8</em></td>\n\t  <td>&amp;<sub>&#946;</sub>-cell zinc transporter ZnT8; insulin storage and secretion</td>\n\t </tr>\n\t <tr>\n\t  <td>rs10811661</td>\n\t  <td>9</td>\n\t  <td>125 kb upstream</td>\n\t  <td><em>CDKN2A/B</em></td>\n\t  <td>Cyclin-dependent kinase inhibitor and p15 tumor suppressor; islet development</td>\n\t </tr>\n\t <tr>\n\t  <td>rs12779790</td>\n\t  <td>10</td>\n\t  <td>Intergenic region</td>\n\t  <td><em>CDC123-CAMK1D</em></td>\n\t  <td>Cell cycle/protein kinase</td>\n\t </tr>\n\t <tr>\n\t  <td>rs7903146</td>\n\t  <td>10</td>\n\t  <td>Intronic</td>\n\t  <td><em>TCF7L2</em></td>\n\t  <td>Transcription factor; transactivates proglucagon and insulin genes</td>\n\t </tr>\n\t <tr>\n\t  <td>rs1111875</td>\n\t  <td>10</td>\n\t  <td>7.7 kb downstream</td>\n\t  <td><em>HHEX</em></td>\n\t  <td>Transcription factor involved in pancreatic development</td>\n\t </tr>\n\t <tr>\n\t  <td>rs5219</td>\n\t  <td>11</td>\n\t  <td>Missense: E23K</td>\n\t  <td><em>KCNJ11</em></td>\n\t  <td>Kir6.2 potassium channel; risk allele impairs insulin secretion</td>\n\t </tr>\n\t <tr>\n\t  <td>rs7961581</td>\n\t  <td>12</td>\n\t  <td>Intronic</td>\n\t  <td><em>TSPAN8-LGR5</em></td>\n\t  <td>Cell surface glycoprotein implicated in GI cancers</td>\n\t </tr>\n\t <tr>\n\t  <td>rs8050136</td>\n\t  <td>16</td>\n\t  <td>Intronic</td>\n\t  <td><em>FTO</em></td>\n\t  <td>Alters BMI in general population</td>\n\t </tr>\n\t <tr>\n\t  <td>rs757210</td>\n\t  <td>17</td>\n\t  <td>Intronic</td>\n\t  <td><em>HNF1B</em></td>\n\t  <td>Transcription factor involved in pancreatic development</td>\n\t </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Florez JC. The genetics of type 2 diabetes: A realistic appraisal in 2008. J Clin Endocrine Metab 2008; 93:4633. http://jcem.endojournals.org/. Copyright &#169; 2008 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 64684 Version 6.0</div></div></div>"},"64685":{"type":"graphic_table","displayName":"Drugs prevention osteoporosis","title":"Available FDA-approved medications for the prevention of osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available FDA-approved medications for the prevention of osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td>Estrogens</td> <td>Many</td> <td>Variable</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Bisphosphonates</td> <td>Alendronate</td> <td>35 mg/week or 5 mg/day</td> </tr> <tr> <td>Risedronate</td> <td>35 mg/week or 5 mg/day</td> </tr> <tr> <td>Ibandronate</td> <td>150 mg/month</td> </tr> <tr> <td>Zoledronic acid</td> <td>5 mg IV once every two years</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Selective estrogen receptor modulators (SERMs)</td> <td>Raloxifene</td> <td>60 mg/day</td> </tr> <tr> <td>Bazedoxifene - conjugated equine estrogen</td> <td>20 mg/0.45 mg daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div id=\"graphicVersion\">Graphic 64685 Version 5.0</div></div></div>"},"64686":{"type":"graphic_table","displayName":"General screening ECG","title":"Criteria for a positive 12-lead ECG","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for a positive 12-lead ECG</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">P wave</td> </tr> <tr> <td class=\"indent1\">Left atrial enlargement: negative portion of the P wave in lead V1 &#8805;0.1 mV in depth and &#8805;0.04 in duration</td> </tr> <tr> <td class=\"indent1\">Right atrial enlargement: peaked P wave in leads II and III or V1 &#8805;0.25 mV in amplitude</td> </tr> <tr> <td class=\"subtitle1_single\">QRS complex</td> </tr> <tr> <td class=\"indent1\">Frontal plane axis deviation: right &#8805;+120&ordm; or left &ndash;30&ordm; to &ndash;90&ordm;</td> </tr> <tr> <td class=\"indent1\">Increased voltage: amplitude of R or S wave in a standard lead &#8805;2 mV, S wave in lead V1 or V2 &#8805;3 mV, or R wave in lead V5 or V6 &#8805;3 mV</td> </tr> <tr> <td class=\"indent1\">Abnormal Q waves &#8805;0.04 s in duration or &#8805;25 percent of the height of the ensuing R wave or QS pattern in two or more leads</td> </tr> <tr> <td class=\"indent1\">Right or left bundle branch block with QRS duration &#8805;0.12 s</td> </tr> <tr> <td class=\"indent1\">R or R' wave in lead V1 &#8805;0.5 mV in amplitude and R/S ratio &#8805;1</td> </tr> <tr> <td class=\"subtitle1_single\">ST-segment, T-waves, and QT interval</td> </tr> <tr> <td class=\"indent1\">ST-segment depression or T-wave flattening or inversion in two or more leads</td> </tr> <tr> <td class=\"indent1\">Prolongation of heart rate corrected QT interval &#62;0.44 s in males and &#62;0.46 s in females</td> </tr> <tr> <td class=\"subtitle1_single\">Rhythm and conduction abnormalities</td> </tr> <tr> <td class=\"indent1\">Premature ventricular beats or more severe ventricular arrhythmias</td> </tr> <tr> <td class=\"indent1\">Supraventricular tachycardias, atrial flutter, or atrial fibrillation</td> </tr> <tr> <td class=\"indent1\">Short PR interval (&#60;0.12 s) with or without 'delta' wave</td> </tr> <tr> <td class=\"indent1\">Sinus bradycardia with resting heart rate &#8804;40 beats/min*</td> </tr> <tr> <td class=\"indent1\">First (PR &#8805;0.21 s<sup>&#182;</sup>), second, or third degree atrioventricular block</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Increasing less than 100 beats/min during limited exercise test.<br />&para; Not shortening with hyperventilation or limited exercise test.</div><div class=\"graphic_reference\">Reproduced with permission from: Corrado D, Pelliccia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:516. Copyright &copy;2005 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 64686 Version 4.0</div></div></div>"},"64687":{"type":"graphic_waveform","displayName":"Intermediate case 4","title":"Intermediate case 4","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intermediate case 4</div><div class=\"cntnt\"><img style=\"width:351px; height:283px;\" src=\"images/CARD/64687_Intermediate_case_4.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64687 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"64690":{"type":"graphic_picture","displayName":"Reynders Noppen Tygon stent","title":"Reynders-Noppen tygon tracheal stent with screw threads","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reynders-Noppen tygon tracheal stent with screw threads</div><div class=\"cntnt\"><img style=\"width:370px; height:209px;\" src=\"images/PULM/64690_Reynders_Noppen_Tygon_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">More rigid than the silicone stents, placement requires a specific introducer.</div><div id=\"graphicVersion\">Graphic 64690 Version 2.0</div></div></div>"},"64691":{"type":"graphic_diagnosticimage","displayName":"CT of hepatosplenic candidiasis","title":"Hepatosplenic candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic candidiasis</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/ID/64691_HS_candidiasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple &quot;punched-out&quot; lesions in the liver, spleen, and kidneys in a patient with chronic disseminated candidiasis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rolston K, Bodey GP. Infections in Patients With Cancer. In: Cancer Medicine, 8th ed, Hong WK, Bast RC Jr, Hait W, et al (Eds), People's Medical Publishing House, 2010. Copyright Â© 2010 PMPH-USA, Ltd.</div><div id=\"graphicVersion\">Graphic 64691 Version 6.0</div></div></div>"},"64692":{"type":"graphic_diagnosticimage","displayName":"Pneumonia bulging fissure","title":"Pneumonia bulging fissure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumonia bulging fissure</div><div class=\"cntnt\"><img style=\"width:360px; height:449px;\" src=\"images/ID/64692_Pneumonia_bulging_fissure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph&nbsp;from a 55-year-old female with bacteremic pneumococcal pneumonia. Shows a dense left lower lobe opacity with a bulging fissure.</div><div class=\"graphic_reference\">Courtesy of Thomas J Marrie, MD.</div><div id=\"graphicVersion\">Graphic 64692 Version 5.0</div></div></div>"},"64696":{"type":"graphic_diagnosticimage","displayName":"Plain abdominal film of retained surgical sponge","title":"Plain abdominal film of retained surgical sponge","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain abdominal film of retained surgical sponge</div><div class=\"cntnt\"><img style=\"width:432px; height:301px;\" src=\"images/OBGYN/64696_X-Ray_retained_gauze.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 64696 Version 3.0</div></div></div>"},"64699":{"type":"graphic_table","displayName":"Differential diagnosis of abnormal adult behavior ","title":"Differential diagnosis of abnormal adult behavior","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of abnormal adult behavior</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Life-threatening conditions</td> </tr> <tr> <td>Hypoxia</td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>Sepsis</td> </tr> <tr> <td>Hypertensive encephalopathy</td> </tr> <tr> <td>Wernicke's encephalopathy</td> </tr> <tr> <td>Overdose</td> </tr> <tr> <td>CNS infections (meningitis, encephalitis)</td> </tr> <tr> <td>CNS trauma</td> </tr> <tr> <td>Intracranial hemorrhage (eg, subarachnoid, subdural)</td> </tr> <tr> <td>Epilepsy (eg, non-convulsive status epilepticus)</td> </tr> <tr> <td class=\"subtitle1_single\">Common conditions</td> </tr> <tr> <td>Urinary tract infections</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Electrolyte abnormalities</td> </tr> <tr> <td>Medication adverse effects and interactions</td> </tr> <tr> <td>Medication withdrawal syndromes</td> </tr> <tr> <td>Psychiatric illness</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions</td> </tr> <tr> <td>Endocrine disease (eg, thyroid)</td> </tr> <tr> <td>Stroke without focal motor deficit</td> </tr> <tr> <td>CNS mass lesions</td> </tr> <tr> <td>Dementia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64699 Version 3.0</div></div></div>"},"64700":{"type":"graphic_figure","displayName":"Glucagon resp in prolonged fast","title":"Plasma glucose responses to glucagon after a prolonged fast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma glucose responses to glucagon after a prolonged fast</div><div class=\"cntnt\"><img style=\"width:279px; height:318px;\" src=\"images/ENDO/64700_Glucagon_resp_in_prolonged.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between the plasma glucose concentration after a prolonged fast and the increase in plasma glucose after the administration of 1 mg of intravenous glucagon in normal subjects and patients with an insulinoma. In patients who become hypoglycemic, an increase in plasma glucose of â¥25 mg/dL (1.4 mmol/L) after glucagon is suggestive of an insulinoma. To convert plasma glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Redrawn from Service FJ. Hypoglycemic disorders.&nbsp;N Engl J Med 1995; 332:1144.</div><div id=\"graphicVersion\">Graphic 64700 Version 2.0</div></div></div>"},"64701":{"type":"graphic_diagnosticimage","displayName":"CT scan bile duct stone","title":"Computed tomography scan showing a distal bile duct stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography scan showing a distal bile duct stone</div><div class=\"cntnt\"><img style=\"width:432px; height:287px;\" src=\"images/GAST/64701_CT_scan_bile_duct_stone.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of ML Freeman, MD.</div><div id=\"graphicVersion\">Graphic 64701 Version 3.0</div></div></div>"},"64703":{"type":"graphic_table","displayName":"ECT consent continuation rx","title":"Electroconvulsive Therapy (ECT) Consent Form: Continuation/Maintenance Treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electroconvulsive Therapy (ECT) Consent Form: Continuation/Maintenance Treatment</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n<tr>\n    <td class=\"subtitle2_left\" colspan=\"2\"><p>Name of Patient:</p></td>\n</tr>\n  <tr>\n    <td colspan=\"2\"><p>My doctor, _________________________, has recommended that I receive continuation or maintenance treatment with electroconvulsive therapy (ECT). This treatment, including the risks and benefits that I may experience, has been fully described to me. I give my consent to be treated with this type of ECT.</p>\n\n<p>I will receive ECT to prevent return of my illness. Whether ECT or an alternative treatment, like medication or psychotherapy, is most appropriate for me at this time depends on my prior experience with these treatments in preventing the return of symptoms, the features of my illness, and other considerations. Why continuation/maintenance ECT has been recommended for me has been explained.</p>\n\n<p>Continuation/maintenance ECT involves a series of treatments with each usually separated in time by 1 or more weeks. Continuation/ maintenance ECT is usually given for a period of several months or longer. These treatments may be given on an inpatient or outpatient basis.</p>\n\n<p>To receive each continuation/maintenance treatment I will come to a specially equipped area in this facility. The treatments are usually given in the morning. Because the treatments involve general anesthesia, I will have had nothing to eat or drink for several hours before each treatment. Before the treatment, a small needle will be placed in my vein so that I can be given medications. An anesthetic medication will be injected that will quickly put me to sleep. I will then be given another medication that will relax my muscles. Because I will be asleep, I will not experience pain or discomfort or remember the procedure. Other medications may also be given depending on my needs.</p>\n\n<p>To prepare for the treatment, monitoring sensors will be placed on my head and body. Blood pressure cuffs will be placed on an arm and leg. This monitoring involves no pain or discomfort. After I am asleep, a carefully controlled amount of electricity will be passed between two electrodes that have been placed on my head.</p>\n\n<p>I may receive bilateral ECT or unilateral ECT. In bilateral ECT, one electrode is placed on the left side of the head, the other on the right side. In unilateral ECT, both electrodes are placed on the same side of the head, usually the right side. Right unilateral ECT (electrodes on the right side) is likely to produce less memory difficulty than bilateral ECT. However, for some patients bilateral ECT may be a more effective treatment. My doctor will carefully consider the choice of unilateral or bilateral ECT.</p>\n\n<p>The electrical current produces a seizure in the brain. The amount of electricity used to produce the seizure will be adjusted to my individual needs, based on the judgment of the ECT physician. The medication used to relax my muscles will greatly soften the contractions in my body that would ordinarily accompany the seizure. I will be given oxygen to breathe. The seizure will last for approximately 1 minute. During the procedure, my heart, blood pressure, and brain waves will be monitored. Within a few minutes, the anesthetic medications will wear off and I will awaken. I will then be observed until it is time to leave the ECT area.</p>\n\n<p>The number of continuation/maintenance treatments that I will receive will depend on my clinical course. Continuation ECT is usually given for at least 6 months. If it is felt that continuation ECT is helpful and should be used for a longer period (maintenance ECT), I will be asked to consent to the procedure again.</p>\n\n<p>ECT is expected to prevent the return of my psychiatric condition. Although for most patients ECT is effective in this way, I understand that this cannot be guaranteed. With continuation/maintenance ECT I may remain considerably improved or I may have a partial or complete return of psychiatric symptoms.</p>\n\n<p>Like other medical treatments, ECT has risks and side effects. To reduce the risk of complications, I will receive a medical evaluation before starting ECT. The medications I have been taking may be adjusted. However, in spite of precautions, it is possible that I will experience a medical complication. As with any procedure using general anesthesia, there is a remote possibility of death from ECT. The risk of death from ECT is very low, about one in 10,000 patients. This rate may be higher in patients with severe medical conditions.</p>\n\n<p>ECT very rarely results in serious medical complications, such as heart attack, stroke, respiratory difficulty, or continuous seizure. More often, ECT results in irregularities in heart rate and rhythm. These irregularities are usually mild and short lasting, but in rare instances can be life threatening. With modem ECT technique, dental complications are infrequent and bone fractures or dislocations are very rare.</p>\n\n<p>If serious side effects occur, I understand that medical care and treatment will be instituted immediately and that facilities to handle emergencies are available. I understand, however, that neither the institution nor the treating physicians are required to provide long-term medical treatment. I shall be responsible for the cost of such treatment whether personally or through medical insurance or other medical coverage. I understand that no compensation will be paid for lost wages or other consequential damages.</p>\n\n<p>The minor side effects that are frequent include headache, muscle soreness, and nausea. These side effects usually respond to simple treatment.</p>\n\n<p>When I awaken after each treatment, I may be confused. This confusion usually goes away within 1 hour.</p>\n\n<p>I understand that memory loss is a common side effect of ECT. The memory loss with ECT has a characteristic pattern, including problems remembering past events and new information. The degree of memory problems is often related to the number and type of treatments given. A smaller number of treatments is likely to produce less memory difficulty than a larger number. Shortly following a treatment, the problems with memory are greatest. As time from treatment increases, memory improves.</p>\n\n<p>I may experience difficulties remembering events that happened before and while I received ECT. The spottiness in my memory for past events may extend back to several months before I received ECT, and, less commonly, for longer periods of time, sometimes several years or more. Although many of these memories should return during the first few months following continuation/maintenance ECT, I may be left with some permanent gaps in memory.</p>\n\n<p>For a short period following each treatment, I may also experience difficulty in remembering new information. This difficulty in forming new memories should be temporary and will most likely disappear following completion of continuation/maintenance ECT.</p>\n\n<p>The effects of continuation/maintenance ECT on memory are likely to be less pronounced than those during an acute ECT course. By spreading treatments out in time, with an interval of a week or more between treatments, there should be substantial recovery of memory between each treatment.</p>\n\n<p>Because of the possible problems with confusion and memory, it is important that I not drive or make any important personal or business decisions the day that I receive a continuation/maintenance treatment. Limitations on my activities may be longer depending on the side effects I experience following each treatment and will be discussed with my doctor.</p>\n\n<p>The conduct of ECT at this facility is under the direction of Dr. ______________________. I may contact him/her at _______________________ if I have further questions.</p>\n\n<p>I am free to ask my doctor or members of the ECT treatment team questions about ECT at this time or at any time during or following the ECT course. My decision to agree to continuation/maintenance ECT is being made voluntarily, and I may withdraw my consent for future treatment at any time.</p>\n\n<p>I have been given a copy of this consent form to keep.</p>\n</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\"><p>Signature:</p></td>\n<td class=\"subtitle2_left\"><p>Date:</p></td>\n</tr>\n<tr>\n<td colspan=\"2\">Person Obtaining Consent:</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\"><p>Name:</p></td>\n<td class=\"subtitle2_left\"><p>Signature:</p></td>\n  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">22.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">5/31/2010--Requested permission (JD). 6/2/2010--Permission granted; figures to Terrence, invoice to Jo (JD). The total fee of $&amp;quot;230.00&amp;quot;was originally charged to ECT_consent_acute_phase ECT_consent_continuation_rx</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=62118&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ECT_consent_continuation_rx.htm</title></head></div><div class=\"graphic_reference\">Reprinted with permission from the Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. Copyright Â© 2001 American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 64703 Version 10.0</div></div></div>"},"64705":{"type":"graphic_picture","displayName":"Uveitis in BehÃ§et syndrome","title":"Uveitis in BehÃ§et syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uveitis in BehÃ§et syndrome</div><div class=\"cntnt\"><img style=\"width:393px; height:325px;\" src=\"images/RHEUM/64705_Behcetsuveitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread intraretinal hemorrhage from a patient with BehÃ§et syndrome. The hemorrhage is secondary to retinal vasculitis.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 64705 Version 4.0</div></div></div>"},"64706":{"type":"graphic_picture","displayName":"Cutaneous ulceration in RV","title":"Cutaneous ulceration in rheumatoid vasculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous ulceration in rheumatoid vasculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/RHEUM/64706_Cutaneous_ulceration_in_RV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The classic cutaneous finding of rheumatoid vasculitis is a medium-vessel inflammatory process associated with ulcerated lesions of the lower extremities.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 64706 Version 2.0</div></div></div>"},"64707":{"type":"graphic_figure","displayName":"Types of endoleak after endovascular repair","title":"Types of endoleak after endovascular repair<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Types of endoleak after endovascular repair<SUP>[1]</SUP></div><div class=\"cntnt\"><img style=\"width:479px; height:702px;\" src=\"images/CARD/64707_Typesofendoleakafterendovascularrepair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The types of endoleaks after an endovascular repair of an abdominal aortic aneurysm are as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Type I is due to an incompetent seal at the proximal (Ia)&nbsp;or distal (Ib) attachment site. </LI>&#xD;&#xA;<LI>Type II results from flow into and out of the aneurysm sac from&nbsp;one or more&nbsp;patent branch vessels (lumbar or inferior mesenteric artery). </LI>&#xD;&#xA;<LI>Type III results from dissociation of modular components. </LI>&#xD;&#xA;<LI>Type IV is due to leaks through the porous graft material.</LI>&#xD;&#xA;<LI>Endoleak of undefined origin (type V) is continued aneurysm sac expansion without a demonstrable endoleak on any imaging modality. It&nbsp;is also referred to as endotension.</LI></UL></div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002; 35:1048.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64707 Version 6.0</div></div></div>"},"64708":{"type":"graphic_table","displayName":"Immunocompromised pyo rx","title":"Empiric antibiotic therapy for pyomyositis in immunocompromised adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antibiotic therapy for pyomyositis in immunocompromised adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Vancomycin should be combined with one of the following regimens for empiric gram-negative and anaerobic coverage: </td> </tr> <tr> <td class=\"sublist1_start\">Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following: </td> </tr> <tr> <td class=\"sublist1\">Ampicillin-sulbactam (3 g every six hours) </td> </tr> <tr> <td class=\"sublist1\">Piperacillin/tazobactam (4.5 g every eight hours) </td> </tr> <tr> <td class=\"sublist1\">Ticarcillin-clavulanate (3.1 g every four hours) </td> </tr> <tr> <td>A third-generation cephalosporin such as ceftriaxone (1 g IV every 24 hours) <strong>PLUS</strong> metronidazole (500 mg IV every eight hours)</td> </tr> <tr> <td class=\"subtitle1_single\">Alternative empiric regimens for empiric gram-negative and anaerobic coverage include: </td> </tr> <tr> <td>A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours or levofloxacin 500 mg IV daily) <strong>PLUS</strong> metronidazole (500 mg IV every eight hours)</td> </tr> <tr> <td class=\"sublist1_start\">Monotherapy with a carbapenem*, such as one of the following: </td> </tr> <tr> <td class=\"sublist1\">Imipenem (500 mg every six hours) </td> </tr> <tr> <td class=\"sublist1\">Meropenem (1 g every&nbsp;eight hours) </td> </tr> <tr> <td class=\"sublist1\">Ertapenem (1 g daily) </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Carbapenems should not be used for patients with history of immediate-type hypersensitivity to beta-lactams.</div><div id=\"graphicVersion\">Graphic 64708 Version 3.0</div></div></div>"},"64710":{"type":"graphic_diagnosticimage","displayName":"Transient DWI changes in the splenium after seizures","title":"Transient diffusion weighted imaging changes in the splenium after seizures","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Transient diffusion weighted imaging changes in the splenium after seizures</div><div class=\"cntnt\"><img style=\"width:517px; height:380px;\" src=\"images/NEURO/64710_Splenium_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative images from two patients (upper and lower panels) demonstrate restricted diffusion (left hand images) with associated decreased apparent diffusion coefficients (center images) that resolved in 4-6 weeks (right hand images).</div><div class=\"graphic_reference\">Reproduced with permission from: Oster, J, Doherty, C, Grant, PE, et al. Diffusion-weighted imaging abnormalities in the splenium after seizures. Epilepsia 2003; 44:852. Copyright Â©2003 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 64710 Version 3.0</div></div></div>"},"64711":{"type":"graphic_picture","displayName":"Radiation effects prost CA bx","title":"Radiation therapy effects on prostate adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiation therapy effects on prostate adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:297px; height:574px;\" src=\"images/ONC/64711_Radiation_effects_prost_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The variability in the histologic appearance of prostate cancer following radiation therapy is illustrated by these high-power photomicrographs of two hematoxylin- and eosin-stained tissue sections from the same patient. Top panel: This area of the biopsy is characterized by marked histologic change, with the tumor cells demonstrating significant degenerative changes and atrophy. The cytologic atypia can hardly even be recognized (arrowheads). Bottom panel: In contrast, tumor cells from a different area of the same specimen from the same irradiated patient shown in the above panel demonstrate the characteristic cytologic atypia of prostate cancer (arrows) without significant atrophic changes.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 64711 Version 2.0</div></div></div>"},"64712":{"type":"graphic_picture","displayName":"Chromate allergy PI","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:396px; height:256px;\" src=\"images/PI/64712_Chromate_allergy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin rash caused by an allergy to a chemical in a leather shoe (chromate allergy).</div><div class=\"graphic_reference\">Courtesy of William L Weston, MD.</div><div id=\"graphicVersion\">Graphic 64712 Version 1.0</div></div></div>"},"64713":{"type":"graphic_diagnosticimage","displayName":"Avulsion fracture mallet finger","title":"Avulsion fracture with mallet finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture with mallet finger</div><div class=\"cntnt\"><img style=\"width:365px; height:293px;\" src=\"images/PC/64713_Avulsion_fracture_mallet_fi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 3 to 4 mm avulsion fracture is evident accompanying rupture of the extensor profundus tendon.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 64713 Version 2.0</div></div></div>"},"64716":{"type":"graphic_table","displayName":"External otitis microbiology A","title":"Acute external otitis microbiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute external otitis microbiology</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n\n      <td class=\"subtitle1\">Percent*</td>\n\n    </tr>\n\n    <tr><td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Organism</td></tr><tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle3_left\">Aerobic bacteria</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Pseudomonas</td>\n\n\n      <td>11</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">S. aureus</td>\n\n\n      <td>11</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Strep group D &#38; G</td>\n\n\n      <td>6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist3_start\" colspan=\"1\">Other gram negative </td>\n\n      <td colspan=\"1\" rowspan=\"4\" class=\"sublist_other_start\">4</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist3\">H. influenzae </td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist3\">Proteus sp</td>\n      \n    </tr>\n    <tr>\n      <td class=\"sublist3\">E. coli</td>\n      \n    </tr>\n    <tr>\n\n      <td class=\"subtitle3_left\">Anaerobic bacteria</td>\n\n\n      <td colspan=\"1\" rowspan=\"4\">2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Bacteroides</td>\n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Clostridii</td>\n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Streptococci</td>\n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle3_left\">Commensals</td>\n\n\n      <td colspan=\"1\" rowspan=\"3\">46</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">S. epidermis</td>\n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Diptheroids</td>\n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle3_left\">Fungal</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Candida albicans</td>\n\n\n      <td>8</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent2\">Aspergillus</td>\n\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle3_left\">No growth</td>\n\n\n      <td>7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" rowspan=\"1\" colspan=\"2\">Number of organisms</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Single organism</td>\n\n\n      <td>32</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mixed</td>\n\n\n      <td>5</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Percent of total patients with growth of this organism (n = 100).</div><div class=\"graphic_reference\">Data from Russell, JD, Donnelly, M, McShane, DP, et al, J Laryngol Otol 1993; 107:898.</div><div id=\"graphicVersion\">Graphic 64716 Version 1.0</div></div></div>"},"64718":{"type":"graphic_diagnosticimage","displayName":"Retinal vasculitis in toxo","title":"Retinal vasculitis in toxoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal vasculitis in toxoplasmosis</div><div class=\"cntnt\"><img style=\"width:338px; height:252px;\" src=\"images/RHEUM/64718_Retinal_vasculitis_in_toxo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescein angiogram in a patient with toxoplasmosis shows retinal vasculitis.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 64718 Version 2.0</div></div></div>"},"64720":{"type":"graphic_figure","displayName":"Mental nerve block","title":"Mental (infraoral) nerve block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mental (infraoral) nerve block</div><div class=\"cntnt\"><img style=\"width:365px; height:589px;\" src=\"images/EM/64720_Mentalnerveblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mental nerve block anesthetizes the lower lip, skin below the lip, and chin as shown in A above. To perform, locate the mental nerve foramen by palpation of the mandible in line with the infraorbital and supraorbital foramen as shown in B above. After cleansing, insert a small needle (eg, 25 or 27 gauge) through the skin just medial and directed towards the foramen (see A above). Insert the needle to a depth of approximately 0.5 cm and inject one to two mL of local anesthetic (eg, buffered lidocaine 1 percent with epinephrine). In older children and adolescents, who report paresthesias, withdraw the needle until paresthesias resolve prior to injection of anesthetic. </div><div class=\"graphic_reference\">Reproduced with permission from: Cimpello LB, Deutsch RJ, Dixon C, et al. Illustrated techniques of pediatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64720 Version 9.0</div></div></div>"},"64722":{"type":"graphic_figure","displayName":"Appearance of Yersinia","title":"Microbiology of yersinia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microbiology of yersinia</div><div class=\"cntnt\"><img style=\"width:322px; height:445px;\" src=\"images/ID/64722_Appearance_of_Yersinia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top panel shows the characteristic colony pattern of yersinia enterocolitica on CIN agar. The lower panel illustrates the Gram stain appearance of the organism.</div><div class=\"graphic_reference\">Courtesy of James Gathany, MD.</div><div id=\"graphicVersion\">Graphic 64722 Version 1.0</div></div></div>"},"64723":{"type":"graphic_table","displayName":"Empiric treatment psoas abscess","title":"Empiric antiobitic therapy for psoas abscess in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antiobitic therapy for psoas abscess in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Empiric therapy with activity against methicillin-resistant <em>Staphylococcus aureus </em></td> </tr> <tr> <td>Preferred</td> <td>Vancomycin (30 mg/kg IV every 24 hours in&nbsp;two equally divided doses)</td> </tr> <tr> <td rowspan=\"2\">Alternatives </td> <td>Daptomycin (6 mg/kg IV once daily)</td> </tr> <tr> <td colspan=\"2\">Linezolid (600 mg IV or orally twice daily) </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">PLUS </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Empiric therapy with activity against gram-negative and anaerobic pathogens </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Monotherapy with a beta-lactam-beta-lactamase inhibitor, such as one of the following: </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">Ampicillin-sulbactam (3 g every 6 hours) </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">Piperacillin/tazobactam (3.375 g every 6 hours) </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">Ticarcillin-clavulanate (3.1 g every 4 to 6 hours) </td> </tr> <tr> <td colspan=\"2\">A third-generation cephalosporin such as ceftriaxone (1 g IV every 24 hours) <strong>PLUS</strong> metronidazole (500 mg IV every 8 hours) </td> </tr> <tr> <td colspan=\"2\">A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours or levofloxacin 500 mg IV daily) <strong>PLUS</strong> metronidazole (500 mg IV every 8 hours) </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Monotherapy with a carbapenem<sup>&#182;</sup> such as one of the following: </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">Imipenem (500 mg every 6 hours) </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">Meropenem (1 g every 8 hours) </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">Ertapenem (1 g daily) </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Antibiotic therapy should be tailored to culture and sensitivity data when available.<br />Â¶&nbsp;Carbapenems should not be used for patients with history of immediate-type hypersensitivity to beta-lactams.</div><div id=\"graphicVersion\">Graphic 64723 Version 4.0</div></div></div>"},"64724":{"type":"graphic_figure","displayName":"Age and stroke rate","title":"Age and stroke rate","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Age and stroke rate</div><div class=\"cntnt\"><img style=\"width:512px; height:436px;\" src=\"images/NEURO/64724_Age_and_stroke_rate.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Number of patients according to age and age-specific occurrence rates per 100,000.</div><div class=\"graphic_footnotes\">R: correlation coefficient of the trend line illustrating the exponential increase in occurrence as a function of age.<br> * P&lt;0.001 in comparison of age-specific proportions between genders by Chi-Sq test.</div><div class=\"graphic_reference\">Reproduced with permission from: Putaala, J, Metso, AJ, Metso, TM, et al. Stroke: The Helsinki Young Stroke Registry Analysis of 1008 Consecutive Patients Aged 15 to 49 With First-Ever Ischemic Stroke: The Helsinki Young Stroke Registry. Stroke 2009; 40:1195. Copyright Â© 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64724 Version 8.0</div></div></div>"},"64725":{"type":"graphic_picture","displayName":"CRAO with macular sparing","title":"Central retinal artery occlusion with macular sparing","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Central retinal artery occlusion with macular sparing</div><div class=\"cntnt\"><img style=\"width:504px; height:408px;\" src=\"images/NEURO/64725_CRAO_with_macular_sparing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph of a central retinal artery occlusion with sparing of the macular region due to the presence of a cilioretinal artery.</div><div id=\"graphicVersion\">Graphic 64725 Version 3.0</div></div></div>"},"64727":{"type":"graphic_diagnosticimage","displayName":"Croup lateral neck radiograph","title":"Lateral neck radiograph of a child with croup","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral neck radiograph of a child with croup</div><div class=\"cntnt\"><img style=\"width:368px; height:389px;\" src=\"images/PEDS/64727_Croup_lateral_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral neck radiograph showing subglottic narrowing (arrow) and distended hypopharynx (arrowheads) consistent with acute laryngotracheitis.</div><div class=\"graphic_reference\">Courtesy of Joe Black, Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 64727 Version 4.0</div></div></div>"},"64728":{"type":"graphic_picture","displayName":"Inverse pityriasis rosea","title":"Atypical (inverse) pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical (inverse) pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:399px; height:326px;\" src=\"images/DERM/64728_Inverse_pityriasis_rosea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical (inverse) pityriasis rosea in an inguinal distribution. The herald patch is present in the left inguinal area.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64728 Version 2.0</div></div></div>"},"64729":{"type":"graphic_picture","displayName":"Polistes dominula worker","title":"Polistes dominula worker","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polistes dominula worker</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/64729_Polistes_dominula_worker.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 64729 Version 1.0</div></div></div>"},"64736":{"type":"graphic_figure","displayName":"Flexion hip deformity in AS I","title":"Masking of flexion deformity of the hip in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Masking of flexion deformity of the hip in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:360px; height:195px;\" src=\"images/RHEUM/64736_Flexion_hip_deformity_in_AS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexion deformity of the hip in ankylosing spondylitis may be masked in the supine position because the patient compensates by an exaggerated lordosis of the lumbar spine.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 64736 Version 3.0</div></div></div>"},"64737":{"type":"graphic_diagnosticimage","displayName":"Color and pulsed Doppler sonogram of acardiac twin","title":"Color and pulsed Doppler sonogram of acardiac twin","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Color and pulsed Doppler sonogram of acardiac twin</div><div class=\"cntnt\"><img style=\"width:465px; height:562px;\" src=\"images/OBGYN/64737_Color_doppler_twin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the arterial flow is going towards the fetal body, indicating perfusion from the normal co-twin.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 64737 Version 3.0</div></div></div>"},"64738":{"type":"graphic_picture","displayName":"Seborrehic keratosis - pigmented","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64738_Seborrehic_kerat_pigmented.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A brown plaque with a &quot;stuck-on&quot; appearance is present on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64738 Version 3.0</div></div></div>"},"64739":{"type":"graphic_movie","displayName":"TEE left atrial myxoma 2","title":"Left atrial myxoma seen on TEE","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma seen on TEE</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/64739_teelatm2conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:250px; height:441px;\" src=\"images/CARD/64739_teelatm2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large left atrial myxoma adherent to the interatrial septum by a broad stalk. Part of the myxoma extends into the left ventricle during diastole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 64739 Version 3.0</div></div></div>"},"64740":{"type":"graphic_diagnosticimage","displayName":"Cholesterol emboli in transit","title":"Emboli in transit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emboli in transit</div><div class=\"cntnt\"><img style=\"width:357px; height:504px;\" src=\"images/CARD/64740_Cholesterol_emboli_in_trans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiogram of the descending thoracic aorta in a patient who later died from cholesterol crystal embolization syndrome, with intestinal infarction and renal failure. Note the massive atherosclerotic plaque. The pictures on the right (1A, 2A, 3A) were taken one or two seconds after their respective pictures on the left. The arrows point to small particles of embolic material moving in transit in the aortic lumen.</div><div class=\"graphic_reference\">Reproduced with permission from: Freedberg, RS, Tunick, PA, Kronzon, I. Emboli in Transit: The Missing Link. J Am Soc Echocardiogr 1998, 11:826. Copyright Â© 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 64740 Version 2.0</div></div></div>"},"64742":{"type":"graphic_table","displayName":"Chemical and physical agents that are reproductive hazards ","title":"Chemical and physical agents that are reproductive hazards for women in the workplace","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemical and physical agents that are reproductive hazards for women in the workplace</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Agent</td>\n<td class=\"subtitle1\">Observed effects</td>\n<td class=\"subtitle1\">Potentially exposed workers</td>\n</tr>\n<tr>\n<td>Cancer treatment drugs (eg., methotrexate)</td>\n<td>Infertility, miscarriage, birth defects, low birth weight</td>\n<td>Health care workers, pharmacists</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Certain ethylene glycol ethers such as:</td>\n<td colspan=\"1\" rowspan=\"3\">Miscarriage</td>\n<td colspan=\"1\" rowspan=\"3\">Electronic and semiconductor workers</td>\n</tr>\n<tr>\n<td class=\"sublist1\">2-ethoxyethanol (2EE) and</td>\n\n\n</tr>\n<tr>\n<td class=\"sublist1\">2-methoxyethanol (2ME)</td>\n\n\n</tr>\n<tr>\n<td>Carbon disulfide (CS2)</td>\n<td>Menstrual cycle changes</td>\n<td>Viscose rayon workers</td>\n</tr>\n<tr>\n<td>Lead</td>\n<td>Infertility, miscarriage, low birth weight, developmental disorders</td>\n<td>Battery makers, solderers, welders, radiator repairers, bridge repainters, firing range workers, home remodelers</td>\n</tr>\n<tr>\n<td>Ionizing radiation (eg., X-rays and gamma rays)</td>\n<td>Infertility, miscarriage, birth defects, low birth weight, developmental disorders, childhood cancers</td>\n<td>Health care workers, dental personnel, atomic workers</td>\n</tr>\n<tr>\n<td>Strenuous physical labor (eg., prolonged standing, heavy lifting)</td>\n<td>Miscarriage, premature delivery</td>\n<td>Many types of workers</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">National Institute for Occupational Safety and Health.</div><div id=\"graphicVersion\">Graphic 64742 Version 2.0</div></div></div>"},"64744":{"type":"graphic_figure","displayName":"Dorsal plication for correction of penile curvature","title":"Dorsal plication for correction of penile curvature","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsal plication for correction of penile curvature</div><div class=\"cntnt\"><img style=\"width:380px; height:364px;\" src=\"images/PEDS/64744_Correctionpenilecurvature.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baskin LS, Kogan BA. Handbook of Pediatric Urology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright Â© 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64744 Version 11.0</div></div></div>"},"64745":{"type":"graphic_table","displayName":"Moderate and severe alcohol withdrawal - Rapid overview","title":"Moderate and severe alcohol withdrawal: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Moderate and severe alcohol withdrawal: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Syndromes</td> </tr> <tr> <td>Alcohol tremulousness - occurs early, characterized by hypertension, tachycardia, tremors, and anxiety, with normal mental status</td> </tr> <tr> <td>Alcohol withdrawal seizures - occurs early, usually single or brief flurry of seizures with short post-ictal period</td> </tr> <tr> <td>Alcoholic hallucinosis - occurs early, no evidence of autonomic instability</td> </tr> <tr> <td>Delirium tremens - occurs late, characterized by delirium and autonomic instability</td> </tr> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td>Pattern of alcohol use, history of withdrawal symptoms; inquire about reasons for cessation of alcohol</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td>Vital signs, mental status, presence of tremor; examine for signs of trauma, abdominal tenderness, other findings consistent with complications of chronic alcohol use</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory testing</td> </tr> <tr> <td>No test truly assesses withdrawal; ancillary data (eg, serum ethanol concentration, lumbar puncture (CSF), head CT, lipase) frequently needed to assess patient and rule out coexistent illness</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">First line therapy for ALL alcohol withdrawal syndromes</td> </tr> <tr> <td class=\"indent1\">Most patients with symptoms require IV therapy initially</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Give:</strong></td> </tr> <tr> <td class=\"sublist2\">Diazepam, 5 to 10 mg IV, repeat every 5 to 10 minutes, <strong>OR</strong></td> </tr> <tr> <td class=\"sublist2\">Lorazepam, 2 to 4 mg IV, repeat every 15 to 20 minutes</td> </tr> <tr> <td class=\"indent1\">Massive doses (&#62;2000 mg diazepam in 48 hours) may be required</td> </tr> <tr> <td class=\"indent1\">Clinically stable patients with minimal symptoms may be treated with oral medications</td> </tr> <tr> <td class=\"subtitle2_single\">Barbiturates</td> </tr> <tr> <td class=\"indent1\">Synergistic with benzodiazepines; give if patient refractory to high-dose benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Phenobarbital 130 to 260 mg IV, repeat every 15 to 20 minutes</td> </tr> <tr> <td class=\"indent1\">Intubation frequently required with concurrent benzodiazepine and barbiturate use</td> </tr> <tr> <td class=\"indent1\">ALL patients requiring barbiturates are monitored in an intensive care unit</td> </tr> <tr> <td class=\"subtitle2_single\">Propofol</td> </tr> <tr> <td class=\"indent1\">Excellent agent if patient refractory to benzodiazepines and barbiturates</td> </tr> <tr> <td class=\"indent1\">Intubation almost always required</td> </tr> <tr> <td class=\"indent1\">1 mg/kg IV push as induction agent for intubation; titrate continuous infusion for sedation</td> </tr> <tr> <td class=\"subtitle2_single\">Supportive care</td> </tr> <tr> <td class=\"indent1\">Assure adequate fluid and electrolyte replacement</td> </tr> <tr> <td class=\"indent1\">Give parenteral thiamine 100 mg and glucose daily</td> </tr> <tr> <td class=\"indent1\">Give multivitamin supplements</td> </tr> <tr> <td class=\"indent1\">Ensure adequate caloric support</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64745 Version 7.0</div></div></div>"},"64747":{"type":"graphic_table","displayName":"Cervical cancer survival","title":"Survival by FIGO stage for patients with cervical cancer: 1999 to 2001 FIGO statistics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival by FIGO stage for patients with cervical cancer: 1999 to 2001 FIGO statistics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">FIGO stage</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" colspan=\"3\">Overall survival (percent)</td> </tr> <tr> <td class=\"subtitle2\">One year</td> <td class=\"subtitle2\">Two years</td> <td class=\"subtitle2\">Five years</td> </tr> <tr> <td class=\"centered\">IA1</td> <td class=\"centered\">829</td> <td class=\"centered\">99.8</td> <td class=\"centered\">99.5</td> <td class=\"centered\">97.5</td> </tr> <tr> <td class=\"centered\">IA2</td> <td class=\"centered\">275</td> <td class=\"centered\">98.5</td> <td class=\"centered\">96.9</td> <td class=\"centered\">94.8</td> </tr> <tr> <td class=\"centered\">IB1</td> <td class=\"centered\">3020</td> <td class=\"centered\">98.2</td> <td class=\"centered\">95.0</td> <td class=\"centered\">89.1</td> </tr> <tr> <td class=\"centered\">IB2</td> <td class=\"centered\">1090</td> <td class=\"centered\">95.8</td> <td class=\"centered\">88.3</td> <td class=\"centered\">75.7</td> </tr> <tr> <td class=\"centered\">IIA</td> <td class=\"centered\">1007</td> <td class=\"centered\">96.1</td> <td class=\"centered\">88.3</td> <td class=\"centered\">73.4</td> </tr> <tr> <td class=\"centered\">IIB</td> <td class=\"centered\">2510</td> <td class=\"centered\">91.7</td> <td class=\"centered\">79.8</td> <td class=\"centered\">65.8</td> </tr> <tr> <td class=\"centered\">IIIA</td> <td class=\"centered\">211</td> <td class=\"centered\">76.7</td> <td class=\"centered\">59.8</td> <td class=\"centered\">39.7</td> </tr> <tr> <td class=\"centered\">IIIB</td> <td class=\"centered\">2028</td> <td class=\"centered\">77.9</td> <td class=\"centered\">59.5</td> <td class=\"centered\">41.5</td> </tr> <tr> <td class=\"centered\">IVA</td> <td class=\"centered\">326</td> <td class=\"centered\">51.9</td> <td class=\"centered\">35.1</td> <td class=\"centered\">22.0</td> </tr> <tr> <td class=\"centered\">IVB</td> <td class=\"centered\">343</td> <td class=\"centered\">42.2</td> <td class=\"centered\">22.7</td> <td class=\"centered\">9.3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics.</div><div class=\"graphic_reference\">Original table modified for this publication. From: Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet 2006; 95:S43. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64747 Version 13.0</div></div></div>"},"64748":{"type":"graphic_picture","displayName":"Mild Hunter syndrome A","title":"Mild mucopolysaccharidosis type II (MPS II, Hunter syndrome) A","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild mucopolysaccharidosis type II (MPS II, Hunter syndrome) A</div><div class=\"cntnt\"><img style=\"width:151px; height:366px;\" src=\"images/PEDS/64748_Mild_Hunter_syndrome_A_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild Hunter syndrome (MPS II) in a 12-year-old boy (frontal view).</div><div class=\"graphic_reference\">Courtesy of Ed Wraith, MD.</div><div id=\"graphicVersion\">Graphic 64748 Version 5.0</div></div></div>"},"64749":{"type":"graphic_diagnosticimage","displayName":"Agenesis right lung","title":"Agenesis of right lung in newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Agenesis of right lung in newborn</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/64749_Agenesis_right_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cardiomediastinal silhouette is completely shifted into right hemithorax. Multiple rib anomalies and vertebral anomalies are present.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64749 Version 2.0</div></div></div>"},"64750":{"type":"graphic_figure","displayName":"Food allergy oral tolerance","title":"Mechanisms of oral tolerance: Antigen dose","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Mechanisms of oral tolerance: Antigen dose</div><div class=\"cntnt\"><img style=\"width:497px; height:635px;\" src=\"images/ALLRG/64750_Food_allergy_oral_tolerance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oral tolerance is mediated through different mechanisms, depending upon the antigen dose.<br />(A) Low doses of ingested antigen induce tolerance via activation of regulatory T cells that produce suppressive cytokines, such as IL-10 and TGF-beta.<br />(B) High doses of oral antigen lead to induction of tolerance via anergy (TCR cross-linking occurs without costimulation) or deletion (TCR is cross-linked in the presence of inhibitory molecules, CD95 and CD95L, leading to FAS-mediated apoptosis).</div><div class=\"graphic_footnotes\">Th3: T helper cell type 3; CD: cluster of differentiation; Tr1: regulatory T cell type 1; TGF-beta: transforming growth factor-beta; R: receptor; IL-10: interleukin-10; MHC: major histocompatibility complex; TCR: T cell receptor; L: ligand.</div><div class=\"graphic_reference\">Modified with permission from: Chehade M, Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005; 115:3. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2005 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 64750 Version 3.0</div></div></div>"},"64751":{"type":"graphic_diagnosticimage","displayName":"Breast MRI of multifocal breast cancer","title":"Breast MRI of multifocal breast cancer","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Breast MRI of multifocal breast cancer</div><div class=\"cntnt\"><img style=\"width:514px; height:216px;\" src=\"images/SURG/64751_Breast_MRI_multifocal_br_cx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be useful for determining disease extent in newly diagnosed cancer patients. These images show the MRI of a patient with a palpable retroareolar mass.<br />(A) T2-weighted imaging demonstrates an intermediate signal irregular mass just beneath the nipple as well as a T2-hypointense area posteriorly.<br />(B) Post contrast T1-weighted sagittal image demonstrates a suspiciously enhancing lesion in the inferior subareolar breast as well as an ill-defined area of non-mass enhancement posteriorly within the same ductal unit.<br />(C) Subtraction of pre and post contrast images confirm the two separate lesions with the posterior lesion being occult to both mammography and ultrasound. Biopsy of both areas was performed revealing invasive ductal carcinoma anteriorly and ductal carcinoma in situ posteriorly.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 64751 Version 4.0</div></div></div>"},"64752":{"type":"graphic_table","displayName":"Neurologic follow-up in GD","title":"Minimum clinical protocol for neurologic follow-up in Gaucher disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimum clinical protocol for neurologic follow-up in Gaucher disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Clinical examination</td> </tr> <tr> <td class=\"indent1\">Neurologic examination: Every three months during year 1, every six months thereafter. Neurologic examination to include scoring as defined in the Severity Scoring Tool for NGD<sup>[1]</sup> to monitor changes. In adolescent and adult patients who are stable, neurologic examination once a year may be sufficient.</td> </tr> <tr> <td class=\"indent1\">If eye movements were considered to be normal at the time of initial assessment or if the result was equivocal (often the case with very young or sick children), such testing should be repeated.</td> </tr> <tr> <td class=\"indent1\">Additional neuroophthalmological investigation: Only if clinically indicated (eg, development of sixth-nerve palsy).</td> </tr> <tr> <td class=\"indent1\">Peripheral hearing (audiometry or electroacoustical emissions depending on age, as stated above): Evaluating trends every two or three years.</td> </tr> <tr> <td class=\"subtitle1_single\">2. Brain imaging</td> </tr> <tr> <td class=\"indent1\">Only if clinically indicated. The risk of anesthesia should be considered. An exception to this may be made in patients who have the D409H allele. Such patients may be at risk of hydrocephalus<sup>[2,3]</sup> and may therefore need to be scanned on a regular basis.</td> </tr> <tr> <td class=\"subtitle1_single\">3. Neurophysiology</td> </tr> <tr> <td class=\"indent1\">EEG: Only if clinically indicated (eg, by presence of seizures). If myoclonus is suspected, telemetry may be needed.</td> </tr> <tr> <td class=\"indent1\">Nerve conduction velocity: Only if clinically indicated with reported symptoms of tingling, numbness, or pins and needles.</td> </tr> <tr> <td class=\"subtitle1_single\">4. Neuropsychometry</td> </tr> <tr> <td class=\"indent1\">Annual assessments are probably not necessary as they are time consuming. We suggest the following: Assessment at school entry, then at transition from primary to secondary school, then when transitioning to college/adult education. Age-appropriate scales should be used.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NGD: neuronopathic Gaucher disease; EEG: electroencephalography.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Davies EH, Surtees R, DeVile C, et al. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 2007b; 30:768. </li>&#xD;&#xA;    <li>Inui K, Yanagihara K, Otani K, et al. A new variant neuropathic type of Gaucher's disease characterized by hydrocephalus, corneal opacities, deformed toes, and fibrous thickening of spleen and liver capsules. J Pediatr 2001; 138:137. </li>&#xD;&#xA;    <li>Shiihara T, Oka A, Suzaki I, et al. Communicating hydrocephalus in a patient with Gauchers disease type 3. Pediatr Neurol 2000; 22:234. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 2009; 32:660, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 64752 Version 10.0</div></div></div>"},"64753":{"type":"graphic_picture","displayName":"Nail changes in psoriatic juvenile idiopathic arthritis","title":"Nail changes in psoriatic juvenile idiopathic arthritis (psJIA)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nail changes in psoriatic juvenile idiopathic arthritis (psJIA)</div><div class=\"cntnt\"><img style=\"width:540px; height:349px;\" src=\"images/ALLRG/64753_Nail_changes_psoriatic_JIA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail changes in a child with psJIA. Note pitting and onycholysis. Frequently, changes are substantially more subtle, with just a few scattered pits that are evident only after careful inspection.</div><div class=\"graphic_reference\">Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64753 Version 3.0</div></div></div>"},"64754":{"type":"graphic_figure","displayName":"Thoracic dermatomes 2","title":"Thoracic dermatomes","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Thoracic dermatomes</div><div class=\"cntnt\"><img style=\"width:539px; height:447px;\" src=\"images/ID/64754_Thoracic_dermatomes_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64754 Version 2.0</div></div></div>"},"64756":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound normal kidneys longitudinal","title":"Prenatal ultrasound longitudinal view, bilateral normal kidneys second trimester","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound longitudinal view, bilateral normal kidneys second trimester</div><div class=\"cntnt\"><img style=\"width:396px; height:342px;\" src=\"images/OBGYN/64756_Normal_kidneys_longitudinal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral normal kidneys (arrows) in the second trimester on longitudinal view. The sonolucent center represents urine in the renal pelvis.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 64756 Version 2.0</div></div></div>"},"64757":{"type":"graphic_algorithm","displayName":"Algorithm for IHC in assessment of HER2 status","title":"Algorithm for IHC in assessment of HER2 status","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Algorithm for IHC in assessment of HER2 status</div><div class=\"cntnt\"><img style=\"width:476px; height:335px;\" src=\"images/ONC/64757_IHC_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry.</div><div class=\"graphic_reference\">Revised with information from:<br /><OL>&#xD;&#xA;<LI>Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013. DOI: JCO.2013.50.9984.</LI></OL>Modified from: Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Onc 2007; 25:118. Copyright Â© 2007 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 64757 Version 5.0</div></div></div>"},"64758":{"type":"graphic_figure","displayName":"Patellar reduction technique","title":"Reduction of patellar dislocation","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Reduction of patellar dislocation</div><div class=\"cntnt\"><img style=\"width:460px; height:232px;\" src=\"images/PEDS/64758_Patellar_reduction_techniqu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The knee is held in mild flexion. The distal thigh is fixed in place by an assistant. While slowly extending the knee, slight pressure is applied to the lateral aspect of the patella to reposition it medially.</div><div id=\"graphicVersion\">Graphic 64758 Version 3.0</div></div></div>"},"64760":{"type":"graphic_diagnosticimage","displayName":"Type II supracondylar fracture 1","title":"Gartland type II supracondylar fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gartland type II supracondylar fracture</div><div class=\"cntnt\"><img style=\"width:298px; height:432px;\" src=\"images/EM/64760_Type_II_supracondylar_fx_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type II extension supracondylar humeral fracture (left elbow). Anterior-posterior radiograph. A: ulna; B: humerus; C: capitellar epiphysis; D: radius.</div><div class=\"graphic_reference\">Reproduced with permission from: Koval KJ, Zuckerman JD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 64760 Version 5.0</div></div></div>"},"64762":{"type":"graphic_table","displayName":"Diseases associated with T-LGL leukemia","title":"Diseases associated with T-cell large granular lymphocyte leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases associated with T-cell large granular lymphocyte leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Associated diseases</td> <td class=\"subtitle1\">Frequency, percent</td> </tr> <tr> <td class=\"subtitle2_left\">Autoimmune diseases</td> <td class=\"subtitle2_left\">15 to 40</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> <td>11 to 36</td> </tr> <tr> <td class=\"indent1\">Sjogren syndrome</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Polymyositis</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Polymyalgia rheumatica</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Multineuritis</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Vasculitis</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Endocrinopathy</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Chronic inflammatory bowel disease</td> <td>Case report</td> </tr> <tr> <td class=\"indent1\">Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy</td> <td>Case report</td> </tr> <tr> <td class=\"subtitle2_left\">Autoimmune cytopenia*</td> <td class=\"subtitle2_left\">5 to 10</td> </tr> <tr> <td class=\"indent1\">Pure red cell aplasia</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Autoimmune hemolytic anemia</td> <td>&#60;2</td> </tr> <tr> <td class=\"indent1\">Idiopathic thrombocytopoenic purpura</td> <td>Rare</td> </tr> <tr> <td><strong>Cyclic neutropenia</strong></td> <td>Rare</td> </tr> <tr> <td><strong>Pulmonary hypertension</strong></td> <td>Rare</td> </tr> <tr> <td class=\"subtitle2_left\">Neoplasia</td> <td class=\"subtitle2_left\">&#60;10</td> </tr> <tr> <td class=\"indent1\">Solid tumors</td> <td>&#60;4</td> </tr> <tr> <td class=\"indent1\">Myelodysplasia</td> <td>&#60;4</td> </tr> <tr> <td class=\"indent1\">B-cell malignancies</td> <td>5 to 7</td> </tr> <tr> <td class=\"indent1\">CML treated with dasatinib</td> <td>Recently described</td> </tr> <tr> <td><strong>Viral infection</strong> (HIV, CMV, HCV, EBV)</td> <td>Rare</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Post-transplantation</td> </tr> <tr> <td class=\"indent1\">Solid and hematopoietic stem cell transplantation</td> <td>Rare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; CMV: cytomegalovirus; HCV: hepatitis C virus; EBV: Epstein-Barr virus; CR: case report.<br> * Excluding chronic neutropenia.</div><div class=\"graphic_reference\">This research was originally published in Blood. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764. Copyright &#169; 2011 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 64762 Version 5.0</div></div></div>"},"64763":{"type":"graphic_diagnosticimage","displayName":"LCH skull","title":"Langerhans cell histiocytosis of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Langerhans cell histiocytosis of bone</div><div class=\"cntnt\"><img style=\"width:344px; height:357px;\" src=\"images/HEME/64763_Eos_granuloma_skull.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axial computed tomography image of the head demonstrates a left-sided lytic skull lesion (arrowhead) with an associated soft tissue mass (arrow), representing a histopathologically-proven Langerhans cell histiocytosis (also known as eosinophilic granuloma).</div><div id=\"graphicVersion\">Graphic 64763 Version 4.0</div></div></div>"},"64765":{"type":"graphic_diagnosticimage","displayName":"Bullae in alpha 1 AT","title":"Severe bullous disease in alpha-1 antitrypsin deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe bullous disease in alpha-1 antitrypsin deficiency</div><div class=\"cntnt\"><img style=\"width:357px; height:301px;\" src=\"images/PULM/64765_Bullae_in_alpha_1_AT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large bilateral subpleural bullae lead to retraction of the underlying normal lung parenchyma. The bullae have an increased compliance and allow normal lung to retract according to its intrinsic elastic recoil. The bullae are not under tension; their effect is similar to that of a pneumothorax (&quot;intrapulmonary pneumothorax&quot;).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64765 Version 2.0</div></div></div>"},"64766":{"type":"graphic_figure","displayName":"Lung volumes by disease state","title":"Changes in lung volumes caused by various disease processes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in lung volumes caused by various disease processes</div><div class=\"cntnt\"><img style=\"width:421px; height:280px;\" src=\"images/PULM/64766_Lung_volumes_by_state.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal persons have an FRC/TLC ratio of about 50 percent and an RV/TLC ratio of 20 to 30 percent. Patients with restrictive pulmonary disorders (first column) can be expected to have reductions in FRC, TLC, and RV, whereas patients with neuromuscular weakness (fourth column) have an elevated RV, reduced TLC, and normal FRC. Asthma (third column) is characterized by elevations in RV, FRC, and in more severe cases, TLC.</div><div class=\"graphic_footnotes\">VC: vital capacity; VT: tidal volume; ERV: expiratory reserve volume; RV: residual volume; TLC: total lung capacity; FRC: functional residual capacity.</div><div id=\"graphicVersion\">Graphic 64766 Version 3.0</div></div></div>"},"64767":{"type":"graphic_figure","displayName":"Obturator nerve anatomy","title":"Obturator nerve anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obturator nerve anatomy</div><div class=\"cntnt\"><img style=\"width:430px; height:652px;\" src=\"images/SURG/64767_Obturator_nerve.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64767 Version 2.0</div></div></div>"},"64768":{"type":"graphic_diagnosticimage","displayName":"Humeral fracture proximal one-part","title":"One part fracture of the proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">One part fracture of the proximal humerus</div><div class=\"cntnt\"><img style=\"width:396px; height:432px;\" src=\"images/EM/64768_Humeral_frac_prox_one-part.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph shows a nondisplaced, one-part fracture (arrows) at the surgical neck of the proximal humerus.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 64768 Version 3.0</div></div></div>"},"64769":{"type":"graphic_figure","displayName":"The Oxygen Cost Diagram","title":"The Oxygen Cost Diagram","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">The Oxygen Cost Diagram</div><div class=\"cntnt\"><img style=\"width:501px; height:499px;\" src=\"images/ONC/64769_The_oxygen_cost_diagram_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients are asked to identify the level of activity they are unable to perform due to dyspnea.</div><div id=\"graphicVersion\">Graphic 64769 Version 1.0</div></div></div>"},"64770":{"type":"graphic_table","displayName":"Dosing ACE inhib and ARBs","title":"Angiotensin-converting enzyme (ACE) inhibitors and receptor antagonists for treatment of adults with hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Angiotensin-converting enzyme (ACE) inhibitors and receptor antagonists for treatment of adults with hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">US brand&nbsp;(trade) name</td> <td class=\"subtitle1\">Usual oral daily dose range (mg)*<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">ACE inhibitors</td> </tr> <tr> <td class=\"indent1\">Benazepril</td> <td>Lotensin</td> <td>10&nbsp;to 40<sup> </sup>(maximum 80 mg)</td> </tr> <tr> <td class=\"indent1\">Captopril</td> <td>Capoten<br /> (only available in US as generic preparation)</td> <td>25 to 150 in two or three divided doses</td> </tr> <tr> <td class=\"indent1\">Cilazapril<sup>&#916;</sup></td> <td>Inhibace<br /> (Canadian trade name)</td> <td>2.5 to 5</td> </tr> <tr> <td class=\"indent1\">Enalapril</td> <td>Vasotec</td> <td>10 to 40<sup> </sup></td> </tr> <tr> <td class=\"indent1\">Fosinopril</td> <td>Monopril<br /> (only available in US as generic preparation)</td> <td>10&nbsp;to 40<sup> </sup>(maximum 80 mg)</td> </tr> <tr> <td class=\"indent1\">Lisinopril</td> <td>Prinivil, Zestril</td> <td>10 to 40</td> </tr> <tr> <td class=\"indent1\">Moexipril</td> <td>Univasc</td> <td>7.5 to 30</td> </tr> <tr> <td class=\"indent1\">Perindopril</td> <td>Aceon</td> <td>4 to 8<sup> </sup>(maximum 16 mg)</td> </tr> <tr> <td class=\"indent1\">Quinapril</td> <td>Accupril</td> <td>10 to 40</td> </tr> <tr> <td class=\"indent1\">Ramipril</td> <td>Altace</td> <td>2.5 to 10<sup> </sup>(maximum 20 mg)</td> </tr> <tr> <td class=\"indent1\">Trandolapril</td> <td>Mavik</td> <td>1&nbsp;to 4<sup> </sup>(maximum 8 mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Angiotensin II receptor antagonists</td> </tr> <tr> <td class=\"indent1\">Azilsartan</td> <td>Edarbi</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Candesartan</td> <td>Atacand</td> <td>8&nbsp;to 32</td> </tr> <tr> <td class=\"indent1\">Eprosartan</td> <td>Teveten</td> <td>600 to 800</td> </tr> <tr> <td class=\"indent1\">Irbesartan</td> <td>Avapro</td> <td>150 to 300</td> </tr> <tr> <td class=\"indent1\">Losartan</td> <td>Cozaar</td> <td>50 to 100</td> </tr> <tr> <td class=\"indent1\">Olmesartan</td> <td>Benicar</td> <td>20 to 40</td> </tr> <tr> <td class=\"indent1\">Telmisartan</td> <td>Micardis</td> <td>40 to 80</td> </tr> <tr> <td class=\"indent1\">Valsartan</td> <td>Diovan</td> <td>80 to 320</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;Doses as low as one-half or one-quarter of the lower dose shown may be used initially in high-risk patients such as those with heart failure, significant renal insufficiency, hyponatremia, intravascular volume depletion, or those receiving concurrent treatment with a diuretic.<br />Â¶&nbsp;Giving one-half the dose twice a day is an alternative that produces a lesser peak effect but a more sustained response; however, patient compliance may be reduced. In patients who do not respond to a moderate dose, we suggest&nbsp;sequential monotherapy&nbsp;for optimizing initial&nbsp;drug selection&nbsp;in most patients&nbsp;rather than use of maximum doses shown in this table.&nbsp;Refer to discussion in UpToDate topic review of choice of drug therapy in primary hypertension for detail.<br />Î Not available in US.</div><div class=\"graphic_reference\">Data from: Lexicomp Online. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved and Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14.</div><div id=\"graphicVersion\">Graphic 64770 Version 12.0</div></div></div>"},"64771":{"type":"graphic_table","displayName":"MMR seroconversion in adults","title":"MMR vaccine in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">MMR vaccine in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Antibody response</td> <td class=\"subtitle1\">Protection against disease</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Most common side effects</td> <td class=\"subtitle1\">Contraindications</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">MMR</td> <td rowspan=\"4\"> <p>Single dose: 0.5 mL SC</p> Second dose if required: 0.5 mL SC at least 28 days later</td> <td rowspan=\"4\"> <p>Most rare after revaccination</p> <p>Fever, rash</p> <p>Lymphadenopathy</p> <p>Febrile seizures</p> <p>Allergic reactions</p> <p>Thrombocytopenia</p> Arthritis, arthralgias</td> <td rowspan=\"4\"> <p>Pregnancy current or planned within 28 days</p> <p>Immunocompromised (refer to&nbsp;related UpToDate&nbsp;topics)</p> <p>Anaphylaxis after eating eggs or receiving neomycin</p> Recent administration of immune globulin (delay vaccine administration for at least six months after intramuscular administration or eight months after intravenous administration)</td> </tr> <tr> <td class=\"indent1\">Measles</td> <td>99 percent&nbsp;(after 2 doses)</td> <td>99 percent&nbsp;- Lifelong</td> </tr> <tr> <td class=\"indent1\">Mumps</td> <td>97 percent&nbsp;(after 1 dose)</td> <td>75 to 95&nbsp;percent &#62;30 years</td> </tr> <tr> <td class=\"indent1\">Rubella</td> <td>95&nbsp;percent (after 1 dose)</td> <td>90 percent&nbsp;&#62;15 years ? lifelong</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMR: measles, mumps, and rubella; SC: subcutaneously.</div><div class=\"graphic_reference\">Adapted from: Watson JC, Pearson JA, Markowitz LE, et al. Pediatrics 1996; 97:613; Weibel RE, Sokes J Jr, Buynak EB, et al. N Engl J Med 1967; 276:245; Balfour HH, Groth KE, Edelman CK. Am J Dis Child 1990; 134:350; O'Shea S, Best JM, Banatvala JE. J Infect Dis 1983; 148:639; Watson JC, Hadler SC, Dykewicz CA, et al. MMWR Recomm Rep 1998; 47:1.</div><div id=\"graphicVersion\">Graphic 64771 Version 8.0</div></div></div>"},"64772":{"type":"graphic_diagnosticimage","displayName":"Urinary tract tuberculosis","title":"Urinary tract tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urinary tract tuberculosis</div><div class=\"cntnt\"><img style=\"width:184px; height:324px;\" src=\"images/NEPH/64772_Urinary_tract_tuberculosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravenous pyelogram in urinary tract tuberculosis. Both upper and lower tract involvement are present on the left side as manifested by blunting of the calyces (caliectasis) and two long ureteral strictures (arrows). Although the caliceal changes can be seen in other disorders (such as reflux nephropathy), the concurrent ureteral abnormalities are virtually diagnostic of tuberculosis. A normal pelvic right kidney is also present but is not well visualized.</div><div class=\"graphic_reference\">From Rose BD, Pathophysiology of Renal Disease, 1st ed, McGraw-Hill, New York 1981.</div><div id=\"graphicVersion\">Graphic 64772 Version 3.0</div></div></div>"},"64773":{"type":"graphic_waveform","displayName":"EEG temporal sharp wave","title":"Left temporal sharp wave in a patient with left temporal lobe epilepsy","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Left temporal sharp wave in a patient with left temporal lobe epilepsy</div><div class=\"cntnt\"><img style=\"width:462px; height:480px;\" src=\"images/NEURO/64773_EEG_temporal_sharp_wave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the high amplitude and the aftergoing slow wave. The sharp wave clearly stands out from the background activity.</div><div id=\"graphicVersion\">Graphic 64773 Version 2.0</div></div></div>"},"64774":{"type":"graphic_table","displayName":"Gemcitabine plus cisplatin regimen for NSCLC","title":"Gemcitabine plus cisplatin for non-small cell lung cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine plus cisplatin for non-small cell lung cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Every 21 days, for a maximum of six cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Gemcitabine</td> <td>1200 mg/m<sup>2</sup> IV*</td> <td>Dilute in 250 mL normal saline (NS) (concentration no more than 40 mg/mL) and administer over 30 to 60 minutes.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Day 1: HIGH;<br /> Day 8: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (risk of neutropenic fever is approximately 4%). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for preexisting baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[2]</sup> A lower starting dose of gemcitabine may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes, renal, and liver function weekly during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Each cycle should not begin until the WBC count is &#62;3000 cells/microL and platelet count is &#62;100,000/microL.<sup>[1]</sup> Gemcitabine should be withheld on day 8 if the WBC count is &#60;2000 cells/microL or platelets are &#60;50,000/microL.<sup>[1]</sup> This is consistent with the United States Prescribing Information that recommends to hold gemcitabine for an ANC &#60;500 cells/microL and platelets &#60;50,000/microL.<sup>[3]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Severe non-hematologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine and cisplatin should be withheld or doses decreased depending on clinical judgement. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; WBC: white blood cell; ANC: absolute neutrophil count.<br />* This dose of gemcitabine differs slightly from that originally published<SUP>[2]</SUP> but is used in the current ECOG protocol.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Institutes of Health Clinical Trials database. Eastern Cooperative Oncology Group protocol E1505. (Available online at www.clinicaltrials.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Scagliotti GV, et al. J Clin Oncol 2008; 26:3543.</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 64774 Version 29.0</div></div></div>"},"64776":{"type":"graphic_picture","displayName":"Position for radial artery puncture","title":"Position for radial artery puncture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Position for radial artery puncture</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/64776_PositionradialartpuncPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wrist is extended as shown to bring the radial artery closer to the surface.</div><div class=\"graphic_reference\">Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64776 Version 6.0</div></div></div>"},"64779":{"type":"graphic_figure","displayName":"DKA nomogram sodium","title":"Nomogram of anticipated serum Na+ versus serum glucose during DKA treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nomogram of anticipated serum Na+ versus serum glucose during DKA treatment</div><div class=\"cntnt\"><img style=\"width:400px; height:632px;\" src=\"images/PEDS/64779_DKA_nomogram_sodium.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Nomogram of anticipated serum sodium versus serum glucose during insulin treatment. This figure depicts the anticipated rise in the plasma sodium concentrations with the correction of hyperglycemia in diabetic ketoacidosis. Because a particular child may have greater or lesser losses of free water before presentation, the initial point plotted may be at different starting positions. However, whatever the starting position, the rise in plasma glucose should be along a line parallel to the isobars (dashed green lines), because the Na+ will rise by approximately 2.4 mEq/L for every 100 mg/dL fall in plasma glucose.<br />(Panel B) Example of the use of the nomogram of anticipated serum sodium versus glucose during insulin treatment. For a typical patient, the measured serum sodium will rise as expected (blue circles). If the patient's sodium does not rise as expected as the glucose falls (red triangles), the child may have been given excessive free water.</div><div class=\"graphic_footnotes\">Na: sodium.</div><div id=\"graphicVersion\">Graphic 64779 Version 2.0</div></div></div>"},"64780":{"type":"graphic_picture","displayName":"Speckled lentiginous nevi","title":"Speckled lentiginous nevi (nevus spilus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Speckled lentiginous nevi (nevus spilus)</div><div class=\"cntnt\"><img style=\"width:432px; height:309px;\" src=\"images/PEDS/64780_Speckled_lentiginous_nevi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple brown spots are superimposed on a background tan patch.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 64780 Version 1.0</div></div></div>"},"64781":{"type":"graphic_waveform","displayName":"Intraventricular conduction delay tutorial","title":"Intraventricular conduction delay","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Intraventricular conduction delay</div><div class=\"cntnt\"><img style=\"width:530px; height:199px;\" src=\"images/CARD/64781_IVCD_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ST-T wave abnormalities secondary to intraventricular conduction disturbances (eg, left or right bundle branch block) look similar to those that occur during ischemia. The ST segments may be depressed or elevated; when there is an ST segment shift present, it is most often in a direction opposite to the polarity of the QRS complex. The T wave also has a polarity opposite to the direction of the QRS complex. Thus, there are typically ST segment depressions and T wave inversions in leads V1 to V3 with a right bundle branch block (RBBB), reflecting repolarization abnormalities of the right ventricular myocardium. Repolarization changes in the left ventricular myocardium due to a left bundle branch block (LBBB) result in downsloping ST depression and T wave inversion in leads V4 or V5 to V6.</div><div id=\"graphicVersion\">Graphic 64781 Version 3.0</div></div></div>"},"64782":{"type":"graphic_table","displayName":"Diagnostic criteria POEMS syndrome","title":"Criteria for the diagnosis of POEMS syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of POEMS syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mandatory major criteria (both required)</td> </tr> <tr> <td class=\"indent1\">Polyneuropathy</td> </tr> <tr> <td class=\"indent1\">Monoclonal plasma cell proliferative disorder (almost always lambda)</td> </tr> <tr> <td class=\"subtitle1_single\">Other major criteria (one required)</td> </tr> <tr> <td class=\"indent1\">Sclerotic bone lesions</td> </tr> <tr> <td class=\"indent1\">Castleman's disease</td> </tr> <tr> <td class=\"indent1\">Elevated levels of vascular endothelial growth factor (VEGF)*</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria (one required)</td> </tr> <tr> <td class=\"indent1\">Organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy)</td> </tr> <tr> <td class=\"indent1\">Extravascular volume overload (edema, pleural effusion, or ascites)</td> </tr> <tr> <td class=\"indent1\">Endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Skin changes (hyperpigmentation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyanosis, flushing, white nails)</td> </tr> <tr> <td class=\"indent1\">Papilledema</td> </tr> <tr> <td class=\"indent1\">Thrombocytosis/polycythemia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The diagnosis of POEMS syndrome is confirmed when both of the mandatory major criteria, one of the three other major criteria, and one of the six minor criteria are present.</div><div class=\"graphic_footnotes\">* The source data do not define an optimal cut off value for considering elevated VEGF level as a major criterion. We suggest that VEGF measured in the serum or plasma should be at least three- to fourfold higher than the normal reference range for the laboratory that is doing the testing to be considered a major criterion.<br />Â¶ In order to consider endocrinopathy as a minor criterion, an endocrine disorder other than diabetes or hypothyroidism is required since these two disorders are common in the general population.</div><div class=\"graphic_reference\">Original figure modified for this publication. Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21:285. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64782 Version 5.0</div></div></div>"},"64783":{"type":"graphic_figure","displayName":"Definition and extent of resection for adenocarcinoma of the EGJ","title":"Definition and extent of resection for type I, II, and III adenocarcinoma of esophagogastric junction","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Definition and extent of resection for type I, II, and III adenocarcinoma of esophagogastric junction</div><div class=\"cntnt\"><img style=\"width:534px; height:658px;\" src=\"images/ONC/64783_Resection-adenocarcinoma-EGJ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures represent the Siewert classification for tumors arising at the esophagogastric junction (EGJ) and the extent of the surgical resection for an EGJ adenocarcinoma, including regional lymph nodes, based upon the Siewert classification.<br> Type I adenocarcinoma is located in the distal esophagus and is resected by a subtotal gastrectomy, subtotal esophagectomy, and regional lymphadenectomy.<br> Type II adenocarcinoma arises from the cardia or the EGJ and is resected by a total gastrectomy, distal esophagectomy, and regional lymphadenectomy.<br> Type III adenocarcinoma originates in the subcardial gastric location, infiltrates the EGJ and distal esophagus from below, and is resected by a total gastrectomy, distal esophagectomy, and regional lymphadenectomy.</div><div class=\"graphic_reference\">Based on information from: Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesphagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 2011; 12:296.</div><div id=\"graphicVersion\">Graphic 64783 Version 17.0</div></div></div>"},"64784":{"type":"graphic_picture","displayName":"Early disseminated Lyme disease","title":"Early disseminated Lyme disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early disseminated Lyme disease</div><div class=\"cntnt\"><img style=\"width:415px; height:504px;\" src=\"images/DERM/64784_Earlydisseminatedlyme.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple lesions of erythema migrans are present.</div><div id=\"graphicVersion\">Graphic 64784 Version 2.0</div></div></div>"},"64789":{"type":"graphic_table","displayName":"Definition of BPD","title":"Definition of bronchopulmonary dysplasia: Diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of bronchopulmonary dysplasia: Diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Gestational age</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle2\">&#60;32 week</td>\n\n\n      <td class=\"subtitle2\">&#8805;32 week</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"1\">Time point of assessment </td>\n\n\n      <td>36 weeks PMA or discharge to home, whichever comes first</td>\n\n\n      <td>&#62;28 days but &#60;56 days postnatal age or discharge to home, whichever comes first</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n\n      <td>&nbsp;</td>\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Treatment with oxygen &#62;21 percent for at least 28 days plus</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Mild BPD</td>\n\n\n      <td>Breathing room air at 36 weeks PMA or discharge, whichever comes first</td>\n\n\n      <td>Breathing room air by 56 days postnatal age or discharge, whichever comes first</td>\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n      <td>Moderate BPD</td>\n\n\n      <td>Need* for &#60;30 percent oxygen at 36 weeks PMA or discharge, whichever comes first</td>\n\n\n      <td>Need* for &#60;30 percent oxygen at 56 days postnatal age or discharge, whichever comes first</td>\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n      <td>Severe BPD</td>\n\n\n      <td>Need* for &#8805;30 percent oxygen and/or positive pressure (PPV or NCPAP) at 36 weeks PMA or discharge, whichever comes first</td>\n\n\n      <td>Need* for &#8805;30 percent oxygen and/or positive pressure (PPV\nor NCPAP) at 56 days postnatal age or discharge, whichever comes first</td>\n\n\n    </tr>\n\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">BPD: bronchopulmonary dysplasia; NCPAP: nasal continuous positive airway pressure; PMA: postmenstrual age; PPV: positive-pressure ventilation.<br>  * A physiologic test confirming that the oxygen requirement at the assessment time point remains to be defined. This assessment may include a pulse oximetry saturation range.<br> BPD usually develops in neonates being treated with oxygen and positive pressure ventilation for respiratory failure, most commonly respiratory distress syndrome. Persistence of clinical features of respiratory disease (tachypnea, retractions, rales) are considered common to the broad description of BPD and have not been included in the diagnostic criteria describing the severity of BPD. Infants treated with oxygen &gt;21 percent and/or positive pressure for nonrespiratory disease (eg, central apnea or diaphragmatic paralysis) do not have BPD unless they also develop parenchymal lung disease and exhibit clinical features of respiratory distress. A day of treatment with oxygen &gt;21 percent means that the infant received oxygen &gt;21 percent for more than 12 hours on that day. Treatment with oxygen &gt;21 percent and/or positive pressure at 36 weeks PMA, or at 56 days postnatal age or discharge, should not reflect an &quot;acute&quot; event, but should rather reflect the infant's usual daily therapy for several days preceding and following 36 weeks PMA, 56 days postnatal age, or discharge.</div><div class=\"graphic_reference\">Reproduced with permission from: Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163:1723. Copyright &#169;2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 64789 Version 2.0</div></div></div>"},"64790":{"type":"graphic_figure","displayName":"Glucose disappearance by weight","title":"Glucose rate of disappearance (Rd)","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Glucose rate of disappearance (Rd)</div><div class=\"cntnt\"><img style=\"width:556px; height:352px;\" src=\"images/PEDS/64790_Glucose_disappearance_by_we.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Total glucose rate of disappearance (Rd) (mmol/min) as a function of body weight from infancy to adulthood (n=141; body weights range from 0.6 to 94 kg).</div><div class=\"graphic_reference\">Data from Haymond, MW, Sunehag, A. Controlling the sugar bowl. Regulation of glucose homeostasis in children. Endocrinol Metab Clin North Am 1999; 28:663.</div><div id=\"graphicVersion\">Graphic 64790 Version 1.0</div></div></div>"},"64794":{"type":"graphic_table","displayName":"NWTS/COG regimens for Wilms tumor","title":"Treatment regimens for Wilms tumor accordingÂ toÂ completed North American (NWTS/COG) trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment regimens for Wilms tumor according&nbsp;to&nbsp;completed North American (NWTS/COG) trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">&nbsp;<br /> &nbsp;&nbsp;NWTS/COG AREN0321, AREN0532, and AREN0533</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;Stage*</td> <td class=\"subtitle2\">Histology&nbsp;and clinical factors</td> <td class=\"subtitle2\">Chemotherapy</td> <td class=\"subtitle2\">Radiation therapy</td> </tr> <tr> <td rowspan=\"4\">&nbsp;I</td> <td>Favorable histology; very low risk<sup>&#182;</sup></td> <td>None</td> <td>&nbsp;None</td> </tr> <tr> <td>Favorable histology; non-very-low-risk<sup>&#182;</sup>; without high-risk molecular markers<sup>&#916;</sup></td> <td>Vincristine and&nbsp;dactinomycin for&nbsp;19 weeks</td> <td>None</td> </tr> <tr> <td>Favorable histology; non-very-low-risk<sup><span style=\"font-size: 13px;\">&#182;</span></sup>; with high-risk molecular markers<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>Vincristine, dactinomycin, and doxorubicin&nbsp;for&nbsp;25 weeks</td> <td>None</td> </tr> <tr> <td>Focal&nbsp;or&nbsp;diffuse anaplasia</td> <td>Vincristine, dactinomycin, and doxorubicin&nbsp;for&nbsp;25 weeks</td> <td>10.8 Gy flank</td> </tr> <tr> <td rowspan=\"4\">II</td> <td>Favorable histology; without high-risk molecular markers<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>Vincristine and&nbsp;dactinomycin for&nbsp;19 weeks</td> <td>None</td> </tr> <tr> <td>Favorable histology; with high-risk molecular markers<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>Vincristine, dactinomycin, and doxorubicin&nbsp;for&nbsp;25 weeks</td> <td>None</td> </tr> <tr> <td>Focal anaplasia</td> <td>Vincristine, dactinomycin, and doxorubicin&nbsp;for&nbsp;25 weeks</td> <td>10.8 Gy flank</td> </tr> <tr> <td>Diffuse anaplasia</td> <td>Vincristine, doxorubicin, carboplatin, cyclophosphamide, and etoposide for 30 weeks</td> <td>10.8 Gy flank</td> </tr> <tr> <td rowspan=\"4\">III</td> <td>Favorable histology; without high-risk molecular markers<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>Vincristine, dactinomycin, and doxorubicin&nbsp;for&nbsp;25 weeks</td> <td>10.8 Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr> <td>Favorable histology; with high-risk molecular markers<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>Vincristine, dactinomycin, doxorubicin, cyclophosphamide, and etoposide for 31 weeks</td> <td>10.8 Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr> <td>Focal anaplasia</td> <td>Vincristine, dactinomycin, and doxorubicin&nbsp;for&nbsp;25 weeks</td> <td>10.8 Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr> <td>Diffuse anaplasia</td> <td>Vincristine, doxorubicin, carboplatin, cyclophosphamide, and etoposide for 30 weeks</td> <td>20&nbsp;Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr> <td rowspan=\"4\">&nbsp;IV</td> <td>Favorable histology; without high-risk molecular markers<sup><span style=\"font-size: 13px;\">&#916;</span></sup> and&nbsp;lung nodule complete response at week 6</td> <td>Vincristine, dactinomycin, and doxorubicin&nbsp;for&nbsp;25 weeks</td> <td>No lung XRT;&nbsp; flank XRT for local stage III<sup>&#9674;</sup></td> </tr> <tr> <td>Favorable histology; with high-risk molecular markers<sup><span style=\"font-size: 13px;\">&#916;</span></sup> and/or lung nodule incomplete response at week 6</td> <td>Vincristine, dactinomycin, doxorubicin, cyclophosphamide, and etoposide for 31 weeks</td> <td>12 Gy lung; flank XRT for local stage III<sup>&#9674;</sup></td> </tr> <tr> <td>Focal anaplasia</td> <td>Vincristine, doxorubicin, carboplatin, cyclophosphamide, and etoposide for 30 weeks</td> <td>12 Gy lung; flank XRT for local stage III<sup>&#9674;</sup></td> </tr> <tr> <td>Diffuse anaplasia</td> <td>&nbsp;Vincristine, doxorubicin, carboplatin, cyclophosphamide, etoposide, and irinotecan&nbsp;for 36 weeks</td> <td>12 Gy lung; flank XRT for local stage III<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NWTS: National Wilms Tumor Study; COG: Children's oncology group; SIOP: International Society of Pediatric Oncology; LOH: loss of heterozygosity; XRT: radiation therapy.<br />* Note that the staging systems in NWTS/COG and SIOP protocols are not equivalent.&nbsp;NWTS/COG stage is determined <STRONG>before</STRONG> surgical resection; SIOP stage is determined <STRONG>after</STRONG> preoperative chemotherapy and surgical resection.<br />Â¶ According to NWTS/COG protocols, very low risk tumors are defined as meeting all of the following criteria: patient age &lt;2 years, stage I favorable histology, tumor weight &lt;550 grams.<br />Îâ According to NWTS/COG protocols, high-risk molecular markers refers to combined loss of heterozygosity [LOH] at chromosomes 1p and 16q.<br />â Metastatic sites other than lung were also irradiated; XRT dose varied according to metastatic site.<br /></div><div class=\"graphic_reference\">Additional references:<br /><OL>&#xD;&#xA;<LI>Fernandez CV, Perlmann E, Mullen EA, et al. Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Childrenâs Oncology Group AREN0532. J Clin Oncol 2015; 33:10023.</LI>&#xD;&#xA;<LI>Dix DB, Fernandez CV, Chi YY, et al. Augmentation of therapy for favorable-histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Childrenâs Oncology Group studies AREN0532 and AREN0533. J Clin Oncol 2015; 33:abstr 10009.</LI>&#xD;&#xA;<LI>Dix DB, Gratias EJ, Seibel Nita, et al. Omission of lung radiation in patients with stage IV favorable histology Wilms Tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Childrenâs Oncology Group study AREN0533. J Clin Oncol 2015; 33:10011.</LI></OL>Adapted from: Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol 2015; 33:2999.</div><div id=\"graphicVersion\">Graphic 64794 Version 7.0</div></div></div>"},"64797":{"type":"graphic_movie","displayName":"Subcostal view tetralogy of Fallot","title":"Subcostal parasagittal view in tetralogy of Fallot (TOF)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcostal parasagittal view in tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/64797_SubviewtetraFallot.mp4\" style=\"width:432px;height:304px\"></div><img style=\"width:488px; height:332px;\" src=\"images/PEDS/64797_SubviewtetralogyFallot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from the accompanying echocardiographic video clip of the subcostal parasagittal view of a patient with tetralogy of Fallot (TOF) demonstrates the anterior deviation of the conal septum (arrow) and resultant infundibular obstruction of the right ventricular outflow tract (RVOT).</div><div class=\"graphic_footnotes\">RV: right ventricle; Ao: aorta; RPA: right pulmonary artery; LPA: left pulmonary artery; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 64797 Version 1.0</div></div></div>"},"64798":{"type":"graphic_picture","displayName":"Metagonimus egg","title":"<EM>Metagonimus</EM> egg","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Metagonimus</EM> egg</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/64798_Metagonimus_egg_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Egg of <EM>Metagonimus</EM> spp from human.</div><div class=\"graphic_reference\">Reproduced with permission from: the Web Atlas of Medical Parasitology. Copyright Â© 2003 The Korean Society for Parasitology.</div><div id=\"graphicVersion\">Graphic 64798 Version 3.0</div></div></div>"},"64800":{"type":"graphic_picture","displayName":"HCC surgical resection Gross","title":"Hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:531px; height:457px;\" src=\"images/GAST/64800_HCC_surgical_resection_Gros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Series of photographs taken during resection of a hepatocellular carcinoma in a patient with Child's A cirrhosis due to chronic hepatitis C. The upper two panels demonstrate the tumor projecting from the inferior aspect of the left lobe of the liver (arrows). The nodular surface of the liver is apparent, indicating underyling cirrhosis. The bottom panel illustrates the resection specimen.</div><div class=\"graphic_reference\">Courtesy of Richard B Freeman, Jr, MD.</div><div id=\"graphicVersion\">Graphic 64800 Version 1.0</div></div></div>"},"64801":{"type":"graphic_algorithm","displayName":"Follow-up testing in histo","title":"Follow-up to evaluate for suspected relapse in patients with disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Follow-up to evaluate for suspected relapse in patients with disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:539px; height:590px;\" src=\"images/ID/64801_Follow-up_testing_in_histo.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64801 Version 1.0</div></div></div>"},"64802":{"type":"graphic_table","displayName":"Babesia seroprevalence","title":"Seroprevalence of babesiosis by area, year, and time of year","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seroprevalence of babesiosis by area, year, and time of year</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Region</td> <td class=\"subtitle1\">Timeframe</td> <td class=\"subtitle1\">Demographic</td> <td class=\"subtitle1\">Seroprevalence</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Nantucket Island, Massachusetts</td> <td>August 1975 to July 1976<sup>[1]</sup>&nbsp;</td> <td>History of tick bite or fever for &#8805;3 days</td> <td>7.5 percent</td> </tr> <tr> <td>August 1975 to July 1976<sup>[1]</sup>&nbsp;</td> <td>Residents and visitors undergoing routine diagnostic</td> <td>1.9 percent</td> </tr> <tr class=\"divider_bottom\"> <td>March 2004<sup>[2]</sup>&nbsp;</td> <td>Blood donors</td> <td>7.3 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Martha's Vineyard, Massachusetts</td> <td>Year-round 2002 to 2007<sup>[2]</sup>&nbsp;</td> <td>Blood donors</td> <td>1.4 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Cape Cod, Massachusetts</td> <td>Summer 1984<sup>[3]</sup>&nbsp;</td> <td>Blood donors</td> <td>3.7 percent</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Block Island, Rhode Island</td> <td>September 1990 to February 1991<sup>[4,5]</sup>&nbsp;</td> <td>Residents</td> <td>4.6 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Biannual serosurveys at beginning of summer and in the fall of 1999 and 2000<sup>[6]</sup>&nbsp;</td> <td>Residents</td> <td>9 percent</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Connecticut, southeastern</td> <td>July 1999<sup>[7]</sup>&nbsp;</td> <td>Blood donors</td> <td>1.9 percent</td> </tr> <tr> <td>September 1999<sup>[7]</sup>&nbsp;</td> <td>Blood donors</td> <td>0.5 percent</td> </tr> <tr> <td>Year 2000<sup>[6]</sup>&nbsp;</td> <td>Blood donors</td> <td>9 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Summer or year-round, 2000 to 2007<sup>[2]</sup>&nbsp;</td> <td>Blood donors</td> <td>1.7 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Connecticut, other than southeastern</td> <td>Summer or year-round, 2000 to 2007<sup>[2]</sup>&nbsp;</td> <td>Blood donors</td> <td>0.5 percent</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Shelter Island, New York</td> <td>June 1978<sup>[8]</sup>&nbsp;</td> <td>Residents</td> <td>4.4 percent</td> </tr> <tr> <td>October 1978<sup>[8]</sup>&nbsp;</td> <td>Residents</td> <td>6.9 percent</td> </tr> <tr class=\"divider_bottom\"> <td>May 1998<sup>[9]</sup>&nbsp;</td> <td>Blood donors</td> <td>4.3 percent</td> </tr> <tr class=\"divider_bottom\"> <td>South Fork - Long Island, New York</td> <td>Fall 1984<sup>[9]</sup>&nbsp;</td> <td>Blood donors</td> <td>15.8 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Eastern Long Island, New York</td> <td>Winter 1994 to 1995<sup>[10]</sup>&nbsp;</td> <td>Residents</td> <td>1 percent</td> </tr> <tr> <td rowspan=\"2\">Minnesota</td> <td>October to November 2010 and April to November 2011<sup>[11]</sup>&nbsp;</td> <td>Blood donors</td> <td>2 percent</td> </tr> <tr> <td>July to August 2011<sup>[11]</sup>&nbsp;</td> <td>Blood donors</td> <td>2.8 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Ruebush TK 2nd, Juranek DD, Chisholm ES, et al. Human babesiosis on Nantucket Island. Evidence for self-limited and subclinical infections. N Engl J Med 1977; 297:825.</li>&#xD;&#xA;    <li>Johnson ST, Cable RG, Tonnetti L, et al. Seroprevalence of Babesia microti in blood donors from Babesia-endemic areas of the northeastern United States: 2000 through 2007. Transfusion 2009; 49:2574.</li>&#xD;&#xA;    <li>Popovsky MA, Lindberg LE, Syrek AL, Page PL. Prevalence of Babesia antibody in a selected blood donor population. Transfusion 1988; 28:59.</li>&#xD;&#xA;    <li>Krause PJ, Telford SR 3rd, Pollack RJ, et al. Babesiosis: an underdiagnosed disease of children. Pediatrics 1992; 89:1045.</li>&#xD;&#xA;    <li>McQuiston JH, Childs JE, Chamberland ME, Tabor E. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000; 40:274.</li>&#xD;&#xA;    <li>Krause PJ, McKay K, Gadbaw J, et al. Increasing health burden of human babesiosis in endemic sites. Am J Trop Med Hyg 2003; 68:431.</li>&#xD;&#xA;    <li>Leiby DA, Chung AP, Gill JE, et al. Demonstrable parasitemia among Connecticut blood donors with antibodies to Babesia microti. Transfusion 2005; 45:1804.</li>&#xD;&#xA;    <li>Filstein MR, Benach JL, White DJ, et al. Serosurvey for human babesiosis in New York. J Infect Dis 1980; 141:518.</li>&#xD;&#xA;    <li>Linden JV, Wong SJ, Chu FK, et al. Transfusion-associated transmission of babesiosis in New York State. Transfusion 2000; 40:285.</li>&#xD;&#xA;    <li>Hilton E, DeVoti J, Benach JL, et al. Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States. Am J Med 1999; 106:404.</li>&#xD;&#xA;    <li>Tonnetti L, Thorp AM, Deisting B, et al. Babesia microti seroprevalence in Minnesota blood donors. Transfusion 2013; 53:1698.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 64802 Version 5.0</div></div></div>"},"64806":{"type":"graphic_picture","displayName":"Scabies interdigital","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64806_Scabies_interdigital.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small excoriated papules involving the interdigital web space in a patient with scabies.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64806 Version 4.0</div></div></div>"},"64808":{"type":"graphic_picture","displayName":"Bcl 2 staining in FL","title":"Follicular lymphoma: bcl-2 staining","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma: bcl-2 staining</div><div class=\"cntnt\"><img style=\"width:527px; height:288px;\" src=\"images/HEME/64808_Bcl_2_staining_in_FL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Neoplastic cells within the lymph node follicle from a patient with follicular lymphoma show strong immunostaining (brown color) for bcl-2. The lymphocytes in the thin mantles and the interfollicular regions also show bcl-2 reactivity. Right panel: In comparison, the germinal centers in a reactive follicle are bcl-2 negative, with the positive cells being located in the mantle and interfollicular regions.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 64808 Version 1.0</div></div></div>"},"64809":{"type":"graphic_table","displayName":"Acute scrotum disposition","title":"The acute scrotum: suggested disposition and treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The acute scrotum: suggested disposition and treatment</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Testicular torsion</td> </tr> <tr> <td class=\"subtitle2_single\">Indications for surgery:</td> </tr> <tr> <td class=\"indent1\">Suggestive history or physical examination</td> </tr> <tr> <td class=\"indent1\">Similar episodes &#62;2 weeks ago</td> </tr> <tr> <td class=\"indent1\">No flow or spermatic cord knot by Doppler ultrasound</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diagnostic uncertainty<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Treatment:</td> </tr> <tr> <td class=\"indent1\">Definitive: surgery</td> </tr> <tr> <td class=\"indent1\">Temporizing: trial of manual detorsion</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Torsion of appendage</td> </tr> <tr> <td class=\"subtitle2_single\">Admission criteria:</td> </tr> <tr> <td class=\"indent1\">Testicular torsion excluded</td> </tr> <tr> <td class=\"indent1\">Severe pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pain refractory to trial of analgesics and conservative management</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment:</td> </tr> <tr> <td class=\"indent1\">Analgesics</td> </tr> <tr> <td class=\"indent1\">Rest</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acute epididymitis</td> </tr> <tr> <td class=\"subtitle2_single\">Admission criteria:</td> </tr> <tr> <td class=\"indent1\">Testicular torsion excluded</td> </tr> <tr> <td class=\"indent1\">Severe pain</td> </tr> <tr> <td class=\"indent1\">Immunocompromised</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Not tolerating oral medications or noncompliant</td> </tr> <tr> <td class=\"subtitle2_single\">Treatment:</td> </tr> <tr> <td class=\"subtitle3_single\">Children:</td> </tr> <tr> <td class=\"indent2\"> <p>If pyuria &#62;3 WBC/hpf or positive culture, or if underlying GU abnormality:</p> Antibiotic course against coliforms*</td> </tr> <tr> <td class=\"indent2\"> <p>If no pyuria and negative culture:</p> <p>Antibiotics not required</p> Extensive evaluation not required</td> </tr> <tr> <td class=\"subtitle3_single\">Sexually active adolescents:</td> </tr> <tr> <td class=\"indent2\">Heterosexual: empiric antibiotics (chlamydia, GC)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Homosexual: empiric antibiotics (chlamydia, GC and coliforms)<sup>&#916;</sup></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Antibiotic choices include: Trimethoprim (TMP)-sulfamethoxazole (6-12 mg TMP component/kg per day divided every 12 hours) <STRONG>or</STRONG> cephalexin (25-50 mg/kg per day divided every 6-8 hours).<br />Â¶ Refer to the 2015 Sexually Transmitted Diseases Guidelines from the Centers for Disease Control and Prevention available at their <A spellcheck=true href=\"http://www.cdc.gov/std/tg2015/default.htm\" target=_blank>website</A>.<br />Î Significant overlap in clinical fndings and diagnostic studies may occur for testicular torsion, torsed appendage, or acute epididymitis. Exploratory surgery may ultimately be necessary to determine the etiology of scrotal pain.</div><div class=\"graphic_reference\">Adapted with permission from:<br />Burgher, SW. Acute scrotal pain. Emerg Med Clin North Am 1998; 16:781.<br /></div><div id=\"graphicVersion\">Graphic 64809 Version 5.0</div></div></div>"},"64811":{"type":"graphic_figure","displayName":"Projected height A","title":"Estimated projected height using current growth channel","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Estimated projected height using current growth channel</div><div class=\"cntnt\"><img style=\"width:540px; height:703px;\" src=\"images/PEDS/64811_Projected_height_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Projected height provides a crude estimate of adult height in healthy children. Projected height is determined by extrapolating the child's growth along the current channel to the 18- to 20-year mark. In the example above, the six-year-old boy is 43.5 inches (point A) which is at the 10th percentile. His projected adult height is the 10th percentile height for a 20-year-old (point B): 66 inches.<br />Projected height is only weakly correlated with actual adult height, especially for young children, and has minimal predictive value for children younger than two years. Projected height does not provide a valid estimate of adult height in children with delayed or advanced bone age, or a variety of pathologic causes of short stature.</div><div class=\"graphic_reference\">From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion.</div><div id=\"graphicVersion\">Graphic 64811 Version 4.0</div></div></div>"},"64812":{"type":"graphic_waveform","displayName":"ECG biventricular pacing","title":"Single lead electrocardiogram (ECG) showing biventricular pacing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing biventricular pacing</div><div class=\"cntnt\"><img style=\"width:395px; height:152px;\" src=\"images/CARD/64812_Biventriculr_pacing.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Jordan Prutkin.</div><div id=\"graphicVersion\">Graphic 64812 Version 4.0</div></div></div>"},"64813":{"type":"graphic_picture","displayName":"Perineal urethrostomy","title":"Perineal urethrostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perineal urethrostomy</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/SURG/64813_Perineal_urethrostomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64813 Version 1.0</div></div></div>"},"64815":{"type":"graphic_diagnosticimage","displayName":"Chest CT cryptococcal pneumonia","title":"TransverseÂ computed tomographyÂ scan in 46-year-old woman shows several nodules in the lung bases (7 mm-thick section)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transverse&nbsp;computed tomography&nbsp;scan in 46-year-old woman shows several nodules in the lung bases (7 mm-thick section)</div><div class=\"cntnt\"><img style=\"width:504px; height:351px;\" src=\"images/ID/64815_Chest_CT_cryptococcal_pneum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most of the nodules have smooth margins.</div><div class=\"graphic_reference\">Reproduced with permission from: Lindell R, Hartman T, Nadrous H, et al. Pulmonary Cryptococcosis: CT findings in immunocompetent patients. Radiology 2005; 236:326. Copyright Â© 2005 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 64815 Version 3.0</div></div></div>"},"64816":{"type":"graphic_table","displayName":"Pathogen-directed therapy for CAP in adults","title":"Recommended antimicrobial therapy for specific pathogens causing community-acquired pneumonia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended antimicrobial therapy for specific pathogens causing community-acquired pneumonia in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Preferred antimicrobial(s)</td> <td class=\"subtitle1\">Alternative antimicrobial(s)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class=\"sublist1\">Penicillin nonresistant; MIC &#60;2 microgram/mL</td> <td class=\"sublist_other\">Penicillin G, amoxicillin</td> <td class=\"sublist_other\">Macrolide, cephalosporins (oral [cefpodoxime, cefprozil, cefuroxime, cefdinir, cefditoren] or parenteral [cefuroxime, ceftriaxone, cefotaxime]), clindamycin, doxycyline, respiratory fluoroquinolone*</td> </tr> <tr> <td class=\"sublist1\">Penicillin resistant; MIC &#8805;2 microgram/mL</td> <td class=\"sublist_other\">Agents chosen on the basis of susceptibility, including cefotaxime, ceftriaxone, fluoroquinolone</td> <td class=\"sublist_other\">Vancomycin, linezolid, high-dose amoxicillin (3 g/day with penicillin MIC &#8804;4 microgram/mL)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Haemophilus influenzae</em></td> </tr> <tr> <td class=\"sublist1\">Non-beta-lactamase producing</td> <td class=\"sublist_other\">Amoxicillin</td> <td class=\"sublist_other\">Fluoroquinolone, doxycycline, azithromycin, clarithromycin<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">Beta-lactamase producing</td> <td class=\"sublist_other\">Second- or third-generation cephalosporin, amoxicillin-clavulanate</td> <td class=\"sublist_other\">Fluoroquinolone, doxycycline, azithromycin, clarithromycin<sup>&#182;</sup></td> </tr> <tr> <td><em>Mycoplasma pneumoniae/Chlamydophila pneumoniae</em></td> <td>Macrolide, a tetracycline</td> <td>Fluoroquinolone</td> </tr> <tr> <td><em>Legionella</em> species</td> <td>Fluoroquinolone, azithromycin</td> <td>Doxycyline</td> </tr> <tr> <td><em>Chlamydophila psittaci</em></td> <td>A tetracycline</td> <td>Macrolide</td> </tr> <tr> <td><em>Coxiella burnetii</em></td> <td>A tetracycline</td> <td>Macrolide</td> </tr> <tr> <td><em>Francisella tularensis</em></td> <td>Doxycycline</td> <td>Gentamicin, streptomycin</td> </tr> <tr> <td><em>Yersinia pestis</em></td> <td>Streptomycin, gentamicin</td> <td>Doxycyline, fluoroquinolone</td> </tr> <tr> <td><em>Bacillus anthracis</em> (inhalation)</td> <td>Ciprofloxacin, levofloxacin, doxycycline (usually with second agent)</td> <td>Other fluoroquinolones; beta-lactam, if susceptible; rifampin; clindamycin; chloramphenicol</td> </tr> <tr> <td>Enterobacteriaceae</td> <td>Third-generation cephalosporin, carbapenem<sup>&#916;</sup> (drug of choice if extended-spectrum beta-lactamase producer)</td> <td>Beta-lactam/beta-lactamase inhibitor<sup>&#9674;</sup>, fluoroquinolone</td> </tr> <tr> <td><em>Pseudomonas aeruginosa</em></td> <td>Antipseudomonal beta-lactam<sup>&#167;</sup> <strong>plus</strong> (ciprofloxacin or levofloxacin<sup>&#165;</sup> or aminoglycoside)</td> <td>Aminoglycoside <strong>plus</strong> (ciprofloxacin or levofloxacin<sup>&#165;</sup>)</td> </tr> <tr> <td><em>Burkholderia pseudomallei</em></td> <td>Carbapenem, ceftazidime</td> <td>Fluoroquinolone, TMP-SMX</td> </tr> <tr> <td><em>Acinetobacter</em> species</td> <td>Carbapenem</td> <td>Cephalosporin-aminoglycoside, ampicillin-sulbactam, colistin</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"sublist1\">Methicillin susceptible</td> <td class=\"sublist_other\">Antistaphylococcal penicillin<sup>&#135;</sup></td> <td class=\"sublist_other\">Cefazolin, clindamycin</td> </tr> <tr> <td class=\"sublist1\">Methicillin resistant</td> <td class=\"sublist_other\">Vancomycin or linezolid</td> <td class=\"sublist_other\">TMP-SMX</td> </tr> <tr> <td><em>Bordetella pertussis</em></td> <td>Macrolide</td> <td>TMP-SMX</td> </tr> <tr> <td>Anaerobe (aspiration)</td> <td>Beta-lactam/beta-lactamase inhibitor<sup>&#9674;</sup>, clindamycin</td> <td>Carbapenem</td> </tr> <tr> <td>Influenza virus</td> <td>Refer to&nbsp;associated topic reviews<sup>&#134;</sup></td> <td>&nbsp;</td> </tr> <tr> <td><em>Mycobacterium tuberculosis</em></td> <td>Isoniazid plus rifampin plus ethambutol plus pyrazinamide</td> <td>Depends on susceptibility pattern.&nbsp;Refer to&nbsp;associated topic reviews.</td> </tr> <tr> <td><em>Coccidioides</em> species</td> <td>For uncomplicated infection in a normal host, no therapy generally recommended; for therapy, itraconazole, fluconazole.</td> <td>Amphotericin B</td> </tr> <tr> <td>Histoplasmosis</td> <td>Itraconazole**</td> <td>Amphotericin B**</td> </tr> <tr> <td>Blastomycosis</td> <td>Itraconazole**</td> <td>Amphotericin B**</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Choices should be modified on the basis of susceptibility test results and advice from local specialists. Refer to local references for appropriate doses.<br />Preferred agent may change over time due to changing resistance patterns and depends on many factors, including severity of illness.&nbsp;Refer to&nbsp;associated UpToDate topic reviews for updated and detailed treatment recommendations for each pathogen.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; ATS: American Thoracic Society; CDC:&nbsp;United States&nbsp;Centers for Disease Control and Prevention; IDSA: Infectious Diseases Society of America; TMP-SMX: trimethoprim-sulfamethoxazole.<br />* Levofloxacin, moxifloxacin, gemifloxacin (not a first-line choice for penicillin susceptible strains); ciprofloxacin is appropriate for <EM>Legionella</EM> and most gram-negative bacilli (including <EM>H. influenzae</EM>).<br />Â¶ Azithromycin is more active in vitro than clarithromycin for <EM>H. influenzae</EM>.<br />Î Imipenem-cilastatin, meropenem, ertapenem.<br /><FONT class=lozenge>â</FONT> Piperacillin-tazobactam for gram-negative bacilli, ticarcillin-clavulanate, ampicillin-sulbactam, or amoxicillin-clavulanate.<br />Â§ Ticarcillin, piperacillin, ceftazidime, cefepime, aztreonam, imipenem, meropenem.<br />Â¥ 750 mg daily.<br />â¡ Nafcillin, oxacillin, flucloxacillin.<br />â  Choice of antiviral regimen depends on type of influenza virus and expected resistance pattern. (Refer to the UpToDate topic on antiviral drugs for the treatment of influenza in adults.)<br />** Preferred agent depends on severity of illness.&nbsp;Refer to&nbsp;associated UpToDate topic reviews for full discussions.</div><div class=\"graphic_reference\">Adapted with permission from: Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thorac Society Consensus Guidelines on the Management of Community-acquired Pneumonia in Adults. Clin Infect Dis 2007; 44:S27. Copyright &copy; 2007 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 64816 Version 9.0</div></div></div>"},"64817":{"type":"graphic_diagnosticimage","displayName":"SCC in Hodgkins disease","title":"Spinal cord compression due to Hodgkin's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinal cord compression due to Hodgkin's disease</div><div class=\"cntnt\"><img style=\"width:360px; height:279px;\" src=\"images/ONC/64817_SCC_in_Hodgkins_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A firm, white epidural mass strangles the cord at the thoracic level in a 32-year-old woman who developed hypesthesias of the lower extremities in the terminal phase of a seven-year course of Hodgkin's disease.</div><div class=\"graphic_reference\">Reproduced with permission from Burger PC. Surgical Pathology of the Nervous System and its Coverings. 3rd edition. Burger PC, Scheithauer BW, Vogel FS. Churchill Livingstone 1991. p. 584, Figure 8.33.</div><div id=\"graphicVersion\">Graphic 64817 Version 3.0</div></div></div>"},"64818":{"type":"graphic_figure","displayName":"Cervical spine contour lines","title":"Cervical spine contour lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical spine contour lines</div><div class=\"cntnt\"><img style=\"width:264px; height:378px;\" src=\"images/PEDS/64818_Cervical_spine_countour_lin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anterior vertebral line. (B) Posterior vertebral line. (C) Spinolaminal line. (D) Tips of the spinous processes. (1) Dens of C2. (2) Anterior arch of C1. (3) Predental space.</div><div class=\"graphic_reference\">Reproduced with permission from: Barkin, RM, Rosen, P, Emergency Pediatrics: A Guide to Ambulatory Care, 5th ed, Mosby, St Louis 1999. p.455. Copyright &#169; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 64818 Version 2.0</div></div></div>"},"64819":{"type":"graphic_diagnosticimage","displayName":"KÃ¶hler disease","title":"KÃ¶hler disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">KÃ¶hler disease</div><div class=\"cntnt\"><img style=\"width:288px; height:480px;\" src=\"images/PEDS/64819_Kohler_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral and oblique views of the foot demonstrate flattening and sclerosis of the navicular bone. The presence of pain on examination or evidence of progression on repeated radiographs performed at&nbsp;two to four weeks is required to differentiate Kohler disease from a normal growth variant.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 64819 Version 4.0</div></div></div>"},"64820":{"type":"graphic_algorithm","displayName":"Suspected infectious pharyngitis","title":"Sore throat: Suspected infectious pharyngitis","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Sore throat: Suspected infectious pharyngitis</div><div class=\"cntnt\"><img style=\"width:471px; height:608px;\" src=\"images/PEDS/64820_Suspected_infectious_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Further diagnostic testing is required to confirm the diagnosis. Refer to UpToDate topics on the diagnosis of infectious mononucleosis, human immunodeficiency virus, diphtheria, and gonococcal pharyngitis.</div><div id=\"graphicVersion\">Graphic 64820 Version 4.0</div></div></div>"},"64822":{"type":"graphic_figure","displayName":"Reapproximation perineal body","title":"Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex</div><div class=\"cntnt\"><img style=\"width:344px; height:517px;\" src=\"images/OBGYN/64822_Reapproximation_perineal_bo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The perineal body is reapproximated longitudinally with interrupted sutures to lengthen it.</div><div id=\"graphicVersion\">Graphic 64822 Version 1.0</div></div></div>"},"64825":{"type":"graphic_diagnosticimage","displayName":"Uterine leiomyoma ultrasound","title":"Cystic degeneration of uterine leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic degeneration of uterine leiomyoma</div><div class=\"cntnt\"><img style=\"width:314px; height:252px;\" src=\"images/PC/64825_Uterine_leiomyoma_ultrasoun.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of a degenerated uterine leiomyoma (arrow) which has the appearance of a complex mass.</div><div class=\"graphic_reference\">Courtesy of Jorge Londono, MD.</div><div id=\"graphicVersion\">Graphic 64825 Version 2.0</div></div></div>"},"64826":{"type":"graphic_picture","displayName":"Mondor disease of the breast","title":"Mondor disease of the breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mondor disease of the breast</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/64826_Mondor_disease_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mondor disease. Thrombophlebitis of the thoracoepigastric vein causes retraction of the lateral portion of the breast, which crosses to the midline at the inferior areolar margin and is accompanied by a palpable cord.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery Scientific Principles And Practice, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64826 Version 1.0</div></div></div>"},"64827":{"type":"graphic_figure","displayName":"Age-related bone loss","title":"Age-related bone loss","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Age-related bone loss</div><div class=\"cntnt\"><img style=\"width:536px; height:566px;\" src=\"images/ENDO/64827_Agerelatedboneloss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mg of hydroxyapatite lost with age was measured using high-resolution peripheral CT of the distal radius in a cross-sectional study of 122 white women with a mean age of 62.8 (range 27 to 98) years. Please note that most bone lost after the age of 65 was cortical. Cortical porosity was measured using scanning electron microscopy of postmortem specimens of femora from 24 women with a mean age of 69 (range 29 to 99) years and is depicted in a schematic fashion.</div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* p&lt;0.0001.</div><div class=\"graphic_reference\">Reproduced from: Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: A cross-sectional study. Lancet 2010; 375:1729. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64827 Version 4.0</div></div></div>"},"64828":{"type":"graphic_picture","displayName":"Lupus vulgaris papule","title":"Lupus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus vulgaris</div><div class=\"cntnt\"><img style=\"width:296px; height:250px;\" src=\"images/DERM/64828_Lupus_vulg_papule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular lesion of lupus vulgaris.</div><div class=\"graphic_reference\">Courtesy of the Research Institute for Tropical Medicine, Philippines.</div><div id=\"graphicVersion\">Graphic 64828 Version 1.0</div></div></div>"},"64829":{"type":"graphic_table","displayName":"Drugs affecting serum amylase","title":"Drugs affecting serum amylase values","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs affecting serum amylase values</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increase</td> </tr> <tr> <td>Adrenocorticotropic hormone</td> </tr> <tr> <td>Aminosalicylic acid</td> </tr> <tr> <td>Some antibiotics (eg, nitrofurantoin)</td> </tr> <tr> <td>Some antineoplastics (eg, asparaginase)</td> </tr> <tr> <td>Aspirin</td> </tr> <tr> <td>Atovaquone</td> </tr> <tr> <td>Calcium salts</td> </tr> <tr> <td>Chloride salts</td> </tr> <tr> <td>Chlorpromazine</td> </tr> <tr> <td>Chlorthalidone</td> </tr> <tr> <td>Cholinergics (eg, bethanechol)</td> </tr> <tr> <td>Cimetidine</td> </tr> <tr> <td>Codeine</td> </tr> <tr> <td>Cyproheptadine</td> </tr> <tr> <td>Didanosine</td> </tr> <tr> <td>Estrogens</td> </tr> <tr> <td>Ethacrynic acid</td> </tr> <tr> <td>Ethanol</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increase (cont.)</td> </tr> <tr> <td>Fluorides</td> </tr> <tr> <td>Iodine-containing contrast media</td> </tr> <tr> <td>Lamivudine</td> </tr> <tr> <td>Meperidine</td> </tr> <tr> <td>Methylcholine</td> </tr> <tr> <td>Methyldopa</td> </tr> <tr> <td>Metoclopramide</td> </tr> <tr> <td>Metronidazole</td> </tr> <tr> <td>Pegaspargase</td> </tr> <tr> <td>Prochlorperazine</td> </tr> <tr> <td>Ranitidine</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td>Sulindac</td> </tr> <tr> <td>Sunitinib</td> </tr> <tr> <td>Sorafenib </td> </tr> <tr> <td>Thiazide diuretics</td> </tr> <tr> <td>Triprolidine/pseudoephedrine </td> </tr> <tr> <td>Valproic acid</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Decrease</td> </tr> <tr> <td>Citrates</td> </tr> <tr> <td>Intravenous dextrose</td> </tr> <tr> <td>Oxalates</td> </tr> <tr> <td>Saquinavir</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64829 Version 3.0</div></div></div>"},"64831":{"type":"graphic_table","displayName":"Stillbirth rate after amnio","title":"Stillbirth rate after amniocentesis in series utilizing ultrasound guidance during the procedure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stillbirth rate after amniocentesis in series utilizing ultrasound guidance during the procedure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\" rowspan=\"2\">Author</td>\n\t\t\t\t\t<td class=\"subtitle1\" colspan=\"2\">Stillbirths</td>\n\t\t\t\t\t<td class=\"subtitle1\" rowspan=\"2\">Difference in rates (95% confidence interval)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2\">Cases (numbers)</td>\n\t\t\t\t\t<td class=\"subtitle2\">Controls (number)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tabor (1986)</td>\n\t\t\t\t\t<td>0.4% (10/2264)</td>\n\t\t\t\t\t<td>0.5% (12/2287)</td>\n\t\t\t\t\t<td>-0.1% (-0.4%; 0.3%)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tongsong (1998)</td>\n\t\t\t\t\t<td>1.4% (29/2009)</td>\n\t\t\t\t\t<td>1.4% (28/2016)</td>\n\t\t\t\t\t<td>0.1% (-0.7%; 0.8%)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Antsaklis (2000)</td>\n\t\t\t\t\t<td>0.6% (22/3617)</td>\n\t\t\t\t\t<td>0.5% (27/5244)</td>\n\t\t\t\t\t<td>0.1% (-0.2%; 0.4%)</td>\n\t\t\t\t</tr>\n\t\t\t\t\n</tbody>\n</table></div><div class=\"graphic_lgnd\">The stillbirth rate was calculated among continuing pregnancies, and it was not significantly different in amniocentesis cases compared with controls. The rates of preterm delivery, premature rupture of membranes, neonatal mortality and perinatal mortality were not different between cases and controls (data not shown).</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 64831 Version 1.0</div></div></div>"},"64832":{"type":"graphic_diagnosticimage","displayName":"MRI appearance Ewing sarcoma","title":"Ewing sarcoma appearance on MRI scan","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Ewing sarcoma appearance on MRI scan</div><div class=\"cntnt\"><img style=\"width:563px; height:389px;\" src=\"images/ONC/64832_MRI_appearance_Ewings_sarco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ewing's sarcoma of the right femur in a 16-year-old boy. Left panel, T1-weighted coronal MRI image of the right femur showing extensive destruction of the entire mid femur by tumor (arrows). Right panel, T1-weighted axial MRI image through the proximal femur with gadolinium and fat saturation. The tumor appeas hyperintense relative to the surrounding tissues (arrowheads).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Thomas DeLaney, MD.</div><div id=\"graphicVersion\">Graphic 64832 Version 4.0</div></div></div>"},"64834":{"type":"graphic_figure","displayName":"Rates of IPD after PCV7","title":"Changes in invasive pneumococcal disease incidence in the era of the conjugate vaccine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in invasive pneumococcal disease incidence in the era of the conjugate vaccine</div><div class=\"cntnt\"><img style=\"width:447px; height:672px;\" src=\"images/PEDS/64834_Rates_of_IPD_after_PCV7.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in invasive pneumococcal disease (IPD) incidence by serotype group among children aged &lt;5 years (A) and adults aged &ge;65 years (B), 1998 to 2007.</div><div class=\"graphic_footnotes\">* Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the United States for routine use among young children and infants in the second half of 2000.</div><div class=\"graphic_reference\">From: Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32. By permission of the Infectious Diseases Society of America. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 64834 Version 6.0</div></div></div>"},"64835":{"type":"graphic_table","displayName":"CIWA-Ar withdrawal scale","title":"Clinical Institute Withdrawal Assessment Scale for Alcohol, revised (CIWA-Ar)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical Institute Withdrawal Assessment Scale for Alcohol, revised (CIWA-Ar)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Nausea and vomiting</td></tr>\n\t\t\t\t\t\t<tr><td>0 No nausea or vomiting</td></tr>\n\t\t\t\t\t\t<tr><td>1</td></tr>\n\t\t\t\t\t\t<tr><td>2</td></tr>\n\t\t\t\t\t\t<tr><td>3</td></tr>\n\t\t\t\t\t\t<tr><td>4 Intermittent nausea with dry heaves</td></tr>\n\t\t\t\t\t\t<tr><td>5</td></tr>\n\t\t\t\t\t\t<tr><td>6</td></tr>\n\t\t\t\t\t\t<tr><td>7 Constant nausea, frequent dry heaves and vomiting</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Paroxysmal sweats</td></tr>\n\t\t\t\t\t\t<tr><td>0 No sweats visible</td></tr>\n\t\t\t\t\t\t<tr><td>1 Barely perceptible sweating, palms moist</td></tr>\n\t\t\t\t\t\t<tr><td>2</td></tr>\n\t\t\t\t\t\t<tr><td>3</td></tr>\n\t\t\t\t\t\t<tr><td>4 Beads of sweat obvious on forehead</td></tr>\n\t\t\t\t\t\t<tr><td>5</td></tr>\n\t\t\t\t\t\t<tr><td>6</td></tr>\n\t\t\t\t\t\t<tr><td>7 Drenching sweats</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Anxiety</td></tr>\n\t\t\t\t\t\t<tr><td>0 No anxiety, at ease</td></tr>\n\t\t\t\t\t\t<tr><td>1</td></tr>\n\t\t\t\t\t\t<tr><td>2</td></tr>\n\t\t\t\t\t\t<tr><td>3</td></tr>\n\t\t\t\t\t\t<tr><td>4 Moderately anxious, guarded</td></tr>\n\t\t\t\t\t\t<tr><td>5</td></tr>\n\t\t\t\t\t\t<tr><td>6</td></tr>\n\t\t\t\t\t\t<tr><td>7 Acute panic state, consistent with severe delirium or acute schizophrenia</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Agitation</td></tr>\n\t\t\t\t\t\t<tr><td>0 Normal activity</td></tr>\n\t\t\t\t\t\t<tr><td>1 Somewhat more than normal activity</td></tr>\n\t\t\t\t\t\t<tr><td>2</td></tr>\n\t\t\t\t\t\t<tr><td>3</td></tr>\n\t\t\t\t\t\t<tr><td>4 Moderately fidgety and restless</td></tr>\n\t\t\t\t\t\t<tr><td>5</td></tr>\n\t\t\t\t\t\t<tr><td>6</td></tr>\n\t\t\t\t\t\t<tr><td>7 Paces back and forth during most of the interview or constantly thrashes about</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Tremor</td></tr>\n\t\t\t\t\t\t<tr><td>0 No tremor</td></tr>\n\t\t\t\t\t\t<tr><td>1 Not visible, but can be felt at fingertips</td></tr>\n\t\t\t\t\t\t<tr><td>2</td></tr>\n\t\t\t\t\t\t<tr><td>3</td></tr>\n\t\t\t\t\t\t<tr><td>4 Moderate when patient's hands extended</td></tr>\n\t\t\t\t\t\t<tr><td>5</td></tr>\n\t\t\t\t\t\t<tr><td>6</td></tr>\n\t\t\t\t\t\t<tr><td>7 Severe, even with arms not extended</td></tr></tbody></table></td>\n\n<td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Headache</td></tr>\n\t\t\t\t\t\t<tr><td>0 Not present</td></tr>\n\t\t\t\t\t\t<tr><td>1 Very mild</td></tr>\n\t\t\t\t\t\t<tr><td>2 Mild</td></tr>\n\t\t\t\t\t\t<tr><td>3 Moderate</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">4 Moderately severe</td></tr>\n\t\t\t\t\t\t<tr><td>5 Severe</td></tr>\n\t\t\t\t\t\t<tr><td>6 Very severe</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">7 Extremely severe</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\" class=\"subtitle1_single\">Auditory disturbances</td></tr>\n\t\t\t\t\t\t<tr><td>0 Not present</td></tr>\n\t\t\t\t\t\t<tr><td>1 Very mild harshness or ability to frighten</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">2 Mild harshness or ability to frighten</td></tr>\n\t\t\t\t\t\t<tr><td>3 Moderate harshness or ability to frighten</td></tr>\n\t\t\t\t\t\t<tr><td>4 Moderately severe hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">5 Severe hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td>6 Extremely severe hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td>7 Continuous hallucinations</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td colspan=\"1\" class=\"subtitle1_single\">Visual disturbances</td></tr>\n\t\t\t\t\t\t<tr><td>0 Not present</td></tr>\n\t\t\t\t\t\t<tr><td>1 Very mild photosensitivity</td></tr>\n\t\t\t\t\t\t<tr><td>2 Mild photosensitivity</td></tr>\n\t\t\t\t\t\t<tr><td>3 Moderate photosensitivity</td></tr>\n\t\t\t\t\t\t<tr><td>4 Moderately severe visual hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">5 Severe visual hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td>6 Extremely severe visual hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td>7 Continuous visual hallucinations</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td colspan=\"1\" class=\"subtitle1_single\">Tactile disturbances</td></tr>\n\t\t\t\t\t\t<tr><td>0 None</td></tr>\n\t\t\t\t\t\t<tr><td>1 Very mild paresthesias</td></tr>\n\t\t\t\t\t\t<tr><td>2 Mild paresthesias</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">3 Moderate paresthesias</td></tr>\n\t\t\t\t\t\t<tr><td>4 Moderately severe hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td>5 Severe hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">6 Extremely severe hallucinations</td></tr>\n\t\t\t\t\t\t<tr><td>7 Continuous hallucinations</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\" colspan=\"1\">Orientation and clouding of sensorium</td></tr>\n\t\t\t\t\t\t<tr><td>0 Oriented and can do serial additions</td></tr>\n\t\t\t\t\t\t<tr><td>1 Cannot do serial additions</td></tr>\n\t\t\t\t\t\t<tr><td>2 Disoriented for date by no more than 2 calendar days</td></tr>\n\t\t\t\t\t\t<tr><td>3 Disoriented for date by more than 2 calendar days</td></tr>\n\t\t\t\t\t\t<tr><td colspan=\"1\">4 Disoriented for place and/or patient</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\" colspan=\"1\">Total score is a simple sum of each item score (maximum score is 67).</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\" colspan=\"1\">Score:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">&#60;10: Very mild withdrawal</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"indent1\" colspan=\"1\">10-15: Mild withdrawal</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\" colspan=\"1\">16-20: Modest withdrawal</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">&#62;20: Severe withdrawal</td></tr></tbody></table></td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57955&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>CIWA-Ar_withdrawal_scale.htm</title></head></div><div class=\"graphic_reference\">Adapted from Sullivan JT, Skyora K, Schneiderman J, et al. Br J Addict 1989; 84:1353.</div><div id=\"graphicVersion\">Graphic 64835 Version 2.0</div></div></div>"},"64836":{"type":"graphic_picture","displayName":"Guttate psoriasis 2","title":"Guttate psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Guttate psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/64836_Guttate_psoriasis_2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules with scale are typically present in guttate psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64836 Version 5.0</div></div></div>"},"64841":{"type":"graphic_table","displayName":"HRCT patterns in ILD I","title":"HRCT patterns in interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HRCT patterns in interstitial lung disease</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Airspace opacities\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Haze or ground glass attenuation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Hypersensitivity pneumonitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Desquamative interstitial pneumonia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Respiratory bronchiolitis-associated interstitial lung disease\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Drug toxicity\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Pulmonary hemorrhage\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Lung consolidation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Chronic or acute eosinophilic pneumonia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Cryptogenic organizing pneumonia (bronchiolitis obliterans with organizing pneumonia)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Aspiration (lipoid pneumonia)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Alveolar carcinoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Lymphoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Alveolar proteinosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Reticular opacities\n   </td>\n   </tr>\n   <tr>\n   <td>Idiopathic pulmonary fibrosis</td>\n   </tr>\n   <tr>\n   <td>Asbestosis</td>\n   </tr>\n   <tr>\n   <td>Connective tissue disease</td>\n   </tr>\n   <tr>\n   <td>Hypersensitivity pneumonitis</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Nodules\n   </td>\n   </tr>\n   <tr>\n   <td>Hypersensitivity pneumonitis</td>\n   </tr>\n   <tr>\n   <td>Respiratory bronchiolitis-associated interstitial lung disease</td>\n   </tr>\n   <tr>\n   <td>Sarcoidosis</td>\n   </tr>\n   <tr>\n   <td>Pulmonary langerhans cell histiocytosis</td>\n   </tr>\n   <tr>\n   <td>Silicosis</td>\n   </tr>\n   <tr>\n   <td>Coal workers' pneumoconiosis</td>\n   </tr>\n   <tr>\n   <td>Metastatic cancer</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Isolated lung cysts\n   </td>\n   </tr>\n   <tr>\n   <td>Pulmonary langerhans cell histiocytosis</td>\n   </tr>\n   <tr>\n   <td>Lymphangioleiomyomatosis</td>\n   </tr>\n   <tr>\n   <td>Chronic Pneumocystis carnii (P. jirovecii) pneumonia</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 64841 Version 1.0</div></div></div>"},"64844":{"type":"graphic_picture","displayName":"Discoid lupus - right cheek","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64844_Discoidlupusrightcheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-defined, erythematous plaques with scale are present on the cheek of this patient with discoid lupus erythematosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64844 Version 4.0</div></div></div>"},"64845":{"type":"graphic_figure","displayName":"Dofetilide dosing","title":"Dofetilide dosing","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Dofetilide dosing</div><div class=\"cntnt\"><img style=\"width:595px; height:785px;\" src=\"images/CARD/64845_Dofetilide_dosing.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">The QT prolonging effects and the risk of torsades de pointes can be increased by coadministration of dofetilide with verapamil, other drugs that also prolong the QT, or drugs that interfere with renal elimination of dofetilide&nbsp;(eg, cimetidine, verapamil, trimethoprim, alone or in combination with sulfamethoxazole, prochlorperazine, hydrochlorothiazide, alone or in combination with triamterene, megestrol, and ketoconazole).</div><div class=\"graphic_reference\">Courtesy of Dr. Raymond L. Woosley.</div><div id=\"graphicVersion\">Graphic 64845 Version 2.0</div></div></div>"},"64846":{"type":"graphic_algorithm","displayName":"Screening implications","title":"HLA-B*5701 screening implications","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">HLA-B*5701 screening implications</div><div class=\"cntnt\"><img style=\"width:485px; height:328px;\" src=\"images/ID/64846_Screening_implications.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The main benefit of screening, regardless of race, is that it identifies the majority of the population to whom it is safe to administer abacavir. Although screening necessarily excludes some patients from abacavir therapy who would have tolerated the drug, this is compensated by the fall in false positive clinical diagnoses achieved in an open screening population.</div><div id=\"graphicVersion\">Graphic 64846 Version 2.0</div></div></div>"},"64849":{"type":"graphic_table","displayName":"Risks kidney stones PI","title":"Dietary factors and medical problems that increase the risk of kidney stones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary factors and medical problems that increase the risk of kidney stones</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diet</td> </tr> <tr> <td>Not drinking enough fluid</td> </tr> <tr> <td>Diet with low levels of calcium</td> </tr> <tr> <td>Use of calcium supplements</td> </tr> <tr> <td>Diet with high levels of animal protein</td> </tr> <tr> <td>Diet with high levels of sugars (sucrose, fructose)</td> </tr> <tr> <td>Diet with low levels of phytate (found in wheat, rice, rye, barley, and bean products)</td> </tr> <tr> <td>High sodium diet</td> </tr> <tr> <td>Frequent spinach consumption</td> </tr> <tr> <td class=\"subtitle1_single\">Other medical conditions</td> </tr> <tr> <td>Primary hyperparathyroidism</td> </tr> <tr> <td>Gout</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>Crohn's disease</td> </tr> <tr> <td>Gastric or intestinal bypass surgery</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64849 Version 5.0</div></div></div>"},"64850":{"type":"graphic_picture","displayName":"Aneurysm in moyamoya disease","title":"Aneurysm in moyamoya disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aneurysm in moyamoya disease</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/NEURO/64850_Aneurysm_in_Moyamoya_diseas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cerebral angiogram showing aneurysm (arrow) in patient with moyamoya disease.</div><div class=\"graphic_reference\">Courtesy of Nijasri Suwanwela, MD.</div><div id=\"graphicVersion\">Graphic 64850 Version 3.0</div></div></div>"},"64851":{"type":"graphic_table","displayName":"Ophthalmologic findings IEM","title":"Ophthalmologic findings in inborn errors of metabolism, according to age of onset","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ophthalmologic findings in inborn errors of metabolism, according to age of onset</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Finding/age of onset </td> <td class=\"subtitle1\">Related disorders </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cataract </td> </tr> <tr> <td class=\"indent1\">Birth </td> <td>Lowe syndrome, peroxisomal biogenesis defects, Cockayne syndrome, sorbitol dehydrogenase deficiency</td> </tr> <tr> <td class=\"indent1\">1 week to 1 month </td> <td>Galactosemia, peripheral epimerase deficiency, 3-phosphoglycerate dehydrogenase deficiency, congenital disorders of glycosylation</td> </tr> <tr> <td class=\"indent1\">1 month to 1 year </td> <td>Galactokinase deficiency, galactitol or sorbitol accumulation, sialidosis, mitochondrial disorders, mevalonic aciduria</td> </tr> <tr> <td class=\"indent1\">1 to 15 years </td> <td>Dominant hyperferritinemia, Wilson disease, lysinuric protein intolerance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Corneal opacity </td> </tr> <tr> <td class=\"indent1\">3 to 12 months </td> <td>Tyrosinosis type II, cystinosis, I-cell disease, mucopolysaccharidosis type I, type VI, steroid sulfatase deficiency</td> </tr> <tr> <td class=\"indent1\">1 to 6 years </td> <td>Mucopolysaccharidosis type IV, alpha mannosidosis, Tangier disease</td> </tr> <tr> <td class=\"indent1\">&#62;6 years </td> <td>Fabry disease, galactosialidosis, Wilson disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cherry red spot </td> </tr> <tr> <td class=\"indent1\">Neonates </td> <td>GM1 gangliosidosis, galactosialidosis (early infantile form), Niemann-Pick disease type IA</td> </tr> <tr> <td class=\"indent1\">3 to 12 months </td> <td>Galactosialidosis (late infantile form), Tay-Sachs disease, Sandhoff disease</td> </tr> <tr> <td class=\"indent1\">&#62;6 years </td> <td>Sialidosis type I, galactosialidosis (juvenile form)</td> </tr> <tr> <td class=\"subtitle2_left\">Retinitis pigmentosa </td> <td>Abetalipoproteinemia, ceroid lipofuscinosis, peroxisomal disorders, congenital&nbsp;disorders of glycosylation, mitochondrial disorders</td> </tr> <tr> <td class=\"subtitle2_left\">Dislocated lens </td> <td>Homocystinuria, sulfite oxidase deficiency, molybdenum cofactor deficiency</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Saudubray JM, Chappentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p. 1327.</div><div id=\"graphicVersion\">Graphic 64851 Version 5.0</div></div></div>"},"64853":{"type":"graphic_diagnosticimage","displayName":"Hiatal hernia after gastric sleeve","title":"Hiatal hernia after gastric sleeve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hiatal hernia after gastric sleeve</div><div class=\"cntnt\"><img style=\"width:432px; height:430px;\" src=\"images/SURG/64853_Hiatal_hernia_gastr_sleeve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a patient with a hiatal hernia, an UGI series will show the GE junction above the diagphragm as shown here. The arrow shows the hiatal hernia and the arrowhead shows the dilated sleeve gastrectomy.</div><div class=\"graphic_footnotes\">UGI: upper gastrointestinal; GE: gastroesophageal.</div><div id=\"graphicVersion\">Graphic 64853 Version 7.0</div></div></div>"},"64854":{"type":"graphic_figure","displayName":"Hand-sewn ileocolic anastomosis - two layer closure","title":"Hand-sewn ileocolic anastomosis - two layer closure posterior wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-sewn ileocolic anastomosis - two layer closure posterior wall</div><div class=\"cntnt\"><img style=\"width:280px; height:339px;\" src=\"images/SURG/64854_Hand-sewn-post-anast.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64854 Version 1.0</div></div></div>"},"64855":{"type":"graphic_picture","displayName":"Epidermal nevus on neck","title":"Epidermal nevus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Epidermal nevus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64855_Epidermal_nevus_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hyperpigmented, verrucous, linear plaque is present on the neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64855 Version 4.0</div></div></div>"},"64856":{"type":"graphic_table","displayName":"VIT schedule 2","title":"Typical conventional dosing schedule for venom immunotherapy: Schedule 2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical conventional dosing schedule for venom immunotherapy: Schedule 2</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Week</td> <td class=\"subtitle1\" colspan=\"2\">Injection 1</td> <td class=\"subtitle1\" colspan=\"2\">Injection 2</td> <td class=\"subtitle1\" colspan=\"2\">Injection 3</td> </tr> <tr> <td class=\"subtitle2\">Concentration, micrograms/mL</td> <td class=\"subtitle2\">Volume, mL</td> <td class=\"subtitle2\">Concentration, micrograms/mL</td> <td class=\"subtitle2\">Volume, mL</td> <td class=\"subtitle2\">Concentration, micrograms/mL</td> <td class=\"subtitle2\">Volume, mL</td> </tr> <tr> <td>1</td> <td>0.01</td> <td>0.1</td> <td>0.1</td> <td>0.1</td> <td>1</td> <td>0.1</td> </tr> <tr> <td>2</td> <td>1</td> <td>0.1</td> <td>1</td> <td>0.5</td> <td>10</td> <td>0.1</td> </tr> <tr> <td>3</td> <td>10</td> <td>0.1</td> <td>10</td> <td>0.5</td> <td>10</td> <td>1</td> </tr> <tr> <td>4</td> <td>100</td> <td>0.1</td> <td>100</td> <td>0.2</td> <td>-</td> <td>-</td> </tr> <tr> <td>5</td> <td>100</td> <td>0.2</td> <td>100</td> <td>0.3</td> <td>-</td> <td>-</td> </tr> <tr> <td>6</td> <td>100</td> <td>0.3</td> <td>100</td> <td>0.3</td> <td>-</td> <td>-</td> </tr> <tr> <td>7</td> <td>100</td> <td>0.4</td> <td>100</td> <td>0.4</td> <td>-</td> <td>-</td> </tr> <tr> <td>8</td> <td>100</td> <td>0.5</td> <td>100</td> <td>0.5</td> <td>-</td> <td>-</td> </tr> <tr> <td>9</td> <td>100</td> <td>1</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Monthly</td> <td>100</td> <td>1</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=1530&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Injections 1, 2, and 3 are given at 30-minute intervals on days when more than one injection is administered (reading from left to right across table in the week 1 row). During weeks 1 through 3, the patient receives&nbsp;three injections per visit. During weeks 4 through 8, the patient receives two injections per visit. Maintenance is achieved by approximately week 8. Thereafter, the patient receives one injection per visit and the interval between visits is extended from weekly to monthly. This schedule is based upon the package insert for ALK-Abello venom extracts (Round Rock, TX).</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced with permission from: Golden DBK. Insect Allergy. In: Middleton's Allergy: Principles &amp; Practice, 7th ed, Adkinson NF Jr, Bochner BS, Busse WW, et al (Eds), Mosby Elsevier, Philadelphia 2009. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64856 Version 10.0</div></div></div>"},"64858":{"type":"graphic_table","displayName":"Classification of primary esophageal motility abnormalities","title":"Classification of primary esophageal motility abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of primary esophageal motility abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Conventional manometry</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Achalasia (the true disorder)</strong></td> <td>Absent distal peristalsis</td> </tr> <tr> <td>Incomplete LES relaxation (residual pressure &#62;8 mmHg)</td> </tr> <tr class=\"divider_bottom\"> <td>Elevated resting LES pressure (&#62;45 mmHg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abnormal motility patterns (nonspecific esophageal dysmotility)*</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Discoordinated motility</td> </tr> <tr> <td class=\"indent2\" rowspan=\"4\">Diffuse (or distal) esophageal spasm</td> <td>Simultaneous contractions (&#8805;20 percent wet swallows)</td> </tr> <tr> <td>Intermittent peristalsis</td> </tr> <tr> <td>Repetitive contractions (&#8805;3 peaks)</td> </tr> <tr> <td>Prolonged duration contractions (&#62;6 sec)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Hypercontracting esophagus</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Hypertensive peristalsis (\"nutcracker esophagus\")</td> <td>Increased distal peristaltic amplitude (mean value &#62;220 mmHg)</td> </tr> <tr> <td>Increased distal peristaltic duration (mean value &#62;6 sec)</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Hypertensive LES</td> <td>Resting LES pressure &#62;45 mmHg</td> </tr> <tr> <td>May be incomplete LES relaxation (residual pressure &#62;8 mmHg)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Hypocontracting esophagus</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Ineffective esophageal motility (IEM)<sup>&#182;</sup></td> <td>Increased low amplitude peristalsis (&#8805;50 percent wet swallows)</td> </tr> <tr> <td>Low distal peristaltic amplitude (&#60;30 mmHg)</td> </tr> <tr> <td class=\"indent2\">Hypotensive LES<sup>&#182;</sup></td> <td>Resting LES pressure &#60;10 mmHg</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\"><strong>Others</strong></td> <td>Retrograde contractions</td> </tr> <tr> <td>Triple peaked contractions</td> </tr> <tr> <td>Isolated incomplete LES relaxation (&#62;8 mmHg)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LES: lower esophageal sphincter.<br />* Defined as exceeding two standard deviations from mean of normal values.<br />Â¶ May be \"secondary\" to gastroesophageal reflux disease (GERD).</div><div id=\"graphicVersion\">Graphic 64858 Version 6.0</div></div></div>"},"64863":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma I MRI","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:357px; height:301px;\" src=\"images/PULM/64863_Malignant_mesothelioma_I_MR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI scan, axial, T1 weighted spin-echo sequence, shows circumferential pleural thickening. The tumor is of intermediate signal intensity. No invasion of the chest is visible.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64863 Version 4.0</div></div></div>"},"64864":{"type":"graphic_picture","displayName":"Nail sarcoidosis","title":"Sarcoidosis involving the nail","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis involving the nail</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64864_Nail_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sarcoidal dactylitis. Swelling and deformity of all fingers are present. Some fingers demonstrate erythema and swelling of the nail folds and beds. Marked onychodystrophy is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64864 Version 3.0</div></div></div>"},"64868":{"type":"graphic_figure","displayName":"Schematic CVVHDF post-filter","title":"Schematic of CVVHDF with post-filter infusion of replacement fluid","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Schematic of CVVHDF with post-filter infusion of replacement fluid</div><div class=\"cntnt\"><img style=\"width:521px; height:291px;\" src=\"images/NEPH/64868_Schematic_CVVHDF_Postfilter.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CVVHDF: continuous venovenous hemodiafiltration.</div><div id=\"graphicVersion\">Graphic 64868 Version 3.0</div></div></div>"},"64869":{"type":"graphic_figure","displayName":"ACST fatal disabling","title":"Fatal or disabling stroke or perioperative death in the Asymptomatic Carotid Surgery Trial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fatal or disabling stroke or perioperative death in the Asymptomatic Carotid Surgery Trial</div><div class=\"cntnt\"><img style=\"width:420px; height:265px;\" src=\"images/NEURO/64869_ACST_fatal_disabling_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The risk of fatal or disabling stroke or perioperative death in the ACST. The net five-year risk for fatal or disabling strokes or perioperative death in the CEA group was reduced by nearly half compared with the CEA deferral group. About one-half of the strokes in the trial were fatal or disabling.</div><div class=\"graphic_footnotes\">ACST: Asymptomatic Carotid Surgery Trial; CEA: carotid endarterectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491. Copyright &copy; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 64869 Version 6.0</div></div></div>"},"64870":{"type":"graphic_picture","displayName":"Clitoromegaly1","title":"Clitoromegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clitoromegaly</div><div class=\"cntnt\"><img style=\"width:264px; height:389px;\" src=\"images/PEDS/64870_Clitoromegaly1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clitoromegaly in a 46,XX infant with 21-hydroxylase deficiency.</div><div class=\"graphic_reference\">Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD</div><div id=\"graphicVersion\">Graphic 64870 Version 1.0</div></div></div>"},"64871":{"type":"graphic_picture","displayName":"Internal hemorrhoids prolapsed","title":"Internal hemorrhoids prolapsed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Internal hemorrhoids prolapsed</div><div class=\"cntnt\"><img style=\"width:339px; height:504px;\" src=\"images/SURG/64871_Int_hemorrhoids_prolapsed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows internal hemorrhoids protruding through the anus.</div><div id=\"graphicVersion\">Graphic 64871 Version 1.0</div></div></div>"},"64872":{"type":"graphic_picture","displayName":"Candida pseudohyphae yeast","title":"<EM>Candida albicans</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Candida albicans</EM></div><div class=\"cntnt\"><img style=\"width:396px; height:330px;\" src=\"images/DERM/64872_Candidapseudohyphaeyeast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudohyphae of <EM>Candida</EM> with budding yeasts&nbsp;in a&nbsp;potassium hydroxide preparation. Pseudohyphae are chains of elongated yeast cells that fail to detach after budding.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 64872 Version 3.0</div></div></div>"},"64873":{"type":"graphic_algorithm","displayName":"Binocular vision loss algorithm","title":"Binocular vision loss algorithm","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Binocular vision loss algorithm</div><div class=\"cntnt\"><img style=\"width:614px; height:687px;\" src=\"images/EM/64873_Bnclr_vsn_lss_alg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IIH: idiopathic intracranial hypertension, ICP: intracranial pressure, CNS: central nervous system, ICI: intracranial injury.<br />* Etiologies are the same as for unilateral eye trauma. Refer to UpToDate topics and algorithms on monocular vision loss. <br />&para; Causes include cerebral ischemia, cerebral stroke, meningoencephalitis, and uremia.</div><div id=\"graphicVersion\">Graphic 64873 Version 4.0</div></div></div>"},"64874":{"type":"graphic_table","displayName":"Iron bioavailability","title":"Factors influencing the absorption and bioavailability of dietary iron","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors influencing the absorption and bioavailability of dietary iron</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absorption of heme iron</td> </tr> <tr> <td>Amount of heme iron, especially in meat</td> </tr> <tr> <td>Content of calcium in the meal (calcium impairs iron absorption)</td> </tr> <tr> <td class=\"subtitle1_single\">Absorption of nonheme iron</td> </tr> <tr> <td>Iron status</td> </tr> <tr> <td>Amount of potentially available nonheme iron</td> </tr> <tr> <td class=\"sublist1_start\">Balance between positive and negative factors</td> </tr> <tr> <td class=\"sublist1\">Positive factors</td> </tr> <tr> <td class=\"sublist2\">Ascorbic acid</td> </tr> <tr> <td class=\"sublist2\">Meat or fish (factors in meat other than heme iron enhance&nbsp;absorption of nonheme iron)</td> </tr> <tr> <td class=\"sublist1\">Negative factors</td> </tr> <tr> <td class=\"sublist2\">Phytate (in bran, oats, rye fiber)</td> </tr> <tr> <td class=\"sublist2\">Polyphenols (in tea, some vegetables and cereals)</td> </tr> <tr> <td class=\"sublist2\">Dietary calcium</td> </tr> <tr> <td class=\"sublist2\">Soy protein</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Hallberg L, Rossander-Hulten L, Burne M. Nutritional anemias. In: Nestle Workshop Series, vol 30, Fomon SJ, Zlotkin S (Eds), Vevey/Raven Press, New York 1992. p.170.</div><div id=\"graphicVersion\">Graphic 64874 Version 7.0</div></div></div>"},"64875":{"type":"graphic_waveform","displayName":"EPS tracing normal intracardiac electrograms","title":"Normal intracardiac electrograms obtained during invasive electrophysiologic study (EPS)","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Normal intracardiac electrograms obtained during invasive electrophysiologic study (EPS)</div><div class=\"cntnt\"><img style=\"width:558px; height:620px;\" src=\"images/CARD/64875_Normal_electrograms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal intracardiac electrograms, during sinus rhythm, obtained during an electrophysiologic study are shown. Three surface electrocardiogram (ECG) leads are monitored (I, aVF, and V1); intracardiac electrograms are obtained from the high right atrium (HRA); the proximal (p), mid (m), and distal (d) bundle of His (HBE); the p, m, and d coronary sinus (CS); and right ventricular apex (RVA). For an ablation procedure, an exploratory catheter (exp) is also used for more extensive mapping. The electrogram obtained includes those from the atrium (A), bundle of His (H), and ventricle (V).</div><div id=\"graphicVersion\">Graphic 64875 Version 4.0</div></div></div>"},"64877":{"type":"graphic_table","displayName":"US poison center plant ingestions","title":"Plant ingestions most frequently reported to US poison control centers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Plant ingestions most frequently reported to US poison control centers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Botanical plant name</td> <td class=\"subtitle1\">Common plant name</td> </tr> <tr> <td><em>Spathiphyllum</em> spp</td> <td>Peace lily</td> </tr> <tr> <td><em>Ilex</em> spp*</td> <td>Holly</td> </tr> <tr> <td><em>Philodendron</em> spp</td> <td>Philodendron</td> </tr> <tr> <td><em>Euphorbia pulcherrima</em>*</td> <td>Poinsetta</td> </tr> <tr> <td><em>Phytolacca americana</em></td> <td>Pokeweed, inkberry</td> </tr> <tr> <td><em>Fragaria</em> spp</td> <td>Wild strawberry</td> </tr> <tr> <td><em>Hemerocallis</em>*</td> <td>Lily</td> </tr> <tr> <td><em>Brassaia actinophylla</em>*</td> <td>Schefflera</td> </tr> <tr> <td><em>Calendula</em> spp*</td> <td>Marigold</td> </tr> <tr> <td><em>Ficus</em> spp*</td> <td>Rubber tree, weeping fig</td> </tr> <tr> <td><em>Coleus</em> spp*</td> <td>Coleus</td> </tr> <tr> <td><em>Prunus</em> spp</td> <td>Cherry, peach, plum</td> </tr> <tr> <td><em>Crassula</em> spp*</td> <td>Jade plant</td> </tr> <tr> <td><em>Dieffenbachia</em> spp</td> <td>Dumbcane</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=94892&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* Minimally or nontoxic plant.</div><div class=\"graphic_reference\">Data from: Krenzelok EP, Mrvos R. Friends and foes in the plant world: a profile of plant ingestion and fatalities. Clin Toxicol (Phil) 2011; 49:142.</div><div id=\"graphicVersion\">Graphic 64877 Version 3.0</div></div></div>"},"64878":{"type":"graphic_picture","displayName":"Advanced stasis dermatitis 4","title":"Chronic stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chronic stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64878_Advancedstasisderm4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with chronic stasis dermatitis presents with hyperpigmentation, lipodermatosclerosis, atrophie blanche, and varicosities on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64878 Version 5.0</div></div></div>"},"64879":{"type":"graphic_figure","displayName":"Taeniasis life cycle","title":"Taeniasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Taeniasis life cycle</div><div class=\"cntnt\"><img style=\"width:591px; height:476px;\" src=\"images/ID/64879_Taeniasis_life_cycle_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Taeniasis is the infection of humans with the adult tapeworm of <EM>Taenia saginata</EM>, <EM>T. solium</EM>, or <EM>T. asiatica</EM>. Humans are the only definitive hosts for these three species. Eggs or gravid proglottids are passed with feces <STRONG>(1)</STRONG>; the eggs can survive for days to months in the environment. Cattle (<EM>T. saginata</EM>) and pigs (<EM>T. solium</EM> and <EM>T. asiatica</EM>) become infected by ingesting vegetation contaminated with eggs or gravid proglottids <STRONG>(2)</STRONG>. In the animal's intestine, the oncospheres hatch <STRONG>(3)</STRONG>, invade the intestinal wall, and migrate to the striated muscles, where they develop into cysticerci. A cysticercus can survive for several years in the animal. Humans become infected by ingesting raw or undercooked infected meat <STRONG>(4)</STRONG>. In the human intestine, the cysticercus develops over two months into an adult tapeworm, which can survive for years. The adult tapeworms attach to the small intestine by their scolex <STRONG>(5)</STRONG> and reside in the small intestine <STRONG>(6)</STRONG>. Length of adult worms is usually 5 m or less for <EM>T. saginata</EM> (however it may reach up to 25 m) and 2 to 7 m for <EM>T. solium</EM>. The adults produce proglottids&nbsp;that mature, become gravid, detach from the tapeworm, and migrate to the anus or are passed in the stool (approximately six per day). <EM>T. saginata</EM> adults usually have 1000 to 2000 proglottids, while <EM>T. solium</EM> adults have an average of 1000 proglottids. The eggs contained in the gravid proglottids are released after the proglottids are passed with the feces. <EM>T. saginata</EM> may produce up to 100,000 and <EM>T. solium</EM> may produce 50,000 eggs per proglottid, respectively.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Taeniasis. Available at: <A href=\"http://www.cdc.gov/dpdx/taeniasis/index.html\">http://www.cdc.gov/dpdx/taeniasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 64879 Version 5.0</div></div></div>"},"64880":{"type":"graphic_picture","displayName":"Abnormally large osteoclasts in pagetic bone","title":"Abnormally large osteoclasts in pagetic bone","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Abnormally large osteoclasts in pagetic bone</div><div class=\"cntnt\"><img style=\"width:540px; height:353px;\" src=\"images/RHEUM/64880_Abnorm_osteocl_pagetic_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormally large, bizarre osteoclasts characterize pagetic bone. There is thickened trabeculae on this H&amp;E stain, with the bone rimmed with osteoblasts and the marrow replaced by stromal cells. Pagetic bone is extremely vascular.</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div class=\"graphic_reference\">Reproduced with permission from: the Paget Foundation. For more information please visit http://www.paget.org/.</div><div id=\"graphicVersion\">Graphic 64880 Version 3.0</div></div></div>"},"64881":{"type":"graphic_figure","displayName":"TIPS high risk varic bleed","title":"Survival after TIPS in high-risk variceal bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival after TIPS in high-risk variceal bleeding</div><div class=\"cntnt\"><img style=\"width:403px; height:281px;\" src=\"images/GAST/64881_TIPS_high_risk_varic_bleed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probability of survival after TIPS placement in patients with active variceal hemorrhage despite emergent endoscopic sclerotherapy who were considered to be at high risk of dying after surgery. Hemostasis was achieved in 90 percent and the 30-day survival was 63 percent; in those without pulmonary compromise (nonaspirators), 30-day survival was above 90 percent. This difference in outcome persisted with long-term follow-up.</div><div class=\"graphic_footnotes\">TIPS: transjugular intrahepatic portosystemic shunt.</div><div class=\"graphic_reference\">Adapted from: Sanyal AJ, Freedman AM, Luketic VA, et al. Gastroenterology 1996; 111:138.</div><div id=\"graphicVersion\">Graphic 64881 Version 2.0</div></div></div>"},"64883":{"type":"graphic_table","displayName":"Water contaminants in HD","title":"Water contaminants and resulting symptoms among hemodialysis patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Water contaminants and resulting symptoms among hemodialysis patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Contaminant</td> <td class=\"subtitle1\">Symptoms of toxicity</td> </tr> <tr> <td>Aluminum</td> <td>Neurologic deterioration, encephalopathy, bone disease, anemia</td> </tr> <tr> <td>Bacteria and endotoxin</td> <td>Pyrogenic reaction, such as hypotension, fever, nausea, and vomiting</td> </tr> <tr> <td>Calcium</td> <td>Nausea and vomiting, muscle weakness, hypertension</td> </tr> <tr> <td>Chloramine</td> <td>Hemolysis, anemia, methemoglobinemia</td> </tr> <tr> <td>Copper</td> <td>Nausea, chills, hemolysis</td> </tr> <tr> <td>Fluoride</td> <td>Bone disease (chronic exposure); pruritus, chest pain, nausea, cardiac arrest (acute exposure to high concentrations)</td> </tr> <tr> <td>Lead</td> <td>Abdominal pain, muscle weakness, peripheral neuropathy, subtle cognitive changes</td> </tr> <tr> <td>Magnesium</td> <td>Nausea and vomiting, muscle weakness</td> </tr> <tr> <td>Nitrates</td> <td>Nausea and vomiting, hypotension, methemoglobinemia</td> </tr> <tr> <td>Sodium</td> <td>Hypertension</td> </tr> <tr> <td>Sulfate</td> <td>Nausea and vomiting, metabolic acidosis</td> </tr> <tr> <td>Zinc</td> <td>Anemia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64883 Version 6.0</div></div></div>"},"64884":{"type":"graphic_figure","displayName":"Lower extremity nerve roots","title":"Nerve roots and peripheral nerves corresponding to the principal movements of the lower extremity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nerve roots and peripheral nerves corresponding to the principal movements of the lower extremity</div><div class=\"cntnt\"><img style=\"width:417px; height:564px;\" src=\"images/NEURO/64884_Lower_extremity_nerve_roots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The letters labeling the movements proceed in order from proximal to distal down the front of the limb, and then repeat from proximal to distal down the back of the limb. The nerve roots and peripheral nerves corresponding to each movement are listed below.</div><div class=\"graphic_reference\">Figure redrawn with permission from Gelb, DJ. The Neurologic Examination. In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.</div><div id=\"graphicVersion\">Graphic 64884 Version 1.0</div></div></div>"},"64885":{"type":"graphic_picture","displayName":"Pubertal gingivitis","title":"Pubertal gingivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pubertal gingivitis</div><div class=\"cntnt\"><img style=\"width:396px; height:243px;\" src=\"images/PEDS/64885_Pubertalgingivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Puberty gingivitis in a 13-year-old black male. The dark pigmentation of the gingiva is a normal racial characteristic.</div><div class=\"graphic_reference\">Reproduced with permission from: Griffen AL. Periodontal problems in children and adolescents. In: Pediatric Dentistry, Infancy Through Adolescence, 3<SUP>rd</SUP> ed, Pinkham JR, Casamassimo PS, Fields HW Jr, McTigue DJ, Nowak AJ (Eds), WB Saunders 1999. p.376. Copyright Â© 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 64885 Version 4.0</div></div></div>"},"64886":{"type":"graphic_table","displayName":"ILD associated BAL eosinophilia","title":"Interstitial lung disease associated with BAL eosinophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interstitial lung disease associated with BAL eosinophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High count (&#8805;25 percent) </td> </tr> <tr> <td>Chronic eosinophilic pneumonia (&#8805;40 percent)</td> </tr> <tr> <td>Churg Strauss syndrome with active pneumonitis</td> </tr> <tr> <td>Idiopathic acute eosinophilic pneumonia (&#8805;25 percent)</td> </tr> <tr> <td>Tropical pulmonary eosinophilia (40 to 70 percent)</td> </tr> <tr> <td class=\"subtitle1_single\">Mild to moderate counts (&#60;25 percent) </td> </tr> <tr> <td>Connective tissue disease</td> </tr> <tr> <td>Drug-induced pneumonitis</td> </tr> <tr> <td>Fungal pneumonia</td> </tr> <tr> <td>Idiopathic pulmonary fibrosis (&#60;10 percent)</td> </tr> <tr> <td>Pulmonary Langerhans cell histiocytosis (Histiocytosis X)</td> </tr> <tr> <td>Sarcoidosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.</div><div id=\"graphicVersion\">Graphic 64886 Version 2.0</div></div></div>"},"64887":{"type":"graphic_table","displayName":"Drugs that potentiate the action of sulfonylureas","title":"Drugs that potentiate the action of sulfonylureas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that potentiate the action of sulfonylureas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inhibition of membrane transporters</td> </tr> <tr> <td class=\"indent1\">Clarithromycin, fluoroquinolones (eg, levofloxacin), verapamil</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased hepatic CYP2C metabolism</td> </tr> <tr> <td class=\"indent1\"> <p>Antiinfectives: Clarithromycin, fluconazole, metronidazole, isoniazid, miconazole (oral), trimethoprim-sulfamethoxazole (and other sulfonamide antibiotics), voriconazole&nbsp;</p> <p>Other: Amiodarone, capecitabine, cimetidine,&nbsp;fluorouracil, fluvastatin, gemfibrozil (and other fibric acid derivatives), losartan, MAO inhibitors<sup>&#182;</sup>, mifepristone,&nbsp;nicardipine, omeprazole, ticagrelor, warfarin</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Intrinsic hypoglycemic activity</td> </tr> <tr> <td class=\"indent1\">Alcohol, androgens (anabolic steroids), beta-blockers (variable effects), fluoroquinolones, MAO inhibitors<sup>&#182;</sup>, pentamidine, quinine, salicylates*, other antihyperglycemic drugs</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased renal excretion</td> </tr> <tr> <td class=\"indent1\">Allopurinol, probenecid, salicylates*</td> </tr> <tr> <td class=\"subtitle1_single\">Masks autonomic signs of hypoglycemia</td> </tr> <tr> <td class=\"indent1\">Beta-blockers</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Examples of drugs that may potentiate the hypoglycemic effect of sulfonylureas. Specific interactions of sulfonylureas may be analyzed by use of the Lexi-Interact program included within UpToDate.</div><div class=\"graphic_footnotes\">MAO inhibitors: Monoamine oxidase inhibitors<br />*&nbsp;Frequently encountered&nbsp;salicylates include: Aspirin, bismuth subsalicylate, choline magnesium trisalicylate, salsalate. <br />Â¶ MAO inhibitors include: Isocarboxazid, linezolid, methylene blue, moclobemide, phenelzine, procarbazine (antineoplastic), rasagiline, selegiline, Syrian Rue (hallucinogen), tedizolid, tranylcypromine</div><div id=\"graphicVersion\">Graphic 64887 Version 6.0</div></div></div>"},"64888":{"type":"graphic_figure","displayName":"Immune clearance of red cells","title":"Immune-mediated clearance of erythrocytes in autoimmune hemolytic anemia (AIHA)","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Immune-mediated clearance of erythrocytes in autoimmune hemolytic anemia (AIHA)</div><div class=\"cntnt\"><img style=\"width:474px; height:300px;\" src=\"images/HEME/64888_Immune_clearance_of_red_cel.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In warm-reactive AIHA, immunoglobulin G (IgG) autoantibodies are bound to erythrocytes, but typically do not fix complement efficiently. IgG-coated cells enter the spleen and other parts of the reticuloendothelial system (RES), where they interact with Fc receptors on macrophages. Erythrocytes may be completely engulfed and destroyed by this interaction or may have only a portion of their membrane removed. In the latter case, the red cells will reshape into spherocytes, which are then destroyed on their next passage through the spleen. In cold-reactive disease, complement is typically fixed very efficiently and intravascular lysis by the complement cascade can occur. Alternatively, the presence of surface-bound complement (C3) can lead to extravascular red cell destruction by the spleen and other portions of the RES, such as the liver.</div><div class=\"graphic_footnotes\">RES: reticuloendothelial system.</div><div class=\"graphic_reference\">Adapted from: Ware RE. Autoimmune Hemolytic Anemia. In: Nathan and Oski's Hematology of Infancy and Childhood, 5th Ed, Nathan DG, Orkin SH (Eds), WB Saunders Company, Philadelphia 1998.</div><div id=\"graphicVersion\">Graphic 64888 Version 5.0</div></div></div>"},"64890":{"type":"graphic_table","displayName":"Transplantation approaches in thalassemia","title":"Accepted and experimental transplantation approaches in thalassemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Accepted and experimental transplantation approaches in thalassemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>HLA-identical sibling transplant; bone marrow as preferred stem cell source</td> <td>Accepted</td> </tr> <tr> <td>HLA-molecularly-matched unrelated donor transplant</td> <td>Accepted</td> </tr> <tr> <td>HLA-identical sibling cord blood transplant</td> <td>Accepted</td> </tr> <tr> <td>HLA-matched unrelated cord blood transplant</td> <td>Experimental</td> </tr> <tr> <td>HLA-mismatched related donor transplant</td> <td>Experimental</td> </tr> <tr> <td>Nonmyeloablative transplant</td> <td>Experimental</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Originally published in Hematology 2010. Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol Educ Program 2010; 2010:456. Copyright Â© 2010 American Society of Hematology. Updated according to Angelucci E, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel. Haematologica 2014; 99:811.</div><div id=\"graphicVersion\">Graphic 64890 Version 3.0</div></div></div>"},"64891":{"type":"graphic_figure","displayName":"Ear compression dressing","title":"Ear compression dressing","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Ear compression dressing</div><div class=\"cntnt\"><img style=\"width:524px; height:556px;\" src=\"images/EM/64891_EarcompressdressPRedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Place sterile gauze with a central cut out to provide padding behind the ear.<BR>(B) Mold&nbsp;petrolatum-impregnated gauze or saline-soaked cotton balls within the contours of the auricle. If the skin was incised, this portion of the dressing needs to reapproximate the skin at the incision site.<BR>(C) Place sterile gauze over the entire ear.<BR>(D) Wrap the ear and head with sterile, rolled gauze to hold the dressing in place.</div><div class=\"graphic_reference\">Reproduced with permission from: Martinez NJ, Friedman MJ. External ear procedures. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64891 Version 8.0</div></div></div>"},"64892":{"type":"graphic_figure","displayName":"Pneumothorax PI","title":"Pneumothorax (collapsed lung)","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Pneumothorax (collapsed lung)</div><div class=\"cntnt\"><img style=\"width:518px; height:616px;\" src=\"images/PI/64892_Pneumothorax-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lungs sit in the chest, inside the ribcage. They are covered with a thin membrane called the \"pleura.\" The windpipe (or trachea) branches into smaller airways. In this drawing, 1 lung is normal, and 1 has collapsed because air has leaked out of it. The air that has leaked out of the lung (shown in blue) has filled the space outside of the lung.</div><div id=\"graphicVersion\">Graphic 64892 Version 2.0</div></div></div>"},"64893":{"type":"graphic_table","displayName":"Erythema multiforme causes","title":"Causes of erythema multiforme","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of erythema multiforme</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Infectious causes of erythema multiforme\n   </td>\n   </tr>\n   <tr>\n   <td>Herpes simplex virus (most common)</td>\n   </tr>\n   <tr>\n   <td>Mycoplasma pneumoniae</td>\n   </tr>\n   <tr>\n   <td>Parapoxvirus</td>\n   </tr>\n   <tr>\n   <td>Varicella zoster virus</td>\n   </tr>\n   <tr>\n   <td>Adenovirus</td>\n   </tr>\n   <tr>\n   <td>Epstein-Barr virus</td>\n   </tr>\n   <tr>\n   <td>Cytomegalovirus</td>\n   </tr>\n   <tr>\n   <td>Viral hepatitis</td>\n   </tr>\n   <tr>\n   <td>Coxsackie virus</td>\n   </tr>\n   <tr>\n   <td>Parvovirus B19</td>\n   </tr>\n   <tr>\n   <td>Human immunodeficiency virus</td>\n   </tr>\n   <tr>\n   <td>Chlamydophila psittaci</td>\n   </tr>\n   <tr>\n   <td>Salmonella</td>\n   </tr>\n   <tr>\n   <td>Mycobacterium tuberculosis</td>\n   </tr>\n   <tr>\n   <td>Histoplasma capsulatum</td>\n   </tr>\n   <tr>\n   <td>Dermatophytes</td>\n   </tr>\n   <tr>\n   <td>Others</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Medications associated with erythema multiforme\n   </td>\n   </tr>\n   <tr>\n   <td>NSAIDs</td>\n   </tr>\n   <tr>\n   <td>Sulfonamides</td>\n   </tr>\n   <tr>\n   <td>Antiepileptics</td>\n   </tr>\n   <tr>\n   <td>Antibiotics</td>\n   </tr>\n   <tr>\n   <td>Others</td>\n   </tr>\n   </table></td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Source: Bolognia, JL, Jorizzo, JL, Rapini, RP. Dermatology, 2nd ed, Elsevier 2008.</div><div id=\"graphicVersion\">Graphic 64893 Version 1.0</div></div></div>"},"64894":{"type":"graphic_picture","displayName":"Bowing fracture fibula","title":"Bowing fracture of the fibula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bowing fracture of the fibula</div><div class=\"cntnt\"><img style=\"width:370px; height:364px;\" src=\"images/EM/64894_Bowingfxfibula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) This two-year-old girl fell four feet and had a normal examination except that she would not bear weight on her left leg. B) The radiograph shows a bowing deformity of the fibula.</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64894 Version 12.0</div></div></div>"},"64895":{"type":"graphic_picture","displayName":"Chronic mucocutaneous candidiasis","title":"Chronic mucocutaneous candidiasis","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Chronic mucocutaneous candidiasis</div><div class=\"cntnt\"><img style=\"width:584px; height:197px;\" src=\"images/ID/64895_Chron_mucocutan_candida_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heaped-up granulomatous lesions of the scalp of a 12-year-old girl with chronic mucocutaneous candidiasis. The same patient also had lesions on the nose and eyelid.</div><div class=\"graphic_reference\">Courtesy of Carol Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 64895 Version 2.0</div></div></div>"},"64898":{"type":"graphic_diagnosticimage","displayName":"Chronic pancreatitis ERCP child","title":"Endoscopic retrograde cholangiopancreatography (ERCP) showing chronic pancreatitis in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic retrograde cholangiopancreatography (ERCP) showing chronic pancreatitis in a child</div><div class=\"cntnt\"><img style=\"width:360px; height:248px;\" src=\"images/PEDS/64898_Chronic_pancreatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe pancreatic duct changes with dilation of the main pancreatic duct and of the primary and secondary branches.</div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright Â© 1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 64898 Version 5.0</div></div></div>"},"64899":{"type":"graphic_picture","displayName":"MPS I hand","title":"Hand deformity in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand deformity in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome)</div><div class=\"cntnt\"><img style=\"width:400px; height:256px;\" src=\"images/PEDS/64899_MPS_I_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand of a 17-year-old male with Hurler-Scheie syndrome, showing severe contractures and deformation of the distal interphalangeal joints. Movement of the hand and fingers is limited. Thenar atrophy seen at the base of the thumb is due to severe carpal tunnel syndrome.</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 64899 Version 3.0</div></div></div>"},"64901":{"type":"graphic_table","displayName":"Physiologic progression of lower-extremity rotation","title":"Normal physiologic/developmental progression of lower-extremity rotation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal physiologic/developmental progression of lower-extremity rotation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Normal rotation at birth</td> </tr> <tr> <td>Hips: Externally rotated 40&#176;</td> </tr> <tr> <td>Tibia: Internally rotated</td> </tr> <tr> <td>Feet: Internally rotated</td> </tr> <tr> <td class=\"subtitle1_single\">Developmental changes</td> </tr> <tr> <td class=\"subtitle2_single\">Tibial torsion</td> </tr> <tr> <td class=\"indent1\">Birth: Thigh-foot angle 5&#176; lateral (external)</td> </tr> <tr> <td class=\"indent1\">Maturity: Thigh-foot angle 15&#176; lateral</td> </tr> <tr> <td class=\"subtitle2_single\">Femoral anteversion</td> </tr> <tr> <td class=\"indent1\">Birth: 40&#176;</td> </tr> <tr> <td class=\"indent1\">Maturity: 8 to 14&#176;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64901 Version 3.0</div></div></div>"},"64902":{"type":"graphic_figure","displayName":"Spine anatomy overview","title":"Spine anatomy overview","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Spine anatomy overview</div><div class=\"cntnt\"><img style=\"width:636px; height:549px;\" src=\"images/EM/64902_Spineanatomyoverview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This anterior view shows the isolated vertebral column.<br> (B) This right lateral view shows the isolated vertebral column. The isolated vertebrae are typical of each of the three mobile regions. Note the increase in size of the vertebrae as the column descends.<br> (C) This posterior view of the vertebral column includes the vertebral ends of ribs, representing the skeleton of the back.<br> (D) This medial view of the axial skeleton in situ demonstrates its regional curvatures and its relationship to the cranium (skull), thoracic cage, and hip bone. The continuous, weight-bearing column of vertebral bodies and IV discs forms the anterior wall of the vertebral canal. The lateral and posterior walls of the canal are formed by the series of vertebral arches. The IV foramina (seen also in part B) are openings in the lateral wall through which spinal nerves exit the vertebral canal. The posterior wall is formed by overlapping laminae and spinous processes, like shingles on a roof.</div><div class=\"graphic_footnotes\">IV: intervertebral.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 64902 Version 9.0</div></div></div>"},"64903":{"type":"graphic_picture","displayName":"Dermatomyositis scalp","title":"Scalp involvement in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scalp involvement in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64903_Dermatomyositis_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scale and erythema are present on the scalp in this patient with dermatomyositis.</div><div id=\"graphicVersion\">Graphic 64903 Version 1.0</div></div></div>"},"64908":{"type":"graphic_picture","displayName":"Morphology transplant vasculop","title":"Morphology of cardiac transplantation vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morphology of cardiac transplantation vasculopathy</div><div class=\"cntnt\"><img style=\"width:281px; height:228px;\" src=\"images/CARD/64908_Morphology_transplant_vascu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracoronary angioscopic images in patients after cardiac transplantation show normal plaques which are white and glistening, pigmented plaques which are yellow, and non- pigmented plaques which are white and dull.</div><div class=\"graphic_reference\">Reprinted with permission from Mehra MR, Ventura HO, Jain SP, et al. J Am Coll Cardiol 1997; 29:1339.</div><div id=\"graphicVersion\">Graphic 64908 Version 3.0</div></div></div>"},"64910":{"type":"graphic_figure","displayName":"Time course bronchoconstriction","title":"Exercise-induced bronchoconstriction","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Exercise-induced bronchoconstriction</div><div class=\"cntnt\"><img style=\"width:514px; height:280px;\" src=\"images/PULM/64910_Time_course_bronchoconstric.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The time course of exercise-induced bronchoconstriction in an asthmatic patient in whom the FEV1 fell by more than 20 percent after cycling.</div><div class=\"graphic_footnotes\">FEV1: forced expiratory volume in&nbsp;one second.</div><div id=\"graphicVersion\">Graphic 64910 Version 2.0</div></div></div>"},"64911":{"type":"graphic_figure","displayName":"Appendiceal anatomy","title":"Variations in the position of the appendix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variations in the position of the appendix</div><div class=\"cntnt\"><img style=\"width:401px; height:558px;\" src=\"images/SURG/64911_Appendiceal_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64911 Version 2.0</div></div></div>"},"64913":{"type":"graphic_diagnosticimage","displayName":"Very large septated fetal cystic hygroma ","title":"Axial image of the fetal head of an early second trimester fetus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial image of the fetal head of an early second trimester fetus</div><div class=\"cntnt\"><img style=\"width:433px; height:353px;\" src=\"images/OBGYN/64913_Large_septated_cystic_hyg1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior and lateral to the cranium is a large septated cystic hygroma. Very little amniotic fluid is present in this image.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 64913 Version 2.0</div></div></div>"},"64916":{"type":"graphic_figure","displayName":"Classification of jejunoileal atresia","title":"Classification of jejunoileal atresia","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Classification of jejunoileal atresia</div><div class=\"cntnt\"><img style=\"width:513px; height:588px;\" src=\"images/PEDS/64916_Classificationofjejunoilealatresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classification of jejunoileal atresia: <br />â¢ <STRONG>Type I</STRONG> (mucosal web)&nbsp;â The lumen is obstructed by an intact diaphragm or membrane composed of mucosa and submucosa. The muscularis and serosa remain intact, resulting in no discontinuity in the bowel.<br />â¢ <STRONG>Type II</STRONG> (fibrous cord)&nbsp;â An obvious gap in bowel continuity occurs. The proximal and distal segments are connected by a short fibrous band.<br />â¢ <STRONG>Type IIIa</STRONG> (mesenteric gap defect)&nbsp;â A gap in bowel continuity, similar to type II, but no tissue connects the blind ends. There is usually an associated V-shaped gap in the mesentery.<br />â¢ <STRONG>Type IIIb </STRONG>(\"apple peel\")&nbsp;â Proximal small bowel atresia, absence of the mid-small bowel that is normally supplied by the distal superior mesenteric artery, and a large gap in the small bowel mesentery. The small bowel distal to the atresia is foreshortened and coiled like an apple peel.<br />â¢ <STRONG>Type IV </STRONG>(multiple atresias)&nbsp;â Multiple type II or IIIA atresias; these appear like a string of sausages. The bowel may also be foreshortened.</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced with permission from: Welch KW, Randolph JG, Ravitch MM, et al (Eds), Pediatric Surgery, 4th ed, St. Louis, Mosby-Year Book Inc 1986. Copyright Â© 1986 Elsevier.</div><div id=\"graphicVersion\">Graphic 64916 Version 5.0</div></div></div>"},"64918":{"type":"graphic_picture","displayName":"Platysmal bands","title":"Platysmal bands on the neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Platysmal bands on the neck</div><div class=\"cntnt\"><img style=\"width:309px; height:272px;\" src=\"images/DERM/64918_Platysmal_bands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical linear bands due to separation and protrusion of the platysma muscle are present on the anterior neck.</div><div id=\"graphicVersion\">Graphic 64918 Version 1.0</div></div></div>"},"64919":{"type":"graphic_picture","displayName":"Trachyonychia","title":"Trachyonychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trachyonychia</div><div class=\"cntnt\"><img style=\"width:258px; height:432px;\" src=\"images/DERM/64919_Trachyonychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rough surfaces of nail plates with longitudinal ridging are present in this patient with trachyonychia secondary to alopecia areata.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64919 Version 4.0</div></div></div>"},"64922":{"type":"graphic_figure","displayName":"Herniated disc PI","title":"Herniation and pain in disc injury","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Herniation and pain in disc injury</div><div class=\"cntnt\"><img style=\"width:557px; height:430px;\" src=\"images/PI/64922_Herniated_disc_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Co. Copyright &#169; 2009.</div><div id=\"graphicVersion\">Graphic 64922 Version 2.0</div></div></div>"},"64923":{"type":"graphic_diagnosticimage","displayName":"Amiodarone toxicity EM","title":"Amiodarone toxicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amiodarone toxicity</div><div class=\"cntnt\"><img style=\"width:372px; height:246px;\" src=\"images/PULM/64923_Amiodarone_toxicity_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph shows an alveolar macrophage with intracytoplasmic lamellar bodies typical of amiodarone toxicity. These phospholipid inclusions account for the foamy appearance of histiocytes and epithelial cells in patients taking amiodarone and can be identified even in patients who lack radiographic or clinical evidence of lung disease.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 64923 Version 2.0</div></div></div>"},"64925":{"type":"graphic_diagnosticimage","displayName":"Tracheal bronchus I","title":"Tracheal bronchus, also called pig bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal bronchus, also called pig bronchus</div><div class=\"cntnt\"><img style=\"width:360px; height:383px;\" src=\"images/PULM/64925_Tracheal_bronchus_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A contrast tracheobronchogram shows an accessory right upper lobe bronchus.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64925 Version 2.0</div></div></div>"},"64926":{"type":"graphic_picture","displayName":"VKC shield ulcer","title":"Corneal ulceration in vernal keratoconjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal ulceration in vernal keratoconjunctivitis</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/RHEUM/64926_VKC_shield_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corneal epithelial ulceration in vernal keratoconjunctivitis (VKC) is sometimes referred to as a &quot;shield ulcer&quot; because of the appearance of the epithelial breakdown. These ulcers can be quite resistant to therapy.</div><div id=\"graphicVersion\">Graphic 64926 Version 2.0</div></div></div>"},"64927":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram D-TGA","title":"Echocardiogram of D-transposition of the great arteries","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of D-transposition of the great arteries</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/PEDS/64927_Echocardiogram_DTGA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram of D-transposition of the great arteries. Subcostal short axis view demonstrates the anteriorly positioned right ventricle (RV) giving rise to the aorta (Ao). The pulmonary artery (PA) is posteriorly related to the aorta and arises from the left ventricle. The aorta is identified as the vessel that gives rise to the head and neck vessels as well as the coronary arteries, while the pulmonary artery branches into the right and left pulmonary arteries. Mixing of blood between the two parallel circuits occurs through the patent ductus arteriosus (PDA).</div><div id=\"graphicVersion\">Graphic 64927 Version 3.0</div></div></div>"},"64928":{"type":"graphic_waveform","displayName":"ECG of atrial enlargement","title":"Electrocardiograms showing atrial enlargement","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Electrocardiograms showing atrial enlargement</div><div class=\"cntnt\"><img style=\"width:456px; height:285px;\" src=\"images/CARD/64928_Atrial_enlargement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">P wave morphology with atrial enlargement in leads I, II, and V1. The P waves in left atrial enlargement (left panel) are wide (&gt;0.12 sec) and notched in leads I and II and the terminal segment has a negative deflection that is deep and delayed in V1. In right atrial enlargement (middle panel), the P wave amplitude is increased (0.28 mV) in lead II. Biatrial enlargement (right panel) has characteristics of both atrial abnormalities: the P wave amplitude (0.22 mV) and duration (0.12 sec) are increased in lead II and there is deep terminal negativity in V1.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 64928 Version 3.0</div></div></div>"},"64929":{"type":"graphic_diagnosticimage","displayName":"CNS PCM CT scans","title":"Head CT scans from a patient with CNS paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Head CT scans from a patient with CNS paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:432px; height:241px;\" src=\"images/ID/64929_CNS_PCM_CT_scans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Head CT at baseline, showing a heterogeneous and expansive hypodense lesion (diameter, 4 cm), with surrounding edema in the right frontal lobe. Note that the frontal horn of the right lateral ventriculum is deformed by compression. (B) Head CT for the same patient after 12 months of therapy with voriconazole, with significant improvement of all lesions and disappearance of edema reaction and ventricular compression.</div><div class=\"graphic_reference\">Reproduced with permission from: Queiroz-Telles, F, Goldani, LZ, Schlamm, HT, et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45:1462. Copyright Â©2007 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 64929 Version 2.0</div></div></div>"},"64931":{"type":"graphic_figure","displayName":"Rhinovirus infection","title":"Proposed sequence of events during rhinovirus infection of nasal epithelium","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Proposed sequence of events during rhinovirus infection of nasal epithelium</div><div class=\"cntnt\"><img style=\"width:474px; height:239px;\" src=\"images/ID/64931_Rhinovirus_nasal_epithelium.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64931 Version 2.0</div></div></div>"},"64932":{"type":"graphic_table","displayName":"Differential diagnosis of ALS","title":"Differential diagnosis of amyotrophic lateral sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of amyotrophic lateral sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Distinguishing features</td> </tr> <tr> <td>Multifocal motor neuropathy</td> <td>Multifocal nerve conduction block, very high GM1 ganglioside antibody titers</td> </tr> <tr> <td>Cervical spondylosis or extramedullary tumor with compressive radiculopathy and myelopathy</td> <td>Sensory symptoms and signs, Lhermitte's symptom, LMN signs at level(s) of compression and UMN signs in legs, sphincter dysfunction, MRI of spine shows significant cord compression with intrinsic spinal cord signal abnormality</td> </tr> <tr> <td>Benign fasciculations</td> <td>No weakness or atrophy, no electromyographic abnormality of motor unit morphology</td> </tr> <tr> <td>Inclusion body myositis</td> <td>Disproportionate finger flexor weakness, no UMN signs, slow progression, diagnosis requires muscle biopsy, electromyography usually with myopathic features</td> </tr> <tr> <td>Primary lateral sclerosis</td> <td>A clinical variant of ALS: Spastic paraparesis, often with pseudobulbar palsy, prominent spasticity and hyperreflexia, no LMN signs</td> </tr> <tr> <td>Progressive bulbar palsy</td> <td>A clinical variant of ALS: Bulbar involvement predominates, pronounced dysarthria and dysphagia, limb musculature mostly spared</td> </tr> <tr> <td>Progressive muscular atrophy</td> <td>A clinical variant of ALS: Muscle weakness and atrophy with no UMN signs</td> </tr> <tr> <td>Myasthenia gravis</td> <td>Diplopia, ptosis, ocular dysmotility, weakness improved by acetylcholinesterase inhibitors, no UMN or LMN features</td> </tr> <tr> <td>Monomelic (benign focal) amyotrophy</td> <td>Onset usually in youth, slow and self limited course, no UMN features</td> </tr> <tr> <td>Hereditary spinal muscular atrophy</td> <td>Symmetric, slow course, no UMN signs, usually diagnostic changes detected in the survival motor neuron 1 gene (SMN1)</td> </tr> <tr> <td>Hereditary spastic paraplegia</td> <td>Slowly progressive lower extremity spastic UMN weakness, minimal or no LMN symptoms and/or signs, sphincter dysfunction, sensory symptoms and signs, HSP gene positive if available</td> </tr> <tr> <td>Post-polio progressive muscular atrophy</td> <td>Slow course, no UMN signs</td> </tr> <tr> <td>Spinobulbar muscular atrophy (Kennedy disease)</td> <td>X-linked recessive disorder, slow progression, expansion of a CAG trinucleotide repeat (&#62;40 CAGs) in the androgen receptor gene</td> </tr> <tr> <td>Late-onset Tay-Sachs disease (GM2 gangliosidosis)</td> <td>Late adolescent and early adult onset, progressive atrophic paralysis, hexosaminidase A deficiency</td> </tr> <tr> <td>Motor neuron syndromes with lymphoproliferative disorders</td> <td>Lymphoma (Hodgkin or non-Hodgkin), multiple myeloma, chronic lymphocytic leukemia, Waldenstr&#246;m macroglobulinemia; some have paraproteinemia</td> </tr> <tr> <td>Motor neuron syndromes in lung, breast, and other cancers</td> <td>May improve on treatment of the tumor, may be paraneoplastic or coincidental</td> </tr> <tr> <td>Radiation brainstem injury/radiation myelopathy</td> <td>History of radiation therapy for cancer, location of injury within the radiation ports, delay of months to a few years from treatment, LMN symptoms and signs at the level of the injury, possible UMN symptoms and signs below the injury, possible sensory symptoms and signs below the level of the injury (eg, Lhermitte sign), self limited: does not progress to a diffuse LMN/UMN disorder</td> </tr> <tr> <td>Thyrotoxic myopathy with fasciculations</td> <td>Overt or covert hyperthyroidism</td> </tr> <tr> <td>Intraspinal tumors and other lesions</td> <td>Imaging studies show syringomyelia, syringobulbia, or intraspinal tumors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALS: amyotrophic lateral sclerosis; LMN: lower motor neuron; UMN: upper motor neuron.</div><div class=\"graphic_reference\">Modified from: Layzer RB. Chapter 415. Hereditary and acquired intrinsic motor neuron diseases. In: Bennett and Plum (Eds), Cecil Textbook of Medicine, W.B. Saunders, Philadelphia 1999.</div><div id=\"graphicVersion\">Graphic 64932 Version 8.0</div></div></div>"},"64933":{"type":"graphic_table","displayName":"Loss rate after MPR by starting and ending number","title":"Loss rate after multifetal pregnancy reduction by starting and ending number","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Loss rate after multifetal pregnancy reduction by starting and ending number</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Starting number of fetuses</td> <td class=\"subtitle1\">Loss rate if ending as a twin gestation<br /> (percent)</td> <td class=\"subtitle1\">Loss rate if ending as a singleton gestation<br /> (percent)</td> </tr> <tr> <td>Five or more</td> <td class=\"centered\">12.1</td> <td class=\"centered\">N/A</td> </tr> <tr> <td>Four</td> <td class=\"centered\">5.8</td> <td class=\"centered\">4.0</td> </tr> <tr> <td>Three</td> <td class=\"centered\">4.5</td> <td class=\"centered\">6.1</td> </tr> <tr> <td>Two</td> <td class=\"centered\">N/A</td> <td class=\"centered\">2.1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Stone J, Ferrara L, Kamrath J, et al. Contemporary outcomes with the latest 1000 cases of multifetal pregnancy reduction (MPR). Am J Obstet Gynecol 2008; 199:406.</div><div id=\"graphicVersion\">Graphic 64933 Version 3.0</div></div></div>"},"64935":{"type":"graphic_table","displayName":"Pediatric version DASH diet","title":"DASH (Dietary Approaches to Stop Hypertension) diet: Servings per day by food group and total daily caloric intake","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DASH (Dietary Approaches to Stop Hypertension) diet: Servings per day by food group and total daily caloric intake</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food group</td> <td class=\"subtitle1\">1200 calories</td> <td class=\"subtitle1\">1400 calories</td> <td class=\"subtitle1\">1600 calories</td> <td class=\"subtitle1\">1800 calories</td> <td class=\"subtitle1\">2000 calories</td> <td class=\"subtitle1\">2600 calories</td> <td class=\"subtitle1\">Serving sizes</td> <td class=\"subtitle1\">Examples and notes</td> <td class=\"subtitle1\">Significance of each food group to the DASH eating plan</td> </tr> <tr class=\"divider_bottom\"> <td>Grains*</td> <td>4 to 5</td> <td>5 to 6</td> <td>6</td> <td>6</td> <td>6 to 8</td> <td>10 to 11</td> <td> <p>1 slice bread</p> <p>1 oz dry cereal<sup>&#182;</sup></p> 1/2 cup cooked rice, pasta, or cereal<sup>&#182;</sup></td> <td>Whole wheat, bread and rolls, whole wheat pasta, English muffin, pita bread, bagel, cereals, grits, oatmeal, brown rice, unsalted pretzels, popcorn</td> <td>Major sources of energy and fiber</td> </tr> <tr class=\"divider_bottom\"> <td>Vegetables</td> <td>3 to 4</td> <td>3 to 4</td> <td>3 to 4</td> <td>4 to 5</td> <td>4 to 5</td> <td>5 to 6</td> <td> <p>1 cup raw leafy vegetable</p> <p>1/2 cup cut-up raw or cooked vegetable</p> 1/2 cup vegetable juice</td> <td>Broccoli, carrots, collards, green beans, green peas, kale, lima beans, potatoes, spinach, squash, sweet potatoes, tomatoes</td> <td>Rich sources of potassium, magnesium, and fiber</td> </tr> <tr class=\"divider_bottom\"> <td>Fruits</td> <td>3 to 4</td> <td>4</td> <td>4</td> <td>4 to 5</td> <td>4 to 5</td> <td>5 to 6</td> <td> <p>1 medium fruit</p> <p>1/4 cup dried fruit</p> <p>1/2 cup fresh, frozen, or canned fruit</p> 1/2 cup fruit juice</td> <td>Apples, apricots, bananas, dates, grapes, oranges, grapefruit, grapefruit juice, mangoes, melons, peaches, pineapples, raisins, strawberries, tangerines</td> <td>Important sources of potassium, magnesium, and fiber</td> </tr> <tr class=\"divider_bottom\"> <td>Fat-free or low-fat milk and milk products</td> <td>2 to 3</td> <td>2 to 3</td> <td>2 to 3</td> <td>2 to 3</td> <td>2 to 3</td> <td>3</td> <td> <p>1 cup milk or yogurt</p> 1.5 oz cheese</td> <td>Fat-free milk or buttermilk, fat-free, low-fat, or reduced-fat cheese, fat-free/low-fat regular or frozen yogurt</td> <td>Major sources of calcium and protein</td> </tr> <tr class=\"divider_bottom\"> <td>Lean meats, poultry, and fish</td> <td>3 or less</td> <td>3 to 4 or less</td> <td>3 to 4 or less</td> <td>6 or less</td> <td>6 or less</td> <td>6 or less</td> <td> <p>1 oz cooked meats, poultry, or fish</p> 1 egg<sup>&#916;</sup></td> <td>Select only lean; trim away visible fats; broil, roast, or poach; remove skin from poultry</td> <td>Rich sources of protein and magnesium</td> </tr> <tr class=\"divider_bottom\"> <td>Nuts, seeds, and legumes</td> <td>3 per week</td> <td>3 per week</td> <td>3 to 4 per week</td> <td>4 per week</td> <td>4 to 5 per week</td> <td>1 per day</td> <td> <p>1/3 cup or 1.5 oz nuts</p> <p>2 Tbsp peanut butter</p> <p>2 Tbsp or 1/2 oz seeds</p> 1/2 cup cooked legumes (dry beans and peas)</td> <td>Almonds, filberts, mixed nuts, peanuts, walnuts, sunflower seeds, peanut butter, kidney beans, lentils, split peas</td> <td>Rich sources of energy, magnesium, protein, and fiber</td> </tr> <tr class=\"divider_bottom\"> <td>Fats and oils<sup>&#9674;</sup></td> <td>1</td> <td>1</td> <td>2</td> <td>2 to 3</td> <td>2 to 3</td> <td>3</td> <td> <p>1 tsp soft margarine</p> <p>1 tsp vegetable oil</p> <p>1 Tbsp mayonnaise</p> 2 Tbsp salad dressing</td> <td>Soft margarine, vegetable oil (such as canola, corn, olive, or safflower), low-fat mayonnaise, light salad dressing</td> <td>The DASH study had 27 percent of calories as fat, including fat in or added to foods</td> </tr> <tr> <td>Sweets and added sugars</td> <td>3 or less per week</td> <td>3 or less per week</td> <td>3 or less per week</td> <td>5 or less per week</td> <td>5 or less per week</td> <td>&#8804;2</td> <td> <p>1 Tbsp sugar</p> <p>1 Tbsp jelly or jam</p> <p>1/2 cup sorbet, gelatin</p> 1 cup lemonade</td> <td>Fruit-flavored gelatin, fruit punch, hard candy, jelly, maple syrup, sorbet and ices, sugar</td> <td>Sweets should be low in fat</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Food and Drug Administration (FDA) and the Environmental Protection Agency are advising women of childbearing age who may become pregnant, pregnant women, nursing mothers, and young children to avoid some types of fish and shellfish and eat fish and shellfish that are low in mercury. For more information, call the FDA's food information line toll free at 1-888-SAFEFOOD or visit http://www.cfsan.fda.gov/~dms/admehg3.html.</div><div class=\"graphic_footnotes\">oz: ounce; Tbsp: tablespoon; tsp: teaspoon.<br />* Whole grains are recommended for most grain servings as a good source of fiber and nutrients.<br />Â¶ Serving sizes vary between 1/2 cup and 1-1/4 cups, depending on cereal type. Check product's Nutrition Facts label.<br />Î Since eggs are high in cholesterol, limit egg yolk intake to no more than four per week; two egg whites have the same protein content as 1 oz meat.<br /><FONT class=lozenge>â</FONT> Fat content changes serving amount for fats and oils. For example, 1 Tbsp regular salad dressing = 1 serving; 1 Tbsp low-fat dressing = 1/2 serving; 1 Tbsp fat-free dressing = zero servings.</div><div class=\"graphic_reference\">Reproduced from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Available at:&nbsp;<A href=\"https://www.nhlbi.nih.gov/node/80139\">https://www.nhlbi.nih.gov/node/80139</A> (Accessed January 3, 2012).</div><div id=\"graphicVersion\">Graphic 64935 Version 5.0</div></div></div>"},"64937":{"type":"graphic_table","displayName":"Secretin stimulation test","title":"Secretin stimulation test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secretin stimulation test</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Purpose</td> </tr> <tr> <td>To diagnose gastrinoma (Zollinger-Ellison syndrome).</td> </tr> <tr> <td class=\"subtitle1_single\">Preparation</td> </tr> <tr> <td>Subject should be fasting on the day of study. Acid suppressive medications should be discontinued well in advance to avoid effects on gastrin release.*</td> </tr> <tr> <td class=\"subtitle1_single\">Method</td> </tr> <tr> <td>Baseline blood samples are taken&nbsp;five minutes and immediately prior to (time -5 minutes and 0 minutes) secretin administration. Secretin (0.4&nbsp;mcg/kg) is given IV over a one minute period. Serum samples are taken at&nbsp;two,&nbsp;five,&nbsp;10, and 30 minutes after injection.</td> </tr> <tr> <td class=\"subtitle1_single\">Contraindications</td> </tr> <tr> <td>Secretin testing should not be performed in patients with acute pancreatitis.</td> </tr> <tr> <td class=\"subtitle1_single\">Interpretation</td> </tr> <tr> <td>Baseline serum gastrin in patients with gastrinoma is greater than 150 pg/mL. A positive secretin stimulation test demonstrates a quick and substantial increase in serum gastrin (by more than&nbsp;120 pg/mL) has a sensitivity and a specificity for gastrinoma&nbsp;of 94 and 100 percent, respectively. </td> </tr> <tr> <td class=\"subtitle1_single\">Note</td> </tr> <tr> <td>Achlorhydria or profound hypochlorhydria can result in increased fasting serum gastrin levels and an exaggerated response to IV secretin stimulation. Proton pump inhibiting medications should be discontinued one week before the test and patients placed on a H2 receptor antagonist, which should be discontinued 24 hours prior to testing.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Some authorities recommend that proton pump inhibitors should not be discontinued because of the risk that patients with severe disease may develop acute complications such as bleeding and perforation (see text).</div><div id=\"graphicVersion\">Graphic 64937 Version 3.0</div></div></div>"},"64938":{"type":"graphic_figure","displayName":"ACEI vs hydralazine in HF","title":"ACE inhibitor more effective than hydralazine and nitrates in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ACE inhibitor more effective than hydralazine and nitrates in HF</div><div class=\"cntnt\"><img style=\"width:434px; height:249px;\" src=\"images/CARD/64938_ACEI_vs_hydralazine_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enalapril is associated with diminished mortality when compared to the combination of hydralazine-isosorbide dinitrate (Hydral-IDN) in patients with moderate NYHA class II or III heart failure. (p = 0.016 at two years [18 versus 25 percent] and p = 0.08 at five years [48 versus 54 percent].)</div><div class=\"graphic_reference\">Data from: Cohn JN, Johnson G, Ziesche S, et al. N Engl J Med 1991; 325:303.</div><div id=\"graphicVersion\">Graphic 64938 Version 2.0</div></div></div>"},"64939":{"type":"graphic_picture","displayName":"Photo birth 2","title":"Delivery sequence from crowning through birth of the newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delivery sequence from crowning through birth of the newborn</div><div class=\"cntnt\"><img style=\"width:432px; height:290px;\" src=\"images/OBGYN/64939_Photo_birth_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Late crowning. Notice that the fetal head is appearing face down. This is the normal OA (occiput anterior)&nbsp;position.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright Â©2009.</div><div id=\"graphicVersion\">Graphic 64939 Version 2.0</div></div></div>"},"64942":{"type":"graphic_diagnosticimage","displayName":"TEE LA and LA appendage thrombi and spontaneous contrast","title":"Left atrial and left atrial appendage thrombi as well as spontaneous echocontrast see on TEE","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Left atrial and left atrial appendage thrombi as well as spontaneous echocontrast see on TEE</div><div class=\"cntnt\"><img style=\"width:528px; height:203px;\" src=\"images/CARD/64942_LA_LAA_thrombi_spont_contra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transverse plane basal short axis transesophageal echocardiography (TEE)&nbsp;view demonstrates left atrial thrombi (T) (panel B and C). Panel A shows spontaneous echo contrast (SEC) in the left atrium (LA).</div><div class=\"graphic_footnotes\">Ao: aorta.</div><div id=\"graphicVersion\">Graphic 64942 Version 4.0</div></div></div>"},"64943":{"type":"graphic_figure","displayName":"Mechanism ANP BNP HF","title":"Natriuretic peptides in heart failure","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Natriuretic peptides in heart failure</div><div class=\"cntnt\"><img style=\"width:464px; height:274px;\" src=\"images/CARD/64943_Mechanism_ANP_BNP_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of the effects of elevated plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in severe heart failure. ANP and BNP may increase (+) the rate of sodium excretion and reduce (-) the effects of the renin-angiotensin (RAS), sympathetic nervous systems (NS), and endothelin (ET)-1; the net effect of these actions is reduced preload and afterload. A similar elevation in inducible nitric oxide synthase (iNOS) is seen in humans with severe heart failure. These initially homeostatic mechanisms paradoxically contribute to the pathophysiology of the failing myocardium.</div><div class=\"graphic_reference\">Reproduced with permission from: Baig M, Mahon N, McKenna WJ, et al. Am Heart J 1998; 135:S217. Copyright Â© 1998 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 64943 Version 2.0</div></div></div>"},"64944":{"type":"graphic_table","displayName":"Aerosol delivery ventilator","title":"Factors affecting aerosol delivery during mechanical ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors affecting aerosol delivery during mechanical ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Nebulizer</td> </tr> <tr> <td>Position of nebulizer placement in the circuit</td> </tr> <tr> <td>Type of nebulizer and fill volume</td> </tr> <tr> <td>Treatment time</td> </tr> <tr> <td>Duty cycle (I:E ratio)</td> </tr> <tr> <td>Ventilator brand</td> </tr> <tr> <td class=\"subtitle1_single\">pMDI</td> </tr> <tr> <td>Type of actuator</td> </tr> <tr> <td>Timing of actuation</td> </tr> <tr> <td class=\"subtitle1_single\">Nebulizer and pMDI</td> </tr> <tr> <td>Endotracheal tube size</td> </tr> <tr> <td>Humidification of the inspired gas</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">pMDI: pressurized metered dose inhaler.</div><div id=\"graphicVersion\">Graphic 64944 Version 2.0</div></div></div>"},"64945":{"type":"graphic_picture","displayName":"Disseminated candidiasis muscle","title":"Muscle abscess in disseminated candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Muscle abscess in disseminated candidiasis</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/64945_Disseminated_candidiasis_mu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, warm, tender gastrocnemius muscle in an older adult male with acute leukemia and neutropenia. Biopsy showed microabscesses containing budding yeasts and pseudohyphae.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 64945 Version 2.0</div></div></div>"},"64946":{"type":"graphic_diagnosticimage","displayName":"Atrial septal defect PA","title":"Atrial septal defect with pulmonary arterial hypertension","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial septal defect with pulmonary arterial hypertension</div><div class=\"cntnt\"><img style=\"width:285px; height:333px;\" src=\"images/CARD/64946_Atrial_septal_defect_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain frontal chest radiograph in a patient with a known atrial septal defect demonstrates typical features including an enlarged right atrium and right ventricle with marked prominence of the hilar or proximal pulmonary arterial vasculature (arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 64946 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"64948":{"type":"graphic_picture","displayName":"Sporotric mold 25 degrees C","title":"<EM>Sporothrix schenckii </EM>as a mold","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Sporothrix schenckii </EM>as a mold</div><div class=\"cntnt\"><img style=\"width:261px; height:292px;\" src=\"images/ID/64948_Sporotric_mold_25_degrees_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Growth of <EM>Sporothrix schenckii</EM> on Sabouraud dextrose agar at 25ÂºC. At this temperature, <EM>S. schenckii</EM> grows as a mold.</div><div class=\"graphic_reference\">Courtesy of Carol A. Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 64948 Version 3.0</div></div></div>"},"64950":{"type":"graphic_table","displayName":"MVAC regimen","title":"MVAC chemotherapy for metastatic urothelial carcinoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">MVAC chemotherapy for metastatic urothelial carcinoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days.<br /> <strong>Total cycles:</strong> 6. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Methotrexate</td> <td>30 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) and administer as a slow IV push.*</td> <td>Days 1, 15, and 22</td> </tr> <tr> <td>Vinblastine</td> <td>3 mg/m<sup>2</sup> IV</td> <td>Administer IV push over one minute.</td> <td>Days 2, 15, and 22</td> </tr> <tr> <td>Doxorubicin</td> <td>30 mg/m<sup>2</sup> IV</td> <td>Dilute with 50 mL NS and administer over three to five minutes or IV push through a peripheral line.*</td> <td>Day 2</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>70 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS and administer over 60 minutes.* Do not administer with aluminum needles or sets.</td> <td>Day 2</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis).</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Due to the potential for nephrotoxicity associated with cisplatin, pretreatment hydration with 1 to 2 liters of fluid is recommended prior to cisplatin administration; adequate post hydration and urinary output (&#62;100 mL/hour) should be maintained for 24 hours after administration.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Both doxorubicin and vinblastine are vesicants and can cause significant tissue damage; avoid extravasation. Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>This regimen was found to have an incidence of febrile neutropenia of 10% in clinical trials.<sup>[1]</sup> The decision whether or not to use hematopoietic growth factors must be individualized.</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction and third-space fluid collections</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of methotrexate may be needed for patients with liver or renal impairment, and in those with third-space fluid collections (ascites, pleural effusion, etc).<sup>[3]</sup> Adjustment of initial vinblastine and doxorubicin doses may be needed for preexisting liver dysfunction.<sup>[4,5]</sup> Adjustment of cisplatin doses may be needed for preexisting renal dysfunction.<sup>[2]</sup></li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiopulmonary issues</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is associated with cardiomyopathy, the incidence of which is related to cumulative dose. Assess LVEF before and regularly during and after treatment with doxorubicin.<sup>[4]</sup> Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines.<sup>[4]</sup></li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each cycle.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolyte and liver and renal function prior to each cycle. Continue close monitoring of renal function after each cycle in high-risk patients.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each cycle.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Evaluate for third-space fluid collections as clinically indicated.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess left ventricular ejection fraction prior to treatment initiation and as clinically indicated during therapy.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle until the WBC count is &#62;3000/mm<sup>3</sup> and platelet count is &#62;90,000 mm<sup>3</sup>.<sup>[1]</sup> Methotrexate and doxorubicin doses should be reduced by 33% in patients who have a nadir WBC &#60;2000/mm<sup>3</sup>.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin therapy should be discontinued when neurologic symptoms are first observed.<sup>[2]</sup> The manufacturer recommends a dose reduction of vinblastine by 1 mg/m<sup>2</sup> in patients with severe neurotoxicity.<sup>[5]</sup></li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Mucositis</strong></td> <td colspan=\"3\"> <ul> <li>Doses of methotrexate should be reduced by 33% in patients who develop grade 3 or grade 4 mucositis.<sup>[3]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Discontinue doxorubicin in patients who develop signs/symptoms of cardiomyopathy.<sup>[4]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL or creatinine clearance &#62;55 mL/min and/or blood urea nitrogen &#60;25 mg/dL.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for liver dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Reduce the dose of vinblastine by 50% for patients with a direct serum bilirubin &#62;3 mg/dL.<sup>[5]</sup> Dose reductions for doxorubicin are recommended for total bilirubin &#62;1.2 mg/dL and doxorubicin is contraindicated in patients with total bilirubin &#62;5 mg/dL.<sup>[4]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; WBC: white blood cell count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Loehrer PJ, et al. J Clin Oncol 1992; 10:1066.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 25, 2016).</LI>&#xD;&#xA;<LI>Methotrexate injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 25, 2016).</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 25, 2016).</LI>&#xD;&#xA;<LI>Vinblastine injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 25, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 64950 Version 27.0</div></div></div>"},"64952":{"type":"graphic_waveform","displayName":"Acute anterolateral MI tutorial","title":"Acute anterolateral transmural myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Acute anterolateral transmural myocardial infarction</div><div class=\"cntnt\"><img style=\"width:534px; height:218px;\" src=\"images/CARD/64952_Acute_anterolateral_MI_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ST elevation is prominent in leads I, aVL, V5, and V6 in patients with an acute anterolateral infarct.</div><div id=\"graphicVersion\">Graphic 64952 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"64953":{"type":"graphic_waveform","displayName":"Left right atrial pressures MR","title":"Left atrial and right atrial pressure in MR","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial and right atrial pressure in MR</div><div class=\"cntnt\"><img style=\"width:400px; height:234px;\" src=\"images/CARD/64953_Leftrightatrialpressures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transseptal catheter is in the left atrium (LA) and the pressure tracing shows large \"v\" waves as a result of mitral regurgitation (MR). The \"v\" wave of 40 mmHg is twice the mean LA pressure which is 20 mmHg. The asterisk shows where the catheter is pulled back to the right atrium (RA); since the pressure tracing is continuous, it accurately reflects the pressure gradient between the LA and RA. The RA pressure is lower, and the a and v waves are diminutive relative to the left side.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd Edition. Mosby-Year Book, Inc., St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 64953 Version 4.0</div></div></div>"},"64956":{"type":"graphic_movie","displayName":"Ultrasound ulnar nerve at the elbow","title":"Ultrasound ulnar nerve at the elbow","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound ulnar nerve at the elbow</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/64956_USulnarnerelbowupdconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:406px; height:321px;\" src=\"images/NEURO/64956_USulnarnerveelbowupdated.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an axial view of the left elbow in a patient with subluxation of the ulnar nerve. At the beginning of the video, the medial epicondyle is between the two arrows; the ulnar nerve (right arrow) is in its normal position just lateral to the medial epicondyle. As the elbow is flexed from 70 to 130 degrees, the ulnar nerve pops out of the ulnar groove to a position just medial to the medial epicondyle (left arrow). As the elbow re-extends, the ulnar nerve pops back into the groove. The patient reports a slightly uncomfortable sensation with sudden translocation of the nerve each time the elbow flexion/extension movement is repeated.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 64956 Version 2.0</div></div></div>"},"64957":{"type":"graphic_table","displayName":"Symptoms and signs of anaphylaxis in infants","title":"Symptoms and signs of anaphylaxis in infants*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of anaphylaxis in infants*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anaphylaxis symptoms that infants cannot describe</td> <td class=\"subtitle1\">Anaphylaxis signs that are potentially difficult to interpret in infants and why</td> <td class=\"subtitle1\">Anaphylaxis signs in infants: Obvious but may be nonspecific</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">General</td> </tr> <tr> <td class=\"indent1\">Feeling of warmth, weakness, anxiety, apprehension, impending doom</td> <td>Nonspecific behavioral changes, such as persistent crying, fussing, irritability, fright</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Skin/mucus membranes</td> </tr> <tr> <td class=\"indent1\">Itching of lips, tongue, palate, uvula, ears, throat, nose, eyes, and so forth; mouth-tingling or metallic taste</td> <td>Flushing (may also occur with fever, hyperthermia, or crying spells)</td> <td>Rapid onset of hives (potentially difficult to discern in infants with acute atopic dermatitis; scratching and excoriations, as such, will be absent in young infants); angioedema (face, tongue, oropharynx)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Respiratory</td> </tr> <tr> <td class=\"indent1\">Nasal congestion, throat tightness; chest tightness; shortness of breath</td> <td>Hoarseness, dysphonia (common after a crying spell); drooling, increased secretions (common in infants)</td> <td>Rapid onset of coughing, choking, stridor, wheezing, dyspnea, apnea, cyanosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Dysphagia, nausea, abdominal pain/cramping</td> <td>Spitting up/regurgitation (common after feeds), loose stools (normal in infants, especially if breastfed); colicky abdominal pain</td> <td>Sudden, profuse vomiting</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Feeling faint, presyncope, dizziness, confusion, blurred vision, difficulty in hearing, palpitations</td> <td>Hypotension; measured with an appropriate size blood pressure cuff, low systolic blood pressure for infants is defined as less than 70 mmHg from age one month to one year and less than (70 mmHg + [2 x age in years]) in the first and second years of life; tachycardia, defined as greater than 120 to 130 beats per minute from the third month to second year of life inclusive; loss of bowel and bladder control (ubiquitous in infants)</td> <td>Weak pulse, arrhythmia, diaphoresis/sweating, pallor, collapse/unconsciousness</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Central nervous system</td> </tr> <tr> <td class=\"indent1\">Headache</td> <td>Drowsiness, somnolence (common in infants after feeds)</td> <td>Rapid onset of unresponsiveness, lethargy, or hypotonia; seizures</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* More than one body system involved.</div><div class=\"graphic_reference\">From: Simons FER. Anaphylaxis in infants: Can recognition and management be improved? J Allergy Clin Immunol 2007; 120:537. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64957 Version 6.0</div></div></div>"},"64959":{"type":"graphic_picture","displayName":"Asymptomatic eye NAION","title":"Asymptomatic eye in a patient with nonarteritic anterior ischemic optic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asymptomatic eye in a patient with nonarteritic anterior ischemic optic neuropathy</div><div class=\"cntnt\"><img style=\"width:370px; height:366px;\" src=\"images/NEURO/64959_Asymptomatic_eye_NAION.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fellow eye in a person with nonarteritic anterior ischemic optic neuropathy (NAION). Note the small cup.</div><div class=\"graphic_reference\">Courtesy of Madhura Tamhankar, MD and Nicholas J Volpe, MD.</div><div id=\"graphicVersion\">Graphic 64959 Version 1.0</div></div></div>"},"64960":{"type":"graphic_figure","displayName":"Abdomen anatomy adult PI","title":"Organs inside the abdomen (belly)","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Organs inside the abdomen (belly)</div><div class=\"cntnt\"><img style=\"width:517px; height:576px;\" src=\"images/PI/64960_Abdomen_anat_adult_PI_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64960 Version 6.0</div></div></div>"},"64961":{"type":"graphic_picture","displayName":"Cupping","title":"Cupping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cupping</div><div class=\"cntnt\"><img style=\"width:259px; height:399px;\" src=\"images/PEDS/64961_Cupping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cupping is used in Middle Eastern, Asian, Latin American, and Eastern European cultures as a means to &quot;draw out&quot; various ailments. Alcohol is placed in a small cup and ignited; the heated cup is then applied to the skin, resulting in circular burns. Central ecchymosis or petechiae result from the suction effect of the heated air as it cools and contracts</div><div class=\"graphic_reference\">Courtesy of Jan E Drutz, MD.</div><div id=\"graphicVersion\">Graphic 64961 Version 1.0</div></div></div>"},"64962":{"type":"graphic_diagnosticimage","displayName":"Erlenmeyer flask deformity","title":"Erlenmeyer flask deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erlenmeyer flask deformity</div><div class=\"cntnt\"><img style=\"width:244px; height:504px;\" src=\"images/PEDS/64962_Erlenmeyer_flask_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 36-year-old gentleman has Gaucher disease, and the shape of his femur mimics the appearance of an Erlenmeyer flask.</div><div class=\"graphic_reference\">Copyright Â© Jeanne Chow, MD.</div><div id=\"graphicVersion\">Graphic 64962 Version 3.0</div></div></div>"},"64964":{"type":"graphic_figure","displayName":"Lumbar epidural nerve block","title":"Approaches for lumbar epidural glucocorticoid injections","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Approaches for lumbar epidural glucocorticoid injections</div><div class=\"cntnt\"><img style=\"width:530px; height:573px;\" src=\"images/PC/64964_Lumbar_epidural_nerve_block.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 64964 Version 3.0</div></div></div>"},"64965":{"type":"graphic_table","displayName":"Treatment of leprosy in children","title":"Multidrug regimens for treatment of leprosy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multidrug regimens for treatment of leprosy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">National Hansen's Disease Program (NHDP)*</td> <td class=\"subtitle1\" colspan=\"2\">World Health Organization (WHO)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Regimen</td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Duration</td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Duration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tuberculoid (\"paucibacillary\"): TT, BT<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Dapsone<sup>&#9674;</sup></td> <td>1 mg/kg daily (not to exceed 100 mg/day)</td> <td class=\"divider_bottom\" rowspan=\"2\">12 months</td> <td>50 mg daily<sup>&#167;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">6 months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rifampin<sup>&#9674;</sup></td> <td>10 to 20 mg/kg daily (not to exceed 600 mg/day)</td> <td>450 mg once a month<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Lepromatous (\"multibacillary\"): LL, BL, BB<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Dapsone<sup>&#9674;</sup></td> <td>1 mg/kg daily (not to exceed 100 mg/day)</td> <td rowspan=\"3\">24 months</td> <td>50 mg daily<sup>&#167;</sup></td> <td rowspan=\"3\">12 months</td> </tr> <tr> <td class=\"indent1\">Rifampin<sup>&#9674;</sup></td> <td>10 to 20 mg/kg daily (not to exceed 600 mg/day)</td> <td>450 mg once a month<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Clofazimine</td> <td>1 mg/kg daily<sup>&#165;</sup> (not to exceed 50 mg daily)</td> <td>150 mg once a month, and 50 mg every other day<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TT: tuberculoid; BT: borderline tuberculoid; LL: lepromatous; BL: borderline lepromatous; BB: mid-borderline.<br />* Additional information available at NHDP website: <A href=\"http://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html\" target=_blank>http://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html</A>.<br />Â¶ Additional information available at WHO website: <A href=\"http://www.who.int/lep/mdt/regimens/en/index.html\" target=_blank>http://www.who.int/lep/mdt/regimens/en/index.html</A>.<br />Î TT, BT, BB, BL, and LL refer to the Ridley-Jopling classification (refer to the&nbsp;text).<br /><FONT class=lozenge>â</FONT> Oral suspension may be compounded.&nbsp;Refer to the&nbsp;Lexicomp pediatric drug information on extemporaneous preparations.<br />Â§ WHO advises dose adjustment for children &lt;10 years: dapsone 25 mg daily and rifampin 300 mg monthly.<br />Â¥ As there is no formulation of clofazimine less than 50 mg and the capsule should never be cut open, alternate-day dosing (2 mg/kg every other day) may be used. Clofazimine should be taken either with or immediately after food or milk to facilitate absorption. In the United States, the NHDP holds the Investigational New Drug (IND) for treatment of leprosy. For further information or to request investigator status to use clofazimine, contact the NHDP: 1-800-642-2477.</div><div id=\"graphicVersion\">Graphic 64965 Version 7.0</div></div></div>"},"64968":{"type":"graphic_figure","displayName":"LV segmentation I","title":"Left ventricular segmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular segmentation</div><div class=\"cntnt\"><img style=\"width:448px; height:585px;\" src=\"images/CARD/64968_LV_segment_I_JASE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental analysis of LV walls based on schematic views, in a parasternal short and long axis orientation, at three different levels. The \"apex segments\" are usually visualized from apical four-chamber, apical two- and three-chamber views. The apical cap can only be appreciated on some contrast studies. A 16-segment model can be used, without the apical cap, as described in an ASE 1989 document<sup>[1]</sup>. A 17-segment model, including the apical cap, has been suggested by the American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging<sup>[2]</sup>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2:358. </li>&#xD;&#xA;    <li>Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American Heart Association. Circulation 2002; 105:539. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 64968 Version 7.0</div></div></div>"},"64969":{"type":"graphic_table","displayName":"Silicone hydrogel contact lens properties","title":"Silicone hydrogel contact lens properties","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Silicone hydrogel contact lens properties</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Proprietary name</td>\r\n                    <td class=\"subtitle1\">Manufacturer</td>\r\n                    <td class=\"subtitle1\">Material</td>\r\n                    <td class=\"subtitle1\">Dk</td>\r\n                    <td class=\"subtitle1\">Dk/t</td>\r\n                    <td class=\"subtitle1\">Modulus</td>\r\n                    <td class=\"subtitle1\">Water content</td>\r\n                    <td class=\"subtitle1\">FDA approved wear</td>\r\n                    <td class=\"subtitle1\">FDA group</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>PureVision</td>\r\n                    <td>Bausch and Lomb</td>\r\n                    <td>Balafilcon A</td>\r\n                    <td>91</td>\r\n                    <td>101</td>\r\n                    <td>1.10</td>\r\n                    <td>36</td>\r\n                    <td>Up to 30 days CW</td>\r\n                    <td>3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Air Optix Night and Day</td>\r\n                    <td>CibaVision</td>\r\n                    <td>Lotrafilcon A</td>\r\n                    <td>140</td>\r\n                    <td>175</td>\r\n                    <td>1.40</td>\r\n                    <td>24</td>\r\n                    <td>Up to 30 days CW</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Air Optix</td>\r\n                    <td>CibaVision</td>\r\n                    <td>Lotrafilcon B</td>\r\n                    <td>110</td>\r\n                    <td>138</td>\r\n                    <td>1.00</td>\r\n                    <td>38</td>\r\n                    <td>Up to 6 days CW</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Acuvue Advance</td>\r\n                    <td>Vistakon</td>\r\n                    <td>Galyfilcon A</td>\r\n                    <td>60</td>\r\n                    <td>86</td>\r\n                    <td>0.40</td>\r\n                    <td>47</td>\r\n                    <td>DW-2 wk disposal</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Acuvue Oasys</td>\r\n                    <td>Vistakon</td>\r\n                    <td>Senfilcon A</td>\r\n                    <td>103</td>\r\n                    <td>147</td>\r\n                    <td>0.75</td>\r\n                    <td>38</td>\r\n                    <td>Up to 6 days CW</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Biofinity</td>\r\n                    <td>CooperVision</td>\r\n                    <td>Comfilcon A</td>\r\n                    <td>128</td>\r\n                    <td>160</td>\r\n                    <td>0.75</td>\r\n                    <td>48</td>\r\n                    <td>Up to 6 days CW</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Avaira</td>\r\n                    <td>CooperVision</td>\r\n                    <td>Enfilcon A</td>\r\n                    <td>100</td>\r\n                    <td>125</td>\r\n                    <td>0.50</td>\r\n                    <td>46</td>\r\n                    <td>DW-2 wk disp</td>\r\n                    <td>1</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">CW: continuous wear; DW: daily wear.</div><div id=\"graphicVersion\">Graphic 64969 Version 4.0</div></div></div>"},"64973":{"type":"graphic_table","displayName":"Office-based self assessment of pediatric emergency readiness","title":"Office-based self assessment of pediatric emergency readiness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Office-based self assessment of pediatric emergency readiness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>As you answer these questions, you may be better able to identify those areas where your office preparedness can be enhanced.</strong></td> </tr> <tr> <td class=\"indent1\">1. Have you ever experienced emergencies in your office setting? What were they, and how often have they occurred?</td> </tr> <tr> <td class=\"indent1\">2. What is your office setting (freestanding office, clinic-based, health center-based, hospital-based, other)? Are there resources on site but outside of your office that you could call on during an office emergency (security, other medical or dental professionals in the same building, hospital code team)?</td> </tr> <tr> <td class=\"indent1\">3. What are the high and low staffing points during the times when your office is open? Include nights and weekends if applicable.</td> </tr> <tr> <td class=\"indent1\">4. What is the emergency readiness of the staff present during those times? Include any training in: <ul> <li>First Aid and Cardio-Pulmonary Resuscitation (CPR) </li> <li>Basic Life Support (BLS) or Advanced Life Support (ALS) </li> <li>Pediatric Advanced Life Support (PALS) </li> <li>Advanced Pediatric Life Support (APLS) </li> <li>Emergency Nurse Pediatric Course (ENPC) </li> <li>Other Continuing Medical Education (CMEs), etc</li> </ul> </td> </tr> <tr> <td class=\"indent1\">5. Have non-clinical staff been trained to recognize a potential or actual emergency?</td> </tr> <tr> <td class=\"indent1\">6. What anticipatory guidance and education do you provide parents regarding injury prevention, first aid and CPR training, recognizing and responding to emergencies, and accessing emergency medical services (EMS)?</td> </tr> <tr> <td class=\"indent1\">7. Is your waiting room under direct observation or screened frequently by a clinical staff member? What child-proofing measures have you implemented?</td> </tr> <tr> <td class=\"indent1\">8. Do all staff know how to access the EMS system? Are staff able to give location of and directions to the office, level of clinical staff present, age and condition of the child (including vital signs if appropriate), desired transport location, and the level of emergency response required (eg, First Responder [ie, police or fire department], BLS [basic life support, emergency medical technician] or ALS [advanced life support, paramedic]).</td> </tr> <tr> <td class=\"indent1\">9. Do you have specific telephone triage protocols for non-clinical and clinical staff? Are all staff currently trained in them?</td> </tr> <tr> <td class=\"indent1\">10. How do you ensure getting the closest available ambulance? Is it 911? a private ambulance? How long does it take for EMS to respond to a call from your office?</td> </tr> <tr> <td class=\"indent1\">11. What is the transport time from your office to a site of definitive care, such as the nearest emergency department or the nearest pediatric center?</td> </tr> <tr> <td class=\"indent1\">12. Have your local EMS providers ever been to visit your office for a non-emergency call, or to receive experience in evaluating pediatric patients?</td> </tr> <tr> <td class=\"indent1\">13. What level of provider comes when you call 911? First Responder (ie, police or fire department), BLS (Basic-Level EMTs), ALS (paramedics)? Does your local EMS have the necessary equipment and expertise to manage children?</td> </tr> <tr> <td class=\"indent1\">14. Do you know the point of entry (hospital of initial destination) for your local 911 response team? (EMS is required by regulation to transport to the closest appropriate hospital, unless they have a state-approved point-of-entry plan to allow a bypass.)</td> </tr> <tr> <td class=\"indent1\">15. If EMS does not go directly to a pediatric center on a 911 call, how do you emergently transport a child to the desired pediatric center when necessary?</td> </tr> <tr> <td class=\"indent1\">16. Does your office use oxygen? If so, how is it supplied? Do all clinical staff know how to operate the oxygen canister? Where is the key kept?</td> </tr> <tr> <td class=\"indent1\">17. What dosage strategy do you use in the office (code card, length-based tape, dosage book, no strategy)?</td> </tr> <tr> <td class=\"indent1\">18. What airway equipment do you stock? Do all clinical staff know how to locate, choose and use the appropriate size equipment for any given child?</td> </tr> <tr> <td class=\"indent1\">19. What equipment and supplies do you have on site to provide you and your staff with universal precautions?</td> </tr> <tr> <td class=\"indent1\">20. Does your practice care for any children who are technology-dependent or have special health care needs? Do you have need for any additional equipment or expertise, should a technology-dependent child have an emergency in your office?</td> </tr> <tr> <td class=\"indent1\">21. Do you have written office protocols for the common office emergencies, such as respiratory distress, anaphylaxis, sepsis, dehydration, supraventricular tachycardia? Are all clinical staff appropriately and currently trained in them?</td> </tr> <tr> <td class=\"indent1\">22. How do you document events during an office emergency (assigned role, tape recorder, retrospective, other)?</td> </tr> <tr> <td class=\"indent1\">23. How do you and your clinical staff maintain skills and readiness? Examples include attending nursery deliveries, moonlighting in the urgent care or pediatric emergency departments, being a PALS or APLS instructor, holding regular \"mock\" office codes and scavenger hunts for infrequently used equipment, and providing expert review of pediatric runs for your local EMS.</td> </tr> <tr> <td class=\"indent1\">24. How do you document parent education, staff training, protocols, and stocking for emergencies?</td> </tr> <tr> <td class=\"indent1\">25. What is your risk management company's policy regarding emergency preparedness of your office?</td> </tr> <tr> <td class=\"indent1\">26. Are there other aspects of your office practice that you think could be improved in order to achieve fewer office emergencies and better outcomes?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EMS: emergency medical services.</div><div class=\"graphic_reference\">Reproduced from: Massachusetts EMSC Task Force. Office Preparedness for Pediatric Emergencies, 3rd ed, O'Malley, P (ed), Massachusetts Department of Public Health, Massachusetts 2003.</div><div id=\"graphicVersion\">Graphic 64973 Version 4.0</div></div></div>"},"64974":{"type":"graphic_table","displayName":"Causes of chronic MR","title":"Causes of chronic mitral regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic mitral regurgitation</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Leaflet</td> </tr> <tr> <td>Degenerative&nbsp;valve disease (mitral valve prolapse)</td> </tr> <tr> <td>Rheumatic fever</td> </tr> <tr> <td>Infective endocarditis (acute and chronic)</td> </tr> <tr> <td class=\"sublist1_start\">Systemic inflammatory disorders</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"sublist1\">Scleroderma</td> </tr> <tr> <td class=\"sublist1_start\">Connective tissue disorders</td> </tr> <tr> <td class=\"sublist1\">Marfan syndrome</td> </tr> <tr> <td class=\"sublist1\">Ehlers-Danlos syndromes</td> </tr> <tr> <td class=\"sublist1\">Pseudoxanthoma elasticum</td> </tr> <tr> <td class=\"sublist1_start\">Congenital</td> </tr> <tr> <td class=\"sublist1\">Mitral valve clefts</td> </tr> <tr> <td class=\"sublist1\">Parachute mitral valve</td> </tr> <tr> <td class=\"sublist1\">Endocardial cushion defects</td> </tr> <tr> <td>Hypertrophic cardiomyopathy (systolic anterior movement of mitral valve)</td> </tr> <tr> <td>Drug-related</td> </tr> <tr> <td class=\"subtitle1_single\">Chordae tendineae</td> </tr> <tr> <td>Myxomatous valve disease (mitral valve prolapse)</td> </tr> <tr> <td>Infective endocarditis (acute and chronic)</td> </tr> <tr> <td>Rheumatic fever</td> </tr> <tr> <td>Spontaneous rupture</td> </tr> <tr> <td>Myocardial infarction</td> </tr> <tr> <td>Trauma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Papillary muscles</td> </tr> <tr> <td>Ischemia or infarction</td> </tr> <tr> <td>Dilated cardiomyopathy</td> </tr> <tr> <td>Left ventricular aneurysm</td> </tr> <tr> <td class=\"sublist1_start\">Papillary muscle rupture</td> </tr> <tr> <td class=\"sublist1\">Myocardial infarction</td> </tr> <tr> <td class=\"sublist1\">Trauma</td> </tr> <tr> <td class=\"subtitle1_single\">Mitral annulus</td> </tr> <tr> <td class=\"sublist1_start\">Calcification</td> </tr> <tr> <td class=\"sublist1\">Idiopathic</td> </tr> <tr> <td class=\"sublist1\">Rheumatic fever</td> </tr> <tr> <td class=\"sublist1\">Chronic renal failure</td> </tr> <tr> <td class=\"sublist1\">Hyperparathyroidism</td> </tr> <tr> <td class=\"sublist1_start\">Dilation</td> </tr> <tr> <td class=\"sublist1\">Connective tissue disorder</td> </tr> <tr> <td class=\"sublist1\">Dilated cardiomyopathy</td> </tr> <tr> <td class=\"sublist1\">Myxomatous mitral valve disease</td> </tr> <tr> <td class=\"subtitle1_single\">Prosthetic valve</td> </tr> <tr> <td>Paravalvular leak</td> </tr> <tr> <td>Infective endocarditis</td> </tr> <tr> <td>Ring or strut fracture</td> </tr> <tr> <td>Occluder dysfunction</td> </tr> <tr> <td>Pannus and/or thrombus&nbsp;formation</td> </tr> <tr> <td>Leaflet deterioration (tissue valves)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64974 Version 4.0</div></div></div>"},"64975":{"type":"graphic_figure","displayName":"Distal tubule transport","title":"Ion transport in the distal tubule","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Ion transport in the distal tubule</div><div class=\"cntnt\"><img style=\"width:470px; height:253px;\" src=\"images/NEPH/64975_Distal_tubule_transport.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the transport mechanisms in the distal tubule. The Na-K-ATPase pump in the basolateral (peritubular) membrane pumps sodium (Na) out of, and potassium (K) into, the cell. This creates a low intracellular Na concentration, which drives many of the cell's reabsorptive processes. The entry of filtered Na and chloride (Cl) into the cell is mediated by a neutral Na-Cl cotransporter NCC in the apical (luminal) membrane. This cotransporter is inhibited by thiazide diuretics. The energy for this process is provided by the favorable inward electrochemical gradient for Na (the intracellular Na concentration is very low and the cell interior is electronegative). The reabsorbed Na that has entered the cell is pumped out by the Na-K-ATPase pump. The reabsorbed Cl exits via a chloride channel. This is the ClC-Kb channel, which requires interaction with a small protein called barttin to function normally. The distal tubule is also a major site of active calcium (Ca) reabsorption. Ca enters the cell via a Ca transporter that is probably a Ca channel. Reabsorbed Ca combines with a vitamin D-induced Ca binding protein (Ca-BP), moves across the cell, and is then extruded at the basolateral membrane by a Ca-ATPase (not shown) and a 3Na:1Ca exchanger that also uses the energy provided by the favorable inward electrochemical gradient for Na.</div><div id=\"graphicVersion\">Graphic 64975 Version 5.0</div></div></div>"},"64976":{"type":"graphic_waveform","displayName":"Positive sharp wave to fibrillation ","title":"Transition of a positive sharp wave to a fibrillation potential","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Transition of a positive sharp wave to a fibrillation potential</div><div class=\"cntnt\"><img style=\"width:484px; height:236px;\" src=\"images/NEURO/64976_PSW_to_FP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In (A) and (B) the sweep is free running. The traces in (B) represent a continuation of the EMG signal after the last trace in (A). In (C), the waveforms from (A) and (B) are superimposed using amplitude trigger and delay line. Calibration is 200 microV/division and 10 ms/division in (A) and (B), and 100 microV/division and 1 ms/division in (C).</div><div class=\"graphic_reference\">Reproduced with permission from: Nandedkar SD, Barkhaus PE, Sanders DB, Stalberg EV. Some observations on fibrillations and positive sharp waves. Muscle Nerve 2004; 23:888. Copyright Â©2004 John Wiley &amp; Sons Inc.</div><div id=\"graphicVersion\">Graphic 64976 Version 4.0</div></div></div>"},"64977":{"type":"graphic_figure","displayName":"Blood pressure measurement","title":"Blood pressure measurement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood pressure measurement</div><div class=\"cntnt\"><img style=\"width:409px; height:262px;\" src=\"images/PEDS/64977_Blood_pressure_measurement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The blood pressure should be measured with the arm supported and the cubital fossa at the level of the heart. The stethoscope bell is placed over the brachial artery pulse below the bottom edge of the cuff, which should be about 2 cm above the cubital fossa.</div><div class=\"graphic_reference\">Adapted from Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 1996; 98:649.</div><div id=\"graphicVersion\">Graphic 64977 Version 1.0</div></div></div>"},"64978":{"type":"graphic_table","displayName":"Framingham ATPIII score men","title":"Framingham/ATP III point scores in men","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Framingham/ATP III point scores in men</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age, years</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\" colspan=\"4\">&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td>20 to 34</td> <td>&nbsp;-9</td> <td rowspan=\"10\" colspan=\"4\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td>35 to 39</td> <td>&nbsp;-4</td> </tr> <tr> <td>40 to 44</td> <td>&nbsp;0</td> </tr> <tr> <td>45 to 49</td> <td>&nbsp;3</td> </tr> <tr> <td>50 to 54</td> <td>&nbsp;6</td> </tr> <tr> <td>55 to 59</td> <td>&nbsp;8</td> </tr> <tr> <td>60 to 64</td> <td>&nbsp;10</td> </tr> <tr> <td>65 to 69</td> <td>&nbsp;11</td> </tr> <tr> <td>70 to 74</td> <td>&nbsp;12</td> </tr> <tr> <td>75 to 79</td> <td>&nbsp;13</td> </tr> <tr> <td class=\"subtitle1\">Total cholesterol, mg/dL (mmol/L)</td> <td class=\"subtitle1\">Age 20 to 39</td> <td class=\"subtitle1\">Age 40 to 49</td> <td class=\"subtitle1\">Age 50 to 59</td> <td class=\"subtitle1\">Age 60 to 69</td> <td class=\"subtitle1\">Age 70 to 79</td> </tr> <tr> <td>&#60;160 (3.4)</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>160 to 199 (3.4 to 5.15)</td> <td>4</td> <td>3</td> <td>2</td> <td>1</td> <td>0</td> </tr> <tr> <td>200 to 239 (5.17 to 6.18)</td> <td>7</td> <td>5</td> <td>3</td> <td>1</td> <td>0</td> </tr> <tr> <td>240 to 279 (6.2 to 7.21)</td> <td>9</td> <td>6</td> <td>4</td> <td>2</td> <td>1</td> </tr> <tr> <td>&#8805;280 (7.24)</td> <td>11</td> <td>8</td> <td>5</td> <td>3</td> <td>1</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Age 20 to 39</td> <td class=\"subtitle1\">Age 40 to 49</td> <td class=\"subtitle1\">Age 50 to 59</td> <td class=\"subtitle1\">Age 60 to 69</td> <td class=\"subtitle1\">Age 70 to 79</td> </tr> <tr> <td>Nonsmoker</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Smoker</td> <td>8</td> <td>5</td> <td>3</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"subtitle1\">HDL cholesterol, mg/dL (mmol/L)</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>&#8805;60 (1.55)</td> <td>-1</td> <td rowspan=\"4\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>50 to 59 (1.29 to 1.53)</td> <td>0</td> </tr> <tr> <td>40 to 49 (1.03 to 1.27)</td> <td>1</td> </tr> <tr> <td>&#60;40 (1.03)</td> <td>2</td> </tr> <tr> <td class=\"subtitle1\">Systolic blood pressure, mmHg</td> <td class=\"subtitle1\">Untreated</td> <td class=\"subtitle1\">Treated</td> <td class=\"subtitle1\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td>&#60;120</td> <td>0</td> <td>0</td> <td rowspan=\"5\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>120 to 129</td> <td>0</td> <td>1</td> </tr> <tr> <td>130 to 139</td> <td>1</td> <td>2</td> </tr> <tr> <td>140 to 159</td> <td>1</td> <td>2</td> </tr> <tr> <td>&#8805;160</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"subtitle1\">Point total</td> <td class=\"subtitle1\">10-year risk, percent</td> <td class=\"subtitle1\">Point total</td> <td class=\"subtitle1\">10-year risk, percent</td> <td class=\"subtitle1\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td>0</td> <td>1</td> <td>9</td> <td>5</td> <td rowspan=\"9\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td>1</td> <td>1</td> <td>10</td> <td>6</td> </tr> <tr> <td>2</td> <td>1</td> <td>11</td> <td>8</td> </tr> <tr> <td>3</td> <td>1</td> <td>12</td> <td>10</td> </tr> <tr> <td>4</td> <td>1</td> <td>13</td> <td>12</td> </tr> <tr> <td>5</td> <td>2</td> <td>14</td> <td>16</td> </tr> <tr> <td>6</td> <td>2</td> <td>15</td> <td>20</td> </tr> <tr> <td>7</td> <td>3</td> <td>16</td> <td>25</td> </tr> <tr> <td>8</td> <td>4</td> <td>&#8805;17</td> <td>&#8805;30</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: These risk estimates for the development of coronary heart disease do not account for all important cardiovascular risk factors. Not included are diabetes mellitus (which is considered a CHD equivalent), family history of CHD, alcohol intake, and the serum C-reactive protein concentration. The point total is determined in each category and the 10-year risk determined in the bottom row.</div><div class=\"graphic_footnotes\">CHD: coronary heart disease.</div><div class=\"graphic_reference\">Adapted from Adult Treatment Panel III at http://www.nhlbi.nih.gov/. </div><div id=\"graphicVersion\">Graphic 64978 Version 4.0</div></div></div>"},"64979":{"type":"graphic_picture","displayName":"Congenital rubella cataract","title":"Congenital rubella cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital rubella cataract</div><div class=\"cntnt\"><img style=\"width:396px; height:269px;\" src=\"images/PEDS/64979_Congenital_rubella_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows cataracts due to congenital rubella syndrome.</div><div class=\"graphic_reference\">Courtesy of Centers for Disease Control and Prevention Public Health Image Library.</div><div id=\"graphicVersion\">Graphic 64979 Version 1.0</div></div></div>"},"64980":{"type":"graphic_picture","displayName":"Superficial spreading melanoma 5","title":"Superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/64980_Superficial_spread_melan_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial spreading melanoma on the left posterior leg of a 29-year-old woman.</div><div id=\"graphicVersion\">Graphic 64980 Version 1.0</div></div></div>"},"64981":{"type":"graphic_picture","displayName":"Cutaneous squamous cell carcinoma - dorsal hand","title":"Cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/64981_Cutan_squam_dorsal_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red papulo-nodule&nbsp;with scale&nbsp;on dorsal hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 64981 Version 4.0</div></div></div>"},"64982":{"type":"graphic_table","displayName":"Advantages and disadvantages of different types of nebulizers","title":"Advantages and disadvantages of different types of nebulizers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of different types of nebulizers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Types of nebulizers</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">Brands</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Jet</strong></td> <td> <ul> <li>Less expensive </li> <li>Enhanced designs have improved performance and reduced aerosol waste during the exhalation phase </li> </ul> </td> <td> <ul> <li>Require a source of compressed air or oxygen </li> <li>Lower efficiency </li> </ul> </td> <td>Breath-enhanced, open-vent:<br /> <ul> <li>Pari LC Plus </li> <li>Pari LC Star </li> <li>Pari Baby </li> <li>Ventstream </li> </ul> <br /> Storage bag:<br /> <ul> <li>Circulaire </li> </ul> <br /> Nebulizers with closed scavenging systems for toxic medications:<br /> <ul> <li>Respigard II </li> <li>SPAG </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ultrasonic</strong>*</td> <td> <ul> <li>Do not require a source of driving gas </li> <li>Can nebulize large volumes of liquid </li> <li>Shorter delivery time than jet nebulizers </li> </ul> </td> <td> <ul> <li>Larger aerosolized particle sizes </li> <li>High-density aerosols can cause bronchospasm and increased airway resistance </li> <li>Lower efficiency </li> <li>May breakdown complex molecules </li> </ul> </td> <td> <ul> <li>Beetle Neb Compact Ultrasonic Nebulizer </li> <li>MiniBreeze Ultrasonic Nebulizer </li> <li>Sonic Mist Ultrasonic Nebulizer </li> </ul> </td> </tr> <tr> <td><strong>Vibrating mesh</strong></td> <td> <ul> <li>Do not require a source of driving gas </li> <li>Shorter delivery time than jet nebulizers </li> <li>Aerosolized particles are highly uniform and respirable </li> <li>More portable (light weight and smaller size) </li> <li>More efficient than jet nebulizer (minimizes drug waste) </li> </ul> </td> <td> <ul> <li>More expensive </li> <li>Require disassembly and cleaning after each use </li> </ul> </td> <td> <ul> <li>eFlow, Altera, Trio </li> <li>Aeroneb </li> <li>MicroAIR, NE-U22 </li> <li>I-neb </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Ultrasonic nebulizers are rarely used.</div><div id=\"graphicVersion\">Graphic 64982 Version 6.0</div></div></div>"},"64984":{"type":"graphic_table","displayName":"NCI CTCAE v5 hematologic toxicity","title":"NCI CTCAE v5.0 hematologic toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 hematologic toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Blood element</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Neutrophils</td> <td>&#60;LLN to 1500/microL</td> <td>1000 to 1500/microL</td> <td>500 to 1000/microL</td> <td>&#60;500/microL</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Platelets</td> <td>&#60;LLN to 75,000/microL</td> <td>50,000 to 75,000/microL</td> <td>25,000 to 50,000/microL</td> <td>&#60;25,000/microL</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Hemoglobin</td> <td>&#60;LLN to 10 g/dL</td> <td>8.0 to 10.0 g/dL</td> <td>&#60;8.0 g/dL</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td>Lymphocytes (total)</td> <td>&#60;LLN to 800/microL</td> <td>500 to 800/microL</td> <td>200 to 500/microL</td> <td>&#60;200/microL</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>CD4 count</td> <td>&#60;LLN to 500/microL</td> <td>200 to 500/microL</td> <td>50 to 200/microL</td> <td>&#60;50/microL</td> <td>&nbsp;</td> </tr> <tr> <td>Febrile neutropenia</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>ANC &#60;1000/microL with a single temperature &#62;38.3&#176;C (100.4&#176;F) or a sustained temperature &#8805;38&#176;C (100&#176;F) for more than one hour</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Neutropenia, thrombocytopenia, anemia, and lymphocytopenia are determined from the complete blood count. All patients with fever in the setting of chemotherapy-induced neutropenia require immediate medical attention regardless of the toxicity grade. Refer to UpToDate topics on febrile neutropenia regarding the management of these patients.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; LLN: lower limit of normal; ANC: absolute neutrophil count. Cells/microL is equivalent to cells/mm<sup>3</sup> or cells x 10<sup>9</sup>/L.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 64984 Version 15.0</div></div></div>"},"64986":{"type":"graphic_table","displayName":"Adjusting Rx 5 to 11 years","title":"Assessing asthma control and adjusting therapy in children 5 to 11 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessing asthma control and adjusting therapy in children 5 to 11 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Components of control</td> <td class=\"subtitle1\" colspan=\"3\">Classification of asthma control (5 to 11 years of age)</td> </tr> <tr> <td class=\"subtitle2\">Well controlled</td> <td class=\"subtitle2\">Not well controlled</td> <td class=\"subtitle2\">Very poorly controlled</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week, but not more than once on each day</td> <td>&#62;2 days/week or multiple times on &#8804;2 days/week</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;1 time/month</td> <td>&#8805;2 times/month</td> <td>&#8805;2 times/week</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td>Short-acting beta<sub>2 </sub>agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Several times per day</td> </tr> <tr> <td colspan=\"4\">Lung function</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>FEV<sub>1</sub> or peak flow </li> <li>FEV<sub>1</sub>/FVC </li> </ul> </td> <td> <ul> <li>&#62;80 percent predicted/personal best </li> <li>&#62;80 percent </li> </ul> </td> <td> <ul> <li>60 to 80 percent predicted/personal best </li> <li>75 to 80 percent </li> </ul> </td> <td> <ul> <li>&#60;60 percent predicted/personal best </li> <li>&#60;75 percent </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Risk</td> <td rowspan=\"2\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year</strong></td> <td colspan=\"2\"><strong>&#8805;2/year (see footnote)</strong></td> </tr> <tr> <td colspan=\"3\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td>Reduction in lung growth</td> <td colspan=\"3\">Evaluation requires long-term follow-up</td> </tr> <tr class=\"divider_bottom\"> <td>Treatment-related adverse effects</td> <td colspan=\"3\">Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.</td> </tr> <tr> <td colspan=\"2\">Recommended action for treatment</td> <td> <ul> <li>Maintain current step. </li> <li>Regular follow-up every one to six months. </li> <li>Consider step down if well controlled for at least three months. </li> </ul> </td> <td> <ul> <li>Step up at least one step and </li> <li>Reevaluate in two to six weeks. </li> <li>For side effects, consider alternative treatment options. </li> </ul> </td> <td> <ul> <li>Consider short course of oral systemic glucocorticoids, </li> <li>Step up one to two steps, and </li> <li>Reevaluate in two weeks. </li> <li>For side effects, consider alternative treatment options. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous two to four weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.<br /><strong>Before step up in therapy:</strong><br />- Review adherence to medication, inhaler technique, environmental control, and comorbid conditions.<br />- If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchospasm; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 64986 Version 9.0</div></div></div>"},"64987":{"type":"graphic_diagnosticimage","displayName":"Pancoast tumor MRI II","title":"Uninvolved right lung in a patient with a left Pancoast tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uninvolved right lung in a patient with a left Pancoast tumor</div><div class=\"cntnt\"><img style=\"width:260px; height:331px;\" src=\"images/PULM/64987_Pancoast_tumor_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A section from the uninvolved right side of the neck is included for comparison with the previous figure. There is no invasion into the base of the neck.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 64987 Version 2.0</div></div></div>"},"64990":{"type":"graphic_picture","displayName":"Gauze grattage of an unroofed hidradenitis suppurativa sinus ","title":"Gauze grattage of an unroofed hidradenitis suppurativa sinus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gauze grattage of an unroofed hidradenitis suppurativa sinus</div><div class=\"cntnt\"><img style=\"width:432px; height:275px;\" src=\"images/SURG/64990_Roughgauzegrattedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the unroofed inflamed hidradenitis suppurativa nodule site and sinus tract. Rough gauze grattage removes the active proliferative inflammatory mass that repopulates the tract with pilosebaceous structures.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 64990 Version 5.0</div></div></div>"},"64991":{"type":"graphic_figure","displayName":"Living donor transplantation","title":"Right lobe liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right lobe liver transplantation</div><div class=\"cntnt\"><img style=\"width:364px; height:348px;\" src=\"images/GAST/64991_Living_donor_transplantatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cartoon depicting the anastamoses in the recipient.</div><div class=\"graphic_reference\">Courtesy of Amadeo Marcos, MD.</div><div id=\"graphicVersion\">Graphic 64991 Version 3.0</div></div></div>"},"64994":{"type":"graphic_table","displayName":"Causes of transient visual loss","title":"Typical features of common causes of transient visual loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical features of common causes of transient visual loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Typical duration</td> <td class=\"subtitle1\">Pattern of visual loss</td> <td class=\"subtitle1\">Associated symptoms and signs</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td>Monocular ischemia, carotid disease, other embolic source</td> <td>1 to 10 minutes</td> <td>Monocular, rapid onset, altitudinal onset</td> <td>Hollenhorst plaque, hemispheric symptoms</td> <td>Retinal embolism (usually)</td> </tr> <tr> <td>Giant Cell arteritis</td> <td>Variable</td> <td>Usually monocular</td> <td>Headache, neck pain, jaw claudication</td> <td>Ischemia of optic nerve</td> </tr> <tr> <td>Papilledema</td> <td>Seconds</td> <td>Monocular graying or blurring</td> <td>Headache, diplopia</td> <td>Elevated intracranial pressure</td> </tr> <tr> <td>Idiopathic retinal vasospasm</td> <td>5 to 60 minutes</td> <td>Monocular positive or negative symptoms</td> <td>Transient retinal arterial narrowing, headache</td> <td>Vasospasm</td> </tr> <tr> <td>Migraine</td> <td>10 to 30 minutes</td> <td>Usually binocular, positive symptoms with spread</td> <td>Usually followed by migraine headache</td> <td>Spreading cortical depression, possibly retinal vasospasm</td> </tr> <tr> <td>Vertebrobasilar ischemia</td> <td>1 to 10 minutes</td> <td>Homonymous hemianopia</td> <td>Isolated or accompanied by other brainstem deficits</td> <td>Embolic</td> </tr> <tr> <td>Seizure: Ictal</td> <td>3 to 5 minutes</td> <td>Binocular, lateralized, positive phenomenon common</td> <td>Altered consciousness, motor symptoms</td> <td>Epileptic discharge</td> </tr> <tr> <td>Postictal</td> <td>20 minutes, longer</td> <td>Binocular visual field loss</td> <td>Preceding ictus</td> <td>Cortical inhibition</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 64994 Version 3.0</div></div></div>"},"64995":{"type":"graphic_table","displayName":"DDx neonatal cholestasis","title":"Causes of neonatal cholestasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of neonatal cholestasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Extrahepatic obstruction</td> </tr> <tr> <td>Extrahepatic biliary atresia</td> </tr> <tr> <td>Choledochal cyst</td> </tr> <tr> <td>Inspissated bile/mucous plug</td> </tr> <tr> <td>Cholelithiasis or biliary sludge</td> </tr> <tr> <td>Tumors/masses (intrinsic and extrinsic)</td> </tr> <tr> <td>Neonatal sclerosing cholangitis</td> </tr> <tr> <td>Spontaneous perforation of the bile ducts</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Adenovirus, cytomegalovirus (CMV), echovirus, enterovirus, herpes simplex virus (HSV), human immunodeficiency virus (HIV), parvovirus B19, rubella</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Urinary tract infection, sepsis, syphilis</td> </tr> <tr> <td class=\"subtitle2_single\">Protozoal</td> </tr> <tr> <td class=\"indent1\">Toxoplasma</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic/genetic diseases</td> </tr> <tr> <td class=\"subtitle2_single\">Disorders of carbohydrate metabolism</td> </tr> <tr> <td class=\"indent1\">Galactosemia</td> </tr> <tr> <td class=\"indent1\">Fructosemia</td> </tr> <tr> <td class=\"indent1\">Type IV glycogenosis</td> </tr> <tr> <td class=\"subtitle2_single\">Disorders of amino acid metabolism</td> </tr> <tr> <td class=\"indent1\">Tyrosinemia</td> </tr> <tr> <td class=\"subtitle2_single\">Disorders of lipid metabolism</td> </tr> <tr> <td class=\"indent1\">Wolman, Niemann-Pick C, Gaucher</td> </tr> <tr> <td class=\"subtitle2_single\">Disorders of bile acid synthesis</td> </tr> <tr> <td class=\"indent1\">3-beta-hydroxy-delta-5-C27-steroid oxidoreductase deficiency (BASD type 1)</td> </tr> <tr> <td class=\"indent1\">Delta[4]-3-oxosteroid 5-beta reductase deficiency (BASD type 2)</td> </tr> <tr> <td class=\"indent1\">Oxysterol 7-alpha-hydroxylase deficiency (BASD type 3)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Alpha-methylacyl-CoA racemase deficiency (BASD type 4)</td> </tr> <tr> <td class=\"indent1\">Zellweger syndrome&nbsp;</td> </tr> <tr> <td class=\"indent1\">Smith-Lemli-Opitz syndrome&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Inherited cholestatic disorders</td> </tr> <tr> <td class=\"indent1\">Alagille syndrome*&nbsp;</td> </tr> <tr> <td class=\"indent1\">ARC syndrome (arthrogryposis-renal dysfunction-cholestasis)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis&nbsp;</td> </tr> <tr> <td class=\"indent1\">NISCH syndrome (neonatal ichthyosis sclerosing cholangitis)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Progressive familial intrahepatic cholestasis (PFIC), including Byler disease</td> </tr> <tr> <td class=\"subtitle2_single\">Mitochondrial disorders</td> </tr> <tr> <td class=\"subtitle2_single\">Other metabolic defects</td> </tr> <tr> <td class=\"indent1\">Alpha-1-antitrypsin deficiency</td> </tr> <tr> <td class=\"indent1\">Citrin deficiency&nbsp;</td> </tr> <tr> <td class=\"indent1\">Congenital disorders of glycosylation&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine&nbsp;</td> </tr> <tr> <td>Hypopituitarism (septo-optic dysplasia)&nbsp;</td> </tr> <tr> <td>Hypothyroidism&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic</td> </tr> <tr> <td>Drugs</td> </tr> <tr> <td>Parenteral nutrition</td> </tr> <tr> <td class=\"subtitle1_single\">Alloimmune&nbsp;</td> </tr> <tr> <td>Gestational alloimmune liver disease (Neonatal hemochromatosis)</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>\"Idiopathic\" neonatal hepatitis</td> </tr> <tr> <td>Nonsyndromic paucity of the interlobular bile ducts&nbsp;</td> </tr> <tr> <td>Shock/hypoperfusion</td> </tr> <tr> <td>Intestinal obstruction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Alagille syndrome is also known as syndromic paucity of the interlobular bile ducts, or arteriohepatic dysplasia.</div><div id=\"graphicVersion\">Graphic 64995 Version 8.0</div></div></div>"},"64996":{"type":"graphic_figure","displayName":"Phases of perinatally-acquired hepatitis B virus infection","title":"Phases of perinatally-acquired hepatitis B virus infection","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Phases of perinatally-acquired hepatitis B virus infection</div><div class=\"cntnt\"><img style=\"width:477px; height:685px;\" src=\"images/PEDS/64996_NaturalHistoryHBVed3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HBV: hepatitis B virus; IU: international units; ALT: alanine aminotrasferase; HBsAg: hepatitis B s antigen; HBsAb: hepatitis B s antibody; HBeAg: hepatitis B e antigen; HBeAb: hepatitis B e antibody; HCC: hepatocellular carcinoma; AFP: alpha fetoprotein.<br />* All patients with HBV infection should have baseline assessment for risk of HCC, and follow-up monitoring. We generally monitor AFP and liver ultrasound every 12 months beginning in late childhood. For patients with elevated AFP, cirrhosis, or a family history of hepatocellular carcinoma, we begin monitoring earlier and monitor more closely.</div><div id=\"graphicVersion\">Graphic 64996 Version 6.0</div></div></div>"},"64997":{"type":"graphic_figure","displayName":"Advancing bladder off cervix","title":"Advancement of the anterior portion of the vaginal mucosa during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advancement of the anterior portion of the vaginal mucosa during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:416px; height:358px;\" src=\"images/OBGYN/64997_Advancing_bladder_off_cervi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blunt or sharp dissection may be used to advance the bladder away from the cervix.</div><div id=\"graphicVersion\">Graphic 64997 Version 2.0</div></div></div>"},"64999":{"type":"graphic_figure","displayName":"Ureter and blood vessels","title":"Identification of the ureter and superior vesical artery during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Identification of the ureter and superior vesical artery during hysterectomy</div><div class=\"cntnt\"><img style=\"width:457px; height:325px;\" src=\"images/OBGYN/64999_Ureter_and_blood_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peritoneal reflection anterior to the uterus is incised and the bladder reflected inferiorly with sharp dissection. The ureter is identified on the medial aspect of the broad ligament during the development of the perivesical and perirectal spaces, as is the superior vesical artery.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 64999 Version 3.0</div></div></div>"}};